Imatinib mesylate
| Title | Journal |
|---|---|
| microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells. | Chemico-biological interactions 20180801 |
| Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. | Chemico-biological interactions 20170801 |
| Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20170801 |
| Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity. | Toxicology 20170501 |
| Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. | Oncotarget 20161129 |
| Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells. | Toxicological sciences : an official journal of the Society of Toxicology 20160501 |
| Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation. | Toxicology in vitro : an international journal published in association with BIBRA 20160301 |
| Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells. | Chemico-biological interactions 20151205 |
| Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells. | Chemico-biological interactions 20150525 |
| Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells. | Oncogene 20141113 |
| Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. | Chemico-biological interactions 20140805 |
| Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. | Haematologica 20140701 |
| Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. | Toxicology and applied pharmacology 20140115 |
| Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. | Cancer science 20140101 |
| Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment. | PloS one 20140101 |
| VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia. | Hematology (Amsterdam, Netherlands) 20131101 |
| Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. | Experimental biology and medicine (Maywood, N.J.) 20130801 |
| Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130501 |
| A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. | Clinical cancer research : an official journal of the American Association for Cancer Research 20130201 |
| Role of platelet-derived growth factor in cerebral vasospasm after subarachnoid hemorrhage in rats. | Acta neurochirurgica. Supplement 20130101 |
| Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib. | Investigational new drugs 20121201 |
| Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. | Medical oncology (Northwood, London, England) 20121201 |
| Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. | Leukemia & lymphoma 20121201 |
| Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. | Leukemia & lymphoma 20121201 |
| Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. | Leukemia & lymphoma 20121201 |
| Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges. | Cancer letters 20121201 |
| Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells. | Leukemia research 20121201 |
| Pathways in pulmonary arterial hypertension: the future is here. | European respiratory review : an official journal of the European Respiratory Society 20121201 |
| Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib. | Molecular pharmaceutics 20121105 |
| Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia. | Molecular pharmaceutics 20121105 |
| Site-specific cleavage of mutant ABL mRNA by DNAzyme is facilitated by peptide nucleic acid binding to RNA substrate. | FEBS letters 20121102 |
| Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. | Pediatric blood & cancer 20121101 |
| Suicide attempt with an overdose of imatinib. | British journal of clinical pharmacology 20121101 |
| Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib. | Pediatric blood & cancer 20121101 |
| Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients. | The Journal of surgical research 20121101 |
| Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor. | Annals of hematology 20121101 |
| Constitutive activation of c-Abl/protein kinase C-δ/Fli1 pathway in dermal fibroblasts derived from patients with localized scleroderma. | The British journal of dermatology 20121101 |
| Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes. | Annals of hematology 20121101 |
| Determination of imatinib mesylate and related compounds by field amplified sample stacking with large volume sample injection capillary electrophoresis. | Journal of pharmaceutical and biomedical analysis 20121101 |
| Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. | Molecular and cellular biochemistry 20121101 |
| Adjuvant therapy in primary GIST: state-of-the-art. | Annals of oncology : official journal of the European Society for Medical Oncology 20121101 |
| Measurement of imatinib uptake by flow cytometry. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20121101 |
| Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. | The American journal of pathology 20121101 |
| In vitro efficacy of the anticancer drug imatinib on Echinococcus multilocularis larvae. | International journal of antimicrobial agents 20121101 |
| The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. | Japanese journal of clinical oncology 20121101 |
| Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. | Expert opinion on pharmacotherapy 20121101 |
| Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis? | Expert opinion on investigational drugs 20121101 |
| ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan. | Genetic testing and molecular biomarkers 20121101 |
| Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans: is sustained partial remission possible? | European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20121101 |
| Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. | Nature chemical biology 20121101 |
| SAMNet: a network-based approach to integrate multi-dimensional high throughput datasets. | Integrative biology : quantitative biosciences from nano to macro 20121101 |
| Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. | American journal of hematology 20121101 |
| Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis. | Journal of Zhejiang University. Science. B 20121101 |
| Adjuvant therapy for high-risk gastrointestinal stromal tumour: considerations for optimal management. | Drugs 20121022 |
| Therapeutic drug monitoring of imatinib--new data strengthen the case. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121015 |
| Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20121015 |
| Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. | Journal of immunology (Baltimore, Md. : 1950) 20121015 |
| Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS/MS assay and ultrafiltration method. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20121015 |
| Genomic Grade Index predicts postoperative clinical outcome of GIST. | British journal of cancer 20121009 |
| CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy. | Pathology oncology research : POR 20121001 |
| Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008. | Pharmacoepidemiology and drug safety 20121001 |
| Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia. | The Prostate 20121001 |
| Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. | Cancer 20121001 |
| Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. | Haematologica 20121001 |
| Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. | Leukemia & lymphoma 20121001 |
| First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. | Leukemia 20121001 |
| DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells. | Leukemia & lymphoma 20121001 |
| High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial. | Haematologica 20121001 |
| Nilotinib-associated vascular events. | Clinical lymphoma, myeloma & leukemia 20121001 |
| Nilotinib protects the murine liver from ischemia/reperfusion injury. | Journal of hepatology 20121001 |
| Philadelphia-positive acute lymphoblastic leukemia: current treatment options. | Current oncology reports 20121001 |
| Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. | Experimental hematology 20121001 |
| Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. | Leukemia 20121001 |
| Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas. | Pediatric radiology 20121001 |
| The tyrosine kinase Abl is a component of macrophage podosomes and is required for podosome formation and function. | European journal of immunology 20121001 |
| Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension. | Omics : a journal of integrative biology 20121001 |
| Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy. | Leukemia research 20121001 |
| A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. | American journal of respiratory and critical care medicine 20121001 |
| Chronic myeloid leukemia: state of the art in 2012. | Current oncology reports 20121001 |
| Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. | British journal of haematology 20121001 |
| Role of operative therapy in treatment of metastatic gastrointestinal stromal tumors. | The Journal of surgical research 20121001 |
| Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. | Annals of surgical oncology 20121001 |
| Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. | Analytical and bioanalytical chemistry 20121001 |
| Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay. | Journal of neurosurgery 20121001 |
| Case of polycythemia vera concurrent with FIP1L1-PDGFRA-positive myeloproliferative neoplasm with eosinophilia. | Cancer genetics 20121001 |
| Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20121001 |
| Imatinib mesylate (Gleevec) induced unilateral optic disc edema. | Optometry and vision science : official publication of the American Academy of Optometry 20121001 |
| Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon. | International journal of hematology 20121001 |
| C-kit-positive acute myelogenous leukemia effectively treated with imatinib: a case report and review of the literature. | Geriatrics & gerontology international 20121001 |
| Fibrous and fibrohistiocytic neoplasms: an update. | Dermatologic clinics 20121001 |
| [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations]. | Annales de dermatologie et de venereologie 20121001 |
| How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages. | Cancer letters 20120928 |
| An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. | Biochemical and biophysical research communications 20120928 |
| Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. | Blood 20120927 |
| Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. | British journal of cancer 20120904 |
| Why are patients with chronic myeloid leukaemia (non-)adherent? | British journal of cancer 20120904 |
| Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy. | Pediatric blood & cancer 20120901 |
| Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia. | Medical oncology (Northwood, London, England) 20120901 |
| Imatinib has adverse effect on growth in children with chronic myeloid leukemia. | Pediatric blood & cancer 20120901 |
| Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia. | Medical oncology (Northwood, London, England) 20120901 |
| Secondary malignancy after imatinib therapy: eight cases and review of the literature. | Leukemia & lymphoma 20120901 |
| Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors. | Leukemia 20120901 |
| Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). | Leukemia 20120901 |
| Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. | Annals of hematology 20120901 |
| Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. | European journal of clinical investigation 20120901 |
| Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations. | Journal of molecular modeling 20120901 |
| Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. | Journal of neuro-oncology 20120901 |
| CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. | Experimental hematology 20120901 |
| Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase. | Toxicological sciences : an official journal of the Society of Toxicology 20120901 |
| Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. | Experimental hematology 20120901 |
| Adjuvant therapy of gastrointestinal stromal tumors (GIST). | Current treatment options in oncology 20120901 |
| Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells. | Leukemia research 20120901 |
| The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line. | Leukemia research 20120901 |
| PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. | Cancer research 20120901 |
| Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120901 |
| Response to imatinib mesylate in patients with hypereosinophilic syndrome. | International journal of hematology 20120901 |
| Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia. | International journal of hematology 20120901 |
| Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review. | Clinical rheumatology 20120901 |
| Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. | The Lancet. Oncology 20120901 |
| Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia. | The Lancet. Oncology 20120901 |
| MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia. | Cancer genetics 20120901 |
| From chemotherapy to targeted treatment. | Annals of oncology : official journal of the European Society for Medical Oncology 20120901 |
| [Responses to treatment and switching tyrosine kinase inhibitors in gastrointestinal stromal tumor(GIST)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20120901 |
| New and established tyrosine kinase inhibitors for chronic myeloid leukemia. | Drugs of today (Barcelona, Spain : 1998) 20120901 |
| [Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells]. | Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20120901 |
| Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. | Expert review of anticancer therapy 20120901 |
| Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. | Blood 20120830 |
| Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. | Biochemical and biophysical research communications 20120824 |
| Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. | International journal of cardiology 20120823 |
| Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120815 |
| Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120815 |
| Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120815 |
| Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. | British journal of cancer 20120807 |
| Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. | Investigational new drugs 20120801 |
| Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. | Cancer treatment reviews 20120801 |
| BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. | Leukemia & lymphoma 20120801 |
| Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia. | Leukemia & lymphoma 20120801 |
| Uveal melanoma. | Cancer treatment reviews 20120801 |
| Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells. | Leukemia 20120801 |
| Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. | Journal of molecular cell biology 20120801 |
| Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. | Experimental hematology 20120801 |
| Advances in adjuvant therapy of gastrointestinal stromal tumors. | Current oncology reports 20120801 |
| A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib. | Leukemia research 20120801 |
| Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management. | Expert review of anticancer therapy 20120801 |
| Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. | The Journal of pathology 20120801 |
| Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome. | American journal of hematology 20120801 |
| Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. | British journal of haematology 20120801 |
| Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. | Molecular cancer therapeutics 20120801 |
| Chronic eosinophilic leukemia presenting with mouth and penile ulcers. | The American journal of medicine 20120801 |
| Erythroid differentiation-associated gene interacts with NPM1 (nucleophosmin/B23) and increases its protein stability, resisting cell apoptosis. | The FEBS journal 20120801 |
| The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. | Molecular cancer therapeutics 20120801 |
| [Protein tyrosine kinase inhibitors in cancer therapy]. | Pathologie-biologie 20120801 |
| [Chronic myeloid leukemia: 'archetype' of the impact of targeted therapies]. | Pathologie-biologie 20120801 |
| Nonaqueous capillary electrophoresis of imatinib mesylate and related substances. | Journal of separation science 20120801 |
| Label-free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance. | Proteomics 20120801 |
| A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. | Cytotherapy 20120801 |
| Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain. | Clinical therapeutics 20120801 |
| Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20120801 |
| Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence. | Cell death & disease 20120801 |
| Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. | Pharmacogenomics 20120801 |
| Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates. | Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 20120801 |
| Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy. | Texas dental journal 20120801 |
| The role of surgery in the multidisciplinary management of patients with localized gastrointestinal stromal tumors. | Expert review of anticancer therapy 20120801 |
| Intellectual property. Challenges to India's pharmaceutical patent laws. | Science (New York, N.Y.) 20120727 |
| Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. | Blood 20120726 |
| Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. | Blood 20120726 |
| Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function. | Journal of agricultural and food chemistry 20120718 |
| Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction. | Journal of clinical pharmacology 20120701 |
| Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. | Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20120701 |
| Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons. | Leukemia & lymphoma 20120701 |
| Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. | Veterinary journal (London, England : 1997) 20120701 |
| Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors. | Leukemia & lymphoma 20120701 |
| Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. | Leukemia & lymphoma 20120701 |
| Exploiting antitumor immunity to overcome relapse and improve remission duration. | Cancer immunology, immunotherapy : CII 20120701 |
| Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers. | Neurotoxicity research 20120701 |
| First-line treatment with imatinib mesylate in patients with chronic phase chronic myeloid leukemia: experience of a public hospital in a developing country of South America. | Leukemia & lymphoma 20120701 |
| Skin fragility and blistering secondary to imatinib. | Clinical and experimental dermatology 20120701 |
| Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. | Leukemia 20120701 |
| Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. | Haematologica 20120701 |
| Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. | Leukemia 20120701 |
| Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20120701 |
| Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. | Annals of oncology : official journal of the European Society for Medical Oncology 20120701 |
| Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120701 |
| Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. | American journal of hematology 20120701 |
| Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. | Leukemia & lymphoma 20120701 |
| Stability-indicating UPLC method for determination of Imatinib Mesylate and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. | Journal of pharmaceutical and biomedical analysis 20120701 |
| Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate. | Liver international : official journal of the International Association for the Study of the Liver 20120701 |
| Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. | Current opinion in oncology 20120701 |
| Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors: long-term follow-up and second malignancy. | Japanese journal of clinical oncology 20120701 |
| Adjuvant therapy of gastrointestinal stromal tumors. | Current opinion in oncology 20120701 |
| Pigmented villonodular synovitis therapy with MSCF-1 inhibitors. | Current opinion in oncology 20120701 |
| Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma. | Oncology reports 20120701 |
| Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. | European journal of haematology 20120701 |
| Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. | International journal of hematology 20120701 |
| Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120701 |
| Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors. | The oncologist 20120701 |
| Novel role for prepatterned nicotinic acetylcholine receptors during myogenesis. | Muscle & nerve 20120701 |
| Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells. | Thyroid : official journal of the American Thyroid Association 20120701 |
| 'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors. | The American journal of pathology 20120701 |
| Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia. | Acta pharmacologica Sinica 20120701 |
| Imatinib mesylate alleviates diarrhea in a mouse model of intestinal allergy. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20120701 |
| Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. | Journal of the American College of Surgeons 20120701 |
| A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. | Current medical research and opinion 20120701 |
| Apoptotic effects of resveratrol, a grape polyphenol, on imatinib-sensitive and resistant K562 chronic myeloid leukemia cells. | Anticancer research 20120701 |
| Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT. | Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20120701 |
| Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. | Chinese medical journal 20120701 |
| Dengue virus infection in a patient with chronic myeloid leukemia. | The Southeast Asian journal of tropical medicine and public health 20120701 |
| Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. | Cancer 20120615 |
| Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. | Biochemical pharmacology 20120615 |
| Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia. | Gene 20120615 |
| Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors. | Journal of gastrointestinal cancer 20120601 |
| Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. | Medical oncology (Northwood, London, England) 20120601 |
| Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy. | Medical oncology (Northwood, London, England) 20120601 |
| Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients. | Medical oncology (Northwood, London, England) 20120601 |
| Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. | Medical oncology (Northwood, London, England) 20120601 |
| Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. | Hematological oncology 20120601 |
| Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120601 |
| Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. | Critical reviews in oncology/hematology 20120601 |
| Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. | Journal of cellular physiology 20120601 |
| Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. | Journal of gastrointestinal cancer 20120601 |
| Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. | Bone marrow transplantation 20120601 |
| Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120601 |
| Allogeneic hematopoietic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in children and adolescents: a retrospective multicenter study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120601 |
| Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. | Leukemia 20120601 |
| Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. | Haematologica 20120601 |
| Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. | Haematologica 20120601 |
| Mucosal pigmentation caused by imatinib: report of three cases. | Head and neck pathology 20120601 |
| Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. | Leukemia & lymphoma 20120601 |
| Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. | Annals of hematology 20120601 |
| Clinical cardiac safety profile of nilotinib. | Haematologica 20120601 |
| Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors. | Leukemia 20120601 |
| c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1. | Angiogenesis 20120601 |
| A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20120601 |
| Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. | Cancer chemotherapy and pharmacology 20120601 |
| BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. | Molecular and cellular biochemistry 20120601 |
| Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. | Cancer science 20120601 |
| Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. | Gynecologic oncology 20120601 |
| Management of chronic myeloid leukemia in childhood. | Current hematologic malignancy reports 20120601 |
| Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. | Leukemia research 20120601 |
| Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib. | Clinical and experimental dermatology 20120601 |
| Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia. | Clinical lymphoma, myeloma & leukemia 20120601 |
| Clinical trials in chronic myeloid leukemia. | Current hematologic malignancy reports 20120601 |
| Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib. | Leukemia research 20120601 |
| Antenatal imatinib treatment reduces pulmonary vascular remodeling in a rat model of congenital diaphragmatic hernia. | American journal of physiology. Lung cellular and molecular physiology 20120601 |
| Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. | Journal of molecular endocrinology 20120601 |
| Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. | Molecular diagnosis & therapy 20120601 |
| A potential role for nilotinib in KIT-mutated melanoma. | Expert opinion on investigational drugs 20120601 |
| Role of Src tyrosine kinases in experimental pulmonary hypertension. | Arteriosclerosis, thrombosis, and vascular biology 20120601 |
| Intervention in gastrointestinal stromal tumour with a high risk of malignancy and associated with thalassaemia minor. | Anti-cancer drugs 20120601 |
| Complete response in a melanoma patient treated with imatinib. | The Journal of laryngology and otology 20120601 |
| Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era. | Frontiers of medicine 20120601 |
| Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120601 |
| Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature. | Journal of pediatric surgery 20120601 |
| [Long-term progression-free survival after reduction surgery and postoperative low-dose imatinib administration for multiple liver metastases of duodenal gastrointestinal stromal tumor]. | Gan to kagaku ryoho. Cancer & chemotherapy 20120601 |
| Resected duodenal gastrointestinal stromal tumour with an affected margin and exon 9 mutation: adjuvant therapy. | Anti-cancer drugs 20120601 |
| Haemoperitoneum as an indicator of GIST. | Anti-cancer drugs 20120601 |
| Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour. | Anti-cancer drugs 20120601 |
| Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib. | Anti-cancer drugs 20120601 |
| Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy? | Anti-cancer drugs 20120601 |
| Clinical management of the hypereosinophilic syndromes. | Expert review of hematology 20120601 |
| [Long-term outcomes of nilotinib treatment for chronic myelogenous leukemia patients with imatinib resistance or intolerance]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20120601 |
| [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib]. | Zhonghua bing li xue za zhi = Chinese journal of pathology 20120601 |
| Extra-gastrointestinal stromal tumor of the pelvic cavity: case report. | Medical molecular morphology 20120601 |
| [Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia]. | Zhonghua yi xue za zhi 20120529 |
| Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors. | World journal of gastroenterology 20120528 |
| Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. | British journal of cancer 20120522 |
| [A new genetic diagnosis of familiar gastrointestinal stromal tumour]. | Ugeskrift for laeger 20120521 |
| Chronic myeloid leukemia: the race is yet to be won. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20120515 |
| EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. | Blood 20120510 |
| BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. | Blood 20120503 |
| Novel molecular targeted therapies for refractory thyroid cancer. | Head & neck 20120501 |
| Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex. | Journal of molecular modeling 20120501 |
| An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report. | Annals of hematology 20120501 |
| Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. | Leukemia 20120501 |
| Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. | Leukemia & lymphoma 20120501 |
| Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study. | Annals of hematology 20120501 |
| Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. | Annals of surgical oncology 20120501 |
| Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. | Leukemia 20120501 |
| Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. | Leukemia 20120501 |
| Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation. | British journal of haematology 20120501 |
| Stakeholder involvement in expensive drug recommendation decisions: an international perspective. | Health policy (Amsterdam, Netherlands) 20120501 |
| Predictors of response to targeted therapies for gastrointestinal stromal tumors. | Archives of pathology & laboratory medicine 20120501 |
| ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. | Experimental hematology 20120501 |
| Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. | British journal of haematology 20120501 |
| Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. | Haematologica 20120501 |
| BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. | British journal of haematology 20120501 |
| Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients. | Current cancer drug targets 20120501 |
| Imatinib resistance due to a novel tri-nucleotide insertion in the SH2/C lobe interface of BCR/ABL kinase domain between position K357 and N358. | Leukemia research 20120501 |
| Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression. | Pharmacogenetics and genomics 20120501 |
| Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. | American journal of hematology 20120501 |
| Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review. | Japanese journal of clinical oncology 20120501 |
| Pulmonary arterial hypertension in patients treated by dasatinib. | Circulation 20120501 |
| Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. | International journal of hematology 20120501 |
| Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study. | Current medical research and opinion 20120501 |
| [A case of long survival after resection and treatment with imatinib mesylate against metachronous liver metastases and a lung metastasis of a small intestine gastrointestinal stromal tumor]. | Gan to kagaku ryoho. Cancer & chemotherapy 20120501 |
| microRNA 30A promotes autophagy in response to cancer therapy. | Autophagy 20120501 |
| Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. | Discovery medicine 20120501 |
| A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells. | Oncotarget 20120501 |
| Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. | Future oncology (London, England) 20120501 |
| Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome. | The Medical clinics of North America 20120501 |
| PAR-2 inhibition reverses experimental pulmonary hypertension. | Circulation research 20120427 |
| Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. | Blood 20120426 |
| Adjuvant treatment of GIST: patient selection and treatment strategies. | Nature reviews. Clinical oncology 20120424 |
| Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120420 |
| Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. | Cancer cell 20120417 |
| Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. | Blood 20120412 |
| N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. | Journal of proteome research 20120406 |
| Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. | Cell stem cell 20120406 |
| Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. | Investigational new drugs 20120401 |
| Systemic mastocytosis presenting with acute oliguric renal failure: report of a case and review of the literature. | International urology and nephrology 20120401 |
| A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20120401 |
| Chronic myeloproliferative disorder with ETV6-PDGFRβ fusion gene. | Annals of hematology 20120401 |
| Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. | Leukemia 20120401 |
| Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib. | Leukemia 20120401 |
| Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. | British journal of pharmacology 20120401 |
| Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. | Leukemia 20120401 |
| Therapy-related acute leukemia with mixed phenotype and t(9;22)(q32;q11.2): a case report and review of the literature. | Human pathology 20120401 |
| Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. | Leukemia research 20120401 |
| Quantification of kinase activity in cell lysates via photopatterned macroporous poly(ethylene glycol) hydrogel arrays in microfluidic channels. | Biomedical microdevices 20120401 |
| Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. | British journal of haematology 20120401 |
| Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. | Cancer chemotherapy and pharmacology 20120401 |
| Treatment of chordoma with imatinib complicated by intracranial hemorrhage: a case showing dissociation between biological effect and therapeutic outcome. | Journal of neuro-oncology 20120401 |
| Characterization of binding mode of imatinib to human α1-acid glycoprotein. | International journal of biological macromolecules 20120401 |
| Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. | Acta oncologica (Stockholm, Sweden) 20120401 |
| Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. | Annals of surgical oncology 20120401 |
| The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. | Annals of surgical oncology 20120401 |
| Alternative splicing of apoptosis-related genes in imatinib-treated K562 cells identified by exon array analysis. | International journal of molecular medicine 20120401 |
| Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation. | Toxicology in vitro : an international journal published in association with BIBRA 20120401 |
| The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line. | Leukemia research 20120401 |
| Molecular resistance: an early indicator for treatment change? | Clinical lymphoma, myeloma & leukemia 20120401 |
| Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients. | American journal of hematology 20120401 |
| Imatinib mesylate prevents cerebral vasospasm after subarachnoid hemorrhage via inhibiting tenascin-C expression in rats. | Neurobiology of disease 20120401 |
| BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients. | Experimental and molecular pathology 20120401 |
| Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery. | World journal of surgery 20120401 |
| Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway. | ChemMedChem 20120401 |
| Updates on the management of gastrointestinal stromal tumors. | Surgical oncology clinics of North America 20120401 |
| Intracranial metastasis from pediatric GI stromal tumor. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120401 |
| Gastrointestinal stromal tumor arising in the rectovaginal septum. | Journal of lower genital tract disease 20120401 |
| ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120401 |
| Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway. | Acta pharmacologica Sinica 20120401 |
| Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure. | American journal of hematology 20120401 |
| Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation. | Pathology 20120401 |
| Is there something other than imatinib mesilate in therapeutic options for GIST? | Expert opinion on therapeutic targets 20120401 |
| Chronic myelogenous leukemia for primary care physicians. | Disease-a-month : DM 20120401 |
| Treatment of hypereosinophilic syndromes--the first 100 years. | Seminars in hematology 20120401 |
| Gastrointestinal stromal tumors treatment in the Imatinib era. The role of fair indication. | Minerva chirurgica 20120401 |
| Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). | Anticancer research 20120401 |
| CML treatment in Asia-Pacific region. | Hematology (Amsterdam, Netherlands) 20120401 |
| Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome. | Archives of dermatology 20120401 |
| Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. | Klinische Padiatrie 20120401 |
| [Suppression of NAMPT expression enhances the sensitivity of K562 cells to imatinib and its relative mechanism]. | Zhongguo shi yan xue ye xue za zhi 20120401 |
| [Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20120401 |
| [A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-α]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120401 |
| Oxaliplatin-induced lung toxicity. Case report and review of the literature. | Current drug safety 20120401 |
| Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor. | Blood 20120329 |
| One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. | JAMA 20120328 |
| Optimal duration of adjuvant therapy for patients with resected gastrointestinal stromal tumors. | JAMA 20120328 |
| NICE backs leukaemia drug after manufacturer drops price. | BMJ (Clinical research ed.) 20120322 |
| The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120320 |
| Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120320 |
| Phase II study of imatinib in advanced chordoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120320 |
| Detection of early Abl kinase activation after ionizing radiation by using a peptide biosensor. | Chembiochem : a European journal of chemical biology 20120319 |
| GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells. | Oncogene 20120315 |
| Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. | Cancer 20120315 |
| KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120315 |
| Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. | Blood cells, molecules & diseases 20120315 |
| Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib. | Experimental cell research 20120310 |
| Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. | Blood 20120308 |
| Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. | Blood 20120308 |
| FDA updates Gleevec label for GIST patients. | Journal of the National Cancer Institute 20120307 |
| BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? | Medical oncology (Northwood, London, England) 20120301 |
| Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression. | International journal of cancer 20120301 |
| Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. | Hematological oncology 20120301 |
| Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia. | Leukemia & lymphoma 20120301 |
| NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. | Leukemia 20120301 |
| Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. | Leukemia research 20120301 |
| Characterization of novel germline c-kit gene mutation, KIT-Tyr553Cys, observed in a family with multiple gastrointestinal stromal tumors. | Laboratory investigation; a journal of technical methods and pathology 20120301 |
| Imatinib does not impair gonadal function. | Leukemia research 20120301 |
| Small intestine gastrointestinal stromal tumors. | Current opinion in gastroenterology 20120301 |
| In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib. | Oncology reports 20120301 |
| Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. | Angiogenesis 20120301 |
| Current treatment strategies in chronic myeloid leukemia. | Current opinion in hematology 20120301 |
| Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. | Blood 20120301 |
| Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy. | The Journal of clinical endocrinology and metabolism 20120301 |
| MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. | Pharmacogenetics and genomics 20120301 |
| Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutations. | Clinical biochemistry 20120301 |
| Imatinib: the controversial discussion on cardiotoxicity induced by endoplasmic reticulum (ER) stress. | Archives of toxicology 20120301 |
| Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. | Clinical pharmacokinetics 20120301 |
| Blockade of PDGFR-β activation eliminates morphine analgesic tolerance. | Nature medicine 20120301 |
| Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | Expert review of anticancer therapy 20120301 |
| [Treatment of recurrent or metastatic gastrointestinal stromal tumor: surgery or not]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20120301 |
| [Clinical analysis of imatinib in patients with advanced gastrointestinal stromal tumor]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20120301 |
| [Prognosis analysis of 216 cases of gastrointestinal stromal tumor]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20120301 |
| [Therapeutic effect of in vitro 5-aza-2'-deoxycytidine combined with imatinib on gastrointestinal stromal tumor]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20120301 |
| [Resistance and treatment strategy of gastrointestinal stromal tumor target therapy]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20120301 |
| Bosutinib for the treatment of chronic myeloid leukemia in chronic phase. | Drugs of today (Barcelona, Spain : 1998) 20120301 |
| The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia. | Cancer genetics 20120301 |
| FDA grants imatinib (Gleevec) full approval for adjuvant treatment of GIST. | Oncology (Williston Park, N.Y.) 20120301 |
| Development, characterization and in vitro evaluation of single or co-loaded imatinib mesylate liposomal formulations. | Journal of nanoscience and nanotechnology 20120301 |
| [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20120301 |
| [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120301 |
| [Analysis of plasma trough level of imatinib in Chinese CML patients]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120301 |
| [The effects of imatinib mesylate on immune globulin and T cell subset in patients with chronic myelocytic leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120301 |
| Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. | Blood 20120223 |
| Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. | Blood 20120223 |
| How I treat childhood CML. | Blood 20120223 |
| Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. | World journal of gastroenterology 20120221 |
| Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. | International journal of cancer 20120215 |
| ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. | Blood cells, molecules & diseases 20120215 |
| Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. | Cancer cell 20120214 |
| Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases. | Journal of controlled release : official journal of the Controlled Release Society 20120210 |
| HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). | Journal of pharmaceutical and biomedical analysis 20120205 |
| Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). | Blood 20120202 |
| Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. | Investigational new drugs 20120201 |
| ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours. | Journal of cellular and molecular medicine 20120201 |
| Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. | Modern rheumatology 20120201 |
| [KIT and KIT: from biology to clinical use]. | Bulletin du cancer 20120201 |
| Imatinib mesylate in thymic epithelial malignancies. | Cancer chemotherapy and pharmacology 20120201 |
| Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. | Leukemia research 20120201 |
| Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib. | Leukemia & lymphoma 20120201 |
| KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. | Leukemia 20120201 |
| Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. | Journal of cellular and molecular medicine 20120201 |
| The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. | Cancer immunology, immunotherapy : CII 20120201 |
| Conformational polymorphism on imatinib mesylate: grinding effects. | Journal of pharmaceutical sciences 20120201 |
| Treatment of polycythemia vera with imatinib mesylate. | Leukemia research 20120201 |
| Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia. | International journal of oncology 20120201 |
| Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120201 |
| Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20120201 |
| Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. | Journal of cancer research and clinical oncology 20120201 |
| Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. | Chinese journal of cancer 20120201 |
| Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. | Carcinogenesis 20120201 |
| Major response to everolimus in melanoma with acquired imatinib resistance. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201 |
| Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. | Current medical research and opinion 20120201 |
| Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia. | Cytokine 20120201 |
| Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate. | Photodermatology, photoimmunology & photomedicine 20120201 |
| An automated analysis of highly complex flow cytometry-based proteomic data. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20120201 |
| The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. | Therapeutic drug monitoring 20120201 |
| PDGF receptor blocker for pulmonary hypertension: a new agent in therapeutic arsenal. | Expert opinion on investigational drugs 20120201 |
| Pediatric gastrointestinal stromal tumor. | Seminars in pediatric surgery 20120201 |
| Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa. | International journal of hematology 20120201 |
| Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. | Clinical therapeutics 20120201 |
| [A case of bleeding giant gastrointestinal stromal tumor of the stomach who achieved partial response by chemotherapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20120201 |
| The case of the harmful herbs. | ONS connect 20120201 |
| NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib. | The Lancet. Oncology 20120201 |
| Trial by media. | The Lancet. Oncology 20120201 |
| [Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20120201 |
| [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120201 |
| C-Kit controls IL-1β-induced effector functions in HMC-cells. | European journal of pharmacology 20120130 |
| BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. | Nature chemical biology 20120129 |
| Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120 |
| Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120120 |
| β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. | Oncogene 20120119 |
| Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. | Cancer cell 20120117 |
| Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. | Cancer 20120115 |
| The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. | Cancer 20120115 |
| Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. | Blood 20120112 |
| SSc in 2011: From mechanisms to medicines. | Nature reviews. Rheumatology 20120110 |
| Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD. | Bone marrow transplantation 20120101 |
| Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294. | Annals of hematology 20120101 |
| [Survival following liver transplant due to imatinib-induced acute liver failure: a case study]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101 |
| The safety profile of imatinib in CML and GIST: long-term considerations. | Archives of toxicology 20120101 |
| Incorporation of adjuvant therapy into the multimodality management of gastrointestinal stromal tumors of the stomach in the United States. | Annals of surgical oncology 20120101 |
| Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. | Cancer 20120101 |
| Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. | Leukemia 20120101 |
| Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients. | Leukemia 20120101 |
| Methyl-β-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling. | Anti-cancer drugs 20120101 |
| Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. | Journal of biochemistry 20120101 |
| Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate. | American journal of hematology 20120101 |
| Validation of the 'French Acute Lymphoblastic Leukaemia Study Group FRALLE prognostic index' for paediatric Philadelphia-chromosome acute lymphoblastic leukaemia. | British journal of haematology 20120101 |
| The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells. | Anti-cancer drugs 20120101 |
| Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. | Journal of neuro-oncology 20120101 |
| Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance. | Cancer science 20120101 |
| Optical, structural and thermodynamic studies of the association of an anti-leucamic drug imatinib mesylate with transport protein. | Journal of fluorescence 20120101 |
| Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib. | Leukemia research 20120101 |
| Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. | Arthritis and rheumatism 20120101 |
| Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension. | American journal of physiology. Renal physiology 20120101 |
| Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20120101 |
| Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. | Acta haematologica 20120101 |
| Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. | Journal of bone and mineral metabolism 20120101 |
| Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro. | Oncology reports 20120101 |
| Bone marrow necrosis secondary to imatinib usage, mimicking spinal metastasis on magnetic resonance imaging and FDG-PET/CT. | Journal of neurosurgery. Spine 20120101 |
| The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. | Annual review of medicine 20120101 |
| Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. | The Journal of clinical endocrinology and metabolism 20120101 |
| Imatinib mesylate for the treatment of pulmonary arterial hypertension. | Expert opinion on investigational drugs 20120101 |
| Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia. | Acta haematologica 20120101 |
| Gastrointestinal stromal tumors of the stomach. | Surgical oncology clinics of North America 20120101 |
| Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457. | British journal of haematology 20120101 |
| Quantitative assessment of Ras over-expression via shotgun deployment of vectors utilizing synthetic promoters. | Integrative biology : quantitative biosciences from nano to macro 20120101 |
| Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML). | Pathology 20120101 |
| [Acquired ichthyosis and haematological malignancies: five cases]. | Annales de dermatologie et de venereologie 20120101 |
| Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. | Acta haematologica 20120101 |
| International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India. | Acta haematologica 20120101 |
| An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia. | Singapore medical journal 20120101 |
| Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture. | The American surgeon 20120101 |
| Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML. | Acta haematologica 20120101 |
| Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders. | Onkologie 20120101 |
| Imatinib sensitizes T-cell lymphocytes from chronic myeloid leukemia patients to FasL-induced cell death: a brief communication. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20120101 |
| The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia. | Progress in molecular biology and translational science 20120101 |
| Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. | PloS one 20120101 |
| [Myeloproliferative neoplasms (including chronic myeloid leukemia)]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20120101 |
| Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib. | Chemotherapy 20120101 |
| Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry. | BMC cancer 20120101 |
| The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. | BMC cancer 20120101 |
| Gastrointestinal stromal tumors (GIST): a single center experience. | Acta chirurgica Belgica 20120101 |
| Therapeutic implications of KIT in melanoma. | Cancer journal (Sudbury, Mass.) 20120101 |
| STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death. | Journal of biomedical science 20120101 |
| Gastrointestinal stromal tumors: diagnosis and treatment. | Cirugia y cirujanos 20120101 |
| Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients. | Acta haematologica 20120101 |
| Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. | PloS one 20120101 |
| [Current therapy of chronic myeloid leukemia]. | Duodecim; laaketieteellinen aikakauskirja 20120101 |
| Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. | Acta haematologica 20120101 |
| Imatinib-induced anasarca without heart failure: capillary leakage? | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20120101 |
| Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL. | PloS one 20120101 |
| 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review. | Clinical imaging 20120101 |
| Esophageal gastrointestinal stromal tumor: report of 7 patients. | Cancer imaging : the official publication of the International Cancer Imaging Society 20120101 |
| Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20120101 |
| Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20120101 |
| Imatinib mesylate induced erythroderma. | Indian journal of dermatology, venereology and leprology 20120101 |
| [Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120101 |
| [Progress in the study of plasma-drug concentration of imatinib for treatment of chronic myeloid leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20120101 |
| Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). | BMC cancer 20120101 |
| Current management of gastrointestinal stromal tumors--a comprehensive review. | International journal of surgery (London, England) 20120101 |
| p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. | PloS one 20120101 |
| LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells. | PloS one 20120101 |
| High-risk CD117-positive gastrointestinal stromal tumor of the colon in a 12-year-old girl: adjuvant treatment with imatinib mesylate. | Tumori 20120101 |
| Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. | Journal of hematology & oncology 20120101 |
| Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. | Clinical and experimental rheumatology 20120101 |
| Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformation. | PloS one 20120101 |
| Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? | World journal of surgical oncology 20120101 |
| Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy. | Acta haematologica 20120101 |
| Imatinib enhances functional outcome after spinal cord injury. | PloS one 20120101 |
| A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate. | Internal medicine (Tokyo, Japan) 20120101 |
| Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. | PloS one 20120101 |
| Optimizing second-line therapy for chronic myeloid leukemia. | Indian journal of cancer 20120101 |
| Effect of plasma membrane cholesterol depletion on glucose transport regulation in leukemia cells. | PloS one 20120101 |
| The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib. | PloS one 20120101 |
| Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. | PloS one 20120101 |
| Platelet-derived growth factor over-expression in retinal progenitors results in abnormal retinal vessel formation. | PloS one 20120101 |
| Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines. | BMC medical genomics 20120101 |
| Affinity purification of protein kinases that adopt a specific inactive conformation. | Methods in molecular biology (Clifton, N.J.) 20120101 |
| An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents. | Methods in molecular biology (Clifton, N.J.) 20120101 |
| Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. | Internal medicine (Tokyo, Japan) 20120101 |
| Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia. | Journal of clinical and experimental hematopathology : JCEH 20120101 |
| α-bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib. | PloS one 20120101 |
| α6 Integrin and CD44 enrich for a primary keratinocyte population that displays resistance to UV-induced apoptosis. | PloS one 20120101 |
| Pancreatic extra-gastrointestinal stromal tumour masquerading as a bleeding duodenal mass. | BMJ case reports 20120101 |
| [True polycythemia: current views of pathogenesis, diagnostics and treatment]. | Klinicheskaia meditsina 20120101 |
| Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase. | Journal of chemical information and modeling 20111227 |
| Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients. | Cancer letters 20111222 |
| Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor. | Cancer letters 20111215 |
| Roth spots in chronic myelogenous leukemia. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20111213 |
| Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. | Cancer cell 20111213 |
| β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. | Cancer cell 20111213 |
| Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS). | Journal of proteomics 20111210 |
| Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni. | The Journal of biological chemistry 20111209 |
| Tyrosine kinase inhibitors in hematological malignancies. | Postepy higieny i medycyny doswiadczalnej (Online) 20111205 |
| Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition. | Journal of clinical pharmacy and therapeutics 20111201 |
| Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study. | The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... 20111201 |
| Management of recurrent gastrointestinal stromal tumors. | Journal of surgical oncology 20111201 |
| Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors. | International journal of clinical oncology 20111201 |
| Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications. | Cancer 20111201 |
| Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. | International journal of cancer 20111201 |
| t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemia. | Human pathology 20111201 |
| Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. | Journal of surgical oncology 20111201 |
| Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. | Journal of clinical immunology 20111201 |
| Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. | Haematologica 20111201 |
| Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111201 |
| Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells. | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20111201 |
| The effects of chemotherapeutic agents on differentiated chordoma cells. | Journal of neurosurgery. Spine 20111201 |
| A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. | Toxicologic pathology 20111201 |
| Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice. | Inflammopharmacology 20111201 |
| Third-line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: case report. | The journal of obstetrics and gynaecology research 20111201 |
| The effects of the c-kit blocker glivec on the contractile response of urinary bladder. | The Journal of surgical research 20111201 |
| Is IL-4 a potential therapeutic target in systemic sclerosis-associated pulmonary fibrosis? | Clinical immunology (Orlando, Fla.) 20111201 |
| Synthesis and apoptosis inducing ability of new anilino substituted pyrimidine sulfonamides as potential anticancer agents. | European journal of medicinal chemistry 20111201 |
| Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. | Clinical immunology (Orlando, Fla.) 20111201 |
| Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma. | International immunopharmacology 20111201 |
| Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors. | Bioorganic & medicinal chemistry letters 20111201 |
| Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. | International journal of hematology 20111201 |
| Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. | Journal of surgical oncology 20111201 |
| Adjuvant imatinib therapy for gastrointestinal stromal tumors. | Journal of surgical oncology 20111201 |
| Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. | Journal of surgical oncology 20111201 |
| Mechanism of action of the multikinase inhibitor Foretinib. | Cell cycle (Georgetown, Tex.) 20111201 |
| Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes. | Cell cycle (Georgetown, Tex.) 20111201 |
| When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201 |
| Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201 |
| PDGFR-α inhibition preserves blood-brain barrier after intracerebral hemorrhage. | Annals of neurology 20111201 |
| Bilateral hip pain caused by adductor pyomyositis as the initial presentation of chronic myeloid leukemia in a 17-year-old child. | Pediatrics and neonatology 20111201 |
| [Inhibitory effect of 4-chlorobenzoyl berbamine on imatinib-resistant K562 cells in vitro and in vivo]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20111201 |
| Imatinib in chronic myeloid leukemia elderly patients. | Aging 20111201 |
| Sorafenib: muscle wasting. | Prescrire international 20111201 |
| AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders. | Oncotarget 20111201 |
| Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate. | Cancer genetics 20111201 |
| [Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20111201 |
| Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis. | European journal of pharmacology 20111130 |
| Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. | Cancer letters 20111128 |
| Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111120 |
| Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. | Blood 20111117 |
| Gastrointestinal stromal tumours: origin and molecular oncology. | Nature reviews. Cancer 20111117 |
| Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. | Cell host & microbe 20111117 |
| Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111115 |
| Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response. | Blood 20111110 |
| The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | Blood 20111110 |
| Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111110 |
| N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl. | ChemMedChem 20111104 |
| Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia. | Annals of hematology 20111101 |
| A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. | Annals of oncology : official journal of the European Society for Medical Oncology 20111101 |
| In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells. | Leukemia research 20111101 |
| Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia. | Leukemia & lymphoma 20111101 |
| Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. | Leukemia & lymphoma 20111101 |
| Abnormal elevated PTEN expression in the mouse antrum of a model of GIST Kit(K641E/K641E). | Cellular signalling 20111101 |
| Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis? | Arthritis and rheumatism 20111101 |
| A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. | Arthritis and rheumatism 20111101 |
| Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. | Arthritis and rheumatism 20111101 |
| Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment. | Cancer science 20111101 |
| Transanal endoscopic microsurgery after neoadjuvant therapy for rectal GIST. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20111101 |
| Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. | The journal of obstetrics and gynaecology research 20111101 |
| Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro. | Oncology reports 20111101 |
| Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. | European journal of haematology 20111101 |
| Hedgehog signalling promotes germ cell survival in the rat testis. | Reproduction (Cambridge, England) 20111101 |
| BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111101 |
| Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells. | Journal of cellular physiology 20111101 |
| Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111101 |
| Managing resistance in chronic myeloid leukemia. | Blood reviews 20111101 |
| Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. | The American journal of surgical pathology 20111101 |
| HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. | Cancer research 20111101 |
| Successful treatment of mast cell sarcoma of the uterus with imatinib. | International journal of hematology 20111101 |
| Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients. | Archives of Iranian medicine 20111101 |
| Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. | Oncotarget 20111101 |
| AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients. | Hematology (Amsterdam, Netherlands) 20111101 |
| [Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib]. | Vojnosanitetski pregled 20111101 |
| [Three cases of giant rectal gastrointestinal stromal tumor]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [A case of ruptured gastrointestinal stromal tumor of the duodenum with intraabdominal bleeding]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [Curative resection for bulky gastrointestinal stromal tumor with conversion therapy by imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [Twenty-one-year survival case of rectal GIST treated with combined therapies]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [A case report of GIST of the small intestine with multiple liver abscesses]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [A case of gastrointestinal stromal tumor (GIST) successfully treated with resection after a long-term control medication by molecular targeted drugs]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| [Hepatic metastasis from gastric GIST radically resected after imatinib mesylate therapy-a case report]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111101 |
| Pulmonary toxicities of tyrosine kinase inhibitors. | Clinical advances in hematology & oncology : H&O 20111101 |
| Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report. | Clinical advances in hematology & oncology : H&O 20111101 |
| Recommendations for the management of adult chronic myeloid leukaemia in South Africa. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20111101 |
| Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. | Blood 20111027 |
| Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. | Blood 20111027 |
| CML: live long and prosper. | Blood 20111027 |
| Direct, metal-free amination of heterocyclic amides/ureas with NH-heterocycles and N-substituted anilines in POCl3. | The Journal of organic chemistry 20111021 |
| Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. | Blood 20111020 |
| Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. | Cancer 20111015 |
| Optimization of the simultaneous determination of imatinib and its major metabolite, CGP74588, in human plasma by a rapid HPLC method using D-optimal experimental design. | Talanta 20111015 |
| Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. | Cell 20111014 |
| Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. | Blood 20111013 |
| A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. | Blood 20111013 |
| The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. | Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20111001 |
| Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. | The British journal of oral & maxillofacial surgery 20111001 |
| The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. | Journal of cellular and molecular medicine 20111001 |
| Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. | International journal of cancer 20111001 |
| Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia. | Leukemia research 20111001 |
| Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. | American journal of respiratory cell and molecular biology 20111001 |
| Abl interconnects oncogenic Met and p53 core pathways in cancer cells. | Cell death and differentiation 20111001 |
| Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis? | British journal of haematology 20111001 |
| Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. | British journal of haematology 20111001 |
| Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib. | Biomolecular NMR assignments 20111001 |
| Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant. | International journal of surgical pathology 20111001 |
| AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib. | Leukemia research 20111001 |
| Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. | The Journal of pediatrics 20111001 |
| A metastatic case of gastrointestinal stromal tumor (GIST) treated with imatinib mesylate (Glivec(®)) in Mali. | Clinics and research in hepatology and gastroenterology 20111001 |
| Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease. | Leukemia & lymphoma 20111001 |
| Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. | Leukemia & lymphoma 20111001 |
| Potential clinical application of imatinib mesylate in patients with leukemic large granular lymphocytes. | Leukemia & lymphoma 20111001 |
| Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: review of the literature. | Anti-cancer drugs 20111001 |
| Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20111001 |
| The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. | Molecular cancer therapeutics 20111001 |
| Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. | Journal of cancer research and clinical oncology 20111001 |
| Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue. | Urology 20111001 |
| Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities. | Japanese journal of clinical oncology 20111001 |
| Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients. | Therapeutic drug monitoring 20111001 |
| Congenital dermatofibrosarcoma protuberans in a newborn infant with a massive back tumor: favorable effects of oral imatinib on the control of residual tumor growth. | Journal of pediatric hematology/oncology 20111001 |
| Will imatinib compromise reproductive capacity? | The oncologist 20111001 |
| Practical management of imatinib in gastrointestinal stromal tumors. | Clinical journal of oncology nursing 20111001 |
| [Chronic myeloid leukemia]. | Deutsche medizinische Wochenschrift (1946) 20111001 |
| Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy. | Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 20111001 |
| Gastrointestinal stromal tumor: advances in diagnosis and management. | Archives of pathology & laboratory medicine 20111001 |
| [Current status and future perspective in imatinib therapy against CML]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20111001 |
| [Roles of the 2nd generation TKIs for CML]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20111001 |
| [A case of small intestinal GIST maintained as a long stable disease by imatinib mesylate 400 mg/day, alternate-day administration for 2 weeks followed by a 2 week interval]. | Gan to kagaku ryoho. Cancer & chemotherapy 20111001 |
| Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience. | Acta medica Okayama 20111001 |
| [Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML]. | Zhongguo shi yan xue ye xue za zhi 20111001 |
| Chronic myeloid leukemia: mechanisms of resistance and treatment. | Hematology/oncology clinics of North America 20111001 |
| Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. | Hematology/oncology clinics of North America 20111001 |
| Chronic myelogenous leukemia. Preface. | Hematology/oncology clinics of North America 20111001 |
| Clinical molecular medicine has finally arrived. | The Netherlands journal of medicine 20111001 |
| New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure. | The Netherlands journal of medicine 20111001 |
| Efficacy evaluation of imatinib in the treatment of patients with gastrointestinal stromal tumors. | The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20111001 |
| Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. | Clinical advances in hematology & oncology : H&O 20111001 |
| [Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic stem cell transplantation in CR1 as the front-line therapy for adult Ph(+) acute lymphoblastic leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20111001 |
| Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration. | European journal of pharmacology 20110930 |
| SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. | Blood 20110929 |
| Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. | Blood 20110922 |
| [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia]. | Medicina clinica 20110917 |
| Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein. | The Journal of biological chemistry 20110916 |
| Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib. | International journal of cardiology 20110915 |
| Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil. | Genetics and molecular research : GMR 20110915 |
| BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. | Blood 20110908 |
| Severe peripheral arterial disease during nilotinib therapy. | Journal of the National Cancer Institute 20110907 |
| Anticancer effects of imatinib via immunostimulation. | Nature medicine 20110907 |
| Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. | Medical oncology (Northwood, London, England) 20110901 |
| Gastrointestinal stromal tumor with primary resistance to imatinib and extensive bone metastases. | American journal of therapeutics 20110901 |
| Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901 |
| Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20110901 |
| The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients. | Hematological oncology 20110901 |
| Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement. | Irish journal of medical science 20110901 |
| A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients. | Cancer chemotherapy and pharmacology 20110901 |
| Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110901 |
| Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. | Annals of oncology : official journal of the European Society for Medical Oncology 20110901 |
| Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study. | Leukemia research 20110901 |
| Nilotinib and dasatinib first-line: are we ready for imatinib replacement? | Leukemia research 20110901 |
| Stochastic dynamics of leukemic cells under an intermittent targeted therapy. | Theory in biosciences = Theorie in den Biowissenschaften 20110901 |
| Subcutaneous metastasis of a GIST tumour unresponsive to Imatinib. | Journal of plastic, reconstructive & aesthetic surgery : JPRAS 20110901 |
| Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger. | Cancer letters 20110901 |
| BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML. | International journal of oncology 20110901 |
| Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. | Leukemia research 20110901 |
| ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro. | Leukemia 20110901 |
| Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. | Current hematologic malignancy reports 20110901 |
| Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. | Leukemia & lymphoma 20110901 |
| Targeted-therapy and imaging response: a new paradigm for clinical evaluation? | Reviews on recent clinical trials 20110901 |
| Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. | British journal of haematology 20110901 |
| The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose. | Expert opinion on pharmacotherapy 20110901 |
| The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110901 |
| Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate. | Leukemia research 20110901 |
| Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. | The Lancet. Oncology 20110901 |
| First-line therapy for CML: nilotinib comes of age. | The Lancet. Oncology 20110901 |
| Comparative quantitative analysis of BCR-ABL transcripts with the T315I mutant clone by polymerase chain reaction (PCR)-Invader method. | Translational research : the journal of laboratory and clinical medicine 20110901 |
| Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. | Nature medicine 20110901 |
| Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: report of a case. | Surgery today 20110901 |
| Complex effects of imatinib on spontaneous and oxytocin-induced contractions in human non-pregnant myometrium. | Acta physiologica Hungarica 20110901 |
| [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy]. | Annales pharmaceutiques francaises 20110901 |
| Pigmentary changes in a patient treated with imatinib. | Journal of drugs in dermatology : JDD 20110901 |
| [Application of selective tyrosine kinase inhibitor to the prevention of coronary restenosis after PCI]. | Nihon rinsho. Japanese journal of clinical medicine 20110901 |
| Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. | Blood 20110825 |
| Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820 |
| [Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients]. | Zhonghua yi xue za zhi 20110816 |
| Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele. | Cancer research 20110815 |
| Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. | Blood 20110811 |
| Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110810 |
| miRNAs in the spotlight: Understanding cancer gene dependency. | Nature medicine 20110804 |
| The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era. | Critical reviews in oncology/hematology 20110801 |
| Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. | Cancer chemotherapy and pharmacology 20110801 |
| Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. | Leukemia research 20110801 |
| A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. | Cancer treatment reviews 20110801 |
| Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy. | Leukemia research 20110801 |
| A sporadic multiple gastrointestinal stromal tumor with unique clinical and molecular features. | Human pathology 20110801 |
| Added value of molecular targeted agents in oncology. | Annals of oncology : official journal of the European Society for Medical Oncology 20110801 |
| Tumour heterogeneity of mucosal melanomas during treatment with imatinib. | The British journal of dermatology 20110801 |
| Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. | Haematologica 20110801 |
| Development of a plate-based assay for high-content analysis of individual untethered non-adherent cells. | Combinatorial chemistry & high throughput screening 20110801 |
| Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry. | European journal of haematology 20110801 |
| Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit. | Critical reviews in biochemistry and molecular biology 20110801 |
| The skeletal effects of the tyrosine kinase inhibitor nilotinib. | Bone 20110801 |
| Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats. | Toxicology and applied pharmacology 20110801 |
| The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma. | Pigment cell & melanoma research 20110801 |
| Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. | Journal of the American Society of Nephrology : JASN 20110801 |
| Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. | International journal of hematology 20110801 |
| Fibrosis, regeneration, and aging: playing chess with evolution. | Journal of the American Society of Nephrology : JASN 20110801 |
| High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis. | American journal of hematology 20110801 |
| Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation. | European journal of haematology 20110801 |
| In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20110801 |
| Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? | Expert review of hematology 20110801 |
| Bringing prognostic scores for chronic myeloid leukemia patients up to date. | Expert review of hematology 20110801 |
| Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. | Clinical lymphoma, myeloma & leukemia 20110801 |
| [Treatment strategy for marginally resectable GIST]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110801 |
| Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia. | Pediatrics international : official journal of the Japan Pediatric Society 20110801 |
| [Gastrointestinal stromal tumour (GIST): current standards in multimodal management]. | Zentralblatt fur Chirurgie 20110801 |
| [Effect of trichostatin alone and combination with imatinb on the proliferation and apoptosis of the K562R cells]. | Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20110801 |
| [Rapamycin for myeloid blast crisis in refractory chronic myeloid leukemia with imatinib-resistance]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110801 |
| Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. | Blood 20110721 |
| Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110720 |
| Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. | Pediatric blood & cancer 20110715 |
| Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. | Veterinary immunology and immunopathology 20110715 |
| 16-Hydroxycleroda-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis. | Toxicology 20110711 |
| Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110710 |
| From genome to drugs: where do we stand? | Journal of the National Cancer Institute 20110706 |
| ASCO 2011: broadening the horizons of cancer research. | Journal of the National Cancer Institute 20110706 |
| Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. | Cancer chemotherapy and pharmacology 20110701 |
| Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells. | Annals of hematology 20110701 |
| Oncogenetics of melanoma: basis for molecular diagnostics and therapy. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20110701 |
| Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. | Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20110701 |
| Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. | Cellular signalling 20110701 |
| Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. | Leukemia research 20110701 |
| Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion. | Leukemia & lymphoma 20110701 |
| Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. | Leukemia & lymphoma 20110701 |
| Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis. | Leukemia research 20110701 |
| TCR transfer induces TCR-mediated tonic inhibition of RAG genes in human T cells. | Molecular immunology 20110701 |
| NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse. | Leukemia research 20110701 |
| Mass spectrometry imaging with high resolution in mass and space (HR(2) MSI) for reliable investigation of drug compound distributions on the cellular level. | Analytical and bioanalytical chemistry 20110701 |
| Treatment of gastrointestinal stromal tumor after imatinib and sunitinib. | Current opinion in oncology 20110701 |
| Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. | Leukemia & lymphoma 20110701 |
| Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment. | Molecular and cellular biology 20110701 |
| Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. | American journal of hematology 20110701 |
| Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. | Current opinion in oncology 20110701 |
| Molecular targeted therapy of gastrointestinal stromal tumors. | Current cancer drug targets 20110701 |
| Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era? | Leukemia & lymphoma 20110701 |
| Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. | American journal of hematology 20110701 |
| Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. | Clinical pharmacology and therapeutics 20110701 |
| Effect of reduced c-Kit signaling on bone marrow adiposity. | Anatomical record (Hoboken, N.J. : 2007) 20110701 |
| Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. | The Journal of pharmacy and pharmacology 20110701 |
| Fibroblasts expressing PDGF-receptor-alpha diminish during alveolar septal thinning in mice. | Pediatric research 20110701 |
| Choosing the right TKI for chronic myeloid leukemia: when the truth lies in 'long-term' safety and efficacy. | American journal of hematology 20110701 |
| Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis. | Journal of the American Academy of Dermatology 20110701 |
| Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients. | Electrophoresis 20110701 |
| Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. | Pakistan journal of pharmaceutical sciences 20110701 |
| Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. | Neuro-oncology 20110701 |
| [A case of gastric gastrointestinal stromal tumor resected after chemotherapy with imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110701 |
| [TKI therapy for CML]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110701 |
| [Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110701 |
| [Clinical analysis of 79 gastrointestinal tract stromal tumor cases]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110701 |
| [Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110701 |
| [Initial therapy of imatinib mesylate for extramedullary T lymphoblastic crisis of chronic myeloid leukemia: a case report and review of the literature]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110701 |
| Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. | Blood 20110623 |
| Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620 |
| Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. | Oncogene 20110616 |
| Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. | International journal of cancer 20110615 |
| Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. | Cancer cell 20110614 |
| KIT as a therapeutic target in metastatic melanoma. | JAMA 20110608 |
| Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. | Blood 20110602 |
| Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment. | Molecular biology reports 20110601 |
| Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. | Medical oncology (Northwood, London, England) 20110601 |
| The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor. | American journal of clinical oncology 20110601 |
| Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST. | International journal of clinical oncology 20110601 |
| Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? | Cancer treatment reviews 20110601 |
| The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). | Leukemia research 20110601 |
| Reversible hair depigmentation in a patient treated with imatinib. | Leukemia research 20110601 |
| Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis. | Modern rheumatology 20110601 |
| Extra-gastrointestinal stromal tumor of the pancreas: clinical characteristics, diagnosis, treatment, and outcome. | Journal of surgical oncology 20110601 |
| Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems. | Scandinavian journal of gastroenterology 20110601 |
| Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment. | Leukemia research 20110601 |
| Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. | Leukemia research 20110601 |
| The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. | Arthritis and rheumatism 20110601 |
| PDGF-induced vascular smooth muscle cell proliferation is associated with dysregulation of insulin receptor substrates. | American journal of physiology. Cell physiology 20110601 |
| New drugs for chronic myelogenous leukemia. | Current hematologic malignancy reports 20110601 |
| Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study. | European journal of cancer (Oxford, England : 1990) 20110601 |
| Chronic myelogenous leukemia: monitoring response to therapy. | Current hematologic malignancy reports 20110601 |
| A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. | European journal of haematology 20110601 |
| Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. | Journal of neuroscience research 20110601 |
| Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. | Experimental hematology 20110601 |
| Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. | Annals of the rheumatic diseases 20110601 |
| A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response. | Leukemia 20110601 |
| A Bayesian approach for the estimation of patient compliance based on the last sampling information. | Journal of pharmacokinetics and pharmacodynamics 20110601 |
| Predicting the response of CML patients to tyrosine kinase inhibitor therapy. | Current hematologic malignancy reports 20110601 |
| PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110601 |
| Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. | Leukemia & lymphoma 20110601 |
| Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia. | European journal of haematology 20110601 |
| Imatinib mesylate induction of ROS-dependent apoptosis in melanoma B16F0 cells. | Journal of dermatological science 20110601 |
| Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia? | Leukemia & lymphoma 20110601 |
| Environmental and genetic factors affecting transport of imatinib by OATP1A2. | Clinical pharmacology and therapeutics 20110601 |
| Fatherhood during imatinib. | Acta oncologica (Stockholm, Sweden) 20110601 |
| Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. | Leukemia & lymphoma 20110601 |
| Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. | Acta dermato-venereologica 20110601 |
| Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. | American journal of hematology 20110601 |
| Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. | International journal of hematology 20110601 |
| The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome. | Leukemia & lymphoma 20110601 |
| Effective salvage therapy of imatinib-resistant gastrointestinal stromal tumor with combination of imatinib and pegylated liposomal doxorubicin. | Journal of the Chinese Medical Association : JCMA 20110601 |
| NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. | Frontiers in bioscience (Elite edition) 20110601 |
| Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110601 |
| Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀? | The oncologist 20110601 |
| Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. | The American journal of pathology 20110601 |
| Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay. | Clinical lymphoma, myeloma & leukemia 20110601 |
| [Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection]. | Revue de pneumologie clinique 20110601 |
| Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. | Expert review of hematology 20110601 |
| [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110601 |
| Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20110601 |
| Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. | PLoS computational biology 20110601 |
| A method for quantitative analysis of an anticancer drug in human plasma with CE-ESI-TOF-MS. | Electrophoresis 20110601 |
| [Apoptosis of KBM5R cell line with T315I point mutation induced by arsenic trioxide]. | Zhongguo shi yan xue ye xue za zhi 20110601 |
| [A case of imatinib mesylate-induced pneumonitis based on the detection of epithelioid granulomas by video-assisted thoracoscopic surgery biopsy in a patient with chronic myeloid leukemia]. | Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20110601 |
| [Effects of HO-1 gene expression on proliferation of imatinib resistant CML cells]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110601 |
| [Effect of bortezomib on the drug sensitivity of imatinib resistant K562/G01 cells]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110601 |
| [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110601 |
| Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. | Clinical lymphoma, myeloma & leukemia 20110601 |
| Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago. | The West Indian medical journal 20110601 |
| [Application of imatinib plus Hyper-CVAD chemotherapy regimen in patients with Ph chromosome positive acute lymphocytic leukemia]. | Zhonghua yi xue za zhi 20110531 |
| Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. | Blood 20110526 |
| Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. | Blood 20110526 |
| [Therapeutic adherence to oral cancer therapy and interdisciplinary management]. | Revue medicale suisse 20110525 |
| Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. | British journal of cancer 20110524 |
| Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia. | Blood 20110519 |
| Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. | Cancer research 20110515 |
| HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110515 |
| Explaining the in vitro and in vivo differences in leukemia therapy. | Cell cycle (Georgetown, Tex.) 20110515 |
| Targeted therapy in pediatric and adolescent oncology. | Cancer 20110515 |
| Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature. | Dermatology online journal 20110515 |
| The renaissance of interferon therapy for the treatment of myeloid malignancies. | Blood 20110505 |
| Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia. | Bulletin of mathematical biology 20110501 |
| [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome]. | La Revue de medecine interne 20110501 |
| Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110501 |
| The role of c-kit-positive interstitial cells in mediating phasic contractions of bladder strips from streptozotocin-induced diabetic rats. | BJU international 20110501 |
| Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. | Leukemia research 20110501 |
| Keratoacanthomas associated with imatinib mesylate. | Acta oncologica (Stockholm, Sweden) 20110501 |
| Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. | Leukemia research 20110501 |
| BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. | Leukemia research 20110501 |
| Peripheral neuropathy as an adverse effect of imatinib therapy. | Journal of clinical pathology 20110501 |
| Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal. | Reproductive toxicology (Elmsford, N.Y.) 20110501 |
| Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy. | The British journal of ophthalmology 20110501 |
| Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20110501 |
| Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses. | Clinical immunology (Orlando, Fla.) 20110501 |
| Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. | Breast cancer research and treatment 20110501 |
| hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications. | Molecular cancer therapeutics 20110501 |
| Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate. | American journal of physiology. Renal physiology 20110501 |
| Application of melt granulation technology using twin-screw extruder in development of high-dose modified-release tablet formulation. | Journal of pharmaceutical sciences 20110501 |
| Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. | International journal of cancer 20110501 |
| Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review. | International journal of cancer 20110501 |
| Interstitial cells and bladder pathophysiology--passive bystanders or active participants? | The Journal of urology 20110501 |
| Interpretation of cytogenetic and molecular results in patients treated for CML. | Blood reviews 20110501 |
| Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time? | The oncologist 20110501 |
| MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. | Molecular cancer research : MCR 20110501 |
| Female adnexal tumor of probable Wolffian origin (FATWO) with recurrence 3 years postsurgery. | International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 20110501 |
| A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies. | Cancer investigation 20110501 |
| Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer. | Molecular carcinogenesis 20110501 |
| The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. | Cancer research 20110501 |
| Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. | Cancer 20110501 |
| Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. | Cytometry. Part B, Clinical cytometry 20110501 |
| Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. | International journal of hematology 20110501 |
| Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. | International journal of hematology 20110501 |
| Gastrointestinal stromal tumor and its targeted therapeutics. | Chinese journal of cancer 20110501 |
| Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. | Journal of chromatographic science 20110501 |
| [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110501 |
| [GIST refractory to imatinib treatment]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110501 |
| [A case of imatinib-resistant GIST treated by sunitinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110501 |
| [Indications and current development of new targeted therapies in pediatric oncology]. | Bulletin du cancer 20110501 |
| [Chronic myelogenous leukemia complicated by drug-induced agranulocytosis]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110501 |
| [Treatment of chronic myeloid leukemia with imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110501 |
| [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110501 |
| [The role of allogenic hematopoietic stem cell transplantation for chronic myeloid leukemia in imatinib era]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110501 |
| [Hematologic malignancies/ pediatric malignancies-chronic myeloid leukemia]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110501 |
| Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110420 |
| Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. | International journal of cancer 20110415 |
| Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. | Toxicology and applied pharmacology 20110415 |
| Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. | Cancer 20110415 |
| Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. | Journal of medicinal chemistry 20110414 |
| Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. | Blood 20110407 |
| Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. | Journal of the National Cancer Institute 20110406 |
| Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects. | Journal of the National Cancer Institute 20110406 |
| A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. | Investigational new drugs 20110401 |
| Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. | Fundamental & clinical pharmacology 20110401 |
| Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells. | Cancer chemotherapy and pharmacology 20110401 |
| Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients. | Leukemia research 20110401 |
| KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro. | Journal of cellular physiology 20110401 |
| Long-term follow-up of patients with chronic myeloid leukemia having received autologous stem cell transplantation. | Annals of hematology 20110401 |
| An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib. | International journal of laboratory hematology 20110401 |
| Hypereosinophilic syndrome presenting as acute myocardial infarction in an adolescent. | The Journal of pediatrics 20110401 |
| V559A and N822I double KIT mutant melanoma with predictable response to imatinib? | Pigment cell & melanoma research 20110401 |
| Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. | Haematologica 20110401 |
| Gastrointestinal stromal tumor presenting as a rectovaginal mass. Clinicopathologic and molecular-genetic characterization of a rare tumor with a literature review. | Human pathology 20110401 |
| Long-term failure of alveologenesis after an early short-term exposure to a PDGF-receptor antagonist. | American journal of physiology. Lung cellular and molecular physiology 20110401 |
| Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment. | Cancer immunology, immunotherapy : CII 20110401 |
| Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro. | International journal of oncology 20110401 |
| Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. | Oncology reports 20110401 |
| Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells. | Leukemia & lymphoma 20110401 |
| Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. | British journal of haematology 20110401 |
| Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20110401 |
| Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. | Pediatric blood & cancer 20110401 |
| Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. | Therapeutic drug monitoring 20110401 |
| Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia. | Leukemia & lymphoma 20110401 |
| Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. | Cancer chemotherapy and pharmacology 20110401 |
| OCT-1 as a determinant of response to antileukemic treatment. | Clinical pharmacology and therapeutics 20110401 |
| Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. | Thyroid : official journal of the American Thyroid Association 20110401 |
| Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate. | International journal of hematology 20110401 |
| Minimal change glomerulopathy in a cat. | Journal of feline medicine and surgery 20110401 |
| Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. | American journal of hematology 20110401 |
| A case of hepatic metastasis from gastric GIST successfully resected following neoadjuvant targeted therapy. | Japanese journal of clinical oncology 20110401 |
| An autopsy case of pulmonary veno-occlusive disease refractory to imatinib. | The European respiratory journal 20110401 |
| Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable? | Expert review of hematology 20110401 |
| Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. | Anticancer research 20110401 |
| Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. | Cancer genetics 20110401 |
| Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. | Clinical lymphoma, myeloma & leukemia 20110401 |
| Chronic myelogenous leukemia in the chronic phase with lymph node swelling which represented extramedullary involvement composed of cells at different stages of maturation. | Rinsho byori. The Japanese journal of clinical pathology 20110401 |
| Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award. | The Journal of clinical investigation 20110401 |
| KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation. | Blood 20110331 |
| High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. | Blood 20110324 |
| Identification and functional analysis of a new phosphorylation site (Y398) in the SH3 domain of Abi-1. | FEBS letters 20110323 |
| Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. | Blood 20110317 |
| Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. | Blood 20110317 |
| Role of c-Abl in L-selectin shedding from the neutrophil surface. | Blood cells, molecules & diseases 20110315 |
| Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. | Cancer 20110315 |
| Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. | Blood 20110310 |
| Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. | Journal of medicinal chemistry 20110310 |
| Large duodenal gastrointestinal stromal tumor presenting with acute bleeding managed by a whipple resection. A review of surgical options and the prognostic indicators of outcome. | JOP : Journal of the pancreas 20110309 |
| Malignant extra-gastrointestinal stromal tumor of the pancreas. A case report and review of literature. | JOP : Journal of the pancreas 20110309 |
| WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. | Medical oncology (Northwood, London, England) 20110301 |
| Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. | Medical oncology (Northwood, London, England) 20110301 |
| Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. | Clinical and experimental dermatology 20110301 |
| Imatinib-resistant lymphoid clone of chronic myelogenous leukemia in blast phase arising from B cell-committed progenitor leukemic stem cells. | Annals of hematology 20110301 |
| Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. | Journal of the European Academy of Dermatology and Venereology : JEADV 20110301 |
| The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia. | Leukemia research 20110301 |
| Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. | Fertility and sterility 20110301 |
| Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. | Cancer 20110301 |
| A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. | The Journal of pharmacology and experimental therapeutics 20110301 |
| Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion. | Pediatric blood & cancer 20110301 |
| Pattern of pediatric chronic myeloid leukemia in Sudan and hematological response to imatinib. | Pediatric hematology and oncology 20110301 |
| Rapid reversal of quadraparesis in chronic eosinophilic leukaemia expressing the FIP1L1-PDGFRA transcript after therapy with imatinib. | Leukemia research 20110301 |
| Long-term follow-up of patients with Philadelphia chromosome-positive chronic myeloid leukemia after stem cell mobilization under imatinib. | Leukemia & lymphoma 20110301 |
| Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. | Haematologica 20110301 |
| Time-specific blockade of PDGFR with Imatinib (Glivec®) causes cataract and disruption of lens fiber cells in neonatal mice. | Virchows Archiv : an international journal of pathology 20110301 |
| An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy. | Virchows Archiv : an international journal of pathology 20110301 |
| Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients. | Radiology 20110301 |
| Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. | European journal of haematology 20110301 |
| Mutational analysis in chronic myeloid leukemia: when and what to do? | Current opinion in hematology 20110301 |
| Navigating the road toward optimal initial therapy for chronic myeloid leukemia. | Current opinion in hematology 20110301 |
| [Chronic myeloid leukemia. Diagnostics, therapy and future strategy]. | Der Internist 20110301 |
| Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical study. | International journal of hematology 20110301 |
| Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials? | American journal of hematology 20110301 |
| Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells. | Hematology (Amsterdam, Netherlands) 20110301 |
| Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib. | Hematology (Amsterdam, Netherlands) 20110301 |
| Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis. | Future medicinal chemistry 20110301 |
| Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia. | Clinical advances in hematology & oncology : H&O 20110301 |
| Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). | Anticancer research 20110301 |
| The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer. | Seminars in cutaneous medicine and surgery 20110301 |
| [Successful resection of a gastrointestinal stromal tumor in the pelvis with imatinib mesylate as neoadjuvant therapy]. | Hinyokika kiyo. Acta urologica Japonica 20110301 |
| Imatinib and inoperable or metastatic gastrointestinal stromal tumours. Longer follow-up confirms the overall survival benefit. | Prescrire international 20110301 |
| Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. | Blood 20110224 |
| The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. | Oncogene 20110224 |
| c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells. | Blood 20110224 |
| Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors. | Journal of the National Cancer Institute 20110216 |
| Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study. | International journal of cancer 20110215 |
| Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. | Cancer 20110215 |
| A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study. | Cancer 20110215 |
| A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells. | Talanta 20110215 |
| Current and emerging pharmacological treatments for gastrointestinal stromal tumour. | Drugs 20110212 |
| Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. | Blood 20110210 |
| Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110210 |
| Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1. | Biochemical and biophysical research communications 20110204 |
| Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. | Blood 20110203 |
| Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. | European journal of radiology 20110201 |
| Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy. | Cancer chemotherapy and pharmacology 20110201 |
| Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors. | Annals of surgical oncology 20110201 |
| Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. | Annals of oncology : official journal of the European Society for Medical Oncology 20110201 |
| The role of stem cell factor and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role? | The British journal of dermatology 20110201 |
| Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. | Leukemia 20110201 |
| Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. | Cancer 20110201 |
| Diplopia as a presenting symptom in a gastric gastrointestinal stromal tumor. | Japanese journal of clinical oncology 20110201 |
| Biologic therapy for systemic sclerosis: a systematic review. | The Journal of rheumatology 20110201 |
| Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. | Current rheumatology reports 20110201 |
| Monitoring response to imatinib using MRI signals in aggressive fibromatosis. | European journal of nuclear medicine and molecular imaging 20110201 |
| [Systemic therapy of soft tissue sarcomas]. | Der Pathologe 20110201 |
| Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate. | Haematologica 20110201 |
| The first case of acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript: imatinib therapy followed by unrelated donor transplantation induces a durable molecular response. | Leukemia 20110201 |
| Imatinib and the treatment of fibrosis: recent trials and tribulations. | Current rheumatology reports 20110201 |
| ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. | Leukemia 20110201 |
| Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy. | Japanese journal of clinical oncology 20110201 |
| Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. | Molecular oncology 20110201 |
| Reduction of imatinib absorption after gastric bypass surgery. | Leukemia & lymphoma 20110201 |
| Cyclophosphamide induces differentiation of Th17 cells in cancer patients. | Cancer research 20110201 |
| Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. | International journal of oncology 20110201 |
| Drug transporters and imatinib treatment: implications for clinical practice. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110201 |
| Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all? | Leukemia & lymphoma 20110201 |
| Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110201 |
| ETV6-ABL1-positive 'chronic myeloid leukemia': clinical and molecular response to tyrosine kinase inhibition. | Haematologica 20110201 |
| Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia. | British journal of clinical pharmacology 20110201 |
| Treatment of chronic myeloid leukemia when imatinib fails. | Expert opinion on pharmacotherapy 20110201 |
| Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. | International journal of hematology 20110201 |
| Metastatic uterine leiomyosarcoma and eosinophilia. | Obstetrics and gynecology 20110201 |
| A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. | International journal of hematology 20110201 |
| Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission? | The Lancet. Oncology 20110201 |
| Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. | International journal of hematology 20110201 |
| Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. | Leukemia & lymphoma 20110201 |
| Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia. | Leukemia & lymphoma 20110201 |
| Mechanisms of resistance to BCR-ABL kinase inhibitors. | Leukemia & lymphoma 20110201 |
| [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20110201 |
| [Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib]. | Annales de dermatologie et de venereologie 20110201 |
| Bilateral masculine mastoplasia associated with imatinib mesylate: a case report and literature review. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20110201 |
| Pharmacotherapy for chronic myelogenous leukemia: a case-based approach. | Journal of the National Comprehensive Cancer Network : JNCCN 20110201 |
| [Preliminary analysis of therapeutic efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in patients with advanced chronic myeloid leukemia]. | Zhongguo shi yan xue ye xue za zhi 20110201 |
| [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia]. | Gan to kagaku ryoho. Cancer & chemotherapy 20110201 |
| [Loss of Philadelphia chromosome after graft failure following cord blood transplantation for Philadelphia chromosome-positive acute myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110201 |
| [Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110201 |
| Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour. | Prescrire international 20110201 |
| Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. | Cancer letters 20110128 |
| Imatinib treatment in chronic myelogenous leukemia: What have we learned so far? | Cancer letters 20110128 |
| Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. | Blood 20110127 |
| Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110120 |
| Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. | Cancer 20110115 |
| Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib? | Cancer 20110115 |
| Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. | Cell cycle (Georgetown, Tex.) 20110115 |
| Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. | Cancer research 20110115 |
| BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. | Oncogene 20110113 |
| Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20110105 |
| BCR-ABL kinase is dead; long live the CML stem cell. | The Journal of clinical investigation 20110104 |
| Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. | The Journal of clinical investigation 20110104 |
| New insights into small-molecule inhibitors of Bcr-Abl. | Medicinal research reviews 20110101 |
| Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. | Journal of neuro-oncology 20110101 |
| Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110101 |
| Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. | Leukemia research 20110101 |
| Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer. | The Prostate 20110101 |
| Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase. | Annals of hematology 20110101 |
| Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. | Leukemia research 20110101 |
| Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. | Annals of hematology 20110101 |
| Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias? | Leukemia research 20110101 |
| Adverse effects of imatinib--dissecting heart from the rest. | Cancer 20110101 |
| A magnetic bead-based protein kinase assay with dual detection techniques. | Analytical biochemistry 20110101 |
| Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor. | Japanese journal of clinical oncology 20110101 |
| Good clinical response to imatinib mesylate in atypical thymic carcinoid With KIT overexpression. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110101 |
| Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. | Leukemia 20110101 |
| Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia? | Leukemia research 20110101 |
| p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. | Carcinogenesis 20110101 |
| Is imatinib-related cardiotoxicity still an open issue? | Leukemia research 20110101 |
| Cardiotoxicity of imatinib: At the heart of the problem. | Leukemia research 20110101 |
| Imatinib mesylate does not increase bone volume in vivo. | Calcified tissue international 20110101 |
| Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention. | British journal of haematology 20110101 |
| A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. | Leukemia research 20110101 |
| Current treatment concepts of CML. | Current cancer drug targets 20110101 |
| Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. | Leukemia 20110101 |
| DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour. | Acta oncologica (Stockholm, Sweden) 20110101 |
| Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. | The Lancet. Oncology 20110101 |
| Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. | Cancer chemotherapy and pharmacology 20110101 |
| Adjuvant and neoadjuvant therapy for primary GIST. | Cancer chemotherapy and pharmacology 20110101 |
| Gastrointestinal Stromal Tumors (GIST) special issue. Preface. | Cancer chemotherapy and pharmacology 20110101 |
| Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. | Chemical biology & drug design 20110101 |
| The expanding role of nilotinib in chronic myeloid leukemia. | Expert opinion on drug safety 20110101 |
| The GIST paradigm: lessons for other kinase-driven cancers. | The Journal of pathology 20110101 |
| Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment. | American journal of hematology 20110101 |
| The role of imatinib plasma level testing in gastrointestinal stromal tumor. | Cancer chemotherapy and pharmacology 20110101 |
| Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma. | Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 20110101 |
| Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. | Cancer chemotherapy and pharmacology 20110101 |
| Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. | Current medicinal chemistry 20110101 |
| How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology. | International journal of dermatology 20110101 |
| Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia. | Biological & pharmaceutical bulletin 20110101 |
| Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism. | Cytogenetic and genome research 20110101 |
| Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba. | MEDICC review 20110101 |
| Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. | International archives of allergy and immunology 20110101 |
| BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. | Journal of hematology & oncology 20110101 |
| Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. | BMC cancer 20110101 |
| Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. | Polskie Archiwum Medycyny Wewnetrznej 20110101 |
| Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. | PloS one 20110101 |
| [Gastrointestinal stromal tumors: diagnosis and treatment. Our experience]. | Il Giornale di chirurgia 20110101 |
| Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Chinese medical journal 20110101 |
| Discontinuation of imatinib may be possible in chronic myelogenous leukemia. | CA: a cancer journal for clinicians 20110101 |
| Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. | Internal medicine (Tokyo, Japan) 20110101 |
| Chronic myelogenous leukemia with mild basophilia as the predominant manifestation at presentation. | Internal medicine (Tokyo, Japan) 20110101 |
| [Acute leukemia of ambiguous lineage with monosomy 7 and Philadelphia chromosome]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20110101 |
| Exfoliative dermatitis with leukemia cutis in a patient with chronic myeloid leukemia: a rare association. | Indian journal of dermatology, venereology and leprology 20110101 |
| [Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110101 |
| Synchronous well differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: a case report. | BMC gastroenterology 20110101 |
| High CD133 expression levels in gastrointestinal stromal tumors. | Cytometry. Part B, Clinical cytometry 20110101 |
| [The giant gastrointestinal tumor of the stomach]. | Khirurgiia 20110101 |
| Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. | Pharmacology 20110101 |
| Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis. | BMC genomics 20110101 |
| A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy. | Pediatric dermatology 20110101 |
| Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells. | Journal of translational medicine 20110101 |
| Is there any protective effect on organs upon higher uric acid level in tumor lysis syndrome? | Renal failure 20110101 |
| Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. | PloS one 20110101 |
| Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. | PloS one 20110101 |
| Insulin suppresses the expression and function of breast cancer resistance protein in primary cultures of rat brain microvessel endothelial cells. | Pharmacological reports : PR 20110101 |
| Imatinib mesylate alters the expression of genes related to disease progression in an animal model of uveal melanoma. | Analytical cellular pathology (Amsterdam) 20110101 |
| Synchronous gastric adenocarcinoma and gastrointestinal stromal tumor (GIST) of the stomach: a case report. | World journal of surgical oncology 20110101 |
| In vitro effects of imatinib on glucose-6-phosphate dehydrogenase and glutathione reductase. | Folia biologica 20110101 |
| Simultaneous visualization of both signaling cascade activity and end-point gene expression in single cells. | PloS one 20110101 |
| Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. | Respiration; international review of thoracic diseases 20110101 |
| Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia. | The Journal of international medical research 20110101 |
| Changing pathology with changing drugs: tumors of the gastrointestinal tract. | Pathobiology : journal of immunopathology, molecular and cellular biology 20110101 |
| [Gastrointestinal stromal tumors]. | Annali italiani di chirurgia 20110101 |
| Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial. | European journal of medical research 20110101 |
| α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients. | Disease markers 20110101 |
| Synthetic lethality-based targets for discovery of new cancer therapeutics. | Cancer genomics & proteomics 20110101 |
| How to manage hypersensitivity reactions to biological agents? | European journal of dermatology : EJD 20110101 |
| Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. | PloS one 20110101 |
| Myeloprolipherative disorder type chronic myeloid leukemia--eosinophilic form. | Medicinski arhiv 20110101 |
| Steroid-unresponsive hypereosinophilic syndrome. | Annals of tropical paediatrics 20110101 |
| Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. | PloS one 20110101 |
| Targeted drug therapies and cancer. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101 |
| Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report. | Hepato-gastroenterology 20110101 |
| [Stromal tumor of esophagus: case report]. | Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 20110101 |
| γ-Secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by imatinib. | Journal of Alzheimer's disease : JAD 20110101 |
| Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia. | Internal medicine (Tokyo, Japan) 20110101 |
| [H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience]. | Przeglad lekarski 20110101 |
| Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India. | Clinical laboratory 20110101 |
| Meningeal tuberculoma mimicking chloroma in a patient with chronic myeloid leukemia on imatinib. | Neurology India 20110101 |
| Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia. | Neoplasma 20110101 |
| Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. | Dermatologic therapy 20110101 |
| Treatment of a multicentric Merkel cell carcinoma using imatinib. | European journal of dermatology : EJD 20110101 |
| Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. | Onkologie 20110101 |
| Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. | PloS one 20110101 |
| Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy. | Journal of translational medicine 20110101 |
| Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. | PloS one 20110101 |
| Advances in the surgical management of gastrointestinal stromal tumor. | Advances in surgery 20110101 |
| Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review. | BMC cancer 20110101 |
| Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. | BMC medical research methodology 20110101 |
| Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. | Journal of atherosclerosis and thrombosis 20110101 |
| Nilotinib in advanced gastrointestinal stromal tumors after imatinib and sunitinib therapy. | Hepato-gastroenterology 20110101 |
| Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event. | BMC gastroenterology 20110101 |
| A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. | Journal of chromatographic science 20110101 |
| Effects of BCR-ABL inhibitors on anti-tumor immunity. | Current medicinal chemistry 20110101 |
| The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines. | PloS one 20110101 |
| Current directions in systemic therapy for gastrointestinal stromal tumors. | Current problems in cancer 20110101 |
| C-kit expression in human osteosarcoma and in vitro assays. | International journal of clinical and experimental pathology 20110101 |
| Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. | BMC cancer 20110101 |
| Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. | Hematology. American Society of Hematology. Education Program 20110101 |
| Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events. | BMC cancer 20110101 |
| Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data. | PloS one 20110101 |
| [Imatinib in the GIST therapy: ten years later]. | La Clinica terapeutica 20110101 |
| Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib. | Journal of cancer research and therapeutics 20110101 |
| A first report of endoscopic ultrasound-guided biopsy in the diagnosis of desmoid-type fibromatosis. | Endoscopy 20110101 |
| Neoadjuvant and adjuvant therapy with imatinib for locally advanced gastrointestinal stromal tumors in eastern Indian patients. | Asian Pacific journal of cancer prevention : APJCP 20110101 |
| Nilotinib as first-line therapy for chronic myeloid leukemia. | Indian journal of cancer 20110101 |
| [Morphological characteristics and prognostic criteria for gastrointestinal stromal tumors]. | Arkhiv patologii 20110101 |
| Overall survival of chronic myeloid leukemia patients treated with related donor hematopoietic stem cell transplant or imatinib. | Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 20110101 |
| Oral lesions associated with hydroxyurea treatment. | Indian journal of dental research : official publication of Indian Society for Dental Research 20110101 |
| Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone. | BMJ case reports 20110101 |
| EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. | Blood 20101223 |
| Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. | The New England journal of medicine 20101223 |
| Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. | Blood 20101223 |
| Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. | Blood 20101216 |
| Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells. | Journal of cellular biochemistry 20101215 |
| Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. | Clinica chimica acta; international journal of clinical chemistry 20101214 |
| Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. | Investigational new drugs 20101201 |
| Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion. | Medical oncology (Northwood, London, England) 20101201 |
| Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. | Leukemia research 20101201 |
| A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. | Leukemia research 20101201 |
| Prompt lightening of acral lentiginosis in a GIST patient after treatment with imatinib mesylate. | Journal of the European Academy of Dermatology and Venereology : JEADV 20101201 |
| Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. | International journal of laboratory hematology 20101201 |
| Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of modeled peritoneum. | Fertility and sterility 20101201 |
| Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. | Biotechnology and bioengineering 20101201 |
| Relationship of serum imatinib trough level and response in CML patients: long term follow-up. | Leukemia research 20101201 |
| Emergence of secondary resistance to imatinib in recurrent gastric GIST. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20101201 |
| Gastrointestinal stromal tumors (GISTs): an updated experience. | Digestive diseases and sciences 20101201 |
| Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. | Clinical pharmacology and therapeutics 20101201 |
| A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone. | Journal of clinical pharmacy and therapeutics 20101201 |
| Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. | American journal of hematology 20101201 |
| Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. | Expert opinion on pharmacotherapy 20101201 |
| Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. | International journal of hematology 20101201 |
| Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. | Expert review of hematology 20101201 |
| Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. | Expert review of hematology 20101201 |
| Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. | Cancer research 20101201 |
| A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months. | International journal of hematology 20101201 |
| Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet. | Current opinion in molecular therapeutics 20101201 |
| GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. | Cancer genetics and cytogenetics 20101201 |
| Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. | Clinical lymphoma, myeloma & leukemia 20101201 |
| [A case of t(3;3)(q21;q26.2) associated with severe multilineage dysplasia and multi-drug resistance in blastic crisis of chronic myelogenous leukemia]. | The Korean journal of laboratory medicine 20101201 |
| [What's new in dermatological treatments?]. | Annales de dermatologie et de venereologie 20101201 |
| [Therapeutic choice for the chronic myeloid leukemia patients in chronic phase showing late suboptimal response to imatinib]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20101201 |
| [Chronic myeloid leukemia complicated with cerebellar hemorrhage and acute hydrocephalus successfully treated with imatinib and intensive supportive care]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20101201 |
| [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors]. | Methods and findings in experimental and clinical pharmacology 20101201 |
| Pericytes regulate the blood-brain barrier. | Nature 20101125 |
| Therapeutic implications of autophagy-mediated cell survival in gastrointestinal stromal tumor after treatment with imatinib mesylate. | Autophagy 20101116 |
| Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. | Cancer 20101115 |
| Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). | Blood 20101111 |
| Congestive heart failure during imatinib mesylate treatment. | International journal of cardiology 20101105 |
| Proteomics analysis of cellular imatinib targets and their candidate downstream effectors. | Journal of proteome research 20101105 |
| Global proteome quantification for discovering imatinib-induced perturbation of multiple biological pathways in K562 human chronic myeloid leukemia cells. | Journal of proteome research 20101105 |
| How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. | Blood 20101104 |
| The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. | International journal of cancer 20101101 |
| Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. | Annals of hematology 20101101 |
| Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. | American journal of respiratory and critical care medicine 20101101 |
| c-Abl mediates high NaCl-induced phosphorylation and activation of the transcription factor TonEBP/OREBP. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20101101 |
| Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate. | Journal of bone and mineral metabolism 20101101 |
| The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors. | Cancer 20101101 |
| Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. | European journal of haematology 20101101 |
| Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). | Cancer 20101101 |
| Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. | Molecular pharmacology 20101101 |
| 'Real-life' results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. | Leukemia research 20101101 |
| Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. | Journal of human genetics 20101101 |
| Response of histiocytoses to imatinib mesylate: fire to ashes. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101 |
| OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1. | Leukemia 20101101 |
| Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia. | Molecular cancer therapeutics 20101101 |
| Inhibitor screening of protein kinases using MALDI-TOF MS combined with separation and enrichment of phosphopeptides by TiO2 nanoparticle deposited capillary column. | The Analyst 20101101 |
| Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter? | American journal of hematology 20101101 |
| A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor. | Virchows Archiv : an international journal of pathology 20101101 |
| Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. | Thyroid : official journal of the American Thyroid Association 20101101 |
| [Multimodality therapy concepts for soft tissue sarcomas]. | Der Internist 20101101 |
| Imatinib treatment of generalized localized scleroderma (morphea). | Journal of the American Academy of Dermatology 20101101 |
| The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101101 |
| Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment. | International journal of hematology 20101101 |
| Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia. | The Lancet. Oncology 20101101 |
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. | The Lancet. Oncology 20101101 |
| Persistent cough: an unusual cause. Idiopathic hypereosinophilic syndrome (HES). | Thorax 20101101 |
| Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line. | Experimental biology and medicine (Maywood, N.J.) 20101101 |
| Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. | Journal of surgical oncology 20101101 |
| Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. | British journal of pharmacology 20101101 |
| Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. | The European respiratory journal 20101101 |
| Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. | Molecular cancer therapeutics 20101101 |
| Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. | Journal of Korean medical science 20101101 |
| [Molecular biology of soft-tissue sarcomas]. | Bulletin du cancer 20101101 |
| [Complete response achieved in a case of gastric gastrointestinal stromal tumor by administration of imatinib mesilate with concurrent relatively high-dose steroid therapy to control side effects]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| Targeting targeted therapies. | Immunotherapy 20101101 |
| Immunotherapy of systemic sclerosis. | Immunotherapy 20101101 |
| Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature. | Transplantation proceedings 20101101 |
| [Chronic myeloid leukemia and targeted therapies: too many choices?]. | Medecine sciences : M/S 20101101 |
| [Usefulness of low-dose and long-term administration of imatinib in patients with liver metastases of rectal GIST and GIST of stomach]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| [More than 20 years of long-term survival case of intraabdominal GIST by combined therapies with frequent surgeries]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| [Curative resection for bulky rectal gastrointestinal stromal tumor after neoadjuvant imatinib mesylate]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101101 |
| Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia. | Cell death & disease 20101101 |
| BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. | Blood 20101028 |
| Imatinib: as adjuvant therapy for gastrointestinal stromal tumour. | Drugs 20101022 |
| Second-generation BCR-ABL kinase inhibitors in CML. | The New England journal of medicine 20101021 |
| Second-generation BCR-ABL kinase inhibitors in CML. | The New England journal of medicine 20101021 |
| Second-generation BCR-ABL kinase inhibitors in CML. | The New England journal of medicine 20101021 |
| Second-generation BCR-ABL kinase inhibitors in CML. | The New England journal of medicine 20101021 |
| Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. | Bioorganic & medicinal chemistry letters 20101015 |
| The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. | Blood 20101014 |
| ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. | Nature 20101014 |
| Cancer: Oncogenes in context. | Nature 20101014 |
| A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). | American journal of clinical oncology 20101001 |
| Gastrointestinal stromal tumors: current management. | Journal of surgical oncology 20101001 |
| Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. | Leukemia research 20101001 |
| Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST). | Annals of surgical oncology 20101001 |
| Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach. | Biochimica et biophysica acta 20101001 |
| A case of imatinib-naive ileal fibrous stromal tumor with unusual morphology and double PDGFRA mutation. | Applied immunohistochemistry & molecular morphology : AIMM 20101001 |
| A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20101001 |
| Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells. | Journal of cellular biochemistry 20101001 |
| BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. | Leukemia research 20101001 |
| Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. | European journal of nuclear medicine and molecular imaging 20101001 |
| Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. | Cancer 20101001 |
| A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats. | The journal of sexual medicine 20101001 |
| Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate. | Pediatric blood & cancer 20101001 |
| Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? | European journal of clinical investigation 20101001 |
| ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma. | Leukemia research 20101001 |
| Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. | Genes, chromosomes & cancer 20101001 |
| Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. | Cancer science 20101001 |
| Overdose with 16,000 mg of imatinib mesylate. | Leukemia research 20101001 |
| WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. | European journal of haematology 20101001 |
| Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production. | Clinical immunology (Orlando, Fla.) 20101001 |
| Optimal control for resistance and suboptimal response in CML. | Mathematical biosciences 20101001 |
| Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. | Current hematologic malignancy reports 20101001 |
| HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. | Leukemia 20101001 |
| Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101001 |
| Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. | Leukemia 20101001 |
| Preparation and characterization of novel 4-bromo-3,4-dimethyl-1-phenyl-2-phospholene 1-oxide and the analogous phosphorus heterocycles or phospha sugars. | Bioorganic & medicinal chemistry letters 20101001 |
| Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. | Leukemia 20101001 |
| Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. | International journal of oncology 20101001 |
| In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells. | International journal of oncology 20101001 |
| Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. | Bioorganic & medicinal chemistry 20101001 |
| Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate. | International journal of hematology 20101001 |
| Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. | Leukemia & lymphoma 20101001 |
| Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country. | Leukemia & lymphoma 20101001 |
| Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. | Cancer research 20101001 |
| Imatinib treatment of metastatic GIST: don't stop (believing). | The Lancet. Oncology 20101001 |
| Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. | The Lancet. Oncology 20101001 |
| Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. | Surgery today 20101001 |
| Towards a cure for chronic myeloid leukemia: are we there yet? | Seminars in hematology 20101001 |
| Current status of imatinib as frontline therapy for chronic myeloid leukemia. | Seminars in hematology 20101001 |
| Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia? | Seminars in hematology 20101001 |
| Practical considerations for monitoring patients with chronic myeloid leukemia. | Seminars in hematology 20101001 |
| Resistance to imatinib: mutations and beyond. | Seminars in hematology 20101001 |
| Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? | Seminars in hematology 20101001 |
| Stem cell transplant for chronic myeloid leukemia in the imatinib era. | Seminars in hematology 20101001 |
| The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? | Seminars in hematology 20101001 |
| Third-generation tyrosine kinase inhibitors and beyond. | Seminars in hematology 20101001 |
| Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML? | Nature reviews. Clinical oncology 20101001 |
| PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. | Genes & development 20101001 |
| Clinical implications of KIT and PDGFRA genotyping in GIST. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20101001 |
| [Cytoplasmic kinase inhibitors]. | Nihon rinsho. Japanese journal of clinical medicine 20101001 |
| [Management of chronic myeloid leukemia by imatinib]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20101001 |
| [The 2nd generation of TKIs for chronic myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20101001 |
| [Current chemotherapy of adult acute lymphoblastic leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20101001 |
| Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. | Clinical lymphoma, myeloma & leukemia 20101001 |
| Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours. | Health technology assessment (Winchester, England) 20101001 |
| Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience. | Vojnosanitetski pregled 20101001 |
| [Clinical manifestation of targeted drugs in individualized therapy of malignant tumors]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101001 |
| Small gastrointestinal stromal tumor of the stomach showing rapid growth and early metastasis to the liver. | Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 20101001 |
| [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia]. | Zhonghua fu chan ke za zhi 20101001 |
| Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. | Blood 20100923 |
| Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. | Blood 20100923 |
| Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia. | ACS chemical biology 20100917 |
| Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. | Cancer research 20100915 |
| Allosteric inhibition of BCR-ABL. | Cell cycle (Georgetown, Tex.) 20100915 |
| Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. | World journal of gastroenterology 20100907 |
| Specific inhibitors of the breast cancer resistance protein (BCRP). | ChemMedChem 20100903 |
| Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. | Nature 20100902 |
| The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia. | Medical oncology (Northwood, London, England) 20100901 |
| Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. | Medical oncology (Northwood, London, England) 20100901 |
| Esophageal gastrointestinal stromal tumor with pulmonary and bone metastases. | Diagnostic and interventional radiology (Ankara, Turkey) 20100901 |
| Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. | Leukemia research 20100901 |
| Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). | Leukemia research 20100901 |
| Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature. | Leukemia research 20100901 |
| Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers. | Biochemical pharmacology 20100901 |
| Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression. | Leukemia research 20100901 |
| Treating imatinib resistance in the few in CML-A key step towards cure in all. | Leukemia research 20100901 |
| Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy. | Haematologica 20100901 |
| Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. | Experimental hematology 20100901 |
| Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature. | Clinical neurology and neurosurgery 20100901 |
| Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability. | World journal of surgery 20100901 |
| In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. | Experimental hematology 20100901 |
| Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. | Cancer science 20100901 |
| PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL. | Endocrinology 20100901 |
| Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents. | Anti-cancer drugs 20100901 |
| Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. | Gastroenterology 20100901 |
| Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. | Cancer science 20100901 |
| How cells respond to interferons. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100901 |
| Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate. | Leukemia research 20100901 |
| Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate. | Pediatric blood & cancer 20100901 |
| The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. | Journal of dermatological science 20100901 |
| New effective inhibitors of the Abelson kinase. | Bioorganic & medicinal chemistry 20100901 |
| Cytogenetic and molecular characterization of double inversion 3 associated with a cryptic BCR-ABL1 rearrangement and additional genetic changes. | Cancer genetics and cytogenetics 20100901 |
| Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib. | Cancer genetics and cytogenetics 20100901 |
| Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate. | Cancer genetics and cytogenetics 20100901 |
| Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. | Veterinary and comparative oncology 20100901 |
| Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. | Clinics in chest medicine 20100901 |
| A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. | Thyroid : official journal of the American Thyroid Association 20100901 |
| Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development. | Expert opinion on drug safety 20100901 |
| Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors. | Journal of managed care pharmacy : JMCP 20100901 |
| Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. | Molecular cancer research : MCR 20100901 |
| Gastrointestinal stromal tumour in a young adult. | Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20100901 |
| Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer. | Anticancer research 20100901 |
| Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20100901 |
| [Temporal arteritis: treatment controversies]. | Neurologia (Barcelona, Spain) 20100901 |
| [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)]. | Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20100901 |
| In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. | Blood 20100826 |
| Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. | International journal of cancer 20100815 |
| Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. | Cancer 20100815 |
| Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. | Cancer 20100815 |
| Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. | Blood 20100812 |
| Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. | British journal of cancer 20100810 |
| Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. | Blood 20100805 |
| Nonadherence to imatinib during an economic downturn. | The New England journal of medicine 20100805 |
| Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia. | Journal of cutaneous pathology 20100801 |
| Allo-SCT in a rare t(8;21) evolution of CML. | Bone marrow transplantation 20100801 |
| Imatinib, cytokines and interstitial lung disease in a patient with primary myelofibrosis. | Annals of hematology 20100801 |
| Molecular characterization and prognostic significance of FLT3 in CML progression. | Leukemia research 20100801 |
| Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib. | Journal of neuro-oncology 20100801 |
| A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. | Leukemia research 20100801 |
| Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach. | Amino acids 20100801 |
| c-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein Galectin-3. | Cell death and differentiation 20100801 |
| Reproductive fitness advantage of BCR-ABL expressing leukemia cells. | Cancer letters 20100801 |
| Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. | Haematologica 20100801 |
| Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia. | Leukemia research 20100801 |
| Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. | Leukemia research 20100801 |
| The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. | Haematologica 20100801 |
| Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. | Haematologica 20100801 |
| Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib. | Leukemia research 20100801 |
| Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy. | Leukemia research 20100801 |
| Primary thoracic cavity gastrointestinal stromal tumor. | The Journal of thoracic and cardiovascular surgery 20100801 |
| Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. | Cellular signalling 20100801 |
| Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. | Drug metabolism and disposition: the biological fate of chemicals 20100801 |
| Signal transduction therapy of cancer. | Molecular aspects of medicine 20100801 |
| Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. | Haematologica 20100801 |
| Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? | The Journal of clinical endocrinology and metabolism 20100801 |
| [Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)]. | Bulletin du cancer 20100801 |
| Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. | Cancer 20100801 |
| Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas. | Cancer 20100801 |
| Current strategies in the management of hypereosinophilic syndrome, including mepolizumab. | Current medical research and opinion 20100801 |
| Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). | Pediatric blood & cancer 20100801 |
| The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo. | Xenobiotica; the fate of foreign compounds in biological systems 20100801 |
| Cytogenomics of cancers: from chromosome to sequence. | Molecular oncology 20100801 |
| Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801 |
| The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. | Bioorganic & medicinal chemistry 20100801 |
| Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice. | Anti-cancer drugs 20100801 |
| Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. | Acta pharmacologica Sinica 20100801 |
| Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. | Leukemia & lymphoma 20100801 |
| Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. | The American journal of medicine 20100801 |
| A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100801 |
| E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib. | Journal of clinical pathology 20100801 |
| The neo-adjuvant treatment in gastrointestinal stromal tumor. | European review for medical and pharmacological sciences 20100801 |
| [Effects of STI571 combined with As₂O₃ on proliferation, apoptosis and caspase 3, Bcl-xL expression of K562 cells]. | Zhongguo shi yan xue ye xue za zhi 20100801 |
| Giant gastrointestinal stromal tumor with remarkable preoperative response to imatinib mesylate. | The American surgeon 20100801 |
| Novel therapies for hypereosinophilic syndromes. | The Netherlands journal of medicine 20100801 |
| [Development of ABL tyrosine kinase inhibitors]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20100801 |
| [Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship with cytogenetic response]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100801 |
| Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. | The journal of medical investigation : JMI 20100801 |
| Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. | Journal of the National Comprehensive Cancer Network : JNCCN 20100801 |
| Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors. | Analytical and quantitative cytology and histology 20100801 |
| Neoadjuvant treatment of rectal gastrointestinal stromal tumors with imatinib. | The American surgeon 20100801 |
| Current and future management options for myelodysplastic syndromes. | Drugs 20100730 |
| Antifungal and cytotoxic activity of withanolides from Acnistus arborescens. | Journal of natural products 20100723 |
| Mast cells and the neurofibroma microenvironment. | Blood 20100715 |
| Imatinib mesylate in children and adolescents with cancer. | Pediatric blood & cancer 20100715 |
| Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. | Cancer cell 20100713 |
| Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. | The Journal of biological chemistry 20100709 |
| Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells. | Cancer chemotherapy and pharmacology 20100701 |
| Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. | Annals of hematology 20100701 |
| Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. | Journal of cancer research and clinical oncology 20100701 |
| Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. | Cell death and differentiation 20100701 |
| Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia. | Leukemia research 20100701 |
| Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. | Haematologica 20100701 |
| Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. | Annals of hematology 20100701 |
| The role of mast cells in parathyroid bone disease. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100701 |
| Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment. | Biochemical pharmacology 20100701 |
| Bcl2 is not required for the development and maintenance of leukemia stem cells in mice. | Carcinogenesis 20100701 |
| Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. | Cancer investigation 20100701 |
| Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance. | British journal of haematology 20100701 |
| Mast cells mediate hyperoxia-induced airway hyper-reactivity in newborn rats. | Pediatric research 20100701 |
| Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. | European journal of haematology 20100701 |
| Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia. | Haematologica 20100701 |
| Imatinib mesylate induces clinical remission in rheumatoid arthritis. | Joint, bone, spine : revue du rhumatisme 20100701 |
| Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. | Current opinion in oncology 20100701 |
| Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. | Leukemia 20100701 |
| Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. | Current opinion in oncology 20100701 |
| Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. | Leukemia 20100701 |
| Imatinib mesylate-induced pseudoporphyria. | Journal of the American Academy of Dermatology 20100701 |
| Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. | Cancer 20100701 |
| Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy. | The oncologist 20100701 |
| XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia. | American journal of hematology 20100701 |
| The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. | American journal of hematology 20100701 |
| Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan. | International journal of hematology 20100701 |
| Oncogenic c-kit transcript is a target for binase. | Cell cycle (Georgetown, Tex.) 20100701 |
| Membranoproliferative glomerulonephritis secondary to chronic myeloid leukemia. | Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 20100701 |
| Knee pain: ACL, MCL, or CML? | Blood 20100701 |
| Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer. | Clinical lung cancer 20100701 |
| [Association of CT image changes and prognosis in gastrointestinal stromal tumor after targeted therapy]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20100701 |
| [Efficacy of tyrosine kinase inhibitor therapy combined with surgical resection in patients with metastatic gastrointestinal stromal tumor]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20100701 |
| [Expression of MDR1 and KIT in imatinib-resistant gastrointestinal stromal tumor cells]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20100701 |
| [Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20100701 |
| [Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20100701 |
| [Successful resection of locally advanced gastrointestinal stromal tumor of the ampulla of Vater after treatment with imatinib]. | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 20100701 |
| Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. | International heart journal 20100701 |
| Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. | Yao xue xue bao = Acta pharmaceutica Sinica 20100701 |
| [The role of pathologists in the target therapy of gastrointestinal tumors]. | Zhonghua bing li xue za zhi = Chinese journal of pathology 20100701 |
| The GIST of a tumor's transformation. | Cancer cytopathology 20100625 |
| Five molecules we would take to a remote island. | Chemistry & biology 20100625 |
| Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. | Proceedings. Biological sciences 20100622 |
| Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620 |
| Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620 |
| Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. | The New England journal of medicine 20100617 |
| Even better kinase inhibitors for chronic myeloid leukemia. | The New England journal of medicine 20100617 |
| Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. | The New England journal of medicine 20100617 |
| Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100615 |
| Molecular basis and management of gastrointestinal stromal tumors. | World journal of gastroenterology 20100614 |
| Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. | Oncogene 20100603 |
| Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells. | Journal of cellular and molecular medicine 20100601 |
| Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. | Hematological oncology 20100601 |
| Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. | Hematological oncology 20100601 |
| Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison. | Leukemia research 20100601 |
| Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. | Journal of cellular and molecular medicine 20100601 |
| Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. | Hematological oncology 20100601 |
| Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20100601 |
| Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). | Leukemia research 20100601 |
| Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. | Leukemia research 20100601 |
| OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathways. | Leukemia research 20100601 |
| Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. | Haematologica 20100601 |
| Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. | Haematologica 20100601 |
| p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells. | Cancer letters 20100601 |
| Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100601 |
| The flavonoid tangeretin activates the unfolded protein response and synergizes with imatinib in the erythroleukemia cell line K562. | Molecular nutrition & food research 20100601 |
| Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease? | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100601 |
| High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 'ISTAHIT' study. | Haematologica 20100601 |
| Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country. | Japanese journal of clinical oncology 20100601 |
| Dasatinib: is it all in the dose? | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20100601 |
| Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. | Cancer 20100601 |
| Mutations in ABL kinase domain are associated with inferior progression-free survival. | Leukemia & lymphoma 20100601 |
| Specificity in the interaction of natural products with their target proteins--a biochemical and structural insight. | Mini reviews in medicinal chemistry 20100601 |
| Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells. | Toxicology mechanisms and methods 20100601 |
| Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20100601 |
| Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100601 |
| Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. | Leukemia 20100601 |
| Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response. | International journal of hematology 20100601 |
| Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100601 |
| Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation. | The American journal of surgical pathology 20100601 |
| Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. | Leukemia 20100601 |
| hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. | Leukemia 20100601 |
| Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms. | Bioorganic & medicinal chemistry 20100601 |
| Bone marrow or peripheral blood. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100601 |
| Imatinib therapy reduces radiation-induced pulmonary mast cell influx and delays lung disease in the mouse. | International journal of radiation biology 20100601 |
| Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. | Cancer genetics and cytogenetics 20100601 |
| Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution. | Cancer genetics and cytogenetics 20100601 |
| Design and synthesis of new anticancer pyrimidines with multiple-kinase inhibitory effect. | Bioorganic & medicinal chemistry 20100601 |
| Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. | Nature genetics 20100601 |
| [Focus on GIST management]. | Bulletin du cancer 20100601 |
| Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. | Cancer 20100601 |
| Gastrointestinal stromal tumors: a paradigm for therapeutic options in solid organ tumors. | Mini reviews in medicinal chemistry 20100601 |
| Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line. | Chinese journal of cancer 20100601 |
| First-line therapy for chronic myeloid leukemia: new horizons and an update. | Clinical lymphoma, myeloma & leukemia 20100601 |
| Hematology. Imatinib--should we have more of a good thing? | Nature reviews. Clinical oncology 20100601 |
| How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia. | Clinical lymphoma, myeloma & leukemia 20100601 |
| Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. | Clinical lymphoma, myeloma & leukemia 20100601 |
| Molecular pathways to CML stem cells. | International journal of hematology 20100601 |
| [Treatment with antiangiogenic drugs]. | Nihon rinsho. Japanese journal of clinical medicine 20100601 |
| [Kinase inhibitors]. | Nihon rinsho. Japanese journal of clinical medicine 20100601 |
| [Surgical news of soft tissue sarcomas, fibromatosis and GIST]. | Bulletin du cancer 20100601 |
| Histopathological study of the hepatic and renal toxicity associated with the co-administration of imatinib and acetaminophen in a preclinical mouse model. | The Malaysian journal of pathology 20100601 |
| Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia. | Computational biology and chemistry 20100601 |
| Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. | Anticancer research 20100601 |
| Role of Pten in leukemia stem cells. | Oncotarget 20100601 |
| Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. | Blood 20100527 |
| Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. | Oncogene 20100520 |
| Generation of iPSCs from cultured human malignant cells. | Blood 20100520 |
| Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. | Cancer cell 20100518 |
| Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment. | Journal of medicine and life 20100515 |
| Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100510 |
| Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line. | The Journal of biological chemistry 20100507 |
| Drug developers unveil strategies aimed at imatinib-resistant CML. | Journal of the National Cancer Institute 20100505 |
| Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases. | Biochemistry 20100504 |
| Toxicity and phototoxicity of Hypocrellin A on malignant human cell lines, evidence of a synergistic action of photodynamic therapy with Imatinib mesylate. | Journal of photochemistry and photobiology. B, Biology 20100503 |
| mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. | Leukemia research 20100501 |
| Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. | Journal of neurosurgery 20100501 |
| LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. | Cancer chemotherapy and pharmacology 20100501 |
| Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. | Leukemia research 20100501 |
| Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. | Journal of neuro-oncology 20100501 |
| Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment. | Leukemia research 20100501 |
| A molecular mechanics model for imatinib and imatinib:kinase binding. | Journal of computational chemistry 20100501 |
| BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. | British journal of haematology 20100501 |
| Possible alternative strategy for stage I imatinib-sensitive testicular seminoma; lessons from a case associated with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Annals of oncology : official journal of the European Society for Medical Oncology 20100501 |
| Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. | Apoptosis : an international journal on programmed cell death 20100501 |
| Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia. | Haematologica 20100501 |
| KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. | Leukemia 20100501 |
| Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment. | Cancer science 20100501 |
| Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. | Gynecologic oncology 20100501 |
| Postnatal development of interstitial cells of Cajal in mouse colon in response to Kit signal blockade with Imatinib (Glivec). | Acta histochemica 20100501 |
| Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). | European journal of cancer (Oxford, England : 1990) 20100501 |
| Targeted cancer therapies in the twenty-first century: lessons from imatinib. | Clinical pharmacology and therapeutics 20100501 |
| Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. | American journal of hematology 20100501 |
| Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. | Acta oncologica (Stockholm, Sweden) 20100501 |
| Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. | The Annals of pharmacotherapy 20100501 |
| Uncommon case of chronic myeloid leukemia with multiple myeloma. | International journal of hematology 20100501 |
| Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells. | Leukemia 20100501 |
| Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation. | Cancer genetics and cytogenetics 20100501 |
| Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia. | American journal of hematology 20100501 |
| Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model. | Molecular cancer therapeutics 20100501 |
| Imatinib mesylate for the treatment of gastrointestinal stromal tumor. | Expert review of anticancer therapy 20100501 |
| [Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20100501 |
| [Effect of imatinib at different concentrations on rat C6 glioma cell apoptosis and cell cycle]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100501 |
| [Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20100501 |
| [Case of pediatric chronic myeloid leukemia with bilateral visual loss onset]. | Nippon Ganka Gakkai zasshi 20100501 |
| Current management of GISTs. | Clinical advances in hematology & oncology : H&O 20100501 |
| Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Annals of oncology : official journal of the European Society for Medical Oncology 20100501 |
| Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. | Clinical therapeutics 20100501 |
| Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. | The Journal of biological chemistry 20100430 |
| Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. | Cancer letters 20100428 |
| The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. | Cancer 20100415 |
| A flow-based synthesis of imatinib: the API of Gleevec. | Chemical communications (Cambridge, England) 20100414 |
| Gastrointestinal stromal tumor of stomach with inguinal lymph nodes metastasis: a case report. | World journal of gastroenterology 20100414 |
| Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. | British journal of cancer 20100413 |
| Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100410 |
| Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. | Cancer chemotherapy and pharmacology 20100401 |
| Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. | Journal of neuro-oncology 20100401 |
| A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm. | Leukemia research 20100401 |
| Skin fragility and blistering with imatinib mesylate. | Journal of the European Academy of Dermatology and Venereology : JEADV 20100401 |
| Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. | Haematologica 20100401 |
| CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. | European journal of clinical pharmacology 20100401 |
| Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry. | Protein science : a publication of the Protein Society 20100401 |
| Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months. | Acta oncologica (Stockholm, Sweden) 20100401 |
| [Fundus leucaemicus as first manifestation of chronic myeloid leukemia. Diagnosis and monitoring with OCT under treatment with imatinib and interferon-alpha]. | Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 20100401 |
| ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells. | Leukemia 20100401 |
| Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. | European journal of clinical pharmacology 20100401 |
| Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. | The Journal of pathology 20100401 |
| Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance. | Journal of biochemistry 20100401 |
| Lck is a key target of imatinib and dasatinib in T-cell activation. | Leukemia 20100401 |
| Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. | Leukemia 20100401 |
| Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. | Leukemia 20100401 |
| Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro. | International journal for parasitology 20100401 |
| [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome]. | La Revue de medecine interne 20100401 |
| Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission. | American journal of hematology 20100401 |
| Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase. | International journal of hematology 20100401 |
| Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100401 |
| Carvedilol in glioma treatment alone and with imatinib in vitro. | International journal of oncology 20100401 |
| Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB. | Molecules and cells 20100401 |
| Imatinib treatment of ankylosing spondylitis in a patient resistant to NSAIDs and infliximab. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20100401 |
| Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts. | Journal of biomolecular screening 20100401 |
| Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. | Leukemia & lymphoma 20100401 |
| Counterpoint: Data first. | Nature 20100401 |
| RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cells. | Molecular cancer therapeutics 20100401 |
| Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. | Nanomedicine (London, England) 20100401 |
| [Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100401 |
| Tyrosine kinase inhibitors: the first decade. | Current hematologic malignancy reports 20100401 |
| Targeting chronic myeloid leukemia stem cells. | Current hematologic malignancy reports 20100401 |
| Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. | Transplantation proceedings 20100401 |
| NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. | Journal of the National Comprehensive Cancer Network : JNCCN 20100401 |
| [Pharmaceuticals can be cost-effective in the long run]. | Lakartidningen 20100401 |
| The best frontline therapy for CML: imatinib? | Clinical advances in hematology & oncology : H&O 20100401 |
| Improving imatinib delivery to central nervous system. | Internal medicine journal 20100401 |
| A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors. | Anticancer research 20100401 |
| Imatinib plasma levels: correlation with clinical benefit in GIST patients. | British journal of cancer 20100330 |
| Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100320 |
| Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells. | Biochemical and biophysical research communications 20100319 |
| Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. | American journal of respiratory and critical care medicine 20100315 |
| Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. | Cancer 20100315 |
| V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. | Journal of immunology (Baltimore, Md. : 1950) 20100315 |
| Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. | Blood 20100311 |
| Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100310 |
| Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib. | International journal of cardiology 20100304 |
| Usefulness of positron emission and computed tomography scan in early evaluation of treatment response in gastrointestinal stromal tumor. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20100301 |
| Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. | Annals of hematology 20100301 |
| Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties. | Endocrine, metabolic & immune disorders drug targets 20100301 |
| Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. | Biochemical pharmacology 20100301 |
| Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells. | Leukemia & lymphoma 20100301 |
| Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study. | Journal of gastrointestinal cancer 20100301 |
| [Gastrointestinal stromal tumors: evolution of a tumor concept from unclassifiable neoplasms to targeted molecular therapy]. | Der Pathologe 20100301 |
| Malignant appendiceal GIST: case report and review of the literature. | Journal of gastrointestinal cancer 20100301 |
| BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. | European journal of haematology 20100301 |
| Emergence of imatinib resistance associated with downregulation of c-kit expression in recurrent gastrointestinal stromal tumor (GIST): optimal timing of resection. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20100301 |
| Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. | Leukemia & lymphoma 20100301 |
| Managing imatinib resistance in chronic myeloid leukaemia. | Current opinion in hematology 20100301 |
| Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. | Current opinion in hematology 20100301 |
| Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. | Cancer metastasis reviews 20100301 |
| Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301 |
| Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. | American journal of hematology 20100301 |
| Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen? | American journal of hematology 20100301 |
| Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. | European journal of cancer (Oxford, England : 1990) 20100301 |
| Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China. | Leukemia & lymphoma 20100301 |
| Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl. | Bioorganic & medicinal chemistry 20100301 |
| Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. | Biochimica et biophysica acta 20100301 |
| Colony stimulating factor-1 receptor as a target for small molecule inhibitors. | Bioorganic & medicinal chemistry 20100301 |
| Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case. | Surgery today 20100301 |
| Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. | The oncologist 20100301 |
| [Successful treatment of a gastrointestinal stromal tumor with liver metastases in a case that tolerated imatinib administration, by radiofrequency ablation using contrast-enhanced ultrasonography]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20100301 |
| Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. | Haematologica 20100301 |
| [Successful induction of complete cytogenetic response with low-dose imatinib mesylate in an accelerated phase chronic myelogenous leukemia patient who developed severe bone marrow aplasia following standard-dose imatinib mesylate therapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20100301 |
| Molecular response prediction in gastrointestinal stromal tumors. | Targeted oncology 20100301 |
| Chronic myelogenous leukemia therapy beyond imatinib. | Clinical advances in hematology & oncology : H&O 20100301 |
| [Clinical study of imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20100301 |
| Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. | Blood 20100225 |
| Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. | Cancer research 20100215 |
| BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. | The Journal of biological chemistry 20100212 |
| Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. | Oncogene 20100204 |
| SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. | Blood 20100204 |
| TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. | Nature 20100204 |
| Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. | Leukemia research 20100201 |
| Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? | Annals of oncology : official journal of the European Society for Medical Oncology 20100201 |
| In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. | Journal of neuro-oncology 20100201 |
| Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. | American journal of clinical oncology 20100201 |
| Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. | Journal of neuro-oncology 20100201 |
| Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient. | Journal of the European Academy of Dermatology and Venereology : JEADV 20100201 |
| Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment. | Leukemia research 20100201 |
| Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy. | Investigative ophthalmology & visual science 20100201 |
| Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100201 |
| Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. | Haematologica 20100201 |
| Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. | Clinica chimica acta; international journal of clinical chemistry 20100201 |
| A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. | Leukemia research 20100201 |
| Targeted therapies: the rare cancer paradigm. | Molecular oncology 20100201 |
| Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. | Cancer treatment reviews 20100201 |
| Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia. | Genetic testing and molecular biomarkers 20100201 |
| Anticipating drug resistance in the MAP kinase pathway. | Pigment cell & melanoma research 20100201 |
| Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Leukemia & lymphoma 20100201 |
| RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. | Journal of cellular biochemistry 20100201 |
| Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. | Anti-cancer drugs 20100201 |
| AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. | Chemical biology & drug design 20100201 |
| Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. | Leukemia & lymphoma 20100201 |
| Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. | The American journal of pathology 20100201 |
| Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. | Mayo Clinic proceedings 20100201 |
| Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. | Cancer research 20100201 |
| C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines. | Chinese journal of cancer 20100201 |
| T-cell lymphoproliferative disorder potentially induced by imatinib in a patient with GIST. | Nature reviews. Clinical oncology 20100201 |
| Why doesn't imatinib cure chronic myeloid leukemia? | The oncologist 20100201 |
| Whither the bone marrow transplant? | Hematology (Amsterdam, Netherlands) 20100201 |
| Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts. | Hematology (Amsterdam, Netherlands) 20100201 |
| [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment]. | Zhongguo shi yan xue ye xue za zhi 20100201 |
| [Reversal of multidrug-resistance in human leukemia cell line K562/A02 by tyrosine kinase inhibitors]. | Zhongguo shi yan xue ye xue za zhi 20100201 |
| [Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia]. | Zhongguo shi yan xue ye xue za zhi 20100201 |
| [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate]. | Zhongguo shi yan xue ye xue za zhi 20100201 |
| Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. | Haematologica 20100201 |
| Chronic myelogenous leukemia: treatment and monitoring. | Deutsches Arzteblatt international 20100201 |
| Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. | Anticancer research 20100201 |
| Studies on lipid peroxidation and non-enzymatic antioxidant status as indices of oxidative stress in patients with chronic myeloid leukaemia. | Singapore medical journal 20100201 |
| Reversible cardiotoxicity with tyrosine kinase inhibitors. | Clinical advances in hematology & oncology : H&O 20100201 |
| Molecular and cellular bases of chronic myeloid leukemia. | Protein & cell 20100201 |
| Dysregulation of bone remodeling by imatinib mesylate. | Blood 20100128 |
| Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. | Nature 20100128 |
| Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. | Biochemical and biophysical research communications 20100122 |
| Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120 |
| Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120 |
| Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. | Chinese medical journal 20100120 |
| A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. | Blood 20100114 |
| A potential role for colony-stimulating factor 1 in the genesis of the early endometriotic lesion. | Fertility and sterility 20100101 |
| In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs). | Recent patents on anti-cancer drug discovery 20100101 |
| Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. | Leukemia research 20100101 |
| Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations. | European journal of haematology 20100101 |
| Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. | Leukemia research 20100101 |
| Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. | Leukemia 20100101 |
| Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. | Haematologica 20100101 |
| Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. | Leukemia 20100101 |
| Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. | British journal of haematology 20100101 |
| Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. | The Journal of investigative dermatology 20100101 |
| Oral lichenoid eruption associated with imatinib treatment. | European journal of dermatology : EJD 20100101 |
| Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. | Experimental hematology 20100101 |
| Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib. | Experimental hematology 20100101 |
| Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. | Cancer science 20100101 |
| Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. | American journal of physiology. Renal physiology 20100101 |
| Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib. | Cytotherapy 20100101 |
| Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. | Cancer 20100101 |
| The growth factor independence-1 (Gfi1) is overexpressed in chronic myelogenous leukemia. | Acta haematologica 20100101 |
| Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template. | Chemical biology & drug design 20100101 |
| Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management. | Acta oncologica (Stockholm, Sweden) 20100101 |
| Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. | Current medical research and opinion 20100101 |
| Cytoprotective effect of imatinib mesylate in non-BCR-ABL-expressing cells along with autophagosome formation. | Biochemical and biophysical research communications 20100101 |
| Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. | Leukemia 20100101 |
| Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients. | International journal of surgery (London, England) 20100101 |
| Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors. | ChemMedChem 20100101 |
| Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells. | Oncology reports 20100101 |
| Imatinib treatment for gastrointestinal stromal tumour (GIST). | Journal of cellular and molecular medicine 20100101 |
| Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. | Annals of the rheumatic diseases 20100101 |
| Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. | Dermatology (Basel, Switzerland) 20100101 |
| CML mouse model in translational research. | Methods in molecular biology (Clifton, N.J.) 20100101 |
| Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. | Future cardiology 20100101 |
| Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia. | Pathology 20100101 |
| Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. | Cancer research 20100101 |
| A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. | International journal of hematology 20100101 |
| K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100101 |
| Paper spray for direct analysis of complex mixtures using mass spectrometry. | Angewandte Chemie (International ed. in English) 20100101 |
| Pyogenic liver abscess associated with a gastrointestinal stromal tumor of the stomach. | The American journal of gastroenterology 20100101 |
| Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. | International journal of hematology 20100101 |
| Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. | Leukemia & lymphoma 20100101 |
| HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice. | Pakistan journal of pharmaceutical sciences 20100101 |
| Imatinib mesylate. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101 |
| Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. | British journal of haematology 20100101 |
| Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction? | International journal of clinical practice 20100101 |
| Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec). | Acta oncologica (Stockholm, Sweden) 20100101 |
| Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. | Acta dermato-venereologica 20100101 |
| [Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20100101 |
| Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate. | Ocular immunology and inflammation 20100101 |
| Future treatments in systemic sclerosis. | The Journal of dermatology 20100101 |
| c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. | Arthritis research & therapy 20100101 |
| Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006. | Journal of experimental & clinical cancer research : CR 20100101 |
| PDGF receptor and its antagonists: role in treatment of PAH. | Advances in experimental medicine and biology 20100101 |
| Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia. | Hematology/oncology and stem cell therapy 20100101 |
| [Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20100101 |
| Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital. | Acta medica Indonesiana 20100101 |
| Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors. | BMC biotechnology 20100101 |
| [An elderly case of chronic myeloid leukemia in which BCR/ABL decreased or disappeared, following imatinib therapy after each episode of blast crisis]. | Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20100101 |
| A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use. | Acta haematologica 20100101 |
| Imatinib (Gleevec) as a paradigm of targeted cancer therapies. | The Keio journal of medicine 20100101 |
| Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia. | Journal of hematology & oncology 20100101 |
| Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes. | Arthritis research & therapy 20100101 |
| [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis]. | Terapevticheskii arkhiv 20100101 |
| Optimal use of targeted agents for advanced gastrointestinal stromal tumours. | Oncology 20100101 |
| Good clinical practice in chronic myeloid leukemia: advances and prospects at the Institute of Oncology of Moldova. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20100101 |
| Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? | Swiss medical weekly 20100101 |
| Late hepatic metastasis in the evolution of gastrointestinal stromal tumors. | Hepato-gastroenterology 20100101 |
| WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. | International journal of medical sciences 20100101 |
| Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. | Neoplasma 20100101 |
| Involvement of mast cells in systemic sclerosis. | Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20100101 |
| A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. | BMC cancer 20100101 |
| Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. | Molecular cancer 20100101 |
| Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. | Molecular cancer 20100101 |
| Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review. | World journal of surgical oncology 20100101 |
| Validation of an HPLC method for determination of imatinib mesylate in rat serum and its application in a pharmacokinetic study. | Journal of chromatographic science 20100101 |
| Cytologic diagnosis of chordoma in a peritoneal effusion: a case report. | Acta cytologica 20100101 |
| Effects of imatinib mesylate in interstitial cells of Cajal from murine small intestine. | Biological & pharmaceutical bulletin 20100101 |
| [Treatment of chronic myeloid leukemia with imatinib. A case of translational medicine]. | Medicina 20100101 |
| Granulocytic sarcoma of the stomach: relapse after hematopoietic stem-cell transplantation for chronic myeloid leukemia. | Hematology/oncology and stem cell therapy 20100101 |
| Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia. | Internal medicine (Tokyo, Japan) 20100101 |
| Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. | Internal medicine (Tokyo, Japan) 20100101 |
| Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. | BMC medical genetics 20100101 |
| Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy. | Srpski arhiv za celokupno lekarstvo 20100101 |
| [Therapeutic observance in haematology: the particular case of chronic myeloid leukemia]. | Revue medicale de Liege 20100101 |
| In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. | BMC cancer 20100101 |
| [Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits]. | Therapie 20100101 |
| Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor. | BMC cancer 20100101 |
| Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia? | Journal of postgraduate medicine 20100101 |
| Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia. | Asian Pacific journal of cancer prevention : APJCP 20100101 |
| Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review. | Tumori 20100101 |
| Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib. | Acta haematologica 20100101 |
| [Gastrointestinal stromal tumor (GIST)--medical rarities?]. | Chirurgia (Bucharest, Romania : 1990) 20100101 |
| Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. | PloS one 20100101 |
| Colorectal GISTs: from presentation to survival. An analysis of 13 cases. | Hepato-gastroenterology 20100101 |
| Gastrointestinal stromal tumors: a 7-year experience from a tertiary care hospital. | Indian journal of pathology & microbiology 20100101 |
| Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. | Journal of medical economics 20100101 |
| Gastrointestinal stromal tumors: review on morphology, molecular pathology, diagnostics, prognosis and treatment options. | Acta gastro-enterologica Belgica 20100101 |
| First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. | Journal of hematology & oncology 20100101 |
| Synchronous carcinoma breast with chronic myelogenous leukemia: a rare presentation. | Indian journal of cancer 20100101 |
| Cyclooxygenase-2 expression in gastrointestinal stromal tumours. | Asian Pacific journal of cancer prevention : APJCP 20100101 |
| Treatment of gastrointestinal stromal tumors--initial experience. | Chirurgia (Bucharest, Romania : 1990) 20100101 |
| Chronic myeloid leukemia--from the National to the European Registry--limited experience of a single center. | Romanian journal of internal medicine = Revue roumaine de medecine interne 20100101 |
| Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. | Journal of experimental & clinical cancer research : CR 20100101 |
| Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment. | Clinical & developmental immunology 20100101 |
| Perspectives in the development of novel treatment approaches. | Tumori 20100101 |
| [Expression of c-kit and PDGFR and possibility of tyrosine kinase inhibitor employment in treatment of neuroblastoma in children]. | Przeglad lekarski 20100101 |
| Intestinal permeability, vitamin A absorption and serum alpha-tocopherol in gastrointestinal stromal tumor patients treated with imatinib. | Journal of nutritional science and vitaminology 20100101 |
| Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST). | Nuclear medicine review. Central & Eastern Europe 20100101 |
| Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy. | Cancer biomarkers : section A of Disease markers 20100101 |
| Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? | Blood 20091224 |
| Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry. | Organic & biomolecular chemistry 20091221 |
| Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. | Veterinary immunology and immunopathology 20091215 |
| Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). | Pediatric blood & cancer 20091215 |
| Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. | British journal of cancer 20091215 |
| Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. | Cancer research 20091215 |
| Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. | Blood 20091210 |
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091210 |
| Chakalaka-induced vasodilatation in patients with chronic myeloid leukaemia on tyrosine kinase inhibitors. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20091207 |
| Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent. | Hematological oncology 20091201 |
| Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). | Neuro-oncology 20091201 |
| Imatinib in breast milk. | Annals of hematology 20091201 |
| Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. | Biomedical chromatography : BMC 20091201 |
| Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. | Leukemia research 20091201 |
| Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia. | Leukemia research 20091201 |
| Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. | Haematologica 20091201 |
| The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. | Pediatric blood & cancer 20091201 |
| Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. | Leukemia research 20091201 |
| Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. | American journal of clinical oncology 20091201 |
| High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. | Haematologica 20091201 |
| Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML). | European journal of haematology 20091201 |
| Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20091201 |
| [Internal medical therapy of gastrointestinal stroma tumors]. | Der Radiologe 20091201 |
| Clinical pharmacokinetics of tyrosine kinase inhibitors. | Cancer treatment reviews 20091201 |
| A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. | British journal of haematology 20091201 |
| Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression. | Toxicology in vitro : an international journal published in association with BIBRA 20091201 |
| Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. | Cancer 20091201 |
| Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment. | Japanese journal of clinical oncology 20091201 |
| Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry. | Therapeutic drug monitoring 20091201 |
| The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091201 |
| Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. | American journal of hematology 20091201 |
| On being metachromatic: mystique and misunderstanding in mastocytosis. | American journal of hematology 20091201 |
| Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. | Cancer research 20091201 |
| Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. | The Journal of allergy and clinical immunology 20091201 |
| Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. | Leukemia & lymphoma 20091201 |
| [Aspects of surgical treatment for gastro-intestinal stromal tumors]. | Der Radiologe 20091201 |
| Gastrointestinal stromal tumors: diagnostics, therapy and beyond? | Minerva gastroenterologica e dietologica 20091201 |
| Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months. | The oncologist 20091201 |
| An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. | American journal of clinical oncology 20091201 |
| Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20091201 |
| [A case of rectal GIST treated with imatinib mesylate neoadjuvant therapy to preserve the anus]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20091201 |
| Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era. | International journal of clinical oncology 20091201 |
| Bartonella henselae neuroretinitis in a 15-year-old girl with chronic myelogenous leukemia. | Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 20091201 |
| [Successful resection of an advanced gastrointestinal stromal tumor by neoadjuvant chemotherapy with imatinib- a case report]. | Gan to kagaku ryoho. Cancer & chemotherapy 20091201 |
| Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study. | Polskie Archiwum Medycyny Wewnetrznej 20091201 |
| A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report. | Polskie Archiwum Medycyny Wewnetrznej 20091201 |
| Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. | Leukemia & lymphoma 20091201 |
| Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors. | Leukemia & lymphoma 20091201 |
| Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors. | Leukemia & lymphoma 20091201 |
| Tyrosine kinase inhibitor-induced macrocytosis. | Anticancer research 20091201 |
| T-regulatory cell response in psoriasis and changes with imatinib therapy. | Clinical and experimental dermatology 20091201 |
| [Resistance against tyrosine kinase inhibitors in the treatment of GIST. New therapeutic possibilities appear]. | Lakartidningen 20091201 |
| Imatinib: high dose versus standard dose. | Clinical advances in hematology & oncology : H&O 20091201 |
| The GLIVEC international patient assistance programme: the Nairobi experience. | East African medical journal 20091201 |
| [A case of lichen planus associated to treatment with imatinib]. | Medicina clinica 20091128 |
| The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. | Blood 20091112 |
| Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. | Clinical science (London, England : 1979) 20091109 |
| Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. | Leukemia research 20091101 |
| Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy. | Annals of hematology 20091101 |
| Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells. | Leukemia research 20091101 |
| ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. | Leukemia research 20091101 |
| Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature. | Leukemia research 20091101 |
| Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib? | Leukemia research 20091101 |
| Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. | Biochemical pharmacology 20091101 |
| Response to imatinib plus sirolimus in advanced chordoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20091101 |
| Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery. | Leukemia research 20091101 |
| PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. | Leukemia 20091101 |
| JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. | Leukemia research 20091101 |
| Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era? | Leukemia research 20091101 |
| Imatinib mesylate causes growth plate closure in vivo. | Leukemia 20091101 |
| Dynamin- and lipid raft-dependent entry of decay-accelerating factor (DAF)-binding and non-DAF-binding coxsackieviruses into nonpolarized cells. | Journal of virology 20091101 |
| Harmonization of molecular monitoring of CML therapy in Europe. | Leukemia 20091101 |
| Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. | Leukemia 20091101 |
| Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20091101 |
| Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models? | European journal of cancer (Oxford, England : 1990) 20091101 |
| MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N'-nitro-N-nitrosoguanidine. | Experimental cell research 20091101 |
| Predicting recurrence-free survival after surgery for GIST. | The Lancet. Oncology 20091101 |
| Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. | The Lancet. Oncology 20091101 |
| Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro. | International journal of radiation oncology, biology, physics 20091101 |
| Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091101 |
| Gastric oncology: an update. | Current opinion in gastroenterology 20091101 |
| Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20091101 |
| The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. | Cell cycle (Georgetown, Tex.) 20091101 |
| The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy. | Leukemia & lymphoma 20091101 |
| [Positron emission tomography and evaluation of response to targeted therapies]. | Bulletin du cancer 20091101 |
| ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. | Haematologica 20091101 |
| Overcoming resistance in chronic myelogenous leukemia. | Leukemia & lymphoma 20091101 |
| Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. | Leukemia & lymphoma 20091101 |
| [Targeted therapies in soft-tissue and visceral sarcomas]. | Annales de pathologie 20091101 |
| Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome. | Archives of dermatology 20091101 |
| Issues of imatinib and pregnancy outcome. | Journal of the National Comprehensive Cancer Network : JNCCN 20091101 |
| Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. | Clinical breast cancer 20091101 |
| Diffuse pigmentation of the palate. | Journal - Oklahoma Dental Association 20091101 |
| Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20091101 |
| Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. | Anticancer research 20091101 |
| Influence of imatinib mesylate on radiosensitivity of astrocytoma cells. | Anticancer research 20091101 |
| A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence. | Anticancer research 20091101 |
| [A patient with acute Philadelphia-chromosome-positive mixed phenotype leukemia developing ecthyma gangrenosum while undergoing combined imatinib mesylate chemotherapy]. | Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20091101 |
| [Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleural metastasis]. | Gan to kagaku ryoho. Cancer & chemotherapy 20091101 |
| [A case of rapid growth GIST successfully treated with resection after long-term use of imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20091101 |
| Managing relapse of CML using therapeutic imatinib plasma level. | Clinical advances in hematology & oncology : H&O 20091101 |
| Review: Imatinib plasma trough levels in the management of CML: Ready for prime time? | Clinical advances in hematology & oncology : H&O 20091101 |
| Drug plasma monitoring in CML and GIST: A case-based discussion. | Clinical advances in hematology & oncology : H&O 20091101 |
| Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia. | Clinical therapeutics 20091101 |
| [Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China.]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20091101 |
| Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis. | Future medicinal chemistry 20091101 |
| Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. | Blood 20091022 |
| Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells. | Molecules (Basel, Switzerland) 20091019 |
| [Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans]. | Orvosi hetilap 20091011 |
| Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. | Journal of cellular and molecular medicine 20091001 |
| Lichenoid drug eruption related to imatinib: report of a new case and review of the literature. | Clinical and experimental dermatology 20091001 |
| The role of tyrosine kinase inhibitors in tuberous sclerosis. | British journal of haematology 20091001 |
| In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice. | Laboratory investigation; a journal of technical methods and pathology 20091001 |
| Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. | International journal of hematology 20091001 |
| Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib. | Leukemia & lymphoma 20091001 |
| A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. | American journal of hematology 20091001 |
| Neurological adverse effects caused by cytotoxic and targeted therapies. | Nature reviews. Clinical oncology 20091001 |
| Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. | Haematologica 20091001 |
| High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001 |
| A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. | Therapeutic drug monitoring 20091001 |
| Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy. | Acta radiologica (Stockholm, Sweden : 1987) 20091001 |
| Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion. | Cancer genetics and cytogenetics 20091001 |
| Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. | Journal of clinical pharmacy and therapeutics 20091001 |
| Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma. | Leukemia & lymphoma 20091001 |
| Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia. | Leukemia & lymphoma 20091001 |
| Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells. | Cancer biology & therapy 20091001 |
| Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. | Nature medicine 20091001 |
| Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20091001 |
| Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options. | Clinical journal of oncology nursing 20091001 |
| Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment? | Clinical journal of oncology nursing 20091001 |
| BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure. | Hong Kong medical journal = Xianggang yi xue za zhi 20091001 |
| Preserving fertility during cancer treatment. | Nature medicine 20091001 |
| Lasker Awards and papal portraiture: turning fields upside down. | Nature medicine 20091001 |
| Perspectives on the development of imatinib and the future of cancer research. | Nature medicine 20091001 |
| Attacking cancer at its foundation. | Nature medicine 20091001 |
| Shifting paradigms: the seeds of oncogene addiction. | Nature medicine 20091001 |
| Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia. | Genetic testing and molecular biomarkers 20091001 |
| [A successfully resected case of liver metastasis of gastrointestinal stromal tumor responding to neoadjuvant chemotherapy with imatinib mesylate and interventional radiology]. | Gan to kagaku ryoho. Cancer & chemotherapy 20091001 |
| Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine. | Internal medicine journal 20091001 |
| [History, current status, and future prospects in clinical study of myeloid leukemia]. | Nihon rinsho. Japanese journal of clinical medicine 20091001 |
| [Molecular pathogenesis of chronic myeloid leukemia]. | Nihon rinsho. Japanese journal of clinical medicine 20091001 |
| [Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias]. | Nihon rinsho. Japanese journal of clinical medicine 20091001 |
| [Current clinical trials using new targeted therapies for myeloid leukemia and the research trends]. | Nihon rinsho. Japanese journal of clinical medicine 20091001 |
| [Clinical problems in the treatment of myeloid leukemia in childhood]. | Nihon rinsho. Japanese journal of clinical medicine 20091001 |
| [Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST)]. | Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20091001 |
| [Clinical progress in chronic myelogenous leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20091001 |
| [Autophagy in hematologic malignancies]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20091001 |
| Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. | Clinical therapeutics 20091001 |
| [Chinese consensus in diagnosis and treatment of gastrointestinal stromal tumor]. | Zhonghua bing li xue za zhi = Chinese journal of pathology 20091001 |
| Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091001 |
| Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. | Blood 20090924 |
| Attacking cancer at its root. | Cell 20090918 |
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). | Cancer 20090915 |
| A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090915 |
| Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090915 |
| Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090915 |
| Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. | Blood 20090910 |
| Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way. | Cancer cell 20090908 |
| The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. | Cancer cell 20090908 |
| Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. | Blood 20090903 |
| Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. | Blood 20090903 |
| Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl. | FEBS letters 20090903 |
| Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations. | Leukemia research 20090901 |
| Fatal combined immune hemolytic anemia after double cord blood transplantation in imatinib-resistant CML. | Bone marrow transplantation 20090901 |
| Inhibition of all-trans retinoic acid-induced granulocytic differentiation of WEHI-3B D+ cells by forced expression of SCL (TAL1) and GATA-1. | Leukemia research 20090901 |
| Hypolipemiant besides antileukemic effect of imatinib mesylate. | Leukemia research 20090901 |
| BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression. | Leukemia 20090901 |
| Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts. | Leukemia research 20090901 |
| Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. | Leukemia 20090901 |
| Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain. | Leukemia research 20090901 |
| Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia. | Leukemia 20090901 |
| Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST. | Leukemia research 20090901 |
| Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. | Leukemia research 20090901 |
| Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. | European journal of cancer (Oxford, England : 1990) 20090901 |
| A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. | European journal of cancer (Oxford, England : 1990) 20090901 |
| [Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets]. | Der Pathologe 20090901 |
| Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. | Cancer 20090901 |
| PDGFR inhibition in brain tumours--oft expectation fails where most it promises. | European journal of cancer (Oxford, England : 1990) 20090901 |
| Impact of allogeneic haematopoietic stem cell transplantation in the outcome of Ph+ acute lymphoblastic leukaemia treated with an imatinib-containing regimen. | British journal of haematology 20090901 |
| Phosphorylation and consequent stimulation of the tyrosine kinase c-Abl by PKA in mouse spermatozoa; its implications during capacitation. | Developmental biology 20090901 |
| A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement. | International journal of hematology 20090901 |
| A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. | Haematologica 20090901 |
| RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia. | British journal of haematology 20090901 |
| Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. | Leukemia 20090901 |
| Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090901 |
| Imatinib and beyond--exploring the full potential of targeted therapy for CML. | Nature reviews. Clinical oncology 20090901 |
| Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. | British journal of pharmacology 20090901 |
| Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? | Current oncology reports 20090901 |
| Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. | Pharmacotherapy 20090901 |
| Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. | The Journal of molecular diagnostics : JMD 20090901 |
| Presence of c-KIT-positive mast cells in obliterative bronchiolitis from diverse causes. | Archives of pathology & laboratory medicine 20090901 |
| Activate and resist: L576P-KIT in GIST. | Molecular cancer therapeutics 20090901 |
| Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. | Molecular cancer therapeutics 20090901 |
| Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia. | Haematologica 20090901 |
| The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. | Molecular cancer research : MCR 20090901 |
| Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. | British journal of clinical pharmacology 20090901 |
| Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. | PLoS computational biology 20090901 |
| Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. | Expert review of anticancer therapy 20090901 |
| Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities. | PLoS computational biology 20090901 |
| Advances in the treatment of gastrointestinal stromal tumor. | Advances in therapy 20090901 |
| [Expression of hOCT1 in patients with chronic myelogeneous leukemia treated by imatinib mesylate]. | Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20090901 |
| [Influence of hOCT1 polymorphism on imatinib mesylate effectiveness in chronic myelogenous leukemia patients]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090901 |
| Introduction: CML in the imatinib era. | Best practice & research. Clinical haematology 20090901 |
| CML: a model for targeted therapy. | Best practice & research. Clinical haematology 20090901 |
| Treatment strategies for CML. | Best practice & research. Clinical haematology 20090901 |
| Interferon in chronic myeloid leukaemia: past and future. | Best practice & research. Clinical haematology 20090901 |
| Prognostic factors in chronic myeloid leukaemia. | Best practice & research. Clinical haematology 20090901 |
| Pharmacologic monitoring and determinants of intracytoplasmic drug levels. | Best practice & research. Clinical haematology 20090901 |
| CML in pregnancy and childhood. | Best practice & research. Clinical haematology 20090901 |
| [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901 |
| [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures]. | Zhonghua bing li xue za zhi = Chinese journal of pathology 20090901 |
| [Carney triad: clinicopathologic study of 2 cases with molecular analysis]. | Zhonghua bing li xue za zhi = Chinese journal of pathology 20090901 |
| The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. | Blood 20090827 |
| Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090820 |
| Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. | Cancer 20090815 |
| Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. | Cancer research 20090815 |
| Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. | Cancer cell 20090804 |
| A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. | Leukemia research 20090801 |
| Imatinib-induced pseudoporphyria. | Clinical and experimental dermatology 20090801 |
| Imatinib use during pregnancy and breast feeding: a case report and review of the literature. | Archives of gynecology and obstetrics 20090801 |
| Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. | Leukemia research 20090801 |
| Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature. | Leukemia research 20090801 |
| Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. | Bone marrow transplantation 20090801 |
| Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. | Bone marrow transplantation 20090801 |
| Vitiligo-like lesions in an adult patient treated with Imatinib mesylate. | Leukemia research 20090801 |
| Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib. | Bone marrow transplantation 20090801 |
| Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT. | Bone marrow transplantation 20090801 |
| Berbamine derivatives: a novel class of compounds for anti-leukemia activity. | European journal of medicinal chemistry 20090801 |
| Imatinib attenuates skeletal muscle dystrophy in mdx mice. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20090801 |
| t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. | Cancer investigation 20090801 |
| Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells. | Leukemia 20090801 |
| Endogenous cAbl regulates receptor endocytosis. | Cellular signalling 20090801 |
| Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. | Leukemia research 20090801 |
| Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. | Leukemia research 20090801 |
| MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines. | Cancer chemotherapy and pharmacology 20090801 |
| Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. | Cancer chemotherapy and pharmacology 20090801 |
| The therapeutic benefits of heme oxygenase (HO-1) inhibition in the management of systemic malignancies besides hepatocellular carcinomas. | International journal of cancer 20090801 |
| STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner. | Biochemical pharmacology 20090801 |
| Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090801 |
| Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090801 |
| The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. | Bioorganic & medicinal chemistry letters 20090801 |
| Abl knockout differentially affects p130 Crk-associated substrate, vinculin, and paxillin in blood vessels of mice. | American journal of physiology. Heart and circulatory physiology 20090801 |
| c-Kit function is necessary for in vitro myogenic differentiation of bone marrow hematopoietic cells. | Stem cells (Dayton, Ohio) 20090801 |
| Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib. | Haematologica 20090801 |
| A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line. | Leukemia & lymphoma 20090801 |
| Abnormal centrosome-centriole cycle in chronic myeloid leukaemia? | British journal of haematology 20090801 |
| The enhancement of interstitial transport of a doxorubicin-lactosaminated albumin conjugate by imatinib: in rat hepatocellular carcinoma it is not preferentially higher than that in liver and bone marrow. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090801 |
| Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. | Cancer research 20090801 |
| Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5. | The Journal of pediatrics 20090801 |
| Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment. | AJR. American journal of roentgenology 20090801 |
| Pulmonary metastases from parachordoma. | The Annals of thoracic surgery 20090801 |
| Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate. | Hematology (Amsterdam, Netherlands) 20090801 |
| Resolution of rheumatoid arthritis symptoms with imatinib mesylate. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20090801 |
| Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. | Future oncology (London, England) 20090801 |
| Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. | Seminars in oncology 20090801 |
| Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. | Molecular cancer therapeutics 20090801 |
| Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. | Molecular cancer therapeutics 20090801 |
| Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. | Current cancer drug targets 20090801 |
| Langerhans cell histiocytosis: treatment failure with imatinib. | Archives of dermatology 20090801 |
| Influence of late treatment on how chronic myeloid leukemia responds to imatinib. | Clinics (Sao Paulo, Brazil) 20090801 |
| Downstaging of a rectal gastrointestinal stromal tumor by neoadjuvant imatinib therapy allowing for a conservative surgical approach. | Clinics (Sao Paulo, Brazil) 20090801 |
| Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. | Clinical lymphoma & myeloma 20090801 |
| [Immunological evaluation for CML and its possibility for an immunotherapy]. | Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20090801 |
| Old disease, new targets. Part-II, haematological malignancies. | JPMA. The Journal of the Pakistan Medical Association 20090801 |
| [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090801 |
| Imatinib mesylate ameliorates the dystrophic phenotype in exercised mdx mice. | Journal of neuroimmunology 20090725 |
| Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090720 |
| Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. | Blood 20090716 |
| Imatinib for refractory chronic graft-versus-host disease with fibrotic features. | Blood 20090716 |
| NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. | International journal of cancer 20090715 |
| Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715 |
| Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090715 |
| JAK2 inhibitors: not the next imatinib but researchers see other possibilities. | Journal of the National Cancer Institute 20090715 |
| Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. | Blood 20090709 |
| Prognosis and predictive value of KIT exon 11 deletion in GISTs. | British journal of cancer 20090707 |
| Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia. | Pathologie-biologie 20090701 |
| Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. | Leukemia research 20090701 |
| Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090701 |
| Spontaneous spinal epidural hematoma as the initial presentation of leukemia. | European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20090701 |
| Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. | Journal of neuro-oncology 20090701 |
| Hits and misses in targeting pediatric cancers. | Pediatric blood & cancer 20090701 |
| Presentation of childhood CML mimicking bone sarcoma. | Pediatric blood & cancer 20090701 |
| Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. | European journal of haematology 20090701 |
| Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy. | Investigative ophthalmology & visual science 20090701 |
| On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study. | Vascular pharmacology 20090701 |
| Merkel cell carcinoma: lack of KIT positivity and implications for the use of imatinib mesylate. | Applied immunohistochemistry & molecular morphology : AIMM 20090701 |
| Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. | European journal of cancer (Oxford, England : 1990) 20090701 |
| Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells. | International journal of cancer 20090701 |
| c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis. | Journal of cellular physiology 20090701 |
| The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism. | Leukemia research 20090701 |
| C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival. | Cellular signalling 20090701 |
| Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. | Pediatric blood & cancer 20090701 |
| Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience. | European journal of gastroenterology & hepatology 20090701 |
| [Endomyocardial fibrosis in chronic eosinophilic leukemia]. | RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 20090701 |
| Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. | Cancer 20090701 |
| Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. | European journal of cancer (Oxford, England : 1990) 20090701 |
| Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701 |
| Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701 |
| High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene. | International journal of hematology 20090701 |
| Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. | International journal of hematology 20090701 |
| Imatinib: a designer drug, another cutaneous complication. | Clinical and experimental dermatology 20090701 |
| Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour? | Current opinion in oncology 20090701 |
| [Surgical treatment of an advanced GIST the age of imatinib]. | Cirugia espanola 20090701 |
| Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. | British journal of haematology 20090701 |
| The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway. | Anatomical record (Hoboken, N.J. : 2007) 20090701 |
| Plasticity of interstitial cells of cajal: a study in the small intestine of adult Guinea pigs. | Anatomical record (Hoboken, N.J. : 2007) 20090701 |
| S-phase fraction as response marker in patients with chronic myeloid leukemia. | Leukemia & lymphoma 20090701 |
| Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. | Molecular cancer therapeutics 20090701 |
| Outpacing cancer. | Nature medicine 20090701 |
| Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. | Archives of dermatology 20090701 |
| [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090701 |
| Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20090701 |
| Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. | Clinical therapeutics 20090701 |
| [Eosinophils and related diseases]. | Zhonghua bing li xue za zhi = Chinese journal of pathology 20090701 |
| Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. | Yonsei medical journal 20090630 |
| Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. | Blood 20090618 |
| Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. | Blood 20090618 |
| New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090615 |
| Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). | Cancer research 20090615 |
| Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks. | The Journal of biological chemistry 20090605 |
| Persistence of molecular remission throughout pregnancy in CML after imatinib. | Leukemia research 20090601 |
| Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. | Leukemia research 20090601 |
| Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia. | Leukemia research 20090601 |
| Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. | Leukemia research 20090601 |
| Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase. | Leukemia research 20090601 |
| Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis. | Leukemia research 20090601 |
| Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia. | Leukemia research 20090601 |
| Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia. | Leukemia 20090601 |
| Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? | Cancer chemotherapy and pharmacology 20090601 |
| Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase. | Leukemia 20090601 |
| A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. | Allergy 20090601 |
| Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. | European journal of clinical pharmacology 20090601 |
| Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy. | Leukemia 20090601 |
| Genome-wide identification of genes required for yeast growth under imatinib stress: vacuolar H+-ATPase function is an important target of this anticancer drug. | Omics : a journal of integrative biology 20090601 |
| A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. | Leukemia 20090601 |
| Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. | Cancer 20090601 |
| Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. | Drug metabolism and disposition: the biological fate of chemicals 20090601 |
| Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. | Leukemia 20090601 |
| Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. | The Journal of allergy and clinical immunology 20090601 |
| The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib. | Haematologica 20090601 |
| Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. | British journal of haematology 20090601 |
| Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient. | American journal of hematology 20090601 |
| Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. | Experimental hematology 20090601 |
| Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. | International journal of hematology 20090601 |
| Surgical management of gastrointestinal stromal tumours. | The British journal of surgery 20090601 |
| A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. | International journal of hematology 20090601 |
| Discontinuing imatinib in chronic myeloid leukemia: don't try this at home. | Leukemia & lymphoma 20090601 |
| Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090601 |
| Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib. | Leukemia & lymphoma 20090601 |
| Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. | Leukemia & lymphoma 20090601 |
| Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues. | Leukemia & lymphoma 20090601 |
| Chronic myelogenous leukaemia market. | Nature reviews. Drug discovery 20090601 |
| Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells. | Hematology (Amsterdam, Netherlands) 20090601 |
| Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer. | Thrombosis and haemostasis 20090601 |
| Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. | Expert review of anticancer therapy 20090601 |
| Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia. | The Journal of rheumatology 20090601 |
| Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL. | Current drug targets 20090601 |
| Basis for resistance to imatinib in 16 BCR-ABL mutants as determined using molecular dynamics. | Recent patents on anti-cancer drug discovery 20090601 |
| Response dynamics in chronic-phase chronic myeloid leukemia. | Clinical lymphoma & myeloma 20090601 |
| [A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090601 |
| Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. | Transplantation proceedings 20090601 |
| First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. | Current opinion in oncology 20090601 |
| [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20090601 |
| Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. | Internal medicine journal 20090601 |
| Gastrointestinal stromal tumor of the stomach with extremely slow-growing hematogenous metastasis. | International journal of clinical oncology 20090601 |
| [Imaging follow-up of gastrointestinal stromal tumors (GIST) during therapy: a case report]. | Journal de radiologie 20090601 |
| Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications. | Histopathology 20090601 |
| The impact of gene profiling in chronic myeloid leukaemia. | Best practice & research. Clinical haematology 20090601 |
| [The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090601 |
| [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis]. | Zhonghua wai ke za zhi [Chinese journal of surgery] 20090601 |
| Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. | Blood 20090528 |
| Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. | Blood 20090521 |
| Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. | Cancer 20090515 |
| Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090515 |
| Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. | Cancer research 20090515 |
| Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. | Blood 20090507 |
| Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. | Blood 20090507 |
| BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). | American journal of hematology 20090501 |
| Imatinib resistance in multidrug-resistant K562 human leukemic cells. | Leukemia research 20090501 |
| Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. | Cancer chemotherapy and pharmacology 20090501 |
| Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. | Lung cancer (Amsterdam, Netherlands) 20090501 |
| Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. | Leukemia 20090501 |
| Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease. | Leukemia research 20090501 |
| Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia? | Leukemia research 20090501 |
| Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib. | Leukemia research 20090501 |
| Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells. | Leukemia 20090501 |
| Current treatment options in dermatofibrosarcoma protuberans. | Journal of cancer research and clinical oncology 20090501 |
| The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. | Drug metabolism and disposition: the biological fate of chemicals 20090501 |
| Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. | Kidney international 20090501 |
| The hypereosinophilic syndromes: current concepts and treatments. | British journal of haematology 20090501 |
| Stage-specific effect of inhibition of autophagy on chemotherapy-induced cytotoxicity. | Autophagy 20090501 |
| c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. | Histology and histopathology 20090501 |
| Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). | European journal of cancer (Oxford, England : 1990) 20090501 |
| First-line therapy for chronic myeloid leukemia: Past, present, and future. | American journal of hematology 20090501 |
| t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia. | International journal of hematology 20090501 |
| Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. | The Annals of pharmacotherapy 20090501 |
| Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma. | Rapid communications in mass spectrometry : RCM 20090501 |
| Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. | American journal of hematology 20090501 |
| The CML stem cell: evolution of the progenitor. | Cell cycle (Georgetown, Tex.) 20090501 |
| Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse? | British journal of haematology 20090501 |
| Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. | International journal of hematology 20090501 |
| Characterization of imatinib metabolites in rat and human liver microsomes: differentiation of hydroxylation from N-oxidation by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. | Rapid communications in mass spectrometry : RCM 20090501 |
| Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. | International journal of hematology 20090501 |
| Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. | The Journal of clinical investigation 20090501 |
| Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. | Cancer research 20090501 |
| Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance. | Leukemia & lymphoma 20090501 |
| Surgical resection of esophageal gastrointestinal stromal tumors. | The Annals of thoracic surgery 20090501 |
| Invited commentary. | The Annals of thoracic surgery 20090501 |
| Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. | Cancer research 20090501 |
| Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. | Cancer genetics and cytogenetics 20090501 |
| Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. | Haematologica 20090501 |
| Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. | The oncologist 20090501 |
| Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. | Molecular cancer therapeutics 20090501 |
| New paradigms in gastrointestinal stromal tumour management. | Annals of oncology : official journal of the European Society for Medical Oncology 20090501 |
| c-KIT in uveal melanoma: big fish or red herring? | Archives of ophthalmology (Chicago, Ill. : 1960) 20090501 |
| Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate. | Bone 20090501 |
| A case of cutaneous Rosai-Dorfman disease refractory to imatinib therapy. | Archives of dermatology 20090501 |
| Gastrointestinal stromal tumor of the esophagus. | Journal of the National Medical Association 20090501 |
| Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. | Journal of cutaneous pathology 20090501 |
| Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. | The Biochemical journal 20090428 |
| Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases. | Journal of medicinal chemistry 20090423 |
| Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. | World journal of gastroenterology 20090421 |
| Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. | Cancer research 20090415 |
| [Spontaneous pneumothorax, an unusual manifestation of imatinib-resistant chronic eosinophilic leukemia: an autopsy study]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090410 |
| Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. | Blood 20090409 |
| Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. | Oncogene 20090409 |
| Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R. | The EMBO journal 20090408 |
| bFGF rescues imatinib/STI571-induced apoptosis of sis-NIH3T3 fibroblasts. | Biochemical and biophysical research communications 20090403 |
| Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients. | Annals of hematology 20090401 |
| EVI1, BAALC and AME: prevalence of the secondary mutations in chronic and accelerated phases of chronic myeloid leukemia patients from eastern India. | Leukemia research 20090401 |
| Is imatinib safe during pregnancy? | Leukemia research 20090401 |
| Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia. | Leukemia research 20090401 |
| A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. | Annals of surgical oncology 20090401 |
| Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT. | Bone marrow transplantation 20090401 |
| Skin and oral lesions associated to imatinib mesylate therapy. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20090401 |
| Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma. | Pediatric blood & cancer 20090401 |
| Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up. | British journal of haematology 20090401 |
| The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. | Leukemia 20090401 |
| Nanoneoadjuvant therapy of gastrointestinal stromal tumor (GIST). | Annals of surgical oncology 20090401 |
| Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. | The Journal of clinical endocrinology and metabolism 20090401 |
| Autophagy induction by trehalose counteracts cellular prion infection. | Autophagy 20090401 |
| Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. | European journal of haematology 20090401 |
| [Hematological disorders and hypereosinophilias]. | La Revue de medecine interne 20090401 |
| The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. | Current opinion in cell biology 20090401 |
| Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. | Clinical research in cardiology : official journal of the German Cardiac Society 20090401 |
| Preadipocyte apoptosis is prevented by macrophage-conditioned medium in a PDGF-dependent manner. | American journal of physiology. Cell physiology 20090401 |
| Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. | American journal of hematology 20090401 |
| Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia. | Cancer genetics and cytogenetics 20090401 |
| Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. | International journal of hematology 20090401 |
| Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo. | Acta pharmacologica Sinica 20090401 |
| Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. | Current rheumatology reports 20090401 |
| Effects of imatinib mesylate in osteoblastogenesis. | Experimental hematology 20090401 |
| Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells. | Cancer research 20090401 |
| Treatment of gastrointestinal stromal tumours: imatinib, sunitinib -- and then? | Expert opinion on investigational drugs 20090401 |
| Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. | Cancer control : journal of the Moffitt Cancer Center 20090401 |
| Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. | Cancer control : journal of the Moffitt Cancer Center 20090401 |
| The toxicities of modern targeted therapies: learning from the price of progress. | Targeted oncology 20090401 |
| Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. | Leukemia & lymphoma 20090401 |
| Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India. | Leukemia & lymphoma 20090401 |
| Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel. | Leukemia & lymphoma 20090401 |
| Maximum tolerated dose: clinical endpoint for a bygone era? | Targeted oncology 20090401 |
| [Strategy for patients with GIST after failure of imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090401 |
| [Circumventing resistance to imatinib therapy in chronic myeloid leukemia]. | Gan to kagaku ryoho. Cancer & chemotherapy 20090401 |
| Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. | Targeted oncology 20090401 |
| Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia. | Expert review of pharmacoeconomics & outcomes research 20090401 |
| [Imatinib]. | Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20090401 |
| Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. | Cancer biology & therapy 20090401 |
| [Imaging of gastrointestinal stromal tumors]. | Journal de radiologie 20090401 |
| New directions in the treatment of patients with chronic myeloid leukemia: introduction. | Seminars in hematology 20090401 |
| Optimizing first-line therapy for patients with chronic myeloid leukemia. | Seminars in hematology 20090401 |
| Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. | Seminars in hematology 20090401 |
| Practical considerations for the management of patients in the tyrosine kinase inhibitor era. | Seminars in hematology 20090401 |
| New directions in the treatment of imatinib failure and/or resistance. | Seminars in hematology 20090401 |
| Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. | Lancet (London, England) 20090328 |
| Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more? | Lancet (London, England) 20090328 |
| Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. | British journal of cancer 20090324 |
| Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells. | Biochemical and biophysical research communications 20090320 |
| Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. | Cancer research 20090315 |
| A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. | Oncogene 20090312 |
| Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. | Blood 20090305 |
| A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. | Proceedings of the National Academy of Sciences of the United States of America 20090303 |
| [Pharmacogenetics and tailored drug therapy]. | Ugeskrift for laeger 20090302 |
| Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib. | Leukemia research 20090301 |
| Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. | Leukemia research 20090301 |
| Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia. | Annals of hematology 20090301 |
| Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor. | Leukemia research 20090301 |
| Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on 'A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients' by Curvo et al. [Leuk. Res.]. | Leukemia research 20090301 |
| Antagonists of CD117 (cKit) signaling inhibit mast cell accumulation in healing skin wounds. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20090301 |
| c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors. | Journal of cellular physiology 20090301 |
| Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. | International journal of cancer 20090301 |
| Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. | International journal of cancer 20090301 |
| Catastrophic tumour lysis syndrome following single dose of imatinib. | European journal of haematology 20090301 |
| HCT116 cells deficient in p21(Waf1) are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. | DNA repair 20090301 |
| Growth deceleration in a girl treated with imatinib. | International journal of hematology 20090301 |
| N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide. | Apoptosis : an international journal on programmed cell death 20090301 |
| Proteasome proteolytic profile is linked to Bcr-Abl expression. | Experimental hematology 20090301 |
| Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells. | Basic & clinical pharmacology & toxicology 20090301 |
| A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib. | Respirology (Carlton, Vic.) 20090301 |
| Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells. | Oncology reports 20090301 |
| A pulse at the heart of targeted therapy. | Nature chemical biology 20090301 |
| Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090301 |
| Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. | The European respiratory journal 20090301 |
| Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease? | Leukemia & lymphoma 20090301 |
| Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. | Molecular cancer therapeutics 20090301 |
| Diagnosing gastrointestinal stromal tumors before the year 2000. | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20090301 |
| Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem. | Cardiovascular & hematological disorders drug targets 20090301 |
| A call for more dermatologic input into chronic graft-vs-host disease clinical trials. | Archives of dermatology 20090301 |
| [Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20090301 |
| [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20090301 |
| Cystic hepatic metastasis from gastrointestinal stromal tumor prior to imatinib mimicking a liver abscess. | Journal of gastrointestinal and liver diseases : JGLD 20090301 |
| Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro. | Leukemia & lymphoma 20090301 |
| Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009. | Current opinion in hematology 20090301 |
| Current standards and progress in understanding and treatment of GIST. | Swiss medical weekly 20090221 |
| Local delivery of poly lactic-co-glycolic acid microspheres containing imatinib mesylate inhibits intracranial xenograft glioma growth. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090215 |
| Is anticancer drug development heading in the right direction? | Cancer research 20090215 |
| Peritoneal tuberculosis after imatinib therapy. | Archives of internal medicine 20090209 |
| Imatinib resistance in CML. | Cancer letters 20090208 |
| T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense. | Journal of the National Cancer Institute 20090204 |
| [Major molecular response to imatinib in a patient with acute mixed lineage leukemia expressing a novel BCR/ABL transcript]. | Zhonghua yi xue za zhi 20090203 |
| The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. | Investigational new drugs 20090201 |
| Effect of antacid on imatinib absorption. | Cancer chemotherapy and pharmacology 20090201 |
| Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias. | Cancer chemotherapy and pharmacology 20090201 |
| Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. | Cancer chemotherapy and pharmacology 20090201 |
| Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. | Journal of cancer research and clinical oncology 20090201 |
| Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia. | Leukemia 20090201 |
| Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. | Leukemia research 20090201 |
| Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. | Leukemia research 20090201 |
| Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward? | Journal of cancer research and clinical oncology 20090201 |
| Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. | The American journal of surgical pathology 20090201 |
| Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. | Leukemia research 20090201 |
| Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. | Drug metabolism and disposition: the biological fate of chemicals 20090201 |
| Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. | Leukemia 20090201 |
| Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). | Genes, chromosomes & cancer 20090201 |
| The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells. | Biochemical pharmacology 20090201 |
| In vitro anti-leukaemia activity of sphingosine kinase inhibitor. | British journal of haematology 20090201 |
| Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). | European journal of radiology 20090201 |
| Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. | Japanese journal of clinical oncology 20090201 |
| Imaging in early phase childhood cancer trials. | Pediatric radiology 20090201 |
| Taming the induced folding of drug-targeted kinases. | Trends in pharmacological sciences 20090201 |
| Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation. | Haematologica 20090201 |
| Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. | Cancer 20090201 |
| The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Cancer 20090201 |
| Interaction of imatinib with liposomes: voltammetric and AFM characterization. | Bioelectrochemistry (Amsterdam, Netherlands) 20090201 |
| The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. | Haematologica 20090201 |
| Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. | Oncology reports 20090201 |
| Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. | Cancer genetics and cytogenetics 20090201 |
| Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. | Diabetes 20090201 |
| Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour. | The Australasian journal of dermatology 20090201 |
| Molecular framework for response to imatinib mesylate in systemic sclerosis. | Arthritis and rheumatism 20090201 |
| Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? | Mayo Clinic proceedings 20090201 |
| Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations. | Cancer biology & therapy 20090201 |
| Multidisciplinary treatment of gastrointestinal stromal tumors. | The Surgical clinics of North America 20090201 |
| Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090201 |
| Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. | The oncologist 20090201 |
| Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes. | Leukemia & lymphoma 20090201 |
| Gastrointestinal stromal tumor: a clinical overview. | Hematology/oncology clinics of North America 20090201 |
| Management of resectable gastrointestinal stromal tumor. | Hematology/oncology clinics of North America 20090201 |
| Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. | Hematology/oncology clinics of North America 20090201 |
| Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML. | Clinical advances in hematology & oncology : H&O 20090201 |
| Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST. | Clinical advances in hematology & oncology : H&O 20090201 |
| Promises and pitfalls of oral cancer chemotherapy. | Clinical advances in hematology & oncology : H&O 20090201 |
| [Review of 32 gastro-intestinal stromal tumours with CD117 antigen]. | La Tunisie medicale 20090201 |
| Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms. | Expert review of hematology 20090201 |
| Role of gene-expression profiling in chronic myeloid leukemia. | Expert review of hematology 20090201 |
| [Gastrointestinal stromal tumors in neurofibromatosis type 1]. | Orvosi hetilap 20090125 |
| Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120 |
| Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120 |
| [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences]. | Ugeskrift for laeger 20090119 |
| A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. | Molecular cell 20090116 |
| Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. | Cancer letters 20090108 |
| Dasatinib induces a response in chronic lymphocytic leukemia. | Blood 20090108 |
| Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20090101 |
| Imatinib-associated hyperpigmentation, a side effect that should be recognized. | Journal of the European Academy of Dermatology and Venereology : JEADV 20090101 |
| Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. | Cancer chemotherapy and pharmacology 20090101 |
| Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature. | Leukemia research 20090101 |
| Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. | Leukemia research 20090101 |
| Pregnancy in a patient with hypereosinophilic syndrome. | Leukemia research 20090101 |
| Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. | Annals of hematology 20090101 |
| Regression of central giant cell granuloma by a combination of imatinib and interferon: a case report. | The British journal of oral & maxillofacial surgery 20090101 |
| Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response. | Leukemia research 20090101 |
| Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. | Bone marrow transplantation 20090101 |
| Catalytically inactive SHIP2 inhibits proliferation by attenuating PDGF signaling in 3T3-L1 preadipocytes. | Journal of cellular physiology 20090101 |
| Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. | International journal of cancer 20090101 |
| A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. | Rheumatology (Oxford, England) 20090101 |
| beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. | Leukemia 20090101 |
| The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia. | Leukemia 20090101 |
| BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. | Cellular signalling 20090101 |
| Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain. | Molecular pharmacology 20090101 |
| Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. | Journal of surgical oncology 20090101 |
| Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). | The Journal of pathology 20090101 |
| 'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor. | Chemotherapy 20090101 |
| Mechanisms behind the synergistic effect of sirolimus and imatinib in preventing restenosis after intimal injury. | Journal of vascular research 20090101 |
| Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. | The Journal of urology 20090101 |
| Imatinib in the treatment of nephrogenic systemic fibrosis. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20090101 |
| Regulation of transferrin receptor 2 in human cancer cell lines. | Blood cells, molecules & diseases 20090101 |
| Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. | Journal of the American Society of Nephrology : JASN 20090101 |
| Synchronous small-cell lung cancer and gastrointestinal stromal tumor: a case report. | Presse medicale (Paris, France : 1983) 20090101 |
| Imatinib as a novel therapeutic approach for fibrotic disorders. | Rheumatology (Oxford, England) 20090101 |
| Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. | Cancer science 20090101 |
| C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. | ChemMedChem 20090101 |
| Fluorescence in situ hybridization dissection of a chronic myeloid leukemia case bearing the apparently balanced translocations (9;22)(q34;q11.2) and (11;11)(p15;q13). | Cancer genetics and cytogenetics 20090101 |
| The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. | International journal of oncology 20090101 |
| Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors. | International journal of hematology 20090101 |
| Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate. | International journal of hematology 20090101 |
| Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor. | Scandinavian journal of gastroenterology 20090101 |
| Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. | Arthritis and rheumatism 20090101 |
| Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090101 |
| Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. | Leukemia & lymphoma 20090101 |
| Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. | Molecular cancer therapeutics 20090101 |
| Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. | Molecular cancer therapeutics 20090101 |
| Successful treatment of refractory idiopathic hypereosinophilic syndrome with etoposide. | American journal of therapeutics 20090101 |
| Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. | BMC cancer 20090101 |
| Imatinib and its successors--how modern chemistry has changed drug development. | Current pharmaceutical design 20090101 |
| Upper abdominal mass with diagnostic dilemma. | Mymensingh medical journal : MMJ 20090101 |
| Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report. | Chemotherapy 20090101 |
| The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. | BMC cancer 20090101 |
| [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20090101 |
| The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). | BMC structural biology 20090101 |
| A gastrointestinal stromal tumor of the jejunum associated with intrahepatic cholangiocarcinoma and pulmonary hamartoma: a case report. | Acta oncologica (Stockholm, Sweden) 20090101 |
| Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia. | Internal medicine (Tokyo, Japan) 20090101 |
| Gastrointestinal stromal tumors (GISTs): a pathology view point. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090101 |
| [GIST: our experience]. | Il Giornale di chirurgia 20090101 |
| Perioperative treatment of gastrointestinal stromal tumors. | Oncology (Williston Park, N.Y.) 20090101 |
| Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation? | Oncology (Williston Park, N.Y.) 20090101 |
| Controversies in the surgical management of GIST in the era of imatinib. | Oncology (Williston Park, N.Y.) 20090101 |
| Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy. | World journal of surgical oncology 20090101 |
| Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. | Methods in molecular biology (Clifton, N.J.) 20090101 |
| A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. | Oncology 20090101 |
| Imatinib is a substrate for various multidrug resistance proteins. | Neoplasma 20090101 |
| Severe esophagitis in a patient with gastrointestinal stromal tumor treated with imatinib. | Endoscopy 20090101 |
| Targeted therapy and hematological malignancy. | Targeted oncology 20090101 |
| Treatment selection after imatinib resistance in chronic myeloid leukemia. | Targeted oncology 20090101 |
| Imatinib in the treatment of solid tumours. | Targeted oncology 20090101 |
| Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of type 1 diabetes. | TheScientificWorldJournal 20090101 |
| Suppression of vascular endothelial growth factor (VEGF) expression by targeting the Bcr-Abl oncogene and protein tyrosine kinase activity in Bcr-Abl-positive leukaemia cells. | The Journal of international medical research 20090101 |
| A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates. | Journal of biopharmaceutical statistics 20090101 |
| Exploiting the promiscuity of imatinib. | Journal of biology 20090101 |
| Stevens-Johnson syndrome induced by combination of imatinib and allopurinol. | Chemotherapy 20090101 |
| Repeated surgery improves survival in recurrent gastrointestinal stromal tumors: a retrospective analysis of 144 patients. | Digestive surgery 20090101 |
| Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia. | Acta dermato-venereologica 20090101 |
| Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia. | International archives of allergy and immunology 20090101 |
| [Gastrointestinal stromal tumour: our experience]. | Chirurgia italiana 20090101 |
| Tyrosine kinase inhibitors and solid tumours: case report and review of the literature. | Pharmacology 20090101 |
| Primary large gastrointestinal stromal tumor of the liver: report of a case. | Surgery today 20090101 |
| [Arsenic trioxide inhibits cell growth in imatinib-resistant bcr-abl mutant cell lines in vitro]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090101 |
| ERK2, but not ERK1, mediates acquired and 'de novo' resistance to imatinib mesylate: implication for CML therapy. | PloS one 20090101 |
| Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. | Modern rheumatology 20090101 |
| Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report. | Tumori 20090101 |
| WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance. | Neoplasma 20090101 |
| Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. | Journal of experimental & clinical cancer research : CR 20090101 |
| Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. | Acta haematologica 20090101 |
| Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. | PloS one 20090101 |
| Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases. | Acta haematologica 20090101 |
| Does imatinib mesylate therapy cause growth hormone deficiency? | Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20090101 |
| Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib. | Internal medicine (Tokyo, Japan) 20090101 |
| Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. | Molecular vision 20090101 |
| [Gastrointestinal stromal tumors: recommendations for diagnosis, treatment and aftercare in Austria]. | Wiener medizinische Wochenschrift (1946) 20090101 |
| [Surgical treatment of gastrointestinal stromal tumors]. | Wiener medizinische Wochenschrift (1946) 20090101 |
| [GIST: adjuvant treatment in Austria]. | Wiener medizinische Wochenschrift (1946) 20090101 |
| [Treatment of extensive disease]. | Wiener medizinische Wochenschrift (1946) 20090101 |
| [GIST: Imaging diagnosis, staging, and response assessment]. | Wiener medizinische Wochenschrift (1946) 20090101 |
| [Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases]. | Terapevticheskii arkhiv 20090101 |
| [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase]. | Terapevticheskii arkhiv 20090101 |
| MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. | Molecular cancer 20090101 |
| Imatinib in gastrointestinal stromal tumor: does treatment duration matter? | Oncology 20090101 |
| Lichen planus associated with imatinib mesylate. | Indian journal of dermatology, venereology and leprology 20090101 |
| Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type. | Indian journal of cancer 20090101 |
| Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia. | The Journal of international medical research 20090101 |
| [Glivec induced autoimmune hepatitis]. | Gastroenterologie clinique et biologique 20090101 |
| Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. | Clinical lymphoma & myeloma 20090101 |
| Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. | Clinical lymphoma & myeloma 20090101 |
| Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells. | Oncology research 20090101 |
| A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. | Drug safety 20090101 |
| Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). | PloS one 20090101 |
| Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. | Klinische Padiatrie 20090101 |
| The Lasker Foundation celebrates medical advances made with help from model organisms. | Disease models & mechanisms 20090101 |
| Extragastrointestinal stromal tumors of the omentum: review apropos of a case with a novel gain-of-function KIT mutation. | Journal of gastrointestinal cancer 20090101 |
| Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. | Molecular cancer 20090101 |
| Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. | Internal medicine (Tokyo, Japan) 20090101 |
| [Gastrointestinal stromal tumor (GIST): pathology in continuous development. Diagnostic-therapeutic strategies]. | Annali italiani di chirurgia 20090101 |
| Standard management of patients with chronic myeloid leukemia. | Clinical lymphoma & myeloma 20090101 |
| Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). | Hematology. American Society of Hematology. Education Program 20090101 |
| Initial treatment for patients with CML. | Hematology. American Society of Hematology. Education Program 20090101 |
| Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. | Hematology. American Society of Hematology. Education Program 20090101 |
| Monitoring disease response to tyrosine kinase inhibitor therapy in CML. | Hematology. American Society of Hematology. Education Program 20090101 |
| Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. | Radiation oncology (London, England) 20090101 |
| Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl. | PloS one 20090101 |
| Gastrointestinal stromal tumor: a bridge between bench and bedside. | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20090101 |
| [Imatinib-induced pulmonary toxicity]. | Gaceta medica de Mexico 20090101 |
| Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. | Hematology/oncology and stem cell therapy 20090101 |
| Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors. | Journal of cancer research and therapeutics 20090101 |
| Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era. | Asian Pacific journal of cancer prevention : APJCP 20090101 |
| Challenging diagnosis of ileal gastrointestinal stromal tumor presenting with obscure digestive bleeding. | Tumori 20090101 |
| Gastrointestinal stromal tumours. Is aggressive surgical treatment reasonable in locally advanced cases? | Chirurgia italiana 20090101 |
| Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20090101 |
| Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20090101 |
| Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase. | The Tokai journal of experimental and clinical medicine 20081220 |
| Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. | Blood 20081215 |
| Translation of the Philadelphia chromosome into therapy for CML. | Blood 20081215 |
| Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081215 |
| Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review. | Dermatology online journal 20081215 |
| Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. | Cancer cell 20081209 |
| Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. | European journal of pharmacology 20081203 |
| Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study. | Hematological oncology 20081201 |
| Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. | Journal of cancer research and clinical oncology 20081201 |
| An evaluation of the cardiotoxicity of imatinib mesylate. | Leukemia research 20081201 |
| An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. | Leukemia 20081201 |
| PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. | Leukemia research 20081201 |
| O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. | Investigational new drugs 20081201 |
| Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. | Leukemia research 20081201 |
| Platelet-derived growth factor receptor beta-subtype regulates proliferation and migration of gonocytes. | Endocrinology 20081201 |
| Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure. | Bone marrow transplantation 20081201 |
| European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. | Blood 20081201 |
| Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report. | Oral and maxillofacial surgery 20081201 |
| Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. | Leukemia 20081201 |
| Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. | Bone marrow transplantation 20081201 |
| Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. | Leukemia 20081201 |
| Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20081201 |
| Structural characterization of novel adenine dinucleotide phosphate conjugates of imatinib in incubations with rat and human liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20081201 |
| Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. | Haematologica 20081201 |
| Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. | British journal of haematology 20081201 |
| Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. | Melanoma research 20081201 |
| Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia. | International journal of laboratory hematology 20081201 |
| [Chronic myeloproliferative diseases. Current therapeutic standards and new developments]. | Der Internist 20081201 |
| FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor. | Nuclear medicine communications 20081201 |
| Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. | Current gastroenterology reports 20081201 |
| Phase II open label trial of imatinib in polycythemia rubra vera. | International journal of hematology 20081201 |
| Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib. | The Annals of pharmacotherapy 20081201 |
| Graft-versus-leukemia effects of transplantation and donor lymphocytes. | Blood 20081201 |
| PET/CT imaging of gastrointestinal stromal tumor with calcified peritoneal implants after imatinib therapy. | Clinical nuclear medicine 20081201 |
| Advanced mast cell disease: an Italian Hematological Multicenter experience. | International journal of hematology 20081201 |
| Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. | International journal of hematology 20081201 |
| Imatinib targeting of KIT-mutant oncoprotein in melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081201 |
| Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. | Leukemia & lymphoma 20081201 |
| Time for reform in the drug-development process. | The Lancet. Oncology 20081201 |
| BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. | Molecular cancer therapeutics 20081201 |
| Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage. | Hong Kong medical journal = Xianggang yi xue za zhi 20081201 |
| Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20081201 |
| A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. | Clinical breast cancer 20081201 |
| [Current state and the future of molecular target drugs: lessons learned from the success of imatinib]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20081201 |
| Transcriptome and proteome analyses of drug interactions with natural products. | Current drug metabolism 20081201 |
| Rho-signaling pathways in chronic myelogenous leukemia. | Cardiovascular & hematological disorders drug targets 20081201 |
| Sonography of multifocal Brucella orchitis. | Ultraschall in der Medizin (Stuttgart, Germany : 1980) 20081201 |
| EUTOS for chronic myeloid leukemia shows improved management and dose optimization is required. | Future oncology (London, England) 20081201 |
| [Experience with imatinib to treat pulmonary arterial hypertension]. | Archivos de bronconeumologia 20081201 |
| Response of Imitanib Meysylate in patients with gastrointestinal stromal cell tumour. | JPMA. The Journal of the Pakistan Medical Association 20081201 |
| The use of contrast-enhanced ultrasound in patients with GIST metastases that are negative in CT and PET. | Ultraschall in der Medizin (Stuttgart, Germany : 1980) 20081201 |
| PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. | Oncogene 20081120 |
| Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120 |
| Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120 |
| Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120 |
| Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells. | Veterinary immunology and immunopathology 20081115 |
| Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. | Blood 20081115 |
| Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. | Journal of immunology (Baltimore, Md. : 1950) 20081115 |
| [Chronic myeloid leukemia 2008]. | Medicina clinica 20081115 |
| Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. | Circulation 20081111 |
| PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. | Cancer letters 20081108 |
| MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. | Biochemical and biophysical research communications 20081107 |
| Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. | British journal of cancer 20081104 |
| Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. | Annals of the rheumatic diseases 20081101 |
| Synthesis and induction of G0-G1 phase arrest with apoptosis of 3,5-dimethyl-6-phenyl-8-(trifluoromethyl)-5,6-dihydropyrazolo[3,4-f][1,2,3,5]tetrazepin-4(3H)-one. | European journal of medicinal chemistry 20081101 |
| Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. | Leukemia research 20081101 |
| Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib. | Leukemia research 20081101 |
| Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. | Journal of cutaneous pathology 20081101 |
| Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20081101 |
| Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy. | Leukemia research 20081101 |
| Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. | Blood 20081101 |
| ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase. | Journal of molecular modeling 20081101 |
| Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. | Toxicological sciences : an official journal of the Society of Toxicology 20081101 |
| Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. | Bone marrow transplantation 20081101 |
| IRF-4 functions as a tumor suppressor in early B-cell development. | Blood 20081101 |
| Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. | Haematologica 20081101 |
| Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter? | American journal of hematology 20081101 |
| Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. | The British journal of dermatology 20081101 |
| Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation. | Anti-cancer drugs 20081101 |
| Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. | Cell cycle (Georgetown, Tex.) 20081101 |
| A case of huge GIST of the stomach successfully resected following effective neoadjuvant chemotherapy. | Japanese journal of clinical oncology 20081101 |
| Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH. | International journal of hematology 20081101 |
| The era of personalized medicine: back to basics. | Nature clinical practice. Oncology 20081101 |
| Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis. | Cancer research 20081101 |
| Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081101 |
| Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. | British journal of haematology 20081101 |
| [Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20081101 |
| [Tolerability of imatinib for patients with chronic myelogeneous leukemia (CML)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20081101 |
| [A resected case of postoperative liver metastasis of a gastrointestinal stromal tumor showing complete response after imatinib treatment]. | Gan to kagaku ryoho. Cancer & chemotherapy 20081101 |
| OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. | Leukemia & lymphoma 20081101 |
| [Porphyria cutanea tarda in a patient presenting hepatitis C treated with imatinib]. | Annales de dermatologie et de venereologie 20081101 |
| [A case of gastrointestinal stromal tumor of the stomach with rapid growth in a short term]. | Gan to kagaku ryoho. Cancer & chemotherapy 20081101 |
| Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. | Journal of the American Academy of Dermatology 20081101 |
| Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O]. | Clinical advances in hematology & oncology : H&O 20081101 |
| STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. | European journal of pharmacology 20081031 |
| Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. | Cell 20081031 |
| Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. | World journal of gastroenterology 20081021 |
| Small molecule recognition of c-Src via the Imatinib-binding conformation. | Chemistry & biology 20081020 |
| Angiotensin II blockade in Marfan's syndrome. | The New England journal of medicine 20081016 |
| Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. | Blood 20081015 |
| Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. | Blood 20081015 |
| Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010 |
| [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20081010 |
| Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. | Leukemia research 20081001 |
| Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy. | Leukemia research 20081001 |
| JAK-2V617F mutation in RARS-t: a target for Imatinib therapy? | Leukemia research 20081001 |
| Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. | Annals of oncology : official journal of the European Society for Medical Oncology 20081001 |
| A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. | Journal of the American Academy of Dermatology 20081001 |
| Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20081001 |
| Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. | Genes, chromosomes & cancer 20081001 |
| Chronic phase of ETV6-ABL1 positive CML responds to imatinib. | Genes, chromosomes & cancer 20081001 |
| A PDE model for imatinib-treated chronic myelogenous leukemia. | Bulletin of mathematical biology 20081001 |
| Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. | International journal of hematology 20081001 |
| A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. | Leukemia 20081001 |
| Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor. | International journal of hematology 20081001 |
| Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. | Rheumatology (Oxford, England) 20081001 |
| The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. | Cell cycle (Georgetown, Tex.) 20081001 |
| Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081001 |
| Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20081001 |
| Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081001 |
| [Management of acute lymphoblastic leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001 |
| [Management of chronic myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001 |
| Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. | Molecular cancer therapeutics 20081001 |
| 'Please, desist RECIST criteria in GIST, at least in me'. | Onkologie 20081001 |
| Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia? | Journal of pediatric surgery 20081001 |
| [Signal pathway in apoptosis of K562 cells induced by STI571]. | Zhongguo shi yan xue ye xue za zhi 20081001 |
| [Effect of a novel tyrosine kinase inhibitor HHGV678 on growth inhibition of Bcr-Abl wild type and IM-resistant cell lines in vitro]. | Zhongguo shi yan xue ye xue za zhi 20081001 |
| [Cardiac toxicity and edema]. | Gan to kagaku ryoho. Cancer & chemotherapy 20081001 |
| [A case of gastric gastrointestinal stromal tumor operated after low-dose chemotherapy with imatinib mesylate]. | Gan to kagaku ryoho. Cancer & chemotherapy 20081001 |
| Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor. | Archives of dermatology 20081001 |
| Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. | International journal of clinical oncology 20081001 |
| Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. | Bone marrow transplantation 20081001 |
| [Clinical practice guidelines in gastrointestinal stromal tumours (GEIS): update 2008]. | Cirugia espanola 20081001 |
| Nilotinib for the treatment of chronic myeloid leukemia. | Expert review of hematology 20081001 |
| Role of allogeneic transplantation in chronic myeloid leukemia. | Expert review of hematology 20081001 |
| Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. | Circulation 20080930 |
| Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. | Oncogene 20080918 |
| The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. | Cancer 20080915 |
| Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. | The Journal of clinical investigation 20080902 |
| Phase II trial of imatinib mesylate in patients with metastatic melanoma. | British journal of cancer 20080902 |
| Imatinib inhibition of fludarabine uptake in T-lymphocytes. | Cancer chemotherapy and pharmacology 20080901 |
| Trisomy 6 in a CML patient receiving imatinib mesylate therapy. | Leukemia research 20080901 |
| Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma. | Leukemia research 20080901 |
| Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. | Leukemia research 20080901 |
| Adjuvant and down-staging treatment with imatinib in gastrointestinal stromal tumors. | Journal of surgical oncology 20080901 |
| Uterine contractions depend on KIT-positive interstitial cells in the mouse: genetic and pharmacological evidence. | Biology of reproduction 20080901 |
| Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate. | Journal of dermatological science 20080901 |
| Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors. | Reproductive sciences (Thousand Oaks, Calif.) 20080901 |
| Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer. | Molecular & cellular proteomics : MCP 20080901 |
| Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20080901 |
| Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20080901 |
| Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. | Blood 20080901 |
| Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. | Blood 20080901 |
| Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan. | International journal of hematology 20080901 |
| Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. | Blood 20080901 |
| Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia. | British journal of haematology 20080901 |
| C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. | Gastroenterology 20080901 |
| Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia. | American journal of hematology 20080901 |
| Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. | Cancer 20080901 |
| Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib. | American journal of hematology 20080901 |
| Heterogeneity of kinase inhibitor resistance mechanisms in GIST. | The Journal of pathology 20080901 |
| Modulation of bladder myofibroblast activity: implications for bladder function. | American journal of physiology. Renal physiology 20080901 |
| Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. | European journal of cancer (Oxford, England : 1990) 20080901 |
| Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia. | International journal of hematology 20080901 |
| [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer]. | Der Urologe. Ausg. A 20080901 |
| ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts. | The Journal of molecular diagnostics : JMD 20080901 |
| Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors. | Gastroenterology 20080901 |
| Modern approaches to treating chronic myelogenous leukemia. | Current oncology reports 20080901 |
| Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Current oncology reports 20080901 |
| Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080901 |
| Inhibition of imatinib transport by uremic toxins during renal failure. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080901 |
| Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. | Expert review of anticancer therapy 20080901 |
| Chronic myeloid leukaemia: the evolution of gene-targeted therapy. | The Medical journal of Australia 20080901 |
| Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080901 |
| Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. | Current clinical pharmacology 20080901 |
| Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. | Molecular cancer therapeutics 20080901 |
| Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. | Archives of otolaryngology--head & neck surgery 20080901 |
| Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. | Archives of dermatology 20080901 |
| UV-spectrophotometric determination of imatinib mesylate and its application in solubility studies. | Die Pharmazie 20080901 |
| What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response. | Clinical advances in hematology & oncology : H&O 20080901 |
| [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]. | Bulletin du cancer 20080901 |
| Education and imaging. Gastrointestinal: Sister Mary Joseph nodule. | Journal of gastroenterology and hepatology 20080901 |
| [Practical approach to hypereosinophilia]. | Revue medicale de Bruxelles 20080901 |
| VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. | British journal of cancer 20080819 |
| KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas. | International journal of cancer 20080815 |
| No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. | Cancer 20080815 |
| Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. | Cancer 20080815 |
| Rationale for combination use of targeted agents in ovarian cancer: do we have one? | Cancer 20080815 |
| [Imatinib therapy in chronic myeloid leukemia]. | Orvosi hetilap 20080810 |
| Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover. | Oncogene 20080807 |
| Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report. | Archives of gynecology and obstetrics 20080801 |
| Gastrointestinal stromal tumor. | Surgical oncology 20080801 |
| Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. | Leukemia research 20080801 |
| Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis. | Leukemia research 20080801 |
| Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib. | Leukemia 20080801 |
| Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway. | Human molecular genetics 20080801 |
| Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. | Reproductive toxicology (Elmsford, N.Y.) 20080801 |
| Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses. | The Journal of biological chemistry 20080801 |
| Sequential tyrosine kinase inhibitor therapy: sustained disease remission in Philadelphia-positive erythroleukaemia. | British journal of haematology 20080801 |
| Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. | Blood 20080801 |
| Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. | Blood 20080801 |
| Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. | Pigment cell & melanoma research 20080801 |
| Letter: clear margins after the use of imatinib mesylate prior to resection of extensive dermatofibrosarcoma protuberans. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20080801 |
| Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. | Haematologica 20080801 |
| Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. | Haematologica 20080801 |
| Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. | Blood 20080801 |
| Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. | Gastroenterology 20080801 |
| Functional clustering of metastasis proteins describes plastic adaptation resources of breast-cancer cells to new microenvironments. | Journal of proteome research 20080801 |
| Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. | Melanoma research 20080801 |
| Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. | Cancer genetics and cytogenetics 20080801 |
| Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response. | International journal of laboratory hematology 20080801 |
| Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia. | International journal of laboratory hematology 20080801 |
| Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. | Arthritis and rheumatism 20080801 |
| Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. | Arthritis and rheumatism 20080801 |
| Is imatinib mesylate a promising drug in systemic sclerosis? | Arthritis and rheumatism 20080801 |
| Imatinib mesylate treatment of nephrogenic systemic fibrosis. | Arthritis and rheumatism 20080801 |
| Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080801 |
| Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia. | The Journal of rheumatology 20080801 |
| A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. | Cancer research 20080801 |
| Imatinib mesilate inhibits neointimal hyperplasia via growth inhibition of vascular smooth muscle cells in a rat model of balloon injury. | The Tohoku journal of experimental medicine 20080801 |
| Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate. | International journal of clinical oncology 20080801 |
| Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20080801 |
| [SphK-1/S1P signal pathway in CML cells]. | Zhongguo shi yan xue ye xue za zhi 20080801 |
| Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007. | Bone marrow transplantation 20080801 |
| Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia. | Scottish medical journal 20080801 |
| [Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080801 |
| Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. | Molecular oncology 20080801 |
| STI571 reduces NER activity in BCR/ABL-expressing cells. | Mutation research 20080731 |
| [Allogeneic stem cell transplantation for patients with Philadelphia positive leukemia resistant to imatinib]. | Zhonghua yi xue za zhi 20080722 |
| Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. | Oncogene 20080717 |
| Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080715 |
| Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080715 |
| XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. | Cancer research 20080715 |
| Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. | Dermatology online journal 20080715 |
| Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. | Lancet (London, England) 20080712 |
| Imatinib therapy for chronic myeloid leukemia: where do we go now? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710 |
| Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710 |
| Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710 |
| Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. | Cancer letters 20080708 |
| Disease progression in some cancers may be due to low blood levels of targeted therapies. | Journal of the National Cancer Institute 20080702 |
| Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia. | Journal of the National Cancer Institute 20080702 |
| Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. | Journal of the National Cancer Institute 20080702 |
| Simple segmental resection of the second portion of the duodenum for the treatment of gastrointestinal stromal tumors. | Langenbeck's archives of surgery 20080701 |
| Ocular side effects in chronic myeloid leukemia patients treated with imatinib. | Leukemia research 20080701 |
| Unusually large extraintestinal GIST presenting as an abdomino-pelvic tumor. | Archives of gynecology and obstetrics 20080701 |
| JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. | Leukemia 20080701 |
| Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis. | Cardiovascular research 20080701 |
| Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. | Annals of oncology : official journal of the European Society for Medical Oncology 20080701 |
| Multiple intracranial tumors in Philadelphia chromosome positive acute lymphoblastic leukemia: successful treatment following aggressive supportive care, early cranial radiation, high dose chemotherapy and imatinib. | Pediatric blood & cancer 20080701 |
| Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. | Blood 20080701 |
| Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. | Leukemia 20080701 |
| Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. | American journal of respiratory and critical care medicine 20080701 |
| Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. | Leukemia & lymphoma 20080701 |
| Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. | Leukemia & lymphoma 20080701 |
| Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. | Leukemia & lymphoma 20080701 |
| Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). | Journal of surgical oncology 20080701 |
| Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission. | British journal of haematology 20080701 |
| Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. | Haematologica 20080701 |
| Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. | Anti-cancer drugs 20080701 |
| Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose? | Current opinion in oncology 20080701 |
| Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. | British journal of haematology 20080701 |
| Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080701 |
| Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. | Leukemia 20080701 |
| [Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors]. | Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20080701 |
| Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. | Expert opinion on therapeutic targets 20080701 |
| Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. | Nature medicine 20080701 |
| Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. | Clinical nuclear medicine 20080701 |
| Skin lesions and mast cells. | Blood 20080701 |
| Possible role of imatinib in clinical pulmonary veno-occlusive disease. | The European respiratory journal 20080701 |
| Nilotinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080701 |
| How complete is 'complete' molecular response in imatinib-treated chronic myeloid leukemia? | Leukemia & lymphoma 20080701 |
| Imatinib buys time for brain after stroke. | Nature medicine 20080701 |
| Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? | Bone marrow transplantation 20080701 |
| Novel approaches to imatinib- and sunitinib-resistant GIST. | Current oncology reports 20080701 |
| [Gastrointestinal stromal tumors. An update]. | Revista medica de Chile 20080701 |
| Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. | The Journal of biological chemistry 20080627 |
| Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate. | World journal of gastroenterology 20080621 |
| Bcr-Abl induces autocrine IGF-1 signaling. | Oncogene 20080619 |
| Imatinib as a possible cause of severe rhabdomyolysis. | The New England journal of medicine 20080619 |
| MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. | Cancer letters 20080618 |
| The effects of imatinib on pregnancy outcome. | Blood 20080615 |
| Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. | International journal of cancer 20080615 |
| Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080615 |
| Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). | Journal of medicinal chemistry 20080612 |
| More on ovarian insufficiency with imatinib. | The New England journal of medicine 20080612 |
| Mathematical models of cancer stem cells. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080610 |
| [Novel medical treatment modalities in hematology]. | Ugeskrift for laeger 20080609 |
| A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. | British journal of cancer 20080603 |
| Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. | Journal of cancer research and clinical oncology 20080601 |
| Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. | Leukemia research 20080601 |
| An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. | Leukemia research 20080601 |
| HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. | Leukemia research 20080601 |
| Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. | Leukemia research 20080601 |
| Irreversible sensorineural hearing loss due to Imatinib. | Leukemia research 20080601 |
| Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080601 |
| 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. | Investigative ophthalmology & visual science 20080601 |
| Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. | Journal of mass spectrometry : JMS 20080601 |
| Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. | American journal of hematology 20080601 |
| Development and dynamics of robust T-cell responses to CML under imatinib treatment. | Blood 20080601 |
| Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. | International journal of cancer 20080601 |
| Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. | Leukemia 20080601 |
| Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. | Neuro-oncology 20080601 |
| RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells. | Leukemia 20080601 |
| Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. | Journal of clinical pathology 20080601 |
| Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. | British journal of clinical pharmacology 20080601 |
| Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. | Leukemia 20080601 |
| Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. | Leukemia 20080601 |
| Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. | Leukemia 20080601 |
| Turning promiscuous kinase inhibitors into safer drugs. | Trends in biotechnology 20080601 |
| Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial. | Anti-cancer drugs 20080601 |
| Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies. | Cancer science 20080601 |
| Chronic myeloid leukemia and HIV-infection. | Leukemia & lymphoma 20080601 |
| Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance? | Leukemia & lymphoma 20080601 |
| Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. | Journal of clinical pharmacy and therapeutics 20080601 |
| The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells. | Biochemical pharmacology 20080601 |
| Electronic clinical challenges and images in GI. Cystic GIST of the lesser omentum. | Gastroenterology 20080601 |
| New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. | Expert opinion on investigational drugs 20080601 |
| Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl. | International journal of oncology 20080601 |
| Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases. | Bioconjugate chemistry 20080601 |
| Early clinical studies of novel therapies for thyroid cancers. | Endocrinology and metabolism clinics of North America 20080601 |
| Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. | Blood 20080601 |
| Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase. | Cancer genetics and cytogenetics 20080601 |
| Part I: Milestones in personalised medicine--imatinib. | The Lancet. Oncology 20080601 |
| Management of gastrointestinal stromal tumors. | The Surgical clinics of North America 20080601 |
| Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis. | Archives of pathology & laboratory medicine 20080601 |
| [Case of GIST of the rectum successfully treated with imatinib mesylate neoadjuvant therapy]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20080601 |
| [Three cases of gastrointestinal stromal tumor (GIST) with bone metastasis]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20080601 |
| Imatinib mesylate for the treatment of chronic myeloid leukemia. | Expert review of anticancer therapy 20080601 |
| Developments in targeted therapy of advanced gastrointestinal stromal tumors. | Recent patents on anti-cancer drug discovery 20080601 |
| Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). | International journal of clinical oncology 20080601 |
| Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance. | Proteomics 20080601 |
| Dynamics and potential impact of the immune response to chronic myelogenous leukemia. | PLoS computational biology 20080601 |
| Leukemic cells with increased telomerase activity exhibit resistance to imatinib. | Leukemia & lymphoma 20080601 |
| Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine. | Nucleosides, nucleotides & nucleic acids 20080601 |
| Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients. | Hematology (Amsterdam, Netherlands) 20080601 |
| Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy. | Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20080601 |
| Imaging characteristics of liver metastasis from gastrointestinal stromal tumor before and after imatinib mesylate treatment. | The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20080601 |
| NESH protein expression switches to the adverse effect of imatinib mesylate. | Molecular oncology 20080601 |
| Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib. | Biomolecular NMR assignments 20080601 |
| Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. | British journal of cancer 20080520 |
| FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. | Chinese medical journal 20080520 |
| Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2. | Journal of cellular biochemistry 20080515 |
| Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. | Cancer 20080515 |
| Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. | Blood 20080515 |
| The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. | Journal of immunology (Baltimore, Md. : 1950) 20080515 |
| Interaction of imatinib with human organic ion carriers. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080515 |
| Dermatitis after suspected imatinib-levothyroxine interaction in a patient with gastrointestinal stromal tumor. | Cancer chemotherapy and pharmacology 20080501 |
| Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment. | Medical mycology 20080501 |
| Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. | Leukemia research 20080501 |
| Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy. | Pediatric blood & cancer 20080501 |
| Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. | Leukemia research 20080501 |
| KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. | Leukemia research 20080501 |
| Locally advanced GISTs need aggressive therapy pending the results of trials. | Annals of surgical oncology 20080501 |
| Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia. | Pediatric blood & cancer 20080501 |
| Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation. | International journal of cancer 20080501 |
| Successful treatment with interferon-alpha-2b and imatinib in an adult Japanese male with Philadelphia chromosome-positive acute lymphoblastic leukemia and minimal residual disease following allogeneic transplantation. | Bone marrow transplantation 20080501 |
| Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? | Journal of cancer research and clinical oncology 20080501 |
| Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits. | Eye (London, England) 20080501 |
| FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement. | Journal of clinical pathology 20080501 |
| Imatinib for the treatment of refractory, diffuse systemic sclerosis. | Rheumatology (Oxford, England) 20080501 |
| STI571/doxorubicin concentration-dependent switch for diverse caspase actions in CML cell line K562. | Biochemical pharmacology 20080501 |
| Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors? | Nature clinical practice. Oncology 20080501 |
| Characterization of compound 584, an Abl kinase inhibitor with lasting effects. | Haematologica 20080501 |
| Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. | Haematologica 20080501 |
| Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. | Haematologica 20080501 |
| The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. | European journal of cancer (Oxford, England : 1990) 20080501 |
| Getting to the stem of chronic myeloid leukaemia. | Nature reviews. Cancer 20080501 |
| Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation. | Leukemia 20080501 |
| Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets. | Current opinion in oncology 20080501 |
| Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. | Leukemia 20080501 |
| Multiple brain infarctions induced by imatinib mesylate in a patient with clonal eosinophilia. | International journal of hematology 20080501 |
| Effects of imatinib mesylate on spontaneous electrical and mechanical activity in smooth muscle of the guinea-pig stomach. | British journal of pharmacology 20080501 |
| Imatinib mesilate for the treatment of gastrointestinal stromal tumour. | Expert opinion on pharmacotherapy 20080501 |
| Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. | European journal of endocrinology 20080501 |
| A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer. | Pancreas 20080501 |
| Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080501 |
| Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis. | Leukemia & lymphoma 20080501 |
| [Imatinib-induced DRESS]. | Annales de dermatologie et de venereologie 20080501 |
| Bedside to bench: interfering with leukemic stem cells. | Nature medicine 20080501 |
| Bench to bedside: BRCA: from therapeutic target to therapeutic shield. | Nature medicine 20080501 |
| Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia. | Cancer genetics and cytogenetics 20080501 |
| Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. | Molecular cancer therapeutics 20080501 |
| Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. | Molecular cancer therapeutics 20080501 |
| [GIST]. | Gan to kagaku ryoho. Cancer & chemotherapy 20080501 |
| [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080501 |
| Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts. | Molecular cancer research : MCR 20080501 |
| Anti-VEGF therapy: the search for clinical biomarkers. | Expert review of molecular diagnostics 20080501 |
| Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. | World journal of pediatrics : WJP 20080501 |
| Major response to imatinib mesylate in KIT-mutated melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080420 |
| Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. | Cancer letters 20080418 |
| Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. | Blood 20080415 |
| Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. | Blood 20080415 |
| Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. | Cancer 20080415 |
| Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. | Cancer genetics and cytogenetics 20080415 |
| Management of patients with resistant or refractory chronic myelogenous leukemia. | Oncology (Williston Park, N.Y.) 20080415 |
| BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells. | Journal of molecular biology 20080404 |
| PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. | Cancer chemotherapy and pharmacology 20080401 |
| A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. | Leukemia 20080401 |
| A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis. | Leukemia research 20080401 |
| Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. | Leukemia research 20080401 |
| Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. | Leukemia research 20080401 |
| Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML). | Leukemia research 20080401 |
| Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia. | Journal of cellular physiology 20080401 |
| Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells. | Pharmaceutical research 20080401 |
| Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. | American journal of hematology 20080401 |
| Erythroid variant of chronic myelogenous leukemia. | Leukemia 20080401 |
| Is there a role for imatinib in inflammatory bowel disease? | Inflammatory bowel diseases 20080401 |
| Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models. | Bulletin of mathematical biology 20080401 |
| Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. | Genes, chromosomes & cancer 20080401 |
| RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. | Blood 20080401 |
| BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. | Leukemia 20080401 |
| Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. | The Journal of allergy and clinical immunology 20080401 |
| Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. | Blood 20080401 |
| Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. | Leukemia 20080401 |
| Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. | Cancer science 20080401 |
| Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). | Annals of oncology : official journal of the European Society for Medical Oncology 20080401 |
| A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. | British journal of haematology 20080401 |
| In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. | Haematologica 20080401 |
| Additional rearrangements affecting the derivative chromosome 9 involved in the standard Philadelphia translocation after imatinib therapy in a patient with chronic myeloid leukemia. | Cancer genetics and cytogenetics 20080401 |
| Chemotherapeutic agents and the skin: An update. | Journal of the American Academy of Dermatology 20080401 |
| Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib? | American journal of clinical pathology 20080401 |
| Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. | International journal of oncology 20080401 |
| Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080401 |
| Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. | American journal of obstetrics and gynecology 20080401 |
| Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. | Leukemia & lymphoma 20080401 |
| New therapeutic approaches and prognostic factors in chronic myeloid leukemia. | Leukemia & lymphoma 20080401 |
| Immunotherapeutic approaches in chronic myelogenous leukemia. | Leukemia & lymphoma 20080401 |
| Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. | Leukemia & lymphoma 20080401 |
| Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy. | Leukemia & lymphoma 20080401 |
| Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. | Future oncology (London, England) 20080401 |
| Therapy options in imatinib failures. | The oncologist 20080401 |
| Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission. | The Israel Medical Association journal : IMAJ 20080401 |
| Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh. | Bangladesh Medical Research Council bulletin 20080401 |
| [Imatinib induces c-kit positive myeloma cells apoptosis]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20080401 |
| Molecular monitoring in patients with chronic myelogenous leukemia. | Current hematologic malignancy reports 20080401 |
| Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications. | Current hematologic malignancy reports 20080401 |
| Development and validation of GC-MS method for the determination of methyl methanesulfonate and ethyl methanesulfonate in imatinib mesylate. | Journal of pharmaceutical and biomedical analysis 20080313 |
| Primary ovarian insufficiency associated with imatinib therapy. | The New England journal of medicine 20080306 |
| Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission. | Pediatric blood & cancer 20080301 |
| A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients. | Leukemia research 20080301 |
| [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate]. | La Revue de medecine interne 20080301 |
| Influence of the tyrosine kinase inhibitors STI571 (Glivec), lavendustin A and genistein on human mast cell line (HMC-1(560)) activation. | Journal of cellular biochemistry 20080301 |
| Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. | Leukemia research 20080301 |
| Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines. | Leukemia research 20080301 |
| Inhibition of PI3K synergistically enhances the apoptotic effect of STI-571 on p210(bcr-abl)-transformed cells in a Rac1-dependent manner. | Leukemia research 20080301 |
| Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. | Leukemia 20080301 |
| Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up. | American journal of hematology 20080301 |
| Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. | Proteins 20080301 |
| Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. | Annals of hematology 20080301 |
| Long-term imatinib therapy promotes bone formation in CML patients. | Blood 20080301 |
| Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells. | Leukemia 20080301 |
| Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib. | Blood 20080301 |
| Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. | Leukemia 20080301 |
| Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. | Cancer biology & therapy 20080301 |
| BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. | Blood 20080301 |
| Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. | Blood 20080301 |
| BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. | Blood 20080301 |
| Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement. | American journal of hematology 20080301 |
| In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. | Biopharmaceutics & drug disposition 20080301 |
| Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis? | Clinical and experimental immunology 20080301 |
| Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine. | Ophthalmology 20080301 |
| Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. | European journal of cancer (Oxford, England : 1990) 20080301 |
| Characterization of neuroprogenitor cells expressing the PDGF beta-receptor within the subventricular zone of postnatal mice. | Molecular and cellular neurosciences 20080301 |
| Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate. | Clinical nuclear medicine 20080301 |
| Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis. | International journal of hematology 20080301 |
| Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. | Leukemia & lymphoma 20080301 |
| Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country. | Leukemia & lymphoma 20080301 |
| Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? | Current opinion in hematology 20080301 |
| Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case. | Japanese journal of clinical oncology 20080301 |
| Transporter pumps and imatinib: a cause of pharmacokinetic resistance? | Cancer biology & therapy 20080301 |
| ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. | Pharmacological research 20080301 |
| Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. | Singapore medical journal 20080301 |
| Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development of in vitro high-speed screening systems. | Expert opinion on drug metabolism & toxicology 20080301 |
| Systemic therapies for recurrent and/or metastatic salivary gland cancers. | Expert review of anticancer therapy 20080301 |
| Commentary: Novel therapies for cancer: why dirty might be better. | The oncologist 20080301 |
| First-Line management of CML: a state of the art review. | Journal of the National Comprehensive Cancer Network : JNCCN 20080301 |
| Resistance and relapse with imatinib in CML: causes and consequences. | Journal of the National Comprehensive Cancer Network : JNCCN 20080301 |
| Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. | Journal of the National Comprehensive Cancer Network : JNCCN 20080301 |
| BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. | Journal of the National Comprehensive Cancer Network : JNCCN 20080301 |
| Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia. | Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20080301 |
| Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. | Clinical lymphoma & myeloma 20080301 |
| Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors. | Clinical lymphoma & myeloma 20080301 |
| Gastrointestinal stromal tumour of the rectum: report of a case and review of literature. | World journal of gastroenterology 20080227 |
| Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha. | Biochemical and biophysical research communications 20080222 |
| Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function. | Cancer letters 20080218 |
| STI571 (Glivec) affects histamine release and intracellular pH after alkalinisation in HMC-1560, 816. | Journal of cellular biochemistry 20080215 |
| In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. | Blood 20080215 |
| Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. | Blood 20080215 |
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. | Blood 20080215 |
| Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. | Blood 20080215 |
| Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? | Cancer 20080215 |
| Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. | Molecular cell 20080215 |
| Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate. | World journal of gastroenterology 20080214 |
| A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. | Pediatric blood & cancer 20080201 |
| Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML. | Leukemia research 20080201 |
| Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. | Clinical pharmacology and therapeutics 20080201 |
| Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects. | Journal of cellular biochemistry 20080201 |
| Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia. | Leukemia research 20080201 |
| Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. | Leukemia 20080201 |
| CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. | Leukemia 20080201 |
| Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate. | Leukemia research 20080201 |
| Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib. | Pediatric blood & cancer 20080201 |
| Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma. | Leukemia research 20080201 |
| Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. | Blood 20080201 |
| Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. | International journal of cancer 20080201 |
| Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. | Annals of oncology : official journal of the European Society for Medical Oncology 20080201 |
| New developments in multitargeted therapy for patients with solid tumours. | Cancer treatment reviews 20080201 |
| Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. | Cell death and differentiation 20080201 |
| Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group. | European journal of haematology 20080201 |
| Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. | Blood 20080201 |
| Dendritic cells and innate defense against tumor cells. | Cytokine & growth factor reviews 20080201 |
| Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate. | Journal of cutaneous pathology 20080201 |
| Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival. | International journal of laboratory hematology 20080201 |
| Disruption of PDGFRalpha-initiated PI3K activation and migration of somite derivatives leads to spina bifida. | Development (Cambridge, England) 20080201 |
| Treatment options in imatinib-resistant chronic myelogenous leukemia. | The Annals of pharmacotherapy 20080201 |
| Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20080201 |
| Multiple bowel perforations complicating imatinib treatment for advanced gastrointestinal stromal tumor. | Journal of the American College of Surgeons 20080201 |
| Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. | Haematologica 20080201 |
| Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. | Haematologica 20080201 |
| Imatinib for patients with liver or kidney dysfunction: no need to modify the dose. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201 |
| Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201 |
| Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201 |
| Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201 |
| Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201 |
| Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment. | Nature clinical practice. Oncology 20080201 |
| Monitoring treatment of chronic myeloid leukemia. | Haematologica 20080201 |
| Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. | Haematologica 20080201 |
| IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. | Molecular cancer therapeutics 20080201 |
| Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders. | Cancer genetics and cytogenetics 20080201 |
| Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells. | Molecular cancer therapeutics 20080201 |
| [Research advance on molecular genetics of CML blast crisis]. | Zhongguo shi yan xue ye xue za zhi 20080201 |
| Episodic angioedema with eosinophilia: successful treatment with imatinib. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20080201 |
| Acquired resistance to tyrosine kinase inhibitors during cancer therapy. | Current opinion in genetics & development 20080201 |
| Phase II study of imatinib in unresectable hepatocellular carcinoma. | American journal of clinical oncology 20080201 |
| New therapeutic options in gastrointestinal stromal tumors. | Oncology (Williston Park, N.Y.) 20080201 |
| Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. | Oncogene 20080131 |
| [Treatment of idiopathic hypereosinophilic syndrome with imatinib]. | Ugeskrift for laeger 20080121 |
| c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy. | International journal of cancer 20080115 |
| Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080115 |
| Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080115 |
| Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. | Respiration; international review of thoracic diseases 20080101 |
| Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. | Leukemia research 20080101 |
| Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia. | Pediatric blood & cancer 20080101 |
| Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia. | Leukemia research 20080101 |
| Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder. | Leukemia research 20080101 |
| Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation. | Medical hypotheses 20080101 |
| Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses. | Journal of molecular medicine (Berlin, Germany) 20080101 |
| Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. | European journal of human genetics : EJHG 20080101 |
| Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. | Leukemia research 20080101 |
| Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. | Annals of oncology : official journal of the European Society for Medical Oncology 20080101 |
| Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. | Clinical science (London, England : 1979) 20080101 |
| Effect of prolonged c-kit receptor inhibition by imatinib mesylate on the uterine contractility of pregnant rabbits. | Gynecologic and obstetric investigation 20080101 |
| Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation. | The Journal of pharmacology and experimental therapeutics 20080101 |
| FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. | Biochimica et biophysica acta 20080101 |
| Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. | Gynecologic oncology 20080101 |
| [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]. | La Revue de medecine interne 20080101 |
| Molecular pathobiology of gastrointestinal stromal sarcomas. | Annual review of pathology 20080101 |
| State-of-the-art in the treatment of chronic myeloid leukaemia. | Current opinion in oncology 20080101 |
| Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case. | Surgery today 20080101 |
| Choroidal metastasis from gastrointestinal stromal tumour: a case report. | The British journal of ophthalmology 20080101 |
| Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080101 |
| Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. | Haematologica 20080101 |
| Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. | European journal of clinical investigation 20080101 |
| Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor. | Medical oncology (Northwood, London, England) 20080101 |
| CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. | Molecular cancer therapeutics 20080101 |
| Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. | Leukemia & lymphoma 20080101 |
| The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. | Dermatology (Basel, Switzerland) 20080101 |
| [Imatinib and solid tumours]. | Bulletin du cancer 20080101 |
| [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. | Bulletin du cancer 20080101 |
| Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. | PLoS medicine 20080101 |
| Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model. | PLoS medicine 20080101 |
| Prognosis of pediatric patients transplanted for Ph+ chronic myeloid leukemia in the period from 1989 to 2006 in the Czech Republic. | Neoplasma 20080101 |
| Beyond chemotherapy--demystifying the new 'targeted' cancer treatments. | Australian family physician 20080101 |
| Neoadjuvant imatinib in a gastrointestinal stromal tumor of the rectum: report of a case. | Surgery today 20080101 |
| Application of PET/CT in the development of novel anticancer drugs. | The oncologist 20080101 |
| [Gastrointestinal stromal tumors: case reports and review of the literature]. | Il Giornale di chirurgia 20080101 |
| Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. | Angiogenesis 20080101 |
| Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13). | Acta haematologica 20080101 |
| Induced disorder in protein-ligand complexes as a drug-design strategy. | Molecular pharmaceutics 20080101 |
| From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. | Current medicinal chemistry 20080101 |
| Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. | Biochemistry. Biokhimiia 20080101 |
| Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia. | Clinical chemistry and laboratory medicine 20080101 |
| Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment. | Acta dermato-venereologica 20080101 |
| Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. | Clinical & experimental metastasis 20080101 |
| [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. | Annales de dermatologie et de venereologie 20080101 |
| Leiomyosarcoma originating from the superior mesenteric vein: a case report and review of the literature. | Annals of vascular surgery 20080101 |
| [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor]. | Revista espanola de medicina nuclear 20080101 |
| Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect? | Acta haematologica 20080101 |
| The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction. | World journal of surgical oncology 20080101 |
| Overcoming kinase resistance in chronic myeloid leukemia. | The international journal of biochemistry & cell biology 20080101 |
| [Gastrointestinal stromal tumors: role of computed tomography before and after treatment]. | Gastroenterologie clinique et biologique 20080101 |
| Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate. | Internal medicine (Tokyo, Japan) 20080101 |
| Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. | PharmacoEconomics 20080101 |
| [Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]. | Gynakologisch-geburtshilfliche Rundschau 20080101 |
| Response evaluation of gastrointestinal stromal tumors. | The oncologist 20080101 |
| The lessons of GIST--PET and PET/CT: a new paradigm for imaging. | The oncologist 20080101 |
| Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. | Journal of applied genetics 20080101 |
| A multidisciplinary approach for the treatment of GIST liver metastasis. | World journal of surgical oncology 20080101 |
| A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature. | World journal of surgical oncology 20080101 |
| Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. | Medical oncology (Northwood, London, England) 20080101 |
| [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20080101 |
| [Analysis of long-term treatment outcome and related factors in 95 chronic myeloid leukemia patients treated with imatinib]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20080101 |
| The development of metachronous prostate cancer and chronic myeloid leukemia in a patient with metastatic rectal cancer. | Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20080101 |
| Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. | Journal of veterinary internal medicine 20080101 |
| Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. | Acta haematologica 20080101 |
| BCR-ABL in chronic myelogenous leukemia--how does it work? | Acta haematologica 20080101 |
| [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib]. | Revista espanola de medicina nuclear 20080101 |
| KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature. | European journal of gynaecological oncology 20080101 |
| Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate. | Indian journal of cancer 20080101 |
| Need for the appraisal of uncommon side effects of a commonly prescribed drug- Imatinib. | Indian journal of cancer 20080101 |
| Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective. | World journal of surgical oncology 20080101 |
| Gastrointestinal stromal tumors: a case report and review of the literature. | The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 20080101 |
| Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment. | Annals of clinical and laboratory science 20080101 |
| [Pharmazie in unserer Zeit 5/2008]. | Pharmazie in unserer Zeit 20080101 |
| Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma. | Anticancer research 20080101 |
| Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. | Drug metabolism and pharmacokinetics 20080101 |
| [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?]. | Terapevticheskii arkhiv 20080101 |
| Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). | Japanese journal of ophthalmology 20080101 |
| Gastrointestinal stromal tumor of the stomach with lymph node metastasis. | World journal of surgical oncology 20080101 |
| [A step foward in the treatment of GIST]. | La Clinica terapeutica 20080101 |
| Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. | Cancer genomics & proteomics 20080101 |
| P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. | Journal of hematology & oncology 20080101 |
| Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. | Cytotherapy 20080101 |
| Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate. | PloS one 20080101 |
| Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia. | Annals of clinical and laboratory science 20080101 |
| [Molecular approach in the treatment of dermatofibrosarcoma protuberans]. | La Clinica terapeutica 20080101 |
| Molecular profiling of tumours by immunohistochemistry. | The National medical journal of India 20080101 |
| Molecule of the Month. PDGFR-alpha antagonist Gleevec reduces blood vessel leakage and increases the therapeutic window associated with tissue plasminogen activator stroke treatment. | Current topics in medicinal chemistry 20080101 |
| Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant. | Acta haematologica 20080101 |
| [An update of the surgical indications for gastrointestinal stromal tumors]. | Journal de chirurgie 20080101 |
| [Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans]. | Voprosy onkologii 20080101 |
| Milestones and monitoring in patients with CML treated with imatinib. | Hematology. American Society of Hematology. Education Program 20080101 |
| Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. | Hematology. American Society of Hematology. Education Program 20080101 |
| Targeted drugs in chronic myeloid leukemia. | Current medicinal chemistry 20080101 |
| Imatinib-induced tumor lysis syndrome: report of a case and review of the literature. | Chang Gung medical journal 20080101 |
| Clinicopathologic characteristics of gastrointestinal stromal tumor of the stomach. | Hepato-gastroenterology 20080101 |
| A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. | European journal of gynaecological oncology 20080101 |
| [Periferal blood subpopulation and apoptosis indices in the treatment of chronic myelogenous leukemia with Imatinib]. | Likars'ka sprava 20080101 |
| ABL1 fusions in T-cell acute lymphoblastic leukemia. | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20080101 |
| Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia. | Journal of medical economics 20080101 |
| Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia. | Hematology/oncology and stem cell therapy 20080101 |
| Gastrointestinal stromal tumour of the omentum: a case report. | The Gulf journal of oncology 20080101 |
| Imatinib-induced fatal acute liver failure. | World journal of gastroenterology 20071228 |
| [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro]. | Zhonghua yi xue za zhi 20071225 |
| Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. | FEBS letters 20071222 |
| Rectal GI stromal tumor mimicking a prostate mass. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071220 |
| A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. | Proceedings of the National Academy of Sciences of the United States of America 20071218 |
| Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. | International journal of cancer 20071215 |
| Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. | American journal of respiratory and critical care medicine 20071215 |
| Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. | International journal of cancer 20071215 |
| Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. | Blood 20071215 |
| New strategies in controlling drug resistance in chronic myeloid leukemia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215 |
| Chronic myeloid leukemia. Introduction. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215 |
| Leukemia. Q&A highlights. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215 |
| Targeted chronic myeloid leukemia therapy: Seeking a cure. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215 |
| Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071215 |
| Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. | Oncogene 20071213 |
| [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20071210 |
| Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. | The Journal of clinical investigation 20071203 |
| An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. | The Journal of clinical investigation 20071203 |
| Thymic carcinoma in a child with HIV infection. | Pediatric blood & cancer 20071201 |
| Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. | Leukemia research 20071201 |
| Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis. | Leukemia research 20071201 |
| Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response. | Journal of neuro-oncology 20071201 |
| Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells. | Toxicology in vitro : an international journal published in association with BIBRA 20071201 |
| Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. | Blood 20071201 |
| Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells. | Leukemia 20071201 |
| Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. | Blood 20071201 |
| Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. | Leukemia 20071201 |
| Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. | Hematology (Amsterdam, Netherlands) 20071201 |
| Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib. | Hematology (Amsterdam, Netherlands) 20071201 |
| Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. | Cancer science 20071201 |
| Induction of apoptosis increases expression of non-canonical WNT genes in myeloid leukemia cell lines. | Oncology reports 20071201 |
| Defective T cell development and function in the absence of Abelson kinases. | Journal of immunology (Baltimore, Md. : 1950) 20071201 |
| CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. | AJR. American journal of roentgenology 20071201 |
| Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. | Expert opinion on pharmacotherapy 20071201 |
| Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma. | Future oncology (London, England) 20071201 |
| Part II: management of resistance to imatinib in chronic myeloid leukaemia. | The Lancet. Oncology 20071201 |
| Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. | Haematologica 20071201 |
| Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. | Haematologica 20071201 |
| BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071201 |
| Chronic myeloid leukemia--therapy in the 20th and 21st centuries. | Leukemia & lymphoma 20071201 |
| Strategies for overcoming imatinib resistance in chronic myeloid leukemia. | Leukemia & lymphoma 20071201 |
| Pregnancy in patients with chronic myeloid leukemia treated with imatinib. | Leukemia & lymphoma 20071201 |
| PDGF BB induces VEGF secretion in ovarian cancer. | Cancer biology & therapy 20071201 |
| Recurrence of severe pulmonary hypertension following the removal of a lung allograft. | Chest 20071201 |
| [An advance in the treatment of CML]. | Gan to kagaku ryoho. Cancer & chemotherapy 20071201 |
| [STI571 induces apoptosis of K562 cells through down-regulation of anti-apoptotic protein Mcl-1 and Bcl-xl expression]. | Zhongguo shi yan xue ye xue za zhi 20071201 |
| In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. | Drug metabolism and pharmacokinetics 20071201 |
| Imatinib. | The oncologist 20071201 |
| Conjunctival hemorrhagic events associated with imatinib mesylate. | International journal of hematology 20071201 |
| Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. | International journal of hematology 20071201 |
| Molecularly targeted therapy in myeloid leukaemias. | Clinical medicine (London, England) 20071201 |
| [Adverse drug reactions induced by molecular target therapy]. | Arerugi = [Allergy] 20071201 |
| Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. | Clinical genitourinary cancer 20071201 |
| CML: imatinib mesylate (Glivec) or something else? | Nepal Medical College journal : NMCJ 20071201 |
| [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate]. | Zhonghua nei ke za zhi 20071201 |
| [Expert consensus on surgical treatment for gastrointestinal stromal tumors]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20071201 |
| KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. | Oncogene 20071129 |
| Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. | Blood 20071115 |
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. | Blood 20071115 |
| Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071115 |
| Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. | Leukemia research 20071101 |
| Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. | Leukemia 20071101 |
| Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. | Leukemia 20071101 |
| Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. | Journal of neuro-oncology 20071101 |
| Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. | Mathematical biosciences 20071101 |
| Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. | Leukemia 20071101 |
| Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20071101 |
| Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20071101 |
| Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). | Annals of oncology : official journal of the European Society for Medical Oncology 20071101 |
| Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. | Cancer 20071101 |
| A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model. | The Prostate 20071101 |
| Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. | International journal of oncology 20071101 |
| Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. | Leukemia & lymphoma 20071101 |
| Imatinib mesylate induced immune thrombocytopenia. | Leukemia & lymphoma 20071101 |
| (-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. | Leukemia & lymphoma 20071101 |
| A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. | Expert opinion on pharmacotherapy 20071101 |
| Characterization of cancer stem cells in chronic myeloid leukaemia. | Biochemical Society transactions 20071101 |
| Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. | Medical science monitor : international medical journal of experimental and clinical research 20071101 |
| Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. | The Lancet. Oncology 20071101 |
| Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. | The Lancet. Oncology 20071101 |
| [Imatinib-induced toxic hepatitis: description of two cases and review of the literature]. | Gastroenterologia y hepatologia 20071101 |
| PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer. | Cancer biology & therapy 20071101 |
| Management of imatinib-resistant CML patients. | Onkologie 20071101 |
| Kinase packing defects as drug targets. | Drug discovery today 20071101 |
| Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. | Differentiation; research in biological diversity 20071101 |
| Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. | Medicine 20071101 |
| [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20071101 |
| Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase. | Haematologica 20071101 |
| Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. | Clinical therapeutics 20071101 |
| [Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate]. | Gan to kagaku ryoho. Cancer & chemotherapy 20071101 |
| [Consensus on the medical treatment of gastrointestinal stromal tumors]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20071101 |
| [The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20071101 |
| Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. | Oncogene 20071025 |
| Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. | Blood 20071015 |
| How I treat chronic myeloid leukemia in the imatinib era. | Blood 20071015 |
| Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). | Gene 20071015 |
| A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071015 |
| Tyrosine kinase inhibitors for chronic myelogenous leukemia. | The New England journal of medicine 20071011 |
| Tyrosine kinase inhibitors for chronic myelogenous leukemia. | The New England journal of medicine 20071011 |
| Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071010 |
| Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20071001 |
| Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib. | Leukemia research 20071001 |
| Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20071001 |
| What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL? | Leukemia research 20071001 |
| Downstaging of a gastric GIST by neoadjuvant imatinib and endoscopic assisted laparoscopic resection. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20071001 |
| Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. | Blood 20071001 |
| Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. | Blood 20071001 |
| BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? | Leukemia 20071001 |
| EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia. | Leukemia 20071001 |
| Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect. | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20071001 |
| Loeffler endocarditis: what have we learned? | American journal of hematology 20071001 |
| Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. | Annals of hematology 20071001 |
| The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. | Blood 20071001 |
| Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. | Laboratory investigation; a journal of technical methods and pathology 20071001 |
| Dermatofibrosarcoma protuberans: recent clinical progress. | Annals of surgical oncology 20071001 |
| Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. | Hepatology (Baltimore, Md.) 20071001 |
| Systemic Mastocytosis: documented pathologic response to imatinib. | European journal of haematology 20071001 |
| ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. | Leukemia 20071001 |
| The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. | Cancer 20071001 |
| Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma. | Anti-cancer drugs 20071001 |
| Myelofibrosis: biology and treatment options. | European journal of haematology. Supplementum 20071001 |
| Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. | European journal of clinical investigation 20071001 |
| FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment. | Clinical nuclear medicine 20071001 |
| Overdose with 6400 mg of imatinib: is it safe? | Annals of oncology : official journal of the European Society for Medical Oncology 20071001 |
| Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071001 |
| Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. | The Journal of dermatology 20071001 |
| Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071001 |
| Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071001 |
| Imatinib mesylate in the treatment of hematologic malignancies. | Expert opinion on biological therapy 20071001 |
| Where lies the blame for resistance--tumor or host? | Nature medicine 20071001 |
| Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation. | Leukemia & lymphoma 20071001 |
| Future options for imatinib mesilate-resistant tumors. | Expert opinion on investigational drugs 20071001 |
| The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. | International journal of clinical oncology 20071001 |
| An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. | International journal of clinical oncology 20071001 |
| [Trends in molecular targeting therapeutics for chronic myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20071001 |
| [Treatment of chronic myeloid leukemia in 2007]. | Bulletin du cancer 20071001 |
| [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. | Bulletin du cancer 20071001 |
| Targeted chronic myeloid leukemia therapy: seeking a cure. | Journal of managed care pharmacy : JMCP 20071001 |
| New strategies in controlling drug resistance. | Journal of managed care pharmacy : JMCP 20071001 |
| Nilotinib therapy in chronic myelogenous leukemia. | Drugs of today (Barcelona, Spain : 1998) 20071001 |
| Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. | International journal of hematology 20071001 |
| Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. | International journal of hematology 20071001 |
| Targeted therapies in solid tumours: results and promises. | Minerva medica 20071001 |
| [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases]. | Revista medica de Chile 20071001 |
| Farnesyl transferase inhibitor resistance probed by target mutagenesis. | Blood 20070915 |
| Lipid rafts are required for Kit survival and proliferation signals. | Blood 20070915 |
| Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. | Cancer 20070915 |
| Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. | Cancer 20070915 |
| Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. | Genes & development 20070915 |
| Linking the hematopoietic microenvironment to imatinib-resistant Ph+ B-ALL. | Genes & development 20070915 |
| Progressive thoughts about progressive disease. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070915 |
| Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070915 |
| Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. | British journal of cancer 20070911 |
| [Molecular physiopathology and molecular targeting therapy of leukemia]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070910 |
| Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. | The Journal of biological chemistry 20070907 |
| c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration. | The Journal of biological chemistry 20070907 |
| Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. | The Journal of clinical investigation 20070904 |
| FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. | The Journal of clinical investigation 20070904 |
| Is rectal administration an alternative route for imatinib? | Cancer chemotherapy and pharmacology 20070901 |
| Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. | Pharmaceutical research 20070901 |
| Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. | Digestive diseases and sciences 20070901 |
| Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562. | Cancer chemotherapy and pharmacology 20070901 |
| Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). | Journal of cancer research and clinical oncology 20070901 |
| Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. | Blood 20070901 |
| Epigenetic control of MAGE gene expression by the KIT tyrosine kinase. | The Journal of investigative dermatology 20070901 |
| Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. | Cell death and differentiation 20070901 |
| First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. | Hematological oncology 20070901 |
| Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. | American journal of hematology 20070901 |
| Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. | The Journal of pharmacology and experimental therapeutics 20070901 |
| A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. | The Journal of clinical endocrinology and metabolism 20070901 |
| Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases. | Skeletal radiology 20070901 |
| The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. | Molecular pharmacology 20070901 |
| Management of gastrointestinal stromal tumours: a single-centre experience. | Irish journal of medical science 20070901 |
| Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. | Leukemia 20070901 |
| A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. | Cancer 20070901 |
| The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. | Haematologica 20070901 |
| Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate. | Anti-cancer drugs 20070901 |
| Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. | Journal of neurochemistry 20070901 |
| Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy. | Scandinavian journal of gastroenterology 20070901 |
| Therapeutic drug monitoring in CML patients on imatinib. | Blood 20070901 |
| Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. | Nature biotechnology 20070901 |
| Leukemia, an effective model for chemical biology and target therapy. | Acta pharmacologica Sinica 20070901 |
| From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. | Acta pharmacologica Sinica 20070901 |
| Advances in the treatment of gastrointestinal stromal tumours. | Annals of oncology : official journal of the European Society for Medical Oncology 20070901 |
| Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901 |
| Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. | Haematologica 20070901 |
| Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia. | Leukemia & lymphoma 20070901 |
| Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. | Cancer research 20070901 |
| Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901 |
| [Hypereosinophilic syndrome--recent developments in diagnosis and treatment]. | Deutsche medizinische Wochenschrift (1946) 20070901 |
| Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation. | Archives of pathology & laboratory medicine 20070901 |
| Dissecting kinase signaling pathways. | Drug discovery today 20070901 |
| Straight talk from... James Love. | Nature medicine 20070901 |
| Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. | Experimental lung research 20070901 |
| Lymphomatoid granulomatosis induced by imatinib-treatment. | Archives of dermatology 20070901 |
| Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. | PLoS pathogens 20070901 |
| Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor. | Journal of endocrinological investigation 20070901 |
| Hypereosinophilic syndrome: diagnosis and treatment. | Current opinion in pulmonary medicine 20070901 |
| Imatinib mesylate in chronic myeloid leukemia. | Current stem cell research & therapy 20070901 |
| Congestive heart failure is a rare event in patients receiving imatinib therapy. | Blood 20070815 |
| Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. | Cancer 20070815 |
| Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070815 |
| Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumors? | International journal of colorectal disease 20070801 |
| N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity. | Leukemia research 20070801 |
| Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. | Leukemia research 20070801 |
| Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation. | American journal of hematology 20070801 |
| Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. | Thorax 20070801 |
| Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. | Journal of neuro-oncology 20070801 |
| Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. | Journal of cancer research and clinical oncology 20070801 |
| A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. | Leukemia 20070801 |
| Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. | Cancer science 20070801 |
| Detection of FIP1L1-PDGFRA fusion by FISH. | British journal of haematology 20070801 |
| The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells. | Leukemia 20070801 |
| Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. | Laboratory investigation; a journal of technical methods and pathology 20070801 |
| Modulation of T-effector function by imatinib at the level of cytokine secretion. | Experimental hematology 20070801 |
| Charcot-Leyden crystals in the trephine biopsy of a patient with a FIP1L1-PDGFRA - positive myeloproliferative disorder. | British journal of haematology 20070801 |
| Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia. | European journal of haematology 20070801 |
| Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. | International journal of oncology 20070801 |
| Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. | British journal of haematology 20070801 |
| The challenge of opportunities: how far can and should we go with targeted treatments and modern diagnostics in gastrointestinal stromal tumors? | European journal of gastroenterology & hepatology 20070801 |
| Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome. | European journal of gastroenterology & hepatology 20070801 |
| Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. | The Journal of clinical investigation 20070801 |
| Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. | European journal of endocrinology 20070801 |
| New strategies for treating GIST when imatinib fails. | Cancer investigation 20070801 |
| Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070801 |
| Treatment for chronic myelogenous leukemia: the long road to imatinib. | The Journal of clinical investigation 20070801 |
| Applying the discovery of the Philadelphia chromosome. | The Journal of clinical investigation 20070801 |
| A radioprotective effect of imatinib (Gleevec) in human squamous carcinoma cells. | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20070801 |
| Imatinib-induced erythroderma. | The Australasian journal of dermatology 20070801 |
| [Imatinib . Sunitinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070801 |
| Platelet-derived growth factor, transforming growth factor-beta, and connective tissue growth factor in a porcine bronchial model of obliterative bronchiolitis. | Experimental lung research 20070801 |
| Desmoid-type fibromatosis. | Journal of neurosurgery 20070801 |
| Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance. | Leukemia & lymphoma 20070801 |
| Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. | International journal of andrology 20070801 |
| A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. | Drug discovery today 20070801 |
| The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. | Journal of neurovirology 20070801 |
| Novel approaches to therapy of hypereosinophilic syndromes. | Immunology and allergy clinics of North America 20070801 |
| Mutations in gastrointestinal stromal tumors diagnosed by endoscopic ultrasound-guided fine needle aspiration. | Minerva medica 20070801 |
| [The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment]. | Zhonghua nei ke za zhi 20070801 |
| Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors. | Current treatment options in oncology 20070801 |
| Chronic myeloid leukaemia. | Lancet (London, England) 20070728 |
| Inhibition of gut pacemaker cell formation from mouse ES cells by the c-kit inhibitor. | Biochemical and biophysical research communications 20070727 |
| BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. | The New England journal of medicine 20070719 |
| Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). | Blood 20070715 |
| Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. | Blood 20070715 |
| Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. | Blood 20070715 |
| A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. | Cancer 20070715 |
| Unexplored pharmacokinetic opportunities with microdosing in oncology. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070715 |
| Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070715 |
| BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. | Cancer research 20070715 |
| A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript. | Cancer genetics and cytogenetics 20070715 |
| Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. | Cancer genetics and cytogenetics 20070715 |
| [Tyrosine kinase inhibitors]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070710 |
| [Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070710 |
| Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells. | Cancer letters 20070708 |
| A rapid assay for drug sensitivity of glioblastoma stem cells. | Biochemical and biophysical research communications 20070706 |
| Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose. | Annals of hematology 20070701 |
| Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. | Biomedical chromatography : BMC 20070701 |
| Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. | Leukemia 20070701 |
| Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. | Bone marrow transplantation 20070701 |
| Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. | Clinical pharmacology and therapeutics 20070701 |
| The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. | Leukemia 20070701 |
| Second line therapies for the treatment of gastrointestinal stromal tumor. | Current opinion in oncology 20070701 |
| Chordoma. | Current opinion in oncology 20070701 |
| Effect of imatinib mesylate in a patient with a metastatic gastrointestinal stromal tumor with a c-kit mutation in exon 11. | Digestive diseases and sciences 20070701 |
| Mastocytosis: advances in diagnosis and treatment. | Current allergy and asthma reports 20070701 |
| Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas. | Oncology reports 20070701 |
| Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R. | International journal of oncology 20070701 |
| Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. | International journal of oncology 20070701 |
| Recent advances in the understanding of mastocytosis: the role of KIT mutations. | British journal of haematology 20070701 |
| Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. | British journal of haematology 20070701 |
| Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour. | Gut 20070701 |
| Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells. | Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20070701 |
| Surgical resection in metastatic gastrointestinal stromal tumors. | Current oncology reports 20070701 |
| Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature. | Onkologie 20070701 |
| JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. | The Lancet. Oncology 20070701 |
| Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. | Cancer control : journal of the Moffitt Cancer Center 20070701 |
| Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. | Archives of ophthalmology (Chicago, Ill. : 1960) 20070701 |
| NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. | Journal of the National Comprehensive Cancer Network : JNCCN 20070701 |
| [Drug-induced pneumonia that may have been caused by imatinib mesylate administered for gastrointestinal stromal tumor]. | Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20070701 |
| Drugs offer new hope for patients with CML who are resistant to imatinib. | ONS connect 20070701 |
| [Clinical observation of Gleevec combined with myeloablative allogeneic stem cells transplantation in treatment of chronic myeloid leukemia]. | Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20070701 |
| Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia. | Anti-cancer drugs 20070701 |
| [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology]. | Zhonghua bing li xue za zhi = Chinese journal of pathology 20070701 |
| [KIT mutation analysis in pathological diagnosis and target-therapy of gastrointestinal stromal tumors: an update]. | Zhonghua bing li xue za zhi = Chinese journal of pathology 20070701 |
| Imatinib mesylate induced skin hypopigmentation. | The Journal of the Association of Physicians of India 20070701 |
| New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. | Current hematologic malignancy reports 20070701 |
| Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. | Cancer letters 20070628 |
| Therapeutic procedures for submucosal tumors in the gastrointestinal tract. | World journal of gastroenterology 20070628 |
| Multiple malignant extragastrointestinal stromal tumors of the greater omentum and results of immunohistochemistry and mutation analysis: a case report. | World journal of gastroenterology 20070628 |
| [Hypereosinophilic syndrome and Löffler endocarditis caused by FIP1L-PDGFRA rearrangement: effectiveness of imatinib mesylate therapy]. | Medicina clinica 20070623 |
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. | Blood 20070615 |
| Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. | Blood 20070615 |
| Characterization of Ph-negative abnormal clones emerging during imatinib therapy. | Cancer 20070615 |
| Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. | Oncogene 20070614 |
| [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)]. | Postepy higieny i medycyny doswiadczalnej (Online) 20070609 |
| Imatinib mesylate inhibits proliferation and modulates cytokine expression of human cancer-associated stromal fibroblasts from colorectal metastases. | Cancer letters 20070608 |
| A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. | Oncogene 20070607 |
| Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). | British journal of cancer 20070604 |
| Hemopoietic stem cell transplantation from a donor with indeterminate HTLV-1 status. | American journal of hematology 20070601 |
| Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. | Cancer immunology, immunotherapy : CII 20070601 |
| BCR-ABL mutant kinetics in CML patients treated with dasatinib. | Leukemia research 20070601 |
| Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. | Blood 20070601 |
| Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome. | American journal of hematology 20070601 |
| Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070601 |
| Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors? | Annals of surgical oncology 20070601 |
| Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. | Arteriosclerosis, thrombosis, and vascular biology 20070601 |
| Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. | Leukemia 20070601 |
| Translational approaches for the prevention of estrogen receptor-negative breast cancer. | European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20070601 |
| A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20070601 |
| Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission. | British journal of haematology 20070601 |
| Intraoral granulocytic sarcoma presenting as multiple maxillary and mandibular masses: a case report and literature review. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20070601 |
| Current and emerging treatment options in chronic myeloid leukemia. | Cancer 20070601 |
| Therapeutic targets in chronic myeloid leukaemia. | Hematological oncology 20070601 |
| Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. | Best practice & research. Clinical haematology 20070601 |
| Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. | Best practice & research. Clinical haematology 20070601 |
| Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. | British journal of haematology 20070601 |
| A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. | Virchows Archiv : an international journal of pathology 20070601 |
| Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? | Annals of the rheumatic diseases 20070601 |
| Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. | Leukemia 20070601 |
| Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. | Cell proliferation 20070601 |
| Imatinib effect on growth and signal transduction in polycythemia vera. | Experimental hematology 20070601 |
| Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. | Cancer biology & therapy 20070601 |
| Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. | The Journal of invasive cardiology 20070601 |
| Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070601 |
| BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. | Cancer research 20070601 |
| Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20070601 |
| Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. | Haematologica 20070601 |
| Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. | Haematologica 20070601 |
| [Two cases of gastrointestinal stromal tumor (GIST) of the stomach and a consideration of its malignancy potential and treatment strategy - report of two cases]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070601 |
| Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. | International journal of clinical oncology 20070601 |
| Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach. | Urology 20070601 |
| Proposals for the management of gastrointestinal stromal tumours of the stomach. | The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 20070601 |
| Massive intraperitoneal stromal tumour: two-year follow-up. | The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 20070601 |
| Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. | Archives of dermatology 20070601 |
| Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia. | Leukemia & lymphoma 20070601 |
| FLT3 as a therapeutic target in childhood acute leukemia. | Current drug targets 20070601 |
| Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with Imatinib. | Annals of oncology : official journal of the European Society for Medical Oncology 20070601 |
| Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. | The oncologist 20070601 |
| [Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases]. | Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20070601 |
| Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. | Clinical and experimental medicine 20070601 |
| Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. | Stem cells and development 20070601 |
| [Overactive bladder in female and new strategy]. | Hinyokika kiyo. Acta urologica Japonica 20070601 |
| [Current status and future perspectives of the Glivec Registration System established by JSCH/JSH-TARGET]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20070601 |
| [Novel anti-CML agents beyond imatinib]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20070601 |
| [Reappearance of t(12;17)-positive primary myelofibrosis following Ph+ CML cell reduction by imatinib]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20070601 |
| A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. | Clinical genitourinary cancer 20070601 |
| Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. | Experimental oncology 20070601 |
| [Promising new treatment options for metastatic androgen-independent prostate cancer]. | Actas urologicas espanolas 20070601 |
| [Is positron emission tomography (PET) scan useful for studying the extent of gastrointestinal stromal tumors]. | Anales de medicina interna (Madrid, Spain : 1984) 20070601 |
| The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. | Molecular biotechnology 20070601 |
| Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. | Oncogene 20070531 |
| Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells. | Oncogene 20070524 |
| Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility. | Oncogene 20070524 |
| Gastrointestinal stromal tumour. | Lancet (London, England) 20070519 |
| Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. | Blood 20070515 |
| Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). | Cancer 20070515 |
| Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta. | Oncogene 20070510 |
| Resistance to imatinib mesylate in chronic myeloid leukaemia. | Cancer letters 20070508 |
| Chronic myelogenous leukemia progenitors display a genetically unstable personality. | Journal of the National Cancer Institute 20070502 |
| Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. | Journal of the National Cancer Institute 20070502 |
| Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response? | Leukemia research 20070501 |
| Expression analysis of PCNA gene in chronic myelogenous leukemia--combined application of siRNA silencing and expression arrays. | Leukemia research 20070501 |
| 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. | Leukemia research 20070501 |
| Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. | Journal of the American Academy of Dermatology 20070501 |
| Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. | American journal of hematology 20070501 |
| The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. | Cancer chemotherapy and pharmacology 20070501 |
| Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. | Annals of hematology 20070501 |
| Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. | Blood 20070501 |
| Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. | Blood 20070501 |
| MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. | Blood 20070501 |
| Chronic myeloid leukemia blast crisis arises from progenitors. | Stem cells (Dayton, Ohio) 20070501 |
| Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. | Journal of neuro-oncology 20070501 |
| Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. | The European respiratory journal 20070501 |
| Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. | Leukemia 20070501 |
| Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. | Leukemia 20070501 |
| The anticancer drug imatinib induces cellular autophagy. | Leukemia 20070501 |
| Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. | Molecular therapy : the journal of the American Society of Gene Therapy 20070501 |
| Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment. | Histopathology 20070501 |
| Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial. | Cancer 20070501 |
| The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation. | International journal of oncology 20070501 |
| Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. | Oncology reports 20070501 |
| An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20070501 |
| Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. | British journal of haematology 20070501 |
| Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. | Trends in pharmacological sciences 20070501 |
| Recent advances in therapy for gastrointestinal stromal tumors. | Current oncology reports 20070501 |
| Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. | European journal of haematology 20070501 |
| The role of KIT in the management of patients with gastrointestinal stromal tumors. | Human pathology 20070501 |
| Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. | Blood 20070501 |
| Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. | Nature reviews. Cancer 20070501 |
| Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias. | Expert opinion on investigational drugs 20070501 |
| Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501 |
| We should desist using RECIST, at least in GIST. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501 |
| Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070501 |
| Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. | Cancer research 20070501 |
| Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. | Cancer research 20070501 |
| Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells. | Leukemia & lymphoma 20070501 |
| Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. | Haematologica 20070501 |
| Targeted therapies for soft-tissue sarcomas. | Expert review of anticancer therapy 20070501 |
| Cutaneous Lichenoid dermatitis associated with imatinib mesylate. | Dermatology online journal 20070501 |
| The kinase inhibitor imatinib--an immunosuppressive drug? | Current cancer drug targets 20070501 |
| Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. | Journal of the National Comprehensive Cancer Network : JNCCN 20070501 |
| Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs. | Xenobiotica; the fate of foreign compounds in biological systems 20070501 |
| Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate. | Journal of gastroenterology 20070501 |
| Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? | Oncology (Williston Park, N.Y.) 20070501 |
| [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up]. | Harefuah 20070501 |
| [Chronic myeloid leukemia:specific characteristics and targeted therapy]. | Lijecnicki vjesnik 20070501 |
| Genomic instability: The cause and effect of BCR/ABL tyrosine kinase. | Current hematologic malignancy reports 20070501 |
| Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. | Current hematologic malignancy reports 20070501 |
| Immunotherapeutic strategies in chronic myeloid leukemia. | Current hematologic malignancy reports 20070501 |
| Imatinib in chronic myeloid leukemia. | The New England journal of medicine 20070426 |
| Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging. | World journal of gastroenterology 20070421 |
| Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. | Blood 20070415 |
| Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. | Blood 20070415 |
| Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. | Blood 20070415 |
| An ant algorithm for the conformational analysis of flexible molecules. | Journal of computational chemistry 20070415 |
| Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. | Cancer 20070415 |
| Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. | Cancer 20070415 |
| Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. | Blood 20070415 |
| c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070415 |
| The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070415 |
| Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. | Cancer research 20070415 |
| Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. | Cancer genetics and cytogenetics 20070415 |
| Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients. | Cancer genetics and cytogenetics 20070415 |
| Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. | The Journal of biological chemistry 20070413 |
| Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. | Oncogene 20070412 |
| Identification of imatinib mesylate degradation products obtained under stress conditions. | Journal of pharmaceutical and biomedical analysis 20070411 |
| Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report. | World journal of gastroenterology 20070407 |
| Vascular endothelial growth factor receptor-3 activity is modulated by its association with caveolin-1 on endothelial membrane. | Biochemistry 20070403 |
| Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. | FEBS letters 20070403 |
| Tumour lysis syndrome with acute renal failure during imatinib therapy. | Leukemia research 20070401 |
| Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML). | Leukemia research 20070401 |
| Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate. | Leukemia research 20070401 |
| The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. | Research in veterinary science 20070401 |
| Bone marrow aplasia--a rare complication of imatinib therapy in CML patients. | American journal of hematology 20070401 |
| Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of 'untreated' chronic myeloid leukemia. | American journal of hematology 20070401 |
| Central nervous system metastases from imatinib mesylate resistant gastrointestinal stromal tumor. | Journal of neuro-oncology 20070401 |
| Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. | Blood 20070401 |
| Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. | Blood 20070401 |
| AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate. | Gynecologic oncology 20070401 |
| STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells. | The Journal of pharmacology and experimental therapeutics 20070401 |
| Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. | The Journal of pharmacology and experimental therapeutics 20070401 |
| Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. | Laboratory investigation; a journal of technical methods and pathology 20070401 |
| Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance. | Annals of surgical oncology 20070401 |
| The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22). | Leukemia 20070401 |
| Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. | Neuro-oncology 20070401 |
| Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. | Cancer 20070401 |
| Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. | European journal of cancer (Oxford, England : 1990) 20070401 |
| An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment. | Cancer genetics and cytogenetics 20070401 |
| Follow-up study of patients diagnosed with chronic myelogenous leukemia treated with STI 571 in Ecuador. | Archives of medical research 20070401 |
| CD117 (c-kit) expression in human hepatocellular carcinoma. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20070401 |
| Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. | Journal of perinatology : official journal of the California Perinatal Association 20070401 |
| Optimizing therapy of chronic myeloid leukemia. | Experimental hematology 20070401 |
| A case report of therapeutic leukapheresis in an adult with chronic myelogenous leukemia presenting with hyperleukocytosis and leukostasis. | Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20070401 |
| Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate. | Journal of cutaneous pathology 20070401 |
| Imatinib for the treatment of rheumatic diseases. | Nature clinical practice. Rheumatology 20070401 |
| Activation of Abl by Helicobacter pylori: a novel kinase for CagA and crucial mediator of host cell scattering. | Gastroenterology 20070401 |
| Dasatinib is effective in imatinib-resistant CML. | The Lancet. Oncology 20070401 |
| [Effect of imatinib mesylate on bleomycin-induced pulmonary fibrosis in mice]. | Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue 20070401 |
| The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia. | Leukemia & lymphoma 20070401 |
| Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy. | The oncologist 20070401 |
| Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. | International journal of hematology 20070401 |
| Not all c-kit mutations can be corrected by imatinib. | Laboratory investigation; a journal of technical methods and pathology 20070401 |
| Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. | Haematologica 20070401 |
| Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. | Haematologica 20070401 |
| Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. | Annals of oncology : official journal of the European Society for Medical Oncology 20070401 |
| [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia]. | Zhongguo shi yan xue ye xue za zhi 20070401 |
| [Early blastic transformation within a year of imatinib treatment in 2 cases of chronic myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20070401 |
| The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. | Journal of molecular biology 20070330 |
| Neurofibromatosis type 2. | Neurology 20070327 |
| Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070320 |
| KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070320 |
| Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. | Blood 20070315 |
| Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country. | Cancer 20070315 |
| Another look at imatinib mesylate. | The New England journal of medicine 20070315 |
| Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. | Cancer research 20070315 |
| The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation. | Oncogene 20070308 |
| Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. | The EMBO journal 20070307 |
| Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate. | Leukemia research 20070301 |
| Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. | Blood 20070301 |
| Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. | Blood 20070301 |
| Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib. | Annals of hematology 20070301 |
| Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. | International journal of cancer 20070301 |
| Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. | Annals of surgical oncology 20070301 |
| Morphological and physiological evidence for interstitial cell of Cajal-like cells in the guinea pig gallbladder. | The Journal of physiology 20070301 |
| FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. | Leukemia 20070301 |
| Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate. | Leukemia 20070301 |
| Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. | Cancer 20070301 |
| Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. | Leukemia 20070301 |
| Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines. | Leukemia 20070301 |
| Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. | Current opinion in hematology 20070301 |
| Leukaemic infiltration of the mandible in a young girl. | International journal of paediatric dentistry 20070301 |
| Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis. | American journal of clinical pathology 20070301 |
| Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. | Cancer 20070301 |
| Sweet's syndrome: a spectrum of unusual clinical presentations and associations. | The British journal of dermatology 20070301 |
| A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. | Journal of the European Academy of Dermatology and Venereology : JEADV 20070301 |
| Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations. | Leukemia 20070301 |
| Do affluent societies have the only options for the best therapy? | Leukemia 20070301 |
| Loeffler endocarditis: findings on magnetic resonance imaging. | Heart (British Cardiac Society) 20070301 |
| Imatinib in melanoma: a selective treatment option based on KIT mutation status? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070301 |
| Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. | The Lancet. Oncology 20070301 |
| Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070301 |
| Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia. | Expert review of anticancer therapy 20070301 |
| [Targeted therapy of dermatofibrosarcoma with imatinib]. | Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20070301 |
| Combination therapy and new types of agents for pulmonary arterial hypertension. | Clinics in chest medicine 20070301 |
| Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. | Haematologica 20070301 |
| Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. | Haematologica 20070301 |
| Emerging drugs for the treatment of soft tissue sarcomas. | Expert opinion on emerging drugs 20070301 |
| c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. | Structure (London, England : 1993) 20070301 |
| Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia. | Journal of pediatric hematology/oncology 20070301 |
| Resistance to c-KIT kinase inhibitors conferred by V654A mutation. | Molecular cancer therapeutics 20070301 |
| Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. | Clinical lymphoma & myeloma 20070301 |
| Immunotherapy in chronic myelogenous leukemia. | Clinical lymphoma & myeloma 20070301 |
| The challenges of targeting chronic myeloid leukemia stem cells. | Clinical lymphoma & myeloma 20070301 |
| Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia. | Clinical lymphoma & myeloma 20070301 |
| Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date. | Clinical lymphoma & myeloma 20070301 |
| Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. | Clinical lymphoma & myeloma 20070301 |
| Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. | Clinical lymphoma & myeloma 20070301 |
| Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. | Clinical nephrology 20070301 |
| Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment. | Endocrine-related cancer 20070301 |
| [Dermatofibrosarcoma protuberans]. | Actas dermo-sifiliograficas 20070301 |
| Cocaine abuse may influence the response to imatinib in CML patients. | Haematologica 20070301 |
| Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. | Annals of surgery 20070301 |
| Effective neoadjuvant therapy prior to metastasectomy: a new paradigm. | Annals of surgery 20070301 |
| [NKT cell-mediated immunotherapy for hematological malignancies]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20070301 |
| Coexistence of papillary renal cell carcinoma and gastrointestinal stromal tumor in a case. | The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20070301 |
| Leukaemia stem cells: hit or miss? | British journal of cancer 20070226 |
| A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. | Oncogene 20070222 |
| New insights into oncogene addiction found. | Journal of the National Cancer Institute 20070221 |
| Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. | Blood 20070215 |
| Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. | Blood 20070215 |
| The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. | Blood 20070215 |
| Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. | Blood 20070215 |
| Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. | Journal of immunology (Baltimore, Md. : 1950) 20070215 |
| Imatinib concentrations in human milk. | Blood 20070215 |
| Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. | Cancer research 20070215 |
| Important therapeutic targets in chronic myelogenous leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070215 |
| Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. | The Journal of biological chemistry 20070209 |
| Taking TRIPS to India--Novartis, patent law, and access to medicines. | The New England journal of medicine 20070208 |
| With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model. | Journal of the National Cancer Institute 20070207 |
| Intracranial recurrence of the scalp dermatofibrosarcoma. | Clinical neurology and neurosurgery 20070201 |
| Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. | Investigational new drugs 20070201 |
| Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis. | Oncogene 20070201 |
| Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070201 |
| cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib. | Cancer chemotherapy and pharmacology 20070201 |
| Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070201 |
| Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. | Annals of surgical oncology 20070201 |
| Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20070201 |
| Why is cancer drug discovery so difficult? | Nature reviews. Drug discovery 20070201 |
| STI571 sensitizes nasopharyngeal carcinoma cells to cisplatin: sustained activation of ERK with improved growth inhibition. | International journal of oncology 20070201 |
| KIT mutations in GIST. | Current opinion in genetics & development 20070201 |
| Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. | Bone marrow transplantation 20070201 |
| Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. | Cancer biology & therapy 20070201 |
| Imatinib mesylate (gleevec) hepatotoxicity. | Digestive diseases and sciences 20070201 |
| Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy. | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20070201 |
| KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. | Annals of diagnostic pathology 20070201 |
| Lymphomatoid granulomatosis in a patient previously diagnosed with a gastrointestinal stromal tumour and treated with imatinib. | Journal of clinical pathology 20070201 |
| Novel compounds with antiproliferative activity against imatinib-resistant cell lines. | Molecular cancer therapeutics 20070201 |
| Gastro-intestinal stromal tumours: a review of current management options. | Hong Kong medical journal = Xianggang yi xue za zhi 20070201 |
| Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. | Cancer research 20070201 |
| Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. | Cancer research 20070201 |
| American Society of Hematology--48th Annual Meeting and Exposition. 9-12 December 2006, Orlando, FL, USA. | IDrugs : the investigational drugs journal 20070201 |
| TV6 and PDGFRB: a license to fuse. | Haematologica 20070201 |
| Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. | Haematologica 20070201 |
| Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. | Haematologica 20070201 |
| Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. | Haematologica 20070201 |
| [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070201 |
| [A case of recurrent GIST of the esophagus which completely responded to imatinib mesilate]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070201 |
| [Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia]. | Gan to kagaku ryoho. Cancer & chemotherapy 20070201 |
| Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). | Nuclear medicine and biology 20070201 |
| Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. | Molecular cancer therapeutics 20070201 |
| Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan. | International journal of hematology 20070201 |
| Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy. | International journal of hematology 20070201 |
| A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. | Leukemia & lymphoma 20070201 |
| Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. | Leukemia & lymphoma 20070201 |
| [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors]. | Bulletin du cancer 20070201 |
| Imatinib-induced immune hepatitis: case report and literature review. | Hematology (Amsterdam, Netherlands) 20070201 |
| What is new in chronic myeloid leukaemia? | Scottish medical journal 20070201 |
| [Novartis should discontinue its patent case in India!]. | Lakartidningen 20070201 |
| Pathological and biomolecular analyses of colorectal endocrine carcinoma. | Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20070201 |
| Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. | International ophthalmology 20070201 |
| Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia. | Clinical journal of oncology nursing 20070201 |
| [Experimental advance of targeted medicines for chronic myeloid leukemia--review]. | Zhongguo shi yan xue ye xue za zhi 20070201 |
| Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened. | The Journal of the Association of Physicians of India 20070201 |
| Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response. | The Journal of the Association of Physicians of India 20070201 |
| Hematological and molecular response evaluation of CML patients on imatinib. | The Journal of the Association of Physicians of India 20070201 |
| Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. | Current hematologic malignancy reports 20070201 |
| [Recent advances on molecular targets for treatment of acute leukemia]. | Nihon rinsho. Japanese journal of clinical medicine 20070128 |
| [Overcoming imatinib resistance]. | Nihon rinsho. Japanese journal of clinical medicine 20070128 |
| [Adverse effects of imatinib mesylate]. | Nihon rinsho. Japanese journal of clinical medicine 20070128 |
| [Treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia]. | Nihon rinsho. Japanese journal of clinical medicine 20070128 |
| [The management of chronic phase CML]. | Nihon rinsho. Japanese journal of clinical medicine 20070128 |
| [Treatment of chronic myelogenous leukemia with imatinib: current and future therapeutic strategies]. | Nihon rinsho. Japanese journal of clinical medicine 20070128 |
| MSF challenges Novartis's action over Indian patent for imatinib. | BMJ (Clinical research ed.) 20070127 |
| Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form. | Journal of pharmaceutical and biomedical analysis 20070117 |
| Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. | Blood 20070115 |
| Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. | Cancer 20070115 |
| Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. | British journal of cancer 20070115 |
| Dasatinib (Sprycel) for CML and Ph + ALL. | The Medical letter on drugs and therapeutics 20070115 |
| [Gastrointestinal stromal tumors]. | Praxis 20070110 |
| The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. | The Journal of biological chemistry 20070105 |
| Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. | Cancer chemotherapy and pharmacology 20070101 |
| A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. | Oral oncology 20070101 |
| INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. | Blood 20070101 |
| Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery? | Annals of surgical oncology 20070101 |
| Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. | Blood 20070101 |
| Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. | Blood 20070101 |
| c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase. | Molecular pharmacology 20070101 |
| Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells. | Genes, chromosomes & cancer 20070101 |
| Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. | Annals of surgical oncology 20070101 |
| Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. | Annals of surgical oncology 20070101 |
| Changes in expression of apoptosis-related genes are linked to the molecular response to imatinib treatment in chronic-phase chronic myeloid leukemia patients. | Acta haematologica 20070101 |
| Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy. | Leukemia 20070101 |
| Diagnosis and treatment of hypereosinophilic syndromes. | Current opinion in hematology 20070101 |
| Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation. | American journal of hematology 20070101 |
| Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment. | Acta haematologica 20070101 |
| EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Pediatric drugs, biomarkers and new therapies. | IDrugs : the investigational drugs journal 20070101 |
| Livedoid skin reaction probably due to imatinib therapy. | The Annals of pharmacotherapy 20070101 |
| Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel? | Arthritis and rheumatism 20070101 |
| Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. | Arthritis and rheumatism 20070101 |
| Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070101 |
| Clinical and in vitro studies of imatinib in advanced carcinoid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070101 |
| Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070101 |
| Hypercalcaemia in a patient with a gastrointestinal stromal tumour. | Clinical endocrinology 20070101 |
| Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. | Journal of proteome research 20070101 |
| In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. | Nature medicine 20070101 |
| In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. | Nature medicine 20070101 |
| In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. | Nature medicine 20070101 |
| In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. | Nature medicine 20070101 |
| Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. | Clinical drug investigation 20070101 |
| 3. Imatinib therapy in chronic myelogenous leukemia. | Internal medicine (Tokyo, Japan) 20070101 |
| Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. | British journal of haematology 20070101 |
| Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. | Haematologica 20070101 |
| Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. | British journal of haematology 20070101 |
| Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour. | Singapore medical journal 20070101 |
| Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract. | Amino acids 20070101 |
| Imatinib: a review of its use in chronic myeloid leukaemia. | Drugs 20070101 |
| Introduction: chronic myelogenous leukemia (CML). | Seminars in hematology 20070101 |
| The biology of chronic myelogenous leukemia: implications for imatinib therapy. | Seminars in hematology 20070101 |
| Resistance to targeted therapy in chronic myelogenous leukemia. | Seminars in hematology 20070101 |
| New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. | Seminars in hematology 20070101 |
| [Establishment of an imatinib resistance cell line K562R and its resistant principia]. | Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20070101 |
| Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. | Pathology, research and practice 20070101 |
| Gleevec may be heart toxic. | DukeMedicine healthnews 20070101 |
| Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment. | Acta haematologica 20070101 |
| [Molecular targeting therapy for chronic myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20070101 |
| Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications. | Harvard health letter 20070101 |
| Unusual fluid retention with imatinib therapy for chronic myeloid leukemia. | Leukemia & lymphoma 20070101 |
| Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. | Current medicinal chemistry 20070101 |
| Src kinase signaling in leukaemia. | The international journal of biochemistry & cell biology 20070101 |
| Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo. | Anticancer research 20070101 |
| Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia. | Laboratory hematology : official publication of the International Society for Laboratory Hematology 20070101 |
| Imatinib: a review of its use in the management of gastrointestinal stromal tumours. | Drugs 20070101 |
| Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, 'what worked and what did not'. | BMC nephrology 20070101 |
| [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors]. | Revista espanola de medicina nuclear 20070101 |
| Cancer drug resistance: the central role of the karyotype. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20070101 |
| Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. | Haematologica 20070101 |
| [Pulmonary hypertension: tailored treatment]. | Medicina 20070101 |
| Cell clonality in hypereosinophilic syndrome: what pathogenetic role? | Clinical and experimental rheumatology 20070101 |
| PDGF receptors as targets in tumor treatment. | Advances in cancer research 20070101 |
| Targeted cancer therapy: promise and reality. | Advances in cancer research 20070101 |
| Are various Babesia species a missed cause for hypereosinophilia? A follow-up on the first reported case of imatinib mesylate for idiopathic hypereosinophilia. | MedGenMed : Medscape general medicine 20070101 |
| Hepoxilin analogs, PBT-3 and PBT-4, cause apoptosis of Gleevec-resistant K562 cells in vitro. | In vivo (Athens, Greece) 20070101 |
| Reader's response to 'Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate'. | MedGenMed : Medscape general medicine 20070101 |
| Clinical, radiological, and pathological findings in four children with gastrointestinal stromal tumors of the stomach. | Pediatric hematology and oncology 20070101 |
| Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. | Tumori 20070101 |
| Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model. | Oligonucleotides 20070101 |
| The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors. | Anticancer research 20070101 |
| Imatinib and type 2 diabetes. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20070101 |
| Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. | PharmacoEconomics 20070101 |
| Cancer therapy: new drugs are emerging based on molecular targeting but still many challenges. | The international journal of biochemistry & cell biology 20070101 |
| Imatinib mesylate treatment in a patient with chemoresistant Ph+ acute myeloid leukemia: possible role of Wilms' tumor gene 1. | Tumori 20070101 |
| [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction]. | Terapevticheskii arkhiv 20070101 |
| Primary omental gastrointestinal stromal tumor (GIST). | World journal of surgical oncology 20070101 |
| Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC). | Biochimie 20070101 |
| [Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)]. | Therapie 20070101 |
| Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. | Blood cells, molecules & diseases 20070101 |
| C-kit, GIST, and imatinib. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20070101 |
| [The role of PET scan in gastrointestinal stromal tumors]. | Gastroenterologie clinique et biologique 20070101 |
| Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. | Breast cancer research : BCR 20070101 |
| Roots of imatinib resistance: a question of self-renewal? | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20070101 |
| A karyometric study on ageing and butyrate or imatinib treated human leukemic myeloblasts represented by K562 cells originated from chronic myeloid leukaemia. | Neoplasma 20070101 |
| Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. | Modern rheumatology 20070101 |
| The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. | Advances in experimental medicine and biology 20070101 |
| The role of interferon-alpha in the treatment of chronic myeloid leukemia. | Cytokine & growth factor reviews 20070101 |
| Lack of activity of imatinib in two cases of KIT+ retroperitoneal liposarcoma. | Hepato-gastroenterology 20070101 |
| [No influence of imatinib on type 2 diabetes]. | Przeglad lekarski 20070101 |
| [Gastrointestinal stromal tumors (GIST)]. | Wiadomosci lekarskie (Warsaw, Poland : 1960) 20070101 |
| Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. | BMC genomics 20070101 |
| Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice. | Acta haematologica 20070101 |
| The future is now for the treatment of chronic myelogenous leukemia. | ONS connect 20070101 |
| What's blasting off in CML? | ONS connect 20070101 |
| Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. | Angiogenesis 20070101 |
| Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. | Acta haematologica 20070101 |
| Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia. | American journal of therapeutics 20070101 |
| Effect of cellular quiescence on the success of targeted CML therapy. | PloS one 20070101 |
| RNA interference--about the reality to be exploited in cancer therapy. | Methods and findings in experimental and clinical pharmacology 20070101 |
| Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20070101 |
| [Recovery of polyclonial hemopoiesis in females with chronic myeloid leukemia with a complete cytogenetic response]. | Terapevticheskii arkhiv 20070101 |
| [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia]. | Terapevticheskii arkhiv 20070101 |
| Laparoscopic gastric tailoring for huge subcardial gastrointestinal stromal tumor. | JSLS : Journal of the Society of Laparoendoscopic Surgeons 20070101 |
| Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism. | European journal of dermatology : EJD 20070101 |
| Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562. | Acta biochimica Polonica 20070101 |
| Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. | Neurosurgical focus 20070101 |
| Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. | BMC pharmacology 20070101 |
| Idiopathic hypereosinophilic syndrome with infiltration of cerebrospinal fluid by immature eosinophils: a case report and literature review. | Surgical neurology 20070101 |
| Gastric GISTs. Personal experience. | Annali italiani di chirurgia 20070101 |
| Medical management of CML. | Hematology. American Society of Hematology. Education Program 20070101 |
| Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. | Hematology. American Society of Hematology. Education Program 20070101 |
| Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. | Acta haematologica 20070101 |
| Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: report of a case. | Surgery today 20070101 |
| Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. | Cancer journal (Sudbury, Mass.) 20070101 |
| Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia. | Drugs 20070101 |
| Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann. | Drugs 20070101 |
| Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords. | Drugs 20070101 |
| Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein. | Drugs 20070101 |
| Irreversible imatinib-induced pneumonitis following long-term imatinib administration. | Internal medicine (Tokyo, Japan) 20070101 |
| Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area. | Acta haematologica 20070101 |
| Dermatofibrosarcoma protuberans is CD117 negative even after extreme antigen retrieval conditions. | Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 20070101 |
| Study of the interaction surface for the c-Src-imatinib complex by a molecular dicing technique. | Asian Pacific journal of cancer prevention : APJCP 20070101 |
| Gastrointestinal stromal tumor--paradigm for successful targeted therapy. | Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20070101 |
| Gastrointestinal stromal tumors: a single institution experience of 50 cases. | Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20070101 |
| The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics. | Oncology research 20070101 |
| [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. | Verhandlungen der Deutschen Gesellschaft fur Pathologie 20070101 |
| [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis]. | Verhandlungen der Deutschen Gesellschaft fur Pathologie 20070101 |
| [Gastrointestinal stromal tumours: a broad spectrum of clinical presentations]. | Chirurgia italiana 20070101 |
| Telomerase inhibition combined with other chemotherapeutic reagents to enhance anti-cancer effect. | Methods in molecular biology (Clifton, N.J.) 20070101 |
| [Treatment of hematologic neoplasms during pregnancy]. | Medicina 20070101 |
| [Gastrointestinal stromal tumors (GIST) - clinical experience and current therapeutical aspects]. | Khirurgiia 20070101 |
| Critical update and emerging trends in imatinib treatment for gastrointestinal stromal tumor. | Reviews on recent clinical trials 20070101 |
| Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection. | Oncology 20070101 |
| New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. | Annals of internal medicine 20061219 |
| Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. | Journal of cellular biochemistry 20061215 |
| Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061215 |
| [Future aspects of the treatment of pulmonary arterial hypertension]. | Deutsche medizinische Wochenschrift (1946) 20061208 |
| Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. | Oncogene 20061207 |
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. | The New England journal of medicine 20061207 |
| Another look at imatinib mesylate. | The New England journal of medicine 20061207 |
| Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. | The New England journal of medicine 20061207 |
| Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. | European journal of pharmacology 20061203 |
| Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. | Leukemia research 20061201 |
| Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. | Leukemia research 20061201 |
| Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier. | Drug metabolism and disposition: the biological fate of chemicals 20061201 |
| Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. | Annals of surgical oncology 20061201 |
| Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. | Hematological oncology 20061201 |
| Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. | Annals of hematology 20061201 |
| Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. | Cell biology international 20061201 |
| Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients. | Rheumatology (Oxford, England) 20061201 |
| Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. | Gastroenterology 20061201 |
| Chlordiazepoxide for imatinib-induced muscular cramps. | European journal of haematology 20061201 |
| [Molecular targeted therapy]. | Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20061201 |
| In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. | Cancer research 20061201 |
| Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute. | The Kaohsiung journal of medical sciences 20061201 |
| Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia. | The Tohoku journal of experimental medicine 20061201 |
| Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. | The American journal of pathology 20061201 |
| Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. | The American journal of pathology 20061201 |
| Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib. | Future oncology (London, England) 20061201 |
| Distinct roles of IL-7 and stem cell factor in the OP9-DL1 T-cell differentiation culture system. | Experimental hematology 20061201 |
| Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy. | Current cancer drug targets 20061201 |
| Presentation of extramedullary Philadelphia chromosome-positive biphenotypic acute leukemia as testicular mass: Response to imatinib-combined chemotherapy. | Leukemia & lymphoma 20061201 |
| Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. | Cell cycle (Georgetown, Tex.) 20061201 |
| First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. | Expert review of anti-infective therapy 20061201 |
| [Current events about echography in 2006: position of the ultrasound functional imaging for the early evaluation of targeted therapeutics]. | Bulletin du cancer 20061201 |
| Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. | International journal of dermatology 20061201 |
| Usefulness of quantitative assessment of JunB gene expression as a marker for monitoring chronic myeloid leukemia patients undergoing imatinib therapy. | International journal of hematology 20061201 |
| Pregnancies in patients with chronic myeloid leukemia in the era of imatinib. | International journal of hematology 20061201 |
| [A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20061201 |
| Expression of c-KIT oncoprotein in gastrointestinal stromal tumors in adults and children: guideline for diagnosis and treatment. | Prilozi 20061201 |
| A clonal hypereosinophilic syndrome with specific and effective therapy: a report of two cases. | The Israel Medical Association journal : IMAJ 20061201 |
| Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. | The American surgeon 20061201 |
| [Gastrointestinal stromal tumors (GIST)--a paradigm of successful targeted therapy of solid tumors]. | Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 20061201 |
| Cancer drug effective in RA. | DukeMedicine healthnews 20061201 |
| Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor. | Journal of experimental & clinical cancer research : CR 20061201 |
| [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061201 |
| Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience. | The Medical journal of Malaysia 20061201 |
| [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors]. | Zhonghua yi xue za zhi 20061121 |
| CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. | Blood 20061115 |
| Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. | Blood 20061115 |
| Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. | Blood 20061115 |
| NUP214-ABL1 in adult T-ALL: the GMALL study group experience. | Blood 20061115 |
| Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. | Veterinary immunology and immunopathology 20061115 |
| Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. | American journal of respiratory and critical care medicine 20061115 |
| Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice. | Biochemical pharmacology 20061115 |
| A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. | Cancer research 20061115 |
| BNP as a marker of the heart failure in the treatment of imatinib mesylate. | Cancer letters 20061108 |
| Mathematical models of targeted cancer therapy. | British journal of cancer 20061106 |
| Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. | Cancer chemotherapy and pharmacology 20061101 |
| In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. | Leukemia research 20061101 |
| Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. | Annals of oncology : official journal of the European Society for Medical Oncology 20061101 |
| Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. | Leukemia research 20061101 |
| Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro. | Journal of hepatology 20061101 |
| Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20061101 |
| Synergistic and additive antiproliferative effects on human leukemia cell lines induced by combining acetylenehexacarbonyldicobalt complexes with the tyrosine kinase inhibitor imatinib. | Journal of inorganic biochemistry 20061101 |
| Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor. | Apoptosis : an international journal on programmed cell death 20061101 |
| Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA. | Leukemia 20061101 |
| Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. | Cancer 20061101 |
| Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. | Biochimica et biophysica acta 20061101 |
| A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. | Leukemia 20061101 |
| Philadelphia chromosome unmasked as a secondary genetic change in acute myeloid leukemia on imatinib treatment. | Leukemia 20061101 |
| Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment. | Langenbeck's archives of surgery 20061101 |
| Antituberculosis therapy and imatinib for chronic myeloid leukemia. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061101 |
| Gastrointestinal stromal tumors: imatinib and beyond. | Current treatment options in oncology 20061101 |
| Imatinib mesylate-induced acute hepatitis with autoimmune features. | European journal of gastroenterology & hepatology 20061101 |
| Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. | AJR. American journal of roentgenology 20061101 |
| Follicular acneiform eruption induced by imatinib. | Journal of the European Academy of Dermatology and Venereology : JEADV 20061101 |
| Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases. | The American journal of surgical pathology 20061101 |
| Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. | The Journal of molecular diagnostics : JMD 20061101 |
| Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. | Japanese journal of clinical oncology 20061101 |
| Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. | Anti-cancer drugs 20061101 |
| Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. | Inflammatory bowel diseases 20061101 |
| Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. | Journal of the National Cancer Institute 20061101 |
| Malignant gastrointestinal stromal neoplasm. | Surgery 20061101 |
| Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061101 |
| [A case of gastrointestinal stromal tumor with liver and bone metastases effectively treated with radiofrequency ablation and imatinib mesylate]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20061101 |
| Protein kinases as drug targets in cancer. | Current cancer drug targets 20061101 |
| Practical aspects of managing gastrointestinal stromal tumors. | Clinical colorectal cancer 20061101 |
| Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials. | Clinical colorectal cancer 20061101 |
| The molecular pathogenesis of gastrointestinal stromal tumors. | Clinical colorectal cancer 20061101 |
| Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia. | Leukemia & lymphoma 20061101 |
| Imatinib mesylate for the treatment of hypereosinophilic syndromes. | Current opinion in investigational drugs (London, England : 2000) 20061101 |
| Oral administration of imatinib to P230 BCR/ABL-expressing transgenic mice changes clones with high BCR/ABL complementary DNA expression into those with low expression. | International journal of hematology 20061101 |
| Advances in the management of Ph-positive ALL. | Clinical advances in hematology & oncology : H&O 20061101 |
| Development and validation of a liquid chromatography method for the simultaneous determination of alpha-tocopherol, retinol and retinyl esters in human serum using a monolithic column for the monitoring of anticancer therapy side effects. | Journal of separation science 20061101 |
| [Neoadjuvant therapy with imatinib mesilate for gastrointestinal stromal tumor of the stomach before subsequent successful surgical resection]. | Gan to kagaku ryoho. Cancer & chemotherapy 20061101 |
| Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate. | The Journal of the Association of Physicians of India 20061101 |
| Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. | Clinical colorectal cancer 20061101 |
| [Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia]. | Deutsche medizinische Wochenschrift (1946) 20061027 |
| Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. | British journal of cancer 20061023 |
| Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. | Blood 20061015 |
| Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. | Cancer 20061015 |
| Varying response to escalating the dose of imatinib in patients with CML who 'acquire' a BCR-ABL M244V mutant allele. | Blood 20061015 |
| Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061015 |
| Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061015 |
| Sunitinib for imatinib-resistant GIST. | Lancet (London, England) 20061014 |
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. | Lancet (London, England) 20061014 |
| Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061010 |
| ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. | British journal of cancer 20061009 |
| Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. | Oncogene 20061005 |
| Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. | The Journal of clinical investigation 20061002 |
| Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. | Cancer chemotherapy and pharmacology 20061001 |
| Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. | Leukemia research 20061001 |
| Exploiting oxidative damage to overcome resistance. | Leukemia research 20061001 |
| Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia. | Leukemia research 20061001 |
| Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. | Blood 20061001 |
| A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. | BJU international 20061001 |
| Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. | Genes, chromosomes & cancer 20061001 |
| Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. | Leukemia 20061001 |
| Treatment of metastatic sarcoma to the liver with bland embolization. | Cancer 20061001 |
| Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome? | British journal of haematology 20061001 |
| Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis. | The British journal of dermatology 20061001 |
| Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. | Cancer genetics and cytogenetics 20061001 |
| Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up. | Cancer genetics and cytogenetics 20061001 |
| Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. | Cell cycle (Georgetown, Tex.) 20061001 |
| Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. | Nature medicine 20061001 |
| Metastatic gastrointestinal stromal tumor and hypercalcemia in a patient with ulcerative colitis. | Saudi medical journal 20061001 |
| Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061001 |
| Targeted cancer treatment: resisting arrest. | Nature medicine 20061001 |
| Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia. | International journal of dermatology 20061001 |
| Image of the month. Cecal gastrointestinal stromal tumor. | Archives of surgery (Chicago, Ill. : 1960) 20061001 |
| Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061001 |
| [The anti-tumoral effect of PI3K inhibitor and MEK inhibitor combined with STI571 on chronic myeloid leukemia cells in a bone marrow stromal cell co-culture system]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20061001 |
| Systemic mastocytosis: current classification and novel therapeutic options. | Clinical advances in hematology & oncology : H&O 20061001 |
| Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines. | Cell cycle (Georgetown, Tex.) 20061001 |
| A short note on the nuclear diameter in human early granulocytic progenitors. | Hematology (Amsterdam, Netherlands) 20061001 |
| Imatinib inhibits spontaneous rhythmic contractions of human uterus and intestine. | European journal of pharmacology 20060928 |
| Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. | Journal of medicinal chemistry 20060921 |
| Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant. | Journal of medicinal chemistry 20060921 |
| Stimulatory autoantibodies to the PDGF receptor in scleroderma. | The New England journal of medicine 20060921 |
| A resectable case of gastrointestinal stromal tumor derived from the rectal wall after oral targeted molecular therapy with imatinib mesylate. | The Tokai journal of experimental and clinical medicine 20060920 |
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. | Blood 20060915 |
| Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. | Blood 20060915 |
| Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. | Circulation research 20060915 |
| Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. | Cancer research 20060915 |
| Somatic activation of KIT in distinct subtypes of melanoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060910 |
| [Etiology of and therapy for gastrointestinal stromal tumor]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060910 |
| Dasatinib in chronic myelogenous leukemia. | The New England journal of medicine 20060907 |
| [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia]. | Nederlands tijdschrift voor geneeskunde 20060902 |
| Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. | Leukemia research 20060901 |
| Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. | Leukemia research 20060901 |
| Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. | Blood 20060901 |
| Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). | Blood 20060901 |
| Constitutional pericentric inversion of chromosome 9 and hematopoietic recovery after allogeneic stem cell transplantation. | Annals of hematology 20060901 |
| Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. | Cancer science 20060901 |
| Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. | Leukemia 20060901 |
| Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells. | Leukemia 20060901 |
| Gene expression signatures associated with the resistance to imatinib. | Leukemia 20060901 |
| Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). | European journal of cancer (Oxford, England : 1990) 20060901 |
| Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. | Cancer 20060901 |
| Antivascular therapy of cancer metastasis. | Journal of surgical oncology 20060901 |
| Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation. | Current oncology reports 20060901 |
| Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. | Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20060901 |
| Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells. | Journal of immunology (Baltimore, Md. : 1950) 20060901 |
| Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML. | Blood 20060901 |
| Pulmonary arterial hypertension and chronic myeloproliferative disorders. | American journal of respiratory and critical care medicine 20060901 |
| Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate. | Diabetes care 20060901 |
| Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia. | Cancer genetics and cytogenetics 20060901 |
| Pharmacy benefit spending on oral chemotherapy drugs. | Journal of managed care pharmacy : JMCP 20060901 |
| [Hypereosinophilic syndrome--difficult-to-catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to gene discovery]. | Lakartidningen 20060901 |
| [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20060901 |
| [Clinical analysis of 60 cases with malignant gastrointestinal stromal tumors]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20060901 |
| Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. | Leukemia & lymphoma 20060901 |
| Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia. | Leukemia & lymphoma 20060901 |
| [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase]. | Vnitrni lekarstvi 20060901 |
| [Idiopathic interstitial pneumonia: treatment]. | Revue des maladies respiratoires 20060901 |
| Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases. | Journal of experimental & clinical cancer research : CR 20060901 |
| Current status of clinical trials for glioblastoma. | Reviews on recent clinical trials 20060901 |
| Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate. | Current hematologic malignancy reports 20060901 |
| Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction. | Current hematologic malignancy reports 20060901 |
| The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. | Current hematologic malignancy reports 20060901 |
| Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy. | Current hematologic malignancy reports 20060901 |
| [Effects of Imatinib mesylate on the development of dendritic cells derived from bone marrow mononuclear cells of patients with chronic myeloid leukemia]. | Zhonghua yi xue za zhi 20060829 |
| Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity. | The Journal of biological chemistry 20060825 |
| Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060820 |
| Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. | Biochemical and biophysical research communications 20060818 |
| Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. | Blood 20060815 |
| Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). | Blood 20060815 |
| Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. | Blood 20060815 |
| Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. | Blood 20060815 |
| Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha. | Blood 20060815 |
| Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | Human molecular genetics 20060815 |
| [Requirements for the development of molecularly defined targeted therapy in oncology]. | Medizinische Klinik (Munich, Germany : 1983) 20060815 |
| Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060815 |
| Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. | Oncogene 20060810 |
| Imatinib and pregnancy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060810 |
| Imatinib and altered bone and mineral metabolism. | The New England journal of medicine 20060810 |
| Imatinib and altered bone and mineral metabolism. | The New England journal of medicine 20060810 |
| Imatinib and altered bone and mineral metabolism. | The New England journal of medicine 20060810 |
| FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. | Leukemia research 20060801 |
| Imatinib-responsive hypereosinophilic syndrome. | Leukemia research 20060801 |
| Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Annals of hematology 20060801 |
| Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. | Leukemia 20060801 |
| Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells. | International journal of oncology 20060801 |
| Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient. | American journal of hematology 20060801 |
| c-Abl is involved in the F-actin assembly triggered by L-selectin crosslinking. | Journal of biochemistry 20060801 |
| Imatinib-induced eccrine squamous syringometaplasia. | Journal of the American Academy of Dermatology 20060801 |
| Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. | Annals of surgery 20060801 |
| Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. | Proteomics 20060801 |
| Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. | The British journal of radiology 20060801 |
| The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. | Nature cell biology 20060801 |
| Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. | Nature medicine 20060801 |
| Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060801 |
| Imatinib-induced cytogenetic remission in chronic eosinophilic leukaemia. | Internal medicine journal 20060801 |
| Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. | Haematologica 20060801 |
| Everolimus alters imatinib blood partition in favour of the erythrocyte. | The Journal of pharmacy and pharmacology 20060801 |
| Long term imatinib treatment in pulmonary arterial hypertension. | Thorax 20060801 |
| Eph tumour suppression: the dark side of Gleevec. | Nature cell biology 20060801 |
| Imatinib mesilate inhibits melanogenesis in vitro. | The British journal of dermatology 20060801 |
| Case histories, magic bullets and the state of drug discovery. | Nature reviews. Drug discovery 20060801 |
| Could imatinib replace surgery in esophageal gastrointestinal stromal tumor. | Saudi medical journal 20060801 |
| c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications. | Cancer research 20060801 |
| Gleevec suppresses p63 expression in head and neck squamous cell carcinoma despite p63 activation by DNA-damaging agents. | The Laryngoscope 20060801 |
| STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. | The Laryngoscope 20060801 |
| Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. | Clinical pharmacology and therapeutics 20060801 |
| Targeted cancer therapeutics: the heartbreak of success. | Nature medicine 20060801 |
| Tyrosine kinase inhibitors: the next generation. | The Lancet. Oncology 20060801 |
| Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20060801 |
| Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation. | International journal of hematology 20060801 |
| [Targeted therapies of cancer: not lost in translation]. | Bulletin du cancer 20060801 |
| Chronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapies. | Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20060801 |
| Desensitization to imatinib in patients with leukemia. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20060801 |
| Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. | Leukemia & lymphoma 20060801 |
| Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. | Leukemia & lymphoma 20060801 |
| Glivec and beyond. | European journal of cancer (Oxford, England : 1990) 20060801 |
| Current and future management of GIST. | Clinical advances in hematology & oncology : H&O 20060801 |
| [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060801 |
| Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. | Annals of internal medicine 20060718 |
| Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. | Blood 20060715 |
| Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. | Blood 20060715 |
| OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. | Blood 20060715 |
| 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors. | Bioorganic & medicinal chemistry letters 20060715 |
| Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. | Cancer 20060715 |
| Random aneuploidy in CML patients at diagnosis and under imatinib treatment. | Cancer genetics and cytogenetics 20060715 |
| [Molecular targeting therapy of hematopoietic tumors]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060710 |
| Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. | Blood 20060701 |
| BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. | Blood 20060701 |
| Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression. | Journal of biomedical science 20060701 |
| Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. | Journal of cellular physiology 20060701 |
| Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice. | Stem cells (Dayton, Ohio) 20060701 |
| Molecular targets and the treatment of myeloid leukemia. | Molecular genetics and metabolism 20060701 |
| Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. | Kidney international 20060701 |
| Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. | The British journal of surgery 20060701 |
| Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations. | Leukemia 20060701 |
| Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. | Current opinion in oncology 20060701 |
| New developments in gastrointestinal stromal tumor. | Current opinion in oncology 20060701 |
| An evidence-based approach to the management of pulmonary arterial hypertension. | Current opinion in cardiology 20060701 |
| Baseline and stimulated turnover of cell surface c-Kit expression in different types of human mast cells. | Experimental dermatology 20060701 |
| Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. | European journal of gastroenterology & hepatology 20060701 |
| Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060701 |
| Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. | Oncology reports 20060701 |
| Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole. | The Annals of thoracic surgery 20060701 |
| Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. | Pharmacotherapy 20060701 |
| Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats. | The Journal of pharmacy and pharmacology 20060701 |
| Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. | International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 20060701 |
| Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia. | Haematologica 20060701 |
| Janus kinase 2: a critical target in chronic myelogenous leukemia. | Cancer research 20060701 |
| beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia. | The Journal of molecular diagnostics : JMD 20060701 |
| Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20060701 |
| [A gastric stromal tumor (GIST) with a prolonged partial response to a reduced dose of imatinib mesilate]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060701 |
| Chronic myeloid leukemia: diagnosis and treatment. | Mayo Clinic proceedings 20060701 |
| [Chronic myelogenous leukemia]. | Nihon rinsho. Japanese journal of clinical medicine 20060701 |
| KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib. | Histopathology 20060701 |
| Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones. | Histopathology 20060701 |
| Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. | British journal of clinical pharmacology 20060701 |
| Activating alleles of JAK3 in acute megakaryoblastic leukemia. | Cancer cell 20060701 |
| [STI571 for gastrointestinal stromal tumors]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20060701 |
| Treatment of rare cancers: gastrointestinal stromal tumours. | British journal of hospital medicine (London, England : 2005) 20060701 |
| Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells. | Molecular cancer therapeutics 20060701 |
| Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. | Anti-cancer drugs 20060701 |
| The effect of imatinib mesylate (Glivec) on human tumor-derived cells. | Anti-cancer drugs 20060701 |
| Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia. | Leukemia & lymphoma 20060701 |
| Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. | Leukemia & lymphoma 20060701 |
| Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. | Leukemia & lymphoma 20060701 |
| [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20060701 |
| Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate. | World journal of gastroenterology 20060621 |
| Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620 |
| A common phosphotyrosine signature for the Bcr-Abl kinase. | Blood 20060615 |
| The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). | Blood 20060615 |
| Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. | The New England journal of medicine 20060615 |
| Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. | The New England journal of medicine 20060615 |
| Circumventing resistance to kinase-inhibitor therapy. | The New England journal of medicine 20060615 |
| Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. | The New England journal of medicine 20060615 |
| Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. | World journal of gastroenterology 20060607 |
| Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. | Journal of the National Cancer Institute 20060607 |
| STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model. | Chinese medical journal 20060605 |
| Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. | Leukemia research 20060601 |
| Imatinib as a potential antiresorptive therapy for bone disease. | Blood 20060601 |
| BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. | Blood 20060601 |
| Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. | Blood 20060601 |
| A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. | Gynecologic oncology 20060601 |
| BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. | Leukemia 20060601 |
| Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. | Leukemia 20060601 |
| Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. | Leukemia 20060601 |
| Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma. | Laboratory investigation; a journal of technical methods and pathology 20060601 |
| The results of imatinib therapy for patients with primary eosinophilic disorders. | European journal of haematology 20060601 |
| [Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy]. | La Revue de medecine interne 20060601 |
| Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). | Leukemia 20060601 |
| Strategies to eliminate cancer stem cells: clinical implications. | European journal of cancer (Oxford, England : 1990) 20060601 |
| Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML. | American journal of hematology 20060601 |
| Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. | American journal of hematology 20060601 |
| Eosinophilia: secondary, clonal and idiopathic. | British journal of haematology 20060601 |
| In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. | European journal of clinical investigation 20060601 |
| Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. | The British journal of dermatology 20060601 |
| Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia. | The British journal of dermatology 20060601 |
| Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia. | Clinical and laboratory haematology 20060601 |
| Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate. | Clinical and laboratory haematology 20060601 |
| Clone wars in CML. | Leukemia 20060601 |
| The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. | Endocrine-related cancer 20060601 |
| An update on molecular genetics of gastrointestinal stromal tumours. | Journal of clinical pathology 20060601 |
| Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach. | Internal medicine journal 20060601 |
| The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. | Cancer research 20060601 |
| Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. | Cancer research 20060601 |
| Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060601 |
| Autocrine PDGFR signaling promotes mammary cancer metastasis. | The Journal of clinical investigation 20060601 |
| [A case of recurrent GIST successfully treated with low-dose imatinib mesilate]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060601 |
| Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. | Surgery 20060601 |
| Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease. | Haematologica 20060601 |
| Corticosteroids can reverse severe imatinib-induced hepatotoxicity. | Haematologica 20060601 |
| Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors. | Analytical and quantitative cytology and histology 20060601 |
| Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. | International journal of hematology 20060601 |
| Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. | Current pharmaceutical biotechnology 20060601 |
| [Ph+ acute lymphoblastic leukemia combined with lung and brain invasive aspergillosis]. | Zhongguo shi yan xue ye xue za zhi 20060601 |
| Ongoing challenges of a global international patient assistance program. | Annals of oncology : official journal of the European Society for Medical Oncology 20060601 |
| Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. | Molecular cancer therapeutics 20060601 |
| Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing. | Leukemia & lymphoma 20060601 |
| Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester. | Leukemia & lymphoma 20060601 |
| [Molecular-targeted therapy for hormone-refractory prostate cancer]. | Hinyokika kiyo. Acta urologica Japonica 20060601 |
| Methodological aspects of current problems in target-based anticancer drug development. | International journal of clinical oncology 20060601 |
| Treatment of chronic myeloid leukemia with imatinib mesylate. | International journal of clinical oncology 20060601 |
| Gastrointestinal stromal tumor (GIST) and imatinib. | International journal of clinical oncology 20060601 |
| Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1. | Digestive diseases and sciences 20060601 |
| [A study to determine the safety and efficacy of imatinib mesylate in patients with chronic phase of chronic myeloid leukemia after interferon therapy failure. Four year follow-up]. | Polskie Archiwum Medycyny Wewnetrznej 20060601 |
| [Cytotoxic activities of Celecoxib on leukemic cells and the synergistic effects of Celecoxib with Imatinib thereupon]. | Zhonghua yi xue za zhi 20060530 |
| [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib]. | Nederlands tijdschrift voor geneeskunde 20060527 |
| [Two patients with hypereosinophilic syndrome]. | Nederlands tijdschrift voor geneeskunde 20060527 |
| Targeting tyrosine kinases in cancer: the second wave. | Science (New York, N.Y.) 20060526 |
| Imatinib mesylate--uncovering a fast track to adaptive immunity. | The New England journal of medicine 20060525 |
| Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060520 |
| Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. | Cancer research 20060515 |
| Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. | Cancer research 20060515 |
| Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060515 |
| Altered bone and mineral metabolism in patients receiving imatinib mesylate. | The New England journal of medicine 20060511 |
| Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy. | World journal of gastroenterology 20060507 |
| [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature]. | Orvosi hetilap 20060507 |
| Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. | Blood 20060501 |
| Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). | Molecular pharmacology 20060501 |
| Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan. | European journal of haematology 20060501 |
| Identification of transcriptional targets associated with the expression of p210 Bcr-Abl. | European journal of haematology 20060501 |
| New assignments for multitasking signal transduction inhibitors. | Molecular pharmacology 20060501 |
| Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. | Leukemia 20060501 |
| Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. | European journal of cancer (Oxford, England : 1990) 20060501 |
| Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia. | Leukemia 20060501 |
| With a little help from small friends: Enhanced chemotherapeutic effects with imatinib. | European journal of cancer (Oxford, England : 1990) 20060501 |
| Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia. | European journal of haematology 20060501 |
| Evaluation of imatinib mesylate effects on glioblastoma aggressiveness with SPECT radiotracer 99mTc-(v)-DMSA. | European journal of cancer (Oxford, England : 1990) 20060501 |
| Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. | Cancer 20060501 |
| STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response. | International journal of molecular medicine 20060501 |
| Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. | International journal of molecular medicine 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. | Current oncology reports 20060501 |
| KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. | European journal of cancer (Oxford, England : 1990) 20060501 |
| A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. | Haematologica 20060501 |
| Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. | Haematologica 20060501 |
| Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factor. | Clinical and experimental immunology 20060501 |
| PDGF receptor tyrosine kinase inhibitor suppresses mesangial cell proliferation involving STAT3 activation. | Clinical and experimental immunology 20060501 |
| A Src-like inactive conformation in the abl tyrosine kinase domain. | PLoS biology 20060501 |
| Dermatofibrosarcoma protuberans: report of a case with a variant ring chromosome and metastases following pregnancy. | Journal of cutaneous pathology 20060501 |
| Effective treatment of a case of refractory mycosis fungoides with imatinib. | British journal of haematology 20060501 |
| The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines. | Haematologica 20060501 |
| Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement. | Cancer genetics and cytogenetics 20060501 |
| Imatinib resistance: obstacles and opportunities. | Archives of pathology & laboratory medicine 20060501 |
| Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status. | Journal of neurosurgery 20060501 |
| Kinase inhibitors in chronic myelogenous leukemia. | Clinical advances in hematology & oncology : H&O 20060501 |
| Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. | Molecular cancer therapeutics 20060501 |
| New therapeutic approach for myeloid leukemia: induction of apoptosis via modulation of reactive oxygen species production by natural compounds. | International journal of hematology 20060501 |
| New strategies in chronic myeloid leukemia. | International journal of hematology 20060501 |
| [Innate defence against tumor cells: the killer cell IKDC]. | Bulletin du cancer 20060501 |
| [Further improving the standard of treatment for chronic myeloid leukemia]. | Zhonghua nei ke za zhi 20060501 |
| [Gastro-intestinal stromal tumours (GISTs): prognostic and therapeutic features]. | Il Giornale di chirurgia 20060501 |
| [Gastrointestinal stromal tumors: report of three cases and review of the literature]. | Il Giornale di chirurgia 20060501 |
| GIST under imatinib therapy. | Seminars in diagnostic pathology 20060501 |
| KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). | Seminars in diagnostic pathology 20060501 |
| Effect of STI-571 (imatinib mesylate) in combination with retinoic acid and gamma-irradiation on viability of neuroblastoma cells. | Biochemical and biophysical research communications 20060421 |
| [Reverse remodeling -- paradigm shift in the treatment of pulmonary hypertension]. | Deutsche medizinische Wochenschrift (1946) 20060421 |
| Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. | Journal of the National Cancer Institute 20060419 |
| Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). | Blood 20060415 |
| Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. | Blood 20060415 |
| BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. | Journal of immunology (Baltimore, Md. : 1950) 20060415 |
| [Pulmonary fibrosis--a therapeutic dilemma?]. | Medizinische Klinik (Munich, Germany : 1983) 20060415 |
| Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060415 |
| Advanced gastrointestinal stromal tumor patients with complete response after treatment with imatinib mesylate. | World journal of gastroenterology 20060407 |
| A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. | Leukemia research 20060401 |
| Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM. | Annals of oncology : official journal of the European Society for Medical Oncology 20060401 |
| Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. | Gynecologic oncology 20060401 |
| Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. | American journal of respiratory and critical care medicine 20060401 |
| Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. | Journal of leukocyte biology 20060401 |
| The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. | Leukemia 20060401 |
| The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. | Leukemia 20060401 |
| Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. | Leukemia 20060401 |
| Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. | Leukemia 20060401 |
| hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. | Leukemia 20060401 |
| Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. | Cancer 20060401 |
| First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. | Gut 20060401 |
| Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. | American journal of hematology 20060401 |
| Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. | Melanoma research 20060401 |
| Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. | Journal of the American College of Surgeons 20060401 |
| The effect of prior exposure to imatinib on transplant-related mortality. | Haematologica 20060401 |
| TGFbeta in cancer and other disease - AACR special conference in cancer research. | IDrugs : the investigational drugs journal 20060401 |
| Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. | The Journal of pharmacy and pharmacology 20060401 |
| Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060401 |
| Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060401 |
| Genzyme launches diagnostic to monitor Gleevec resistance. | Pharmacogenomics 20060401 |
| Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. | Seminars in respiratory and critical care medicine 20060401 |
| [In vitro killing effects of STI571 on esophageal carcinoma cell lines CE-48T and CE-81T]. | Ai zheng = Aizheng = Chinese journal of cancer 20060401 |
| Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). | Journal of cutaneous pathology 20060401 |
| [Tyrosine kinase inhibitor reverses adriamycin resistance mediated by cell adhesion in RPMI8226 cells]. | Zhongguo shi yan xue ye xue za zhi 20060401 |
| Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. | Molecular cancer therapeutics 20060401 |
| [Molecular targets in colon cancer]. | Therapeutische Umschau. Revue therapeutique 20060401 |
| [Tyrosine kinase inhibitors for the treatment of CML]. | Therapeutische Umschau. Revue therapeutique 20060401 |
| [The diagnostic and predictive role of kit (CD117)]. | Therapeutische Umschau. Revue therapeutique 20060401 |
| [State of the art in the treatment of chronic leukemias]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20060401 |
| [New therapeutic strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20060401 |
| [Flushing revealing the recurrence of a rectal gastrointestinal stromal tumour. Efficacy of imatinib]. | Gastroenterologie clinique et biologique 20060401 |
| [Duodenal gastrointestinal stromal tumors. Report of a case]. | Revista medica de Chile 20060401 |
| Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. | Blood 20060315 |
| Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. | Cancer 20060315 |
| Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. | Journal of surgical oncology 20060315 |
| Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060315 |
| Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. | World journal of gastroenterology 20060314 |
| Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. | European journal of pharmacology 20060308 |
| Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures. | Leukemia research 20060301 |
| Gastrointestinal stromal tumors presenting as gynecological tumors. | European journal of obstetrics, gynecology, and reproductive biology 20060301 |
| Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy. | Leukemia research 20060301 |
| Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. | Carcinogenesis 20060301 |
| Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. | Annals of oncology : official journal of the European Society for Medical Oncology 20060301 |
| Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. | Hypertension (Dallas, Tex. : 1979) 20060301 |
| A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. | Bone marrow transplantation 20060301 |
| High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. | Leukemia 20060301 |
| Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. | Cancer 20060301 |
| Pregnancy among patients with chronic myeloid leukemia treated with imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060301 |
| Overcoming drug resistance in chronic myeloid leukemia. | Current opinion in hematology 20060301 |
| The functional effects of a c-kit tyrosine inhibitor on guinea-pig and human detrusor. | BJU international 20060301 |
| Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers. | Journal of mass spectrometry : JMS 20060301 |
| Critical role for c-kit (CD117) in T cell lineage commitment and early thymocyte development in vitro. | European journal of immunology 20060301 |
| Imatinib mesylate as a cause of acute liver failure. | American journal of hematology 20060301 |
| Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia. | American journal of hematology 20060301 |
| Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060301 |
| Making a Notch in the lymphocyte kit. | European journal of immunology 20060301 |
| Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used? | Mayo Clinic proceedings 20060301 |
| Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach. | Clinics in chest medicine 20060301 |
| Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. | Journal of drugs in dermatology : JDD 20060301 |
| Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20060301 |
| Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal cell carcinoma: results of a single- institution phase II trial. | Clinical genitourinary cancer 20060301 |
| Imatinib mesylate: A designer drug. | The Journal of the Association of Physicians of India 20060301 |
| The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. | Cancer letters 20060227 |
| BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. | Oncogene 20060216 |
| Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. | Blood 20060215 |
| BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. | Blood 20060215 |
| Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. | Blood 20060215 |
| STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1. | World journal of gastroenterology 20060207 |
| Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Critical reviews in oncology/hematology 20060201 |
| Molecular interactions in imatinib-DPPC liposomes. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060201 |
| [Targeted therapies in pediatric oncology: a new therapeutic approach?]. | Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20060201 |
| Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. | Leukemia 20060201 |
| Targeted CML therapy: controlling drug resistance, seeking cure. | Current opinion in genetics & development 20060201 |
| Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. | Oncology reports 20060201 |
| Allosteric inhibitors of Bcr-abl-dependent cell proliferation. | Nature chemical biology 20060201 |
| [Hematological side effects of tyrosine kinase inhibition using imatinib]. | Der Pathologe 20060201 |
| MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate. | AJR. American journal of roentgenology 20060201 |
| Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses. | Cancer science 20060201 |
| Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus. | Cellular microbiology 20060201 |
| First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060201 |
| Prognostic variables in patients with chronic myeloid leukemia treated with imatinib. | Haematologica 20060201 |
| Chronic myeloid leukemia in 2006: a perspective. | Haematologica 20060201 |
| Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. | Haematologica 20060201 |
| The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. | Haematologica 20060201 |
| Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. | American journal of clinical oncology 20060201 |
| A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. | Journal of drugs in dermatology : JDD 20060201 |
| Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy. | International journal of hematology 20060201 |
| Beyond Gleevec--the next generation in CML. | European journal of cancer (Oxford, England : 1990) 20060201 |
| [Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20060201 |
| Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry. | Journal of separation science 20060201 |
| An in vitro study of the cytogenetic and cytotoxic effects of imatinib mesylate, STI571 on murine erythroleukemia GM-86 cells. | Journal of chemotherapy (Florence, Italy) 20060201 |
| Modulation of vascular endothelium by imatinib: a study on the EA.hy 926 endothelial cell line. | Journal of chemotherapy (Florence, Italy) 20060201 |
| From the bench to the bed: individualizing treatment in non-small-cell lung cancer. | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060201 |
| [Study on mismatch repair genes of chronic myeloid leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20060201 |
| Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. | Mutation research 20060131 |
| Looking beyond imatinib: next line of targeted drugs for CML shows promise. | JAMA 20060125 |
| High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060120 |
| Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060120 |
| Induction of gastric GIST in rat and establishment of GIST cell line. | Cancer letters 20060118 |
| PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. | Blood 20060115 |
| Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. | Blood 20060115 |
| Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. | Cancer 20060115 |
| Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. | Cancer 20060115 |
| The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation. | Journal of immunology (Baltimore, Md. : 1950) 20060115 |
| [Gastrointestinal stromal tumors (GIST). Clinical characteristics, diagnosis, and therapy in five cases]. | Medizinische Klinik (Munich, Germany : 1983) 20060115 |
| Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. | Cancer research 20060115 |
| Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060115 |
| FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. | Oncogene 20060105 |
| Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. | Leukemia research 20060101 |
| Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. | Annals of hematology 20060101 |
| Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era. | Frontiers in bioscience : a journal and virtual library 20060101 |
| Primary gastrointestinal stromal tumor of the liver with lung metastases successfully treated with STI-571 (imatinib mesylate). | Frontiers in bioscience : a journal and virtual library 20060101 |
| Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. | Journal of hepatology 20060101 |
| Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. | Journal of neuro-oncology 20060101 |
| Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. | The Journal of clinical endocrinology and metabolism 20060101 |
| Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript. | Leukemia 20060101 |
| The role of P-glycoprotein in imatinib resistance. | Leukemia 20060101 |
| The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. | Leukemia 20060101 |
| STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. | International journal of radiation oncology, biology, physics 20060101 |
| Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. | Leukemia 20060101 |
| Pregnancy on imatinib: fatal outcome with meningocele. | Annals of oncology : official journal of the European Society for Medical Oncology 20060101 |
| Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. | Leukemia 20060101 |
| Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens. | Leukemia 20060101 |
| Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? | Leukemia & lymphoma 20060101 |
| A phase II trial of imatinib in patients with refractory/relapsed myeloma. | Leukemia & lymphoma 20060101 |
| Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. | Leukemia & lymphoma 20060101 |
| Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. | European journal of haematology 20060101 |
| Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy. | American journal of hematology 20060101 |
| Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. | Investigational new drugs 20060101 |
| Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells. | Radiation research 20060101 |
| Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060101 |
| Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. | Cancer research 20060101 |
| Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. | British journal of haematology 20060101 |
| Pathology of gastrointestinal stromal tumors. | Pathology international 20060101 |
| Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. | The oncologist 20060101 |
| Synergistic suppression of rat neointimal hyperplasia by rapamycin and imatinib mesylate: implications for the prevention of accelerated arteriosclerosis. | Journal of vascular research 20060101 |
| [Gene expression profiling for prediction of response to chemotherapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060101 |
| Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. | Japanese journal of clinical oncology 20060101 |
| Effects of imatinib mesylate (Glivec) as a c-kit tyrosine kinase inhibitor in the guinea-pig urinary bladder. | Neurourology and urodynamics 20060101 |
| Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. | Blood reviews 20060101 |
| The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib. | Haematologica 20060101 |
| [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients]. | Harefuah 20060101 |
| Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies. | Current pharmaceutical design 20060101 |
| [Treatment of hypereosinophilia]. | Presse medicale (Paris, France : 1983) 20060101 |
| Gastrointestinal stromal tumors. | Abdominal imaging 20060101 |
| Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. | Indian journal of dermatology, venereology and leprology 20060101 |
| Chronic myeloproliferative diseases with the t(5;12)(q33;p13): clonal evolution is associated with blast crisis. | American journal of clinical pathology 20060101 |
| Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. | Cardiology 20060101 |
| Detection of BCR-ABL mutations and resistance to imatinib mesylate. | Methods in molecular medicine 20060101 |
| Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. | Pharmacology 20060101 |
| Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. | Radiographics : a review publication of the Radiological Society of North America, Inc 20060101 |
| Follow up of patient with totally resected gastric stromal tumor. | Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20060101 |
| Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. | Internal medicine (Tokyo, Japan) 20060101 |
| The effect of imatinib mesylate on the contractility of isolated rabbit myometrial strips. | Gynecologic and obstetric investigation 20060101 |
| Durable molecular complete remission induced by low-dose imatinib plus low-dose interferon alpha in a patient with chronic myelogenous leukaemia. | The Journal of international medical research 20060101 |
| Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. | Anticancer research 20060101 |
| [Gastrointestinal stromal tumor: a report of eight cases]. | Revista da Associacao Medica Brasileira (1992) 20060101 |
| Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia. | Acta dermato-venereologica 20060101 |
| Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment. | Pediatric dermatology 20060101 |
| Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm. | Molecular diagnosis & therapy 20060101 |
| Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg. | Digestive diseases (Basel, Switzerland) 20060101 |
| [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience]. | Casopis lekaru ceskych 20060101 |
| Tyrphostins and other tyrosine kinase inhibitors. | Annual review of biochemistry 20060101 |
| [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors]. | Revista espanola de medicina nuclear 20060101 |
| Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients. | Acta haematologica 20060101 |
| Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). | Journal of bone and mineral metabolism 20060101 |
| Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. | Anticancer research 20060101 |
| Periampullary carcinoid tumor in a woman with neurofibromatosis. | Current surgery 20060101 |
| Complete remission of recurrent gastrointestinal stromal tumors after treatment with imatinib: report of a case. | Surgery today 20060101 |
| [Clinical guidelines for the management of gastrointestinal stromal tumors]. | La Clinica terapeutica 20060101 |
| Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment. | Blood cells, molecules & diseases 20060101 |
| Treating imatinib-resistant leukemia: the next generation targeted therapies. | TheScientificWorldJournal 20060101 |
| The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. | Blood cells, molecules & diseases 20060101 |
| [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb]. | Lijecnicki vjesnik 20060101 |
| A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. | Acta bio-medica : Atenei Parmensis 20060101 |
| Differentiation therapy as an effective strategy for the treatment of chronic myelogenous leukemia. | Medical hypotheses 20060101 |
| Activity of AMN107 in gleevec-resistant leukemia. | Cancer biology & therapy 20060101 |
| Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment. | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20060101 |
| Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. | American journal of therapeutics 20060101 |
| [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia]. | Postepy higieny i medycyny doswiadczalnej (Online) 20060101 |
| Atypical chronic myeloid leukaemia with CD117-positive blast cells treated with imatinib: A report of two cases. | Acta haematologica 20060101 |
| [Effectiveness and safety of imatinib in seven gastrointestinal stromal tumor cases]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101 |
| Clinical presentation and treatment of gastrointestinal stromal tumors. | Tumori 20060101 |
| The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. | Molecular cancer 20060101 |
| Postinflammatory glomerular recanalization is established under the accommodation of transformed mesangial cells. | Journal of nephrology 20060101 |
| [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy]. | Annales de dermatologie et de venereologie 20060101 |
| Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate. | BMC gastroenterology 20060101 |
| Gastrointestinal stromal tumors: a contemporary review. | Pathology, research and practice 20060101 |
| Predicting the antitumor effects of STI571 by analysis of c-kit gene mutations in gastrointestinal stromal tumors of the stomach: Report of a case. | Surgery today 20060101 |
| Pathological fracture as a manifestation of extramedullary blastic crisis in chronic myelogenous leukemia: report of one case. | Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi 20060101 |
| Protein kinase inhibitors. | Folia biologica 20060101 |
| Defining and managing imatinib resistance. | Hematology. American Society of Hematology. Education Program 20060101 |
| [Surgery on gastrountestinal stromal tumor CD117+ (G.I.S.T.): personal experience]. | Annali italiani di chirurgia 20060101 |
| [Gastrointestinal stromal tumors: five case reports and review of the literature]. | Il Giornale di chirurgia 20060101 |
| Chronic myelogenous leukaemia (CML): an update. | The National medical journal of India 20060101 |
| Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate. | Anticancer research 20060101 |
| Two cases of complete response after imatinib mesylate treatment of advanced GIST. | Anticancer research 20060101 |
| Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia. | Clinical medicine (London, England) 20060101 |
| [STI571: a summary of targeted therapy]. | Postepy higieny i medycyny doswiadczalnej (Online) 20060101 |
| [Novel inhibitors of Bcr-Abl]. | Postepy higieny i medycyny doswiadczalnej (Online) 20060101 |
| Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells. | Zeitschrift fur Naturforschung. C, Journal of biosciences 20060101 |
| [Imatinib mesylate in treatment of childhood chronic myeloid leukaemia. Preliminary report]. | Medycyna wieku rozwojowego 20060101 |
| Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial. | Acta gastro-enterologica Belgica 20060101 |
| Validation of analytical procedure--control of residual ethanol, 2-propanol and ethyl acetate in pharmaceutical substance--imatinib. | Acta poloniae pharmaceutica 20060101 |
| Update on gastrointestinal stromal tumor [GIST]. | Ethiopian medical journal 20060101 |
| [The hypereosinophilic syndrome: case report]. | Annales Academiae Medicae Stetinensis 20060101 |
| [Gastric stromal tumor. Case report]. | Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20060101 |
| Imatinib mesylate induces responses in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy. | Journal of cancer research and therapeutics 20060101 |
| Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives. | Reviews on recent clinical trials 20060101 |
| Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. | Biochimica et biophysica acta 20051230 |
| Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. | Genetics and molecular research : GMR 20051230 |
| Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. | Biochemical and biophysical research communications 20051223 |
| gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. | The Journal of biological chemistry 20051223 |
| Imatinib and hyperlipidemia. | The New England journal of medicine 20051222 |
| Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220 |
| [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions]. | Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20051218 |
| Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051215 |
| A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. | Journal of the American College of Cardiology 20051206 |
| Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients. | Leukemia research 20051201 |
| Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. | Blood 20051201 |
| Pregnancy outcome of two patients treated with imatinib. | Annals of oncology : official journal of the European Society for Medical Oncology 20051201 |
| NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. | Blood 20051201 |
| Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI. | European radiology 20051201 |
| Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML. | Bone marrow transplantation 20051201 |
| Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. | Bone marrow transplantation 20051201 |
| The hypereosinophilic syndromes: still more heterogeneity. | Current opinion in immunology 20051201 |
| Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib. | Leukemia 20051201 |
| Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. | Leukemia 20051201 |
| Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads. | Analytical biochemistry 20051201 |
| The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. | Bone marrow transplantation 20051201 |
| Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis. | Bone marrow transplantation 20051201 |
| Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT). | Bone marrow transplantation 20051201 |
| Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. | Head & neck 20051201 |
| Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051201 |
| D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients. | Leukemia 20051201 |
| Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. | The Annals of pharmacotherapy 20051201 |
| Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients. | Clinical and laboratory haematology 20051201 |
| BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy? | Cell cycle (Georgetown, Tex.) 20051201 |
| Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. | Arthritis and rheumatism 20051201 |
| Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. | Cancer genetics and cytogenetics 20051201 |
| Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. | Cancer cell 20051201 |
| [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20051201 |
| [Cancer initiation as mini-evolution]. | Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 20051201 |
| [Gastrointestinal stromal tumor successfully treated with re-administration of STI571 despite of serious skin rash: a case report]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20051201 |
| Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. | Molecular cancer therapeutics 20051201 |
| [How should patients with completely resected gastrointestinal stromal tumours (GIST) be followed up?]. | Zentralblatt fur Chirurgie 20051201 |
| [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro]. | Zhongguo shi yan xue ye xue za zhi 20051201 |
| Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. | Journal of cataract and refractive surgery 20051201 |
| Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells. | Journal of biochemistry and molecular biology 20051130 |
| [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients]. | Zhonghua yi xue za zhi 20051130 |
| Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2). | Journal of medicinal chemistry 20051117 |
| [Antineoplastic agents targeting tyrosine kinases]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20051117 |
| Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. | Cancer research 20051115 |
| Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. | Oncogene 20051103 |
| CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib. | Leukemia research 20051101 |
| Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. | Journal of cellular physiology 20051101 |
| Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. | International journal of cancer 20051101 |
| Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. | Blood 20051101 |
| A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. | Genes, chromosomes & cancer 20051101 |
| ZIP kinase, a key regulator of myosin protein phosphatase 1. | Cellular signalling 20051101 |
| A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. | Annals of oncology : official journal of the European Society for Medical Oncology 20051101 |
| Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. | Bone marrow transplantation 20051101 |
| Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. | Leukemia 20051101 |
| Gastrointestinal stromal tumor: 5 years later. | Cancer 20051101 |
| A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. | Leukemia 20051101 |
| Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. | Leukemia 20051101 |
| Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML. | Leukemia 20051101 |
| Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. | Cancer 20051101 |
| Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. | Leukemia 20051101 |
| Dual tyrosine kinase inhibitors in chronic myeloid leukemia. | Leukemia 20051101 |
| Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. | American journal of clinical pathology 20051101 |
| Bcr is a negative regulator of the Wnt signalling pathway. | EMBO reports 20051101 |
| Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. | Journal of the American Academy of Dermatology 20051101 |
| Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction. | Leukemia & lymphoma 20051101 |
| F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib. | Clinical nuclear medicine 20051101 |
| Gastrointestinal stromal tumor in a child and review of the literature. | Pediatric surgery international 20051101 |
| Molecular research directions in the management of gastrointestinal stromal tumors. | Current treatment options in oncology 20051101 |
| CT evaluation of gastrointestinal stromal tumors treated with imatinib mesylate. | AJR. American journal of roentgenology 20051101 |
| Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib. | Haematologica 20051101 |
| Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. | Haematologica 20051101 |
| Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib. | Haematologica 20051101 |
| Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug. | Haematologica 20051101 |
| An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. | Cancer research 20051101 |
| Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051101 |
| Trends in the management of chronic myelogenous leukemia. | Journal of the National Comprehensive Cancer Network : JNCCN 20051101 |
| [Genetic alterations and chemoresistance]. | Gan to kagaku ryoho. Cancer & chemotherapy 20051101 |
| [A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively]. | Gan to kagaku ryoho. Cancer & chemotherapy 20051101 |
| The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. | Cancer cell 20051101 |
| Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA. | Journal of pediatric surgery 20051101 |
| Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. | Cancer biology & therapy 20051101 |
| Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase. | International journal of hematology 20051101 |
| Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. | International journal of hematology 20051101 |
| Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. | Current molecular medicine 20051101 |
| Mitochondria-dependent apoptosis in T-cell homeostasis. | Current opinion in investigational drugs (London, England : 2000) 20051101 |
| Chronic myelogenous leukemia. | Journal of the National Comprehensive Cancer Network : JNCCN 20051101 |
| Resistance to imatinib: mechanisms and management. | Journal of the National Comprehensive Cancer Network : JNCCN 20051101 |
| Testicular involvement in blast crisis of chronic myeloid leukemia. | Indian pediatrics 20051101 |
| Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy. | Internal medicine (Tokyo, Japan) 20051101 |
| [Advances in the molecular target therapy in lung cancer]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20051101 |
| [Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20051101 |
| [Gastrointestinal stromal tumors localized in small intestine and diagnosed preoperatively as gynecological neoplasms]. | Ginekologia polska 20051101 |
| [Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20051101 |
| Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells. | Experimental & molecular medicine 20051031 |
| Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate. | Biochemical and biophysical research communications 20051028 |
| Evaluation of CML model cell lines and imatinib mesylate response: determinants of signaling profiles. | Journal of immunological methods 20051020 |
| Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051020 |
| Antitumor activity of imatinib mesylate in neuroblastoma xenografts. | Cancer letters 20051018 |
| Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. | Cancer research 20051015 |
| Drug discovery: playing dirty. | Nature 20051013 |
| High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. | Journal of molecular biology 20051007 |
| Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. | Blood 20051001 |
| Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. | Cancer chemotherapy and pharmacology 20051001 |
| Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. | Lung cancer (Amsterdam, Netherlands) 20051001 |
| In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. | Blood 20051001 |
| Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. | Leukemia 20051001 |
| Metabolism and disposition of imatinib mesylate in healthy volunteers. | Drug metabolism and disposition: the biological fate of chemicals 20051001 |
| Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. | Annals of oncology : official journal of the European Society for Medical Oncology 20051001 |
| Secondary Ph+ acute lymphoblastic leukemia after temozolomide. | Annals of hematology 20051001 |
| Chronic myeloid leukemia CD34+ cells have elevated levels of phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P3) and lack a PtdIns(3,4,5)P3 response to cytokines and chemotactic factors; effects reversed by imatinib. | Leukemia 20051001 |
| Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. | Leukemia research 20051001 |
| Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. | Leukemia 20051001 |
| Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. | International journal of oncology 20051001 |
| Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. | Cancer genetics and cytogenetics 20051001 |
| Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. | Therapeutic drug monitoring 20051001 |
| CML clonal evolution with resistance to single agent imatinib therapy. | Clinical and laboratory haematology 20051001 |
| Imatinib induces hypothyroidism in patients receiving levothyroxine. | Clinical pharmacology and therapeutics 20051001 |
| Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. | The Lancet. Oncology 20051001 |
| PDGF signaling in pulmonary arterial hypertension. | The Journal of clinical investigation 20051001 |
| Reversal of experimental pulmonary hypertension by PDGF inhibition. | The Journal of clinical investigation 20051001 |
| Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051001 |
| Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. | Cancer research 20051001 |
| BIRB-796 is not an effective ABL(T315I) inhibitor. | Nature biotechnology 20051001 |
| Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. | Experimental hematology 20051001 |
| Chronic myelogenous leukemia. | Clinical journal of oncology nursing 20051001 |
| Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation. | Clinical nephrology 20051001 |
| Update on the use of imatinib mesylate. | Clinical advances in hematology & oncology : H&O 20051001 |
| [Recommendations for the management of GIST patients]. | Bulletin du cancer 20051001 |
| [A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20051001 |
| [Effect of neferine on the chemotherapic sensitivity of STI 571 to K562/A02 cells]. | Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20051001 |
| [Current status and prospect of neoplasm targeted therapy]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20051001 |
| [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20051001 |
| Imatinib for the treatment of pulmonary arterial hypertension. | The New England journal of medicine 20050929 |
| Complete remission with imatinib in metastastic gastrointestinal stromal tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050920 |
| Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050920 |
| High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. | Blood 20050915 |
| AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. | Cancer 20050915 |
| Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. | Cancer research 20050915 |
| Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. | Cancer research 20050915 |
| New targeted approaches in chronic myeloid leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050910 |
| [Treatment of chronic myelogenous leukemia by using imatinib]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050910 |
| An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate. | Leukemia 20050901 |
| Induction of centrosome and chromosome aberrations by imatinib in vitro. | Leukemia 20050901 |
| A key role for Abl family kinases in EphA receptor-mediated growth cone collapse. | Molecular and cellular neurosciences 20050901 |
| Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. | Leukemia 20050901 |
| Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. | Bone marrow transplantation 20050901 |
| The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. | Leukemia 20050901 |
| Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment. | Leukemia 20050901 |
| Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. | Leukemia 20050901 |
| Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. | Leukemia 20050901 |
| Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. | Leukemia 20050901 |
| Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. | Leukemia research 20050901 |
| Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission. | Leukemia research 20050901 |
| Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. | Leukemia 20050901 |
| Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. | Oncology reports 20050901 |
| Imatinib: the narrow line between immune tolerance and activation. | Trends in molecular medicine 20050901 |
| Philadelphia-chromosome positive thrombocythemia in a child. | European journal of haematology 20050901 |
| Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer. | BJU international 20050901 |
| E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib. | Leukemia & lymphoma 20050901 |
| Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo? | The British journal of dermatology 20050901 |
| Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. | The Lancet. Oncology 20050901 |
| Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib. | The Lancet. Oncology 20050901 |
| Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050901 |
| Effects of imatinib on normal hematopoiesis and immune activation. | Stem cells (Dayton, Ohio) 20050901 |
| Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. | Cancer research 20050901 |
| Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050901 |
| Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission. | Haematologica 20050901 |
| Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal. | The Lancet. Oncology 20050901 |
| Natural killer cell-dendritic cell crosstalk in the initiation of immune responses. | Expert opinion on biological therapy 20050901 |
| [Molecular targeted therapy for malignant brain tumors]. | Nihon rinsho. Japanese journal of clinical medicine 20050901 |
| [Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20050901 |
| Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants. | The Journal of biological chemistry 20050826 |
| Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820 |
| Soft-tissue sarcomas in adults. | The New England journal of medicine 20050818 |
| Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. | Blood 20050815 |
| Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. | Cancer 20050815 |
| Autocrine signaling of platelet-derived growth factor regulates disabled-2 expression during megakaryocytic differentiation of K562 cells. | FEBS letters 20050815 |
| PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810 |
| [Current progress in therapy of malignant diseases]. | Deutsche medizinische Wochenschrift (1946) 20050805 |
| Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. | Pharmacoepidemiology and drug safety 20050801 |
| Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate. | Pediatric blood & cancer 20050801 |
| Gene expression profiling of normal hematopoietic progenitor cells under treatment with imatinib in vitro. | Leukemia 20050801 |
| CMV-induced hemorrhagic cystitis as a complication of peripheral blood stem cell transplantation: case report. | Bone marrow transplantation 20050801 |
| Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. | Leukemia research 20050801 |
| The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. | Surgical oncology 20050801 |
| Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. | Annals of the rheumatic diseases 20050801 |
| Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer. | Anti-cancer drugs 20050801 |
| hOCT 1 and resistance to imatinib. | Blood 20050801 |
| An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. | Melanoma research 20050801 |
| Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. | British journal of haematology 20050801 |
| Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia? | Expert opinion on investigational drugs 20050801 |
| Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050801 |
| e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. | Haematologica 20050801 |
| T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. | Molecular cancer therapeutics 20050801 |
| Philadelphia positive acute lymphoblastic leukaemia of childhood. | British journal of haematology 20050801 |
| Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth. | British journal of haematology 20050801 |
| Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. | European journal of cancer (Oxford, England : 1990) 20050801 |
| Gastrointestinal stromal tumors and the evolution of targeted therapy. | Clinical advances in hematology & oncology : H&O 20050801 |
| Conventional and new treatment options for myelofibrosis with myeloid metaplasia. | Seminars in oncology 20050801 |
| [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20050801 |
| Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. | Blood 20050715 |
| Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). | Blood 20050715 |
| Tyrosine kinases as targets for cancer therapy. | The New England journal of medicine 20050714 |
| [Treatment outcome of hematopoietic stem cell transplantation for chronic myelogenous leukemia]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050710 |
| [Present status in hematopoietic stem cell transplantation (discussion)]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050710 |
| Gastrointestinal stromal tumors: CT and MRI findings. | European radiology 20050701 |
| Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. | Leukemia 20050701 |
| Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. | Leukemia 20050701 |
| Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and Imatinib mesylate selection. | Leukemia 20050701 |
| Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. | Leukemia 20050701 |
| Inhibition of c-fms by imatinib: expanding the spectrum of treatment. | Cell cycle (Georgetown, Tex.) 20050701 |
| The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line. | Leukemia research 20050701 |
| In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia. | Anti-cancer drugs 20050701 |
| An omental mass: any hypothesis? | Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20050701 |
| Improved cardiac function in a patient with hypereosinophilic syndrome treated with imatinib. | European journal of haematology 20050701 |
| Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development? | European journal of haematology 20050701 |
| Imatinib resistance in gastrointestinal stromal tumors. | Current oncology reports 20050701 |
| Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib. | Cancer genetics and cytogenetics 20050701 |
| Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. | British journal of clinical pharmacology 20050701 |
| RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. | Experimental hematology 20050701 |
| Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. | Clinical science (London, England : 1979) 20050701 |
| Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. | Cancer biology & therapy 20050701 |
| No GIST-type c-kit gain of function mutations in neuroblastic tumours. | Journal of clinical pathology 20050701 |
| Gastrointestinal stromal tumour treated with neoadjuvant imatinib. | Journal of clinical pathology 20050701 |
| Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. | Nature medicine 20050701 |
| Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. | Histopathology 20050701 |
| Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20050701 |
| Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. | Transfusion 20050701 |
| Cutaneous side-effects of kinase inhibitors and blocking antibodies. | The Lancet. Oncology 20050701 |
| Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. | Haematologica 20050701 |
| AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050701 |
| Imatinib is not a potential alternative treatment for uterine leiomyosarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050701 |
| Transgenomic's WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia. | Pharmacogenomics 20050701 |
| Gleevec casts a pox on poxviruses. | Nature medicine 20050701 |
| The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. | Leukemia & lymphoma 20050701 |
| Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate. | Leukemia & lymphoma 20050701 |
| Cancer biology: summing up cancer stem cells. | Nature 20050630 |
| Dynamics of chronic myeloid leukaemia. | Nature 20050630 |
| ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620 |
| Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). | Blood 20050615 |
| Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. | Blood 20050615 |
| Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050615 |
| Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050610 |
| [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives]. | Deutsche medizinische Wochenschrift (1946) 20050610 |
| In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. | The Prostate 20050601 |
| Additive apoptotic effect of STI571 with the cytoprotective agent amifostine in K-562 cell line. | Cancer chemotherapy and pharmacology 20050601 |
| Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. | American journal of respiratory and critical care medicine 20050601 |
| Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050601 |
| Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant. | Leukemia 20050601 |
| Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case. | Diseases of the colon and rectum 20050601 |
| Can application of serine protease inhibitors TPCK and TLCK provide evidence for possible involvement of serine protease Omi/HtrA2 in imatinib mesylate-induced cell death of BCR-ABL-positive human leukemia cells? | Leukemia 20050601 |
| Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4. | Leukemia 20050601 |
| Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. | Leukemia 20050601 |
| Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death. | Cell death and differentiation 20050601 |
| Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. | Radiology 20050601 |
| The rationale engineering of BCR/ABL blockers: an answer to STI571 acquired resistance in leukemia treatment. | Leukemia research 20050601 |
| Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia. | Leukemia research 20050601 |
| Resistance to tyrosine kinase inhibitors: calling on extra forces. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20050601 |
| Imatinib in pregnancy. | European journal of haematology 20050601 |
| Renal medullary carcinoma and ABL gene amplification. | The Journal of urology 20050601 |
| Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. | Applied immunohistochemistry & molecular morphology : AIMM 20050601 |
| Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. | Journal of surgical oncology 20050601 |
| Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines. | Biochemical pharmacology 20050601 |
| BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. | Cancer genetics and cytogenetics 20050601 |
| STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. | Experimental hematology 20050601 |
| Carcinosarcoma of the liver: a case report and review of the literature. | Archives of pathology & laboratory medicine 20050601 |
| Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050601 |
| In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. | Cancer research 20050601 |
| Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050601 |
| The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. | Structure (London, England : 1993) 20050601 |
| Gastrointestinal stromal tumors. | Hematology/oncology clinics of North America 20050601 |
| A functional approach to questions about life, death, and phosphorylation. | Cancer cell 20050601 |
| Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor. | Journal of Korean medical science 20050601 |
| Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. | Annals of the New York Academy of Sciences 20050601 |
| Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. | Molecular cancer research : MCR 20050601 |
| Soft tissue sarcoma: advances in understanding and management. | The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 20050601 |
| [EBM in the treatment of CML]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20050601 |
| [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals]. | Deutsche medizinische Wochenschrift (1946) 20050527 |
| Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. | British journal of cancer 20050523 |
| PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. | Blood 20050515 |
| Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. | Blood 20050515 |
| Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. | Blood 20050515 |
| Fast apoptosis and erythroid differentiation induced by imatinib mesylate in JURL-MK1 cells. | Journal of cellular biochemistry 20050515 |
| Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. | Cancer 20050515 |
| Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. | Cancer 20050515 |
| Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050515 |
| [Systemic mastocytosis]. | Presse medicale (Paris, France : 1983) 20050514 |
| Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. | Oncogene 20050505 |
| Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. | Pediatric blood & cancer 20050501 |
| Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. | American journal of physiology. Gastrointestinal and liver physiology 20050501 |
| The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. | Blood 20050501 |
| Imatinib blocks spontaneous mechanical activities in the adult mouse small intestine: possible inhibition of c-Kit signaling. | Pharmacology 20050501 |
| Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl. | Leukemia research 20050501 |
| Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. | Leukemia 20050501 |
| Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. | Cancer 20050501 |
| Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. | Cancer 20050501 |
| Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. | Histopathology 20050501 |
| Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia. | American journal of hematology 20050501 |
| Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. | American journal of hematology 20050501 |
| Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. | Experimental hematology 20050501 |
| Chronic myelogenous leukemia in accelerated phase. | Archives of pathology & laboratory medicine 20050501 |
| New agents in myelodysplastic syndromes. | Current hematology reports 20050501 |
| Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. | Current hematology reports 20050501 |
| Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050501 |
| Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. | Cancer research 20050501 |
| Loss of skin pigment caused by imatinib therapy. | British journal of haematology 20050501 |
| Anglo-Swedish Medicinal Chemistry - second symposium. | IDrugs : the investigational drugs journal 20050501 |
| A rare case of rapid growth of exophytic gastrointestinal stromal tumor of the stomach. | Digestive diseases and sciences 20050501 |
| Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. | International journal of hematology 20050501 |
| Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations. | International journal of hematology 20050501 |
| [Stem cell transplantation in the imatinib era]. | Orvosi hetilap 20050501 |
| [The role of imatinib in the treatment of acute lymphoid leukemias]. | Orvosi hetilap 20050501 |
| [Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. | Orvosi hetilap 20050501 |
| [Current aspects of treatment in gastrointestinal stromal tumors (GIST)]. | Orvosi hetilap 20050501 |
| [Clinical studies with imatinib in 2004]. | Orvosi hetilap 20050501 |
| The hypereosinophilic syndrome: idiopathic or not, that is the question. | Haematologica 20050501 |
| The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. | Haematologica 20050501 |
| Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features. | Leukemia & lymphoma 20050501 |
| Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. | Leukemia & lymphoma 20050501 |
| [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy]. | Polskie Archiwum Medycyny Wewnetrznej 20050501 |
| [Molecular signal transduction inhibitor for treatment of chronic myeloid leukemia]. | Zhonghua yi xue za zhi 20050427 |
| [Nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study]. | Zhonghua yi xue za zhi 20050427 |
| Lack of clinical efficacy of imatinib in metastatic melanoma. | British journal of cancer 20050425 |
| Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. | Blood 20050415 |
| Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. | Blood 20050415 |
| Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. | Blood 20050415 |
| Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. | Cancer 20050415 |
| After imatinib: new hopes for chronic myeloid leukaemia. | Drug discovery today 20050415 |
| Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes. | Chemico-biological interactions 20050415 |
| Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB. | The Journal of biological chemistry 20050408 |
| [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20050407 |
| Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. | The Biochemical journal 20050401 |
| Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. | Cancer chemotherapy and pharmacology 20050401 |
| The development of imatinib as a therapeutic agent for chronic myeloid leukemia. | Blood 20050401 |
| Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. | Molecular pharmacology 20050401 |
| Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. | Cancer immunology, immunotherapy : CII 20050401 |
| Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. | Leukemia 20050401 |
| Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy. | Leukemia 20050401 |
| Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. | Cancer chemotherapy and pharmacology 20050401 |
| Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases. | Leukemia research 20050401 |
| Aggressive systemic mastocytosis: is there a role for trisomy 8? | Leukemia research 20050401 |
| Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. | Anti-cancer drugs 20050401 |
| Expression of c-kit (CD117) in neuroendocrine tumours--a target for therapy? | Oncology reports 20050401 |
| Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. | Annals of oncology : official journal of the European Society for Medical Oncology 20050401 |
| Treatment with cyclosporin A cream for the cutaneous reactions associated with imatinib therapy. | Blood 20050401 |
| Immunohistochemical characterization of cutaneous drug eruptions by STI571. | Journal of dermatological science 20050401 |
| Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. | European journal of radiology 20050401 |
| The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. | Cancer research 20050401 |
| p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. | Cancer research 20050401 |
| Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets. | Cancer research 20050401 |
| Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence? | American journal of kidney diseases : the official journal of the National Kidney Foundation 20050401 |
| Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib. | American journal of ophthalmology 20050401 |
| New leukemia drug shows promise against Gleevec resistance. | Drug discovery today 20050401 |
| Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour. | Histopathology 20050401 |
| Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. | The Lancet. Oncology 20050401 |
| Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor. | Gastrointestinal endoscopy 20050401 |
| Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy. | International journal of hematology 20050401 |
| Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. | International journal of hematology 20050401 |
| Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib. | Haematologica 20050401 |
| In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. | Haematologica 20050401 |
| New tyrosine kinase inhibitors in chronic myeloid leukemia. | Haematologica 20050401 |
| Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate. | Haematologica 20050401 |
| Chronic myelogenous leukemia manifested as bilateral proliferative retinopathy. | Archives of ophthalmology (Chicago, Ill. : 1960) 20050401 |
| Post-inflammatory glomerular remodeling is influenced by transformed mesangial cells. | Pathology international 20050401 |
| Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumour. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20050401 |
| Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. | Journal of pediatric hematology/oncology 20050401 |
| Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin. | Cancer biology & therapy 20050401 |
| Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. | Clinical journal of oncology nursing 20050401 |
| How long will chronic myeloid leukemia patients treated with imatinib mesylate live? | Leukemia 20050401 |
| Images in cardiology: Hypereosinophilic syndrome and effect of imatinib mesylate. | Clinical cardiology 20050401 |
| Anti-IL-5 and hypereosinophilic syndromes. | Clinical immunology (Orlando, Fla.) 20050401 |
| Hypereosinophilic syndrome: two case reports of contrasting variants. | Southern medical journal 20050401 |
| Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study. | The Journal of the Association of Physicians of India 20050401 |
| Dermatological toxicity of imatinib mesylate. | The Journal of the Association of Physicians of India 20050401 |
| Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma. | Pharmacogenomics 20050401 |
| Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate. | Leukemia & lymphoma 20050401 |
| Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. | Oncogene 20050331 |
| c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage. | The Journal of biological chemistry 20050325 |
| Diabetes research. Researchers puzzle over possible effect of Gleevec. | Science (New York, N.Y.) 20050318 |
| Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. | Blood 20050315 |
| Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. | Blood 20050315 |
| Nonaqueous capillary electrophoresis method for the analysis of gleevec and its main metabolite in human urine. | Journal of chromatography. A 20050311 |
| Imatinib and regression of type 2 diabetes. | The New England journal of medicine 20050310 |
| [Systemic mastocytosis]. | Deutsche medizinische Wochenschrift (1946) 20050304 |
| Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. | Blood 20050301 |
| c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20050301 |
| Punish the parent not the progeny. | Blood 20050301 |
| Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. | Leukemia 20050301 |
| Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. | Leukemia 20050301 |
| Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. | Pediatric research 20050301 |
| Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. | Leukemia research 20050301 |
| Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML. | Leukemia research 20050301 |
| Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia? | Leukemia 20050301 |
| Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. | World journal of surgery 20050301 |
| A small molecule-kinase interaction map for clinical kinase inhibitors. | Nature biotechnology 20050301 |
| Imatinib mesylate and its potential implications for gynecologic cancers. | Current treatment options in oncology 20050301 |
| Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. | Nature reviews. Cancer 20050301 |
| Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. | Cancer genetics and cytogenetics 20050301 |
| The Philadelphia translocation and pre-existing myeloproliferative disorders. | British journal of haematology 20050301 |
| Cutaneous reactions to imatinib mesylate treated by topical steroid. | American journal of hematology 20050301 |
| Gastrointestinal stromal tumor with metastases in an adult woman treated with imatinib mesylate: MDCT findings. | AJR. American journal of roentgenology 20050301 |
| Innovations in antineoplastic therapy. | The Nursing clinics of North America 20050301 |
| CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050301 |
| A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. | Cell cycle (Georgetown, Tex.) 20050301 |
| Transient respiratory failure possibly associated to imatinib. | Investigational new drugs 20050301 |
| Can we afford to let sleeping dogs lie? | Blood 20050301 |
| Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now. | Haematologica 20050301 |
| Imatinib mesylate (STI-571) and porphyria cutanea tarda in a Chinese patient. | Haematologica 20050301 |
| Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. | Cancer research 20050301 |
| Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050301 |
| Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. | Mayo Clinic proceedings 20050301 |
| New agent overcomes resistance to imatinib. | The Lancet. Oncology 20050301 |
| Interaction maps for kinase inhibitors. | Nature biotechnology 20050301 |
| Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib. | Zeitschrift fur Gastroenterologie 20050301 |
| [GI hemorrhage with fulminant shock induced by jejunal gastrointestinal stromal tumor (GIST) coincident with duodenal neuroendocrine carcinoma (NET) + neurofibromatosis (NF) -- case report and review of the literature]. | Zeitschrift fur Gastroenterologie 20050301 |
| Imatinib and gastrointestinal stromal tumors: Where do we go from here? | Molecular cancer therapeutics 20050301 |
| Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA. | IDrugs : the investigational drugs journal 20050301 |
| Surgery for gastrointestinal stromal tumour in the post-imatinib era. | ANZ journal of surgery 20050301 |
| Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. | Archives of dermatology 20050301 |
| [Surgical management of GIST in the era of Gleevec]. | Annales de chirurgie 20050301 |
| [Imatinib therapy for patients with chronic myelogenous leukemia]. | Gan to kagaku ryoho. Cancer & chemotherapy 20050301 |
| The development and application of imatinib. | Expert opinion on drug safety 20050301 |
| A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. | Breast cancer research and treatment 20050301 |
| Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. | Pharmacotherapy 20050301 |
| [Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors]. | Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 20050301 |
| Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients? | Nature clinical practice. Oncology 20050301 |
| [Targeting Ras related proteins for leukemia therapy]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20050301 |
| Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL. | The Journal of biological chemistry 20050225 |
| [Arsenic treatment for leukemia: new model of human cancer target treatment]. | Zhonghua yi xue za zhi 20050223 |
| [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib]. | Zhonghua yi xue za zhi 20050223 |
| [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction]. | Zhonghua yi xue za zhi 20050223 |
| In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. | International journal of cancer 20050220 |
| Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050220 |
| [Molecular target therapy for malignant tumors]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050220 |
| A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. | Blood 20050215 |
| Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. | Blood 20050215 |
| Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. | Blood 20050215 |
| Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. | Cancer 20050215 |
| A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050210 |
| Imatinib-induced regression of AIDS-related Kaposi's sarcoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050210 |
| [Chronic myeloid leukemia]. | Orvosi hetilap 20050206 |
| A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. | The Prostate 20050201 |
| Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. | Blood 20050201 |
| Signaling function of PSGL-1 in neutrophil: tyrosine-phosphorylation-dependent and c-Abl-involved alteration in the F-actin-based cytoskeleton. | Journal of cellular biochemistry 20050201 |
| Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. | Leukemia 20050201 |
| Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. | Leukemia research 20050201 |
| CML cytogenetic relapse after cessation of imatinib therapy. | Leukemia research 20050201 |
| In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. | Leukemia & lymphoma 20050201 |
| Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. | Leukemia & lymphoma 20050201 |
| Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. | Journal of the American Society of Nephrology : JASN 20050201 |
| Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. | European journal of haematology 20050201 |
| Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation. | Cell cycle (Georgetown, Tex.) 20050201 |
| New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. | Anti-cancer drugs 20050201 |
| Imatinib inhibits the functional capacity of cultured human monocytes. | Immunology and cell biology 20050201 |
| Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases. | Experimental hematology 20050201 |
| Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201 |
| Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib. | The Lancet. Oncology 20050201 |
| Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. | Gastroenterology 20050201 |
| Imatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia. | Clinical and laboratory haematology 20050201 |
| The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. | European journal of nuclear medicine and molecular imaging 20050201 |
| Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms. | Internal medicine journal 20050201 |
| KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient. | Cancer research 20050201 |
| Gastrointestinal stromal tumor of the prostate. | Urology 20050201 |
| Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050201 |
| AMN107: tightening the grip of imatinib. | Cancer cell 20050201 |
| Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. | Cancer cell 20050201 |
| Vaccine development for chronic myelogenous leukaemia. | Lancet (London, England) 20050201 |
| Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. | Lancet (London, England) 20050201 |
| STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. | Cancer science 20050201 |
| St. John's wort reduces effectiveness of anticancer medication. | Health news (Waltham, Mass.) 20050201 |
| [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial]. | Zhongguo shi yan xue ye xue za zhi 20050201 |
| [STI571 used in treating acute myeloid leukemia with Philadelphia chromosome]. | Zhongguo shi yan xue ye xue za zhi 20050201 |
| Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate. | Internal medicine (Tokyo, Japan) 20050201 |
| Cytogenetic abnormalities without evidence of relapse after treatment with imatinib and stem cell transplantation in a patient with Ph-positive ALL. | International journal of hematology 20050201 |
| Staging for CLL-type non-Hodgkin's lymphoma reveals a gastrointestinal stromal tumour. | The Netherlands journal of medicine 20050201 |
| Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. | Transplantation 20050127 |
| Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050120 |
| Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? | Blood 20050115 |
| Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571. | World journal of gastroenterology 20050114 |
| Acid-base profiling of imatinib (gleevec) and its fragments. | Journal of medicinal chemistry 20050113 |
| Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. | American journal of respiratory and critical care medicine 20050101 |
| KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). | Leukemia 20050101 |
| Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. | Leukemia 20050101 |
| Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. | Cancer 20050101 |
| Targeted therapy with imatinib: hits and misses? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050101 |
| Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. | The Annals of pharmacotherapy 20050101 |
| Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. | Cancer 20050101 |
| Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines. | International journal of oncology 20050101 |
| Imatinib (Gleevec)-induced hepatotoxicity. | Journal of clinical gastroenterology 20050101 |
| Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. | Current opinion in hematology 20050101 |
| Interferon-gamma-dependent in vitro model for the putative keratin 17 autoimmune loop in psoriasis: exploration of pharmaco- and gene-therapeutic effects. | Skin pharmacology and physiology 20050101 |
| Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. | American journal of hematology 20050101 |
| C-kit as a target in the treatment of acute myelogenous leukemia. | Current hematology reports 20050101 |
| Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. | Journal of immunology (Baltimore, Md. : 1950) 20050101 |
| Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. | European journal of haematology 20050101 |
| Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050101 |
| Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib. | Haematologica 20050101 |
| Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. | Mayo Clinic proceedings 20050101 |
| Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. | Urology 20050101 |
| Update on the biology and therapy of gastrointestinal stromal tumors. | Cancer control : journal of the Moffitt Cancer Center 20050101 |
| U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050101 |
| Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050101 |
| Growth-factor inhibition as therapy for Kaposi's sarcoma. | The Lancet. Oncology 20050101 |
| Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case. | Surgery today 20050101 |
| [Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies]. | Bulletin du cancer 20050101 |
| Imatinib mesylate in the treatment of gastrointestinal stromal tumour. | Expert opinion on pharmacotherapy 20050101 |
| BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. | Expert opinion on investigational drugs 20050101 |
| Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. | Human pathology 20050101 |
| Recurrent GI bleeding and surgery following the initial response to imatinib therapy in GIST of the stomach. | Digestive diseases and sciences 20050101 |
| Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. | Blood cells, molecules & diseases 20050101 |
| [Expectation of new treatments for idiopathic interstitial pneumonias]. | Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050101 |
| Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha. | Neoplasma 20050101 |
| Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy. | Clinical laboratory science : journal of the American Society for Medical Technology 20050101 |
| A clinical and biological overview of gastrointestinal stromal tumors. | Medical oncology (Northwood, London, England) 20050101 |
| Characteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells. | Folia biologica 20050101 |
| Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. | Digestion 20050101 |
| Clinical pharmacokinetics of imatinib mesylate. | In vivo (Athens, Greece) 20050101 |
| The hepoxilin analog, PBT-3, inhibits growth of K-562 CML solid tumours in vivo in nude mice. | In vivo (Athens, Greece) 20050101 |
| [Optimizing current drugs]. | Annales pharmaceutiques francaises 20050101 |
| Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20050101 |
| Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. | American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101 |
| Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. | Clinical pharmacokinetics 20050101 |
| [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. | Chirurgia italiana 20050101 |
| Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement. | Tumori 20050101 |
| Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma. | Tumori 20050101 |
| Strategies for the design of potent and selective kinase inhibitors. | Current pharmaceutical design 20050101 |
| Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. | PharmacoEconomics 20050101 |
| [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20050101 |
| [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20050101 |
| [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition]. | Annales de biologie clinique 20050101 |
| Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors. | Hepato-gastroenterology 20050101 |
| Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate. | The oncologist 20050101 |
| Systemic mastocytosis: bone marrow pathology, classification, and current therapies. | Acta haematologica 20050101 |
| Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass. | Urologic oncology 20050101 |
| Non-homologous DNA end joining repair in normal and leukemic cells depends on the substrate ends. | Zeitschrift fur Naturforschung. C, Journal of biosciences 20050101 |
| [GIST: a clinical case as a model of surgical and pharmacological therapy of solid tumours]. | Chirurgia italiana 20050101 |
| FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20050101 |
| Effects of imatinib mesylate on adenoid cystic carcinomas. | Anticancer research 20050101 |
| Imatinib may be useful in the management of patients with glioblastoma. | Medical hypotheses 20050101 |
| [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]. | Terapevticheskii arkhiv 20050101 |
| [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek]. | Terapevticheskii arkhiv 20050101 |
| [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy]. | Terapevticheskii arkhiv 20050101 |
| Clinical pharmacokinetics of imatinib. | Clinical pharmacokinetics 20050101 |
| Myeloproliferative disorders. | Clinical medicine (London, England) 20050101 |
| Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. | Biomacromolecules 20050101 |
| Computed tomography and sonographic findings of hepatic metastases from gastrointestinal stromal tumors after chemotherapy. | Journal of computer assisted tomography 20050101 |
| Allogeneic transplantation for chronic myelogenous leukemia. | Hematology (Amsterdam, Netherlands) 20050101 |
| Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. | American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101 |
| Imatinib mesylate as therapy for gastrointestinal stromal tumor. | Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20050101 |
| Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects. | Acta haematologica 20050101 |
| The current management of gastrointestinal stromal tumors. | Advances in surgery 20050101 |
| Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. | Dermatology (Basel, Switzerland) 20050101 |
| Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. | Oncology 20050101 |
| Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. | Hematology. American Society of Hematology. Education Program 20050101 |
| Management of early stage disease. | Hematology. American Society of Hematology. Education Program 20050101 |
| Loss of response to imatinib: mechanisms and management. | Hematology. American Society of Hematology. Education Program 20050101 |
| Pathobiology of lymphoid and myeloid blast crisis and management issues. | Hematology. American Society of Hematology. Education Program 20050101 |
| Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. | Oncology 20050101 |
| Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. | Anticancer research 20050101 |
| Efficacy of STI571 for a patient with metastatic gastrointestinal stromal tumor. | Hepato-gastroenterology 20050101 |
| A simulation study using validated prognostic factors to assess expected long-term survival. | Methods of information in medicine 20050101 |
| A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. | Journal of veterinary internal medicine 20050101 |
| The radiology of gastrointestinal stromal tumours (GIST). | Cancer imaging : the official publication of the International Cancer Imaging Society 20050101 |
| [Tyrosine kinases. New target of anticancer therapy]. | Postepy biochemii 20050101 |
| BCRABL transcript detection by quantitative real-time PCR : are correlated results possible from homebrew assays? | Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology 20050101 |
| Generalized hypopigmentation due to imatinib: a fairness boon? | Indian journal of dermatology, venereology and leprology 20050101 |
| Lichenoid eruption due to imatinib. | Indian journal of dermatology, venereology and leprology 20050101 |
| Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose. | Indian journal of dermatology, venereology and leprology 20050101 |
| [Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case]. | I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20050101 |
| [Treatment of gastrointestinal stromal tumor (GIST)--review of the literature and a case report]. | Annali italiani di chirurgia 20050101 |
| [Gastrointestinal stromal tumors. Actual diagnosis and treatment]. | Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20050101 |
| [Treatment strategies for chronic myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20050101 |
| [Problems in the current target therapy of malignancies]. | Voprosy onkologii 20050101 |
| Leukemia: stem cells, maturation arrest, and differentiation therapy. | Stem cell reviews 20050101 |
| A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. | The Journal of biological chemistry 20041231 |
| Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. | Blood 20041215 |
| Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. | Blood 20041215 |
| Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. | Bioorganic & medicinal chemistry letters 20041206 |
| Inhibition of HMC-1 mast cell proliferation by vitamin E: involvement of the protein kinase B pathway. | The Journal of biological chemistry 20041203 |
| Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. | Blood 20041201 |
| Active transport of imatinib into and out of cells: implications for drug resistance. | Blood 20041201 |
| Establishment and characterization of a new human erythroleukemic cell line, ERY-1. | Leukemia research 20041201 |
| Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. | Cancer 20041201 |
| Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. | Cancer 20041201 |
| Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. | Leukemia 20041201 |
| CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. | AJR. American journal of roentgenology 20041201 |
| Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report. | American journal of hematology 20041201 |
| Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML). | American journal of hematology 20041201 |
| Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. | Liver international : official journal of the International Association for the Study of the Liver 20041201 |
| Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20041201 |
| [Origin of resistance to Imatinib mesylate: lessons learned from this experience]. | Medecine sciences : M/S 20041201 |
| Oncogenic derivatives of platelet-derived growth factor receptors. | Cellular and molecular life sciences : CMLS 20041201 |
| Kit as a human oncogenic tyrosine kinase. | Cellular and molecular life sciences : CMLS 20041201 |
| [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. | Ai zheng = Aizheng = Chinese journal of cancer 20041201 |
| Follicular mucinosis associated with imatinib (STI571). | The British journal of dermatology 20041201 |
| Focus on myeloproliferative diseases and myelodysplastic syndromes. | Cancer cell 20041201 |
| Imatinib mesylate for melanoma: will a new target be revealed? | The Journal of investigative dermatology 20041201 |
| Imatinib mesylate in cutaneous melanoma. | The Journal of investigative dermatology 20041201 |
| Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. | Cell cycle (Georgetown, Tex.) 20041201 |
| Imatinib-responsive hypereosinophilia in a patient with B cell ALL. | Leukemia & lymphoma 20041201 |
| Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. | Leukemia & lymphoma 20041201 |
| [Experimental research on tyrosine-kinase inhibitor STI571 and P21WAF gene clone to treat chronic myeloid leukemia]. | Zhongguo shi yan xue ye xue za zhi 20041201 |
| A treatment using STI571 for jejunal gastrointestinal stromal tumor (GIST) accompanied with liver metastasis and peritoneal dissemination. | Internal medicine (Tokyo, Japan) 20041201 |
| Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia. | Annals of the New York Academy of Sciences 20041201 |
| RET signals through focal adhesion kinase in medullary thyroid cancer cells. | Surgery 20041201 |
| The role of alpha-interferon in chronic myelogenous leukaemia in Imatinib era. | Journal of experimental & clinical cancer research : CR 20041201 |
| Cyclooxygenase-2 induction and prostaglandin E2 accumulation in squamous cell carcinoma as a consequence of epidermal growth factor receptor activation by imatinib mesylate. | Journal of experimental therapeutics & oncology 20041201 |
| Two new agents effective in Gleevec-resistant CML. | Cancer biology & therapy 20041201 |
| Isolated central nervous system blast crisis in chronic myeloid leukemia. | Hematological oncology 20041201 |
| Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment. | Journal of the National Cancer Institute 20041117 |
| FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. | Blood 20041115 |
| Prevalence of KIT expression in human tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041115 |
| Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041115 |
| Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. | The New England journal of medicine 20041111 |
| Researchers optimistic about targeted drugs for pancreatic cancer. | Journal of the National Cancer Institute 20041103 |
| Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. | Blood 20041101 |
| Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. | Blood 20041101 |
| Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. | Blood 20041101 |
| Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. | Blood 20041101 |
| Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias. | Bone marrow transplantation 20041101 |
| Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia. | Leukemia 20041101 |
| A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation. | Molecular & cellular proteomics : MCP 20041101 |
| Recurrent spinal ependymoma showing partial remission under Imatimib. | Acta neurochirurgica 20041101 |
| Imatinib mesylate in chordoma. | Cancer 20041101 |
| Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. | Leukemia research 20041101 |
| Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20041101 |
| A phenomenal response to treatment by an advanced tumour. | Gut 20041101 |
| Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. | European journal of gastroenterology & hepatology 20041101 |
| Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance? | British journal of haematology 20041101 |
| Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. | British journal of cancer 20041101 |
| Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. | American journal of hematology 20041101 |
| KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. | The Journal of molecular diagnostics : JMD 20041101 |
| Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. | Leukemia & lymphoma 20041101 |
| Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. | Leukemia & lymphoma 20041101 |
| Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor. | Leukemia & lymphoma 20041101 |
| Reduced dose imatinib mesylate therapy for chronic myeloid leukemia. | Leukemia & lymphoma 20041101 |
| Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. | The Journal of clinical investigation 20041101 |
| The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. | Pharmacotherapy 20041101 |
| A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein. | Experimental hematology 20041101 |
| Selective effect of imatinib on serum IgM in a patient with CML. | International journal of hematology 20041101 |
| Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. | Clinical therapeutics 20041101 |
| [Targeted drugs in radiation therapy]. | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20041101 |
| Reversing resistance to targeted therapy. | Journal of chemotherapy (Florence, Italy) 20041101 |
| Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors. | Journal of chemotherapy (Florence, Italy) 20041101 |
| [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20041101 |
| Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. | Biochemical and biophysical research communications 20041022 |
| Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass. | The New England journal of medicine 20041021 |
| Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. | Blood 20041015 |
| p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. | Cancer research 20041015 |
| Targeting HIF-alpha: when a magic arrow hits the bull's eye. | Drug discovery today 20041015 |
| Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. | Cancer chemotherapy and pharmacology 20041001 |
| Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. | Blood 20041001 |
| Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. | Blood 20041001 |
| The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. | The Journal of biological chemistry 20041001 |
| Monitoring of plasma imatinib concentration for the effective treatment of CML patients. | Leukemia research 20041001 |
| Recent advances in management of small-cell lung cancer. | Cancer treatment reviews 20041001 |
| A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors. | Proteins 20041001 |
| Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor. | European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 20041001 |
| Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. | Leukemia 20041001 |
| Assessment of the response to imatinib in chronic myeloid leukemia patients--comparison between the FISH, multiplex and RT-PCR methods. | European journal of haematology 20041001 |
| Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. | Nature genetics 20041001 |
| Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. | Journal of molecular graphics & modelling 20041001 |
| Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia. | Histology and histopathology 20041001 |
| Discontinuation of imatinib therapy after achieving a molecular response. | Blood 20041001 |
| Establishment and characterization of an STI571-resistant human myelogenous leukemia cell line, SR-1. | Cancer genetics and cytogenetics 20041001 |
| Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? | Pediatric blood & cancer 20041001 |
| Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. | Gynecologic oncology 20041001 |
| Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20041001 |
| Case of chronic-phase chronic myelogenous leukemia with an abdominal hematopoietic tumor of leukemic clone origin. | American journal of hematology 20041001 |
| An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy. | Journal of the American Geriatrics Society 20041001 |
| [Target-oriented tumor therapy -- proof of the principle]. | Deutsche medizinische Wochenschrift (1946) 20041001 |
| [An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes]. | Deutsche medizinische Wochenschrift (1946) 20041001 |
| [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib]. | Deutsche medizinische Wochenschrift (1946) 20041001 |
| [Therapy of chronic myelogenous leukemia in 2004]. | Deutsche medizinische Wochenschrift (1946) 20041001 |
| Effect of St John's wort on imatinib mesylate pharmacokinetics. | Clinical pharmacology and therapeutics 20041001 |
| Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041001 |
| Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. | Haematologica 20041001 |
| The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. | Haematologica 20041001 |
| Gastrointestinal stromal tumors arising from the stomach: a report of three children. | Journal of pediatric surgery 20041001 |
| [Establishment of K562 cell lines resistant to STI571 and a preliminary biological study]. | Zhongguo shi yan xue ye xue za zhi 20041001 |
| [Resistance mechanism of ST1571 and its prevention research--review]. | Zhongguo shi yan xue ye xue za zhi 20041001 |
| [Two cases of postoperative recurrence of gastric GIST treated by imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20041001 |
| [Clinical management of gastrointestinal stromal tumors]. | Gastroenterologie clinique et biologique 20041001 |
| [Imatinib mesylate-induced acute cytolytic hepatitis]. | Gastroenterologie clinique et biologique 20041001 |
| Imatinib and gastrointestinal stromal tumor (GIST): a selective targeted therapy. | Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20041001 |
| Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. | International journal of hematology 20041001 |
| [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20041001 |
| [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20041001 |
| NMR resonance assignment of selectively labeled proteins by the use of paramagnetic ligands. | Journal of biomolecular NMR 20041001 |
| Investigation of the effect of the c-kit inhibitor Glivec on isolated guinea-pig detrusor preparations. | Autonomic neuroscience : basic & clinical 20040930 |
| Abl tyrosine kinase promotes dendrogenesis by inducing actin cytoskeletal rearrangements in cooperation with Rho family small GTPases in hippocampal neurons. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20040929 |
| Biology of gastrointestinal stromal tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040915 |
| Research unveils the 'who' and 'why' of gefitinib. | Journal of the National Cancer Institute 20040915 |
| [Molecular targeting in the treatment of lung cancer--toward the development of individualized treatment]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20040910 |
| Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. | The New England journal of medicine 20040902 |
| CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. | Blood 20040901 |
| Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. | International journal of cancer 20040901 |
| Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. | Leukemia & lymphoma 20040901 |
| Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. | Leukemia 20040901 |
| Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. | International journal of molecular medicine 20040901 |
| Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. | American journal of hematology 20040901 |
| Trisomy 8 in Philadelphia-negative cells during imatinib therapy. | American journal of hematology 20040901 |
| Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review. | Cancer chemotherapy and pharmacology 20040901 |
| Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases. | The Tohoku journal of experimental medicine 20040901 |
| Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. | Cancer 20040901 |
| Association of platelet-derived growth factor-B chain with simian human immunodeficiency virus encephalitis. | The American journal of pathology 20040901 |
| Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate. | Archives of pathology & laboratory medicine 20040901 |
| A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. | Cancer research 20040901 |
| Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. | Head & neck 20040901 |
| Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. | Haematologica 20040901 |
| Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. | Haematologica 20040901 |
| [Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas]. | Gan to kagaku ryoho. Cancer & chemotherapy 20040901 |
| New generation leukaemia drugs are on their way. | Drug discovery today 20040901 |
| Pushing the imatinib envelope. | Lancet (London, England) 20040901 |
| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. | Lancet (London, England) 20040901 |
| Gastrointestinal stromal tumours: etiology, pathology and clinical management. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20040901 |
| Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. | Pharmacotherapy 20040901 |
| [Inhibition of relapse in leukemia by using molecular targeting therapy]. | Nihon rinsho. Japanese journal of clinical medicine 20040901 |
| Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. | Cell cycle (Georgetown, Tex.) 20040901 |
| Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. | Current opinion in drug discovery & development 20040901 |
| [Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20040901 |
| [Emergence and decrement of Ph-negative clone with trisomy 8 in CML during imatinib therapy]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20040901 |
| [Acute lymphoblastic leukemia in elderly: prognosis and treatment]. | Bulletin du cancer 20040901 |
| Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. | Neoplasia (New York, N.Y.) 20040901 |
| [Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20040901 |
| Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene. | Journal of gastroenterology 20040901 |
| Imatinib mesylate--gold standards and silver linings. | Clinical and experimental medicine 20040901 |
| Indian patients go to court over cancer drug. | BMJ (Clinical research ed.) 20040821 |
| [Diagnosis and conservative treatment of gastrointestinal stromal tumors (GIST)]. | Deutsche medizinische Wochenschrift (1946) 20040820 |
| [Gastrointestinal stromal tumors (GIST)--current concepts of surgical management]. | Deutsche medizinische Wochenschrift (1946) 20040820 |
| Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. | Blood 20040815 |
| Induction of imatinib metabolism by hypericum perforatum. | Blood 20040815 |
| Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040815 |
| A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. | The Journal of biological chemistry 20040813 |
| Chronic myelogenous leukemia--identifying the hydra's heads. | The New England journal of medicine 20040812 |
| Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. | The New England journal of medicine 20040812 |
| Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20040801 |
| Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. | Leukemia 20040801 |
| Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. | Leukemia 20040801 |
| Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. | Hypertension (Dallas, Tex. : 1979) 20040801 |
| Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. | Leukemia 20040801 |
| PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. | Cytokine & growth factor reviews 20040801 |
| Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. | Leukemia 20040801 |
| Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate. | European journal of haematology 20040801 |
| In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. | British journal of clinical pharmacology 20040801 |
| Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. | Lung cancer (Amsterdam, Netherlands) 20040801 |
| Current clinical management of gastrointestinal stromal tumors. | Expert review of anticancer therapy 20040801 |
| Unusual extramedullary relapse of CML. | Annals of oncology : official journal of the European Society for Medical Oncology 20040801 |
| Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST). | Medical science monitor : international medical journal of experimental and clinical research 20040801 |
| Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. | The Journal of clinical investigation 20040801 |
| Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. | Cancer research 20040801 |
| Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040801 |
| Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. | Seminars in cancer biology 20040801 |
| SRCircumventing imatinib resistance. | Cancer cell 20040801 |
| [A case of gastric GIST treated preoperatively by imatinib mesylate]. | Gan to kagaku ryoho. Cancer & chemotherapy 20040801 |
| Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission. | Haematologica 20040801 |
| Re: Lange T et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Leukemia 2004; 89: 49-57. | Haematologica 20040801 |
| Kinase inhibitors translate lab discoveries into exciting new cures for cancers. | Indian journal of pediatrics 20040801 |
| Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. | Leukemia & lymphoma 20040801 |
| Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study. | Leukemia & lymphoma 20040801 |
| Subdural hematomas during CML therapy with imatinib mesylate. | Leukemia & lymphoma 20040801 |
| The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. | Scottish medical journal 20040801 |
| Oral BMS-354825 rescues Gleevec-resistant CML. | Cancer biology & therapy 20040801 |
| Gleevec target Abl important for normal immune activation of T cells. | Cancer biology & therapy 20040801 |
| Requirement for Abl kinases in T cell receptor signaling. | Current biology : CB 20040727 |
| TCR signaling: another Abl-bodied kinase joins the cascade. | Current biology : CB 20040727 |
| Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. | The Journal of biological chemistry 20040723 |
| Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. | The Journal of biological chemistry 20040723 |
| Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). | FEBS letters 20040716 |
| Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance. | Science (New York, N.Y.) 20040716 |
| Overriding imatinib resistance with a novel ABL kinase inhibitor. | Science (New York, N.Y.) 20040716 |
| Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. | Blood 20040715 |
| Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. | Blood 20040715 |
| Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. | Cancer 20040715 |
| The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. | Biochemical and biophysical research communications 20040709 |
| Evolving strategies for targeted cancer therapy--past, present, and future. | Journal of the National Cancer Institute 20040707 |
| Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation. | Annals of hematology 20040701 |
| Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). | Eye (London, England) 20040701 |
| Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. | Annals of hematology 20040701 |
| Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. | Clinical chemistry 20040701 |
| Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. | Cancer chemotherapy and pharmacology 20040701 |
| Imatinib-mesylate for all patients with hypereosinophilic syndrome? | Leukemia research 20040701 |
| Treatment options for small cell lung cancer. | Current oncology reports 20040701 |
| In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. | Biochemical pharmacology 20040701 |
| Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. | Anti-cancer drugs 20040701 |
| c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? | Investigative ophthalmology & visual science 20040701 |
| KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. | The American journal of surgical pathology 20040701 |
| Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. | American journal of hematology 20040701 |
| Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib. | Clinical chemistry 20040701 |
| Tyrosine kinase inhibitors in cancer therapy. | Clinical biochemistry 20040701 |
| A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. | Gastroenterology 20040701 |
| Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. | Health technology assessment (Winchester, England) 20040701 |
| Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells. | Cell cycle (Georgetown, Tex.) 20040701 |
| Imatinib: paradigm or anomaly? | Cell cycle (Georgetown, Tex.) 20040701 |
| Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia. | Haematologica 20040701 |
| Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. | The British journal of dermatology 20040701 |
| [The mechanisms of the resistance to molecular targeting agents]. | Nihon rinsho. Japanese journal of clinical medicine 20040701 |
| [Imatinib therapy for patients with chronic myelogenous leukemia]. | Nihon rinsho. Japanese journal of clinical medicine 20040701 |
| [The effect of imatinib for gastrointestinal tumor]. | Nihon rinsho. Japanese journal of clinical medicine 20040701 |
| [Resistance to target-based therapy and its circumvention]. | Nihon rinsho. Japanese journal of clinical medicine 20040701 |
| Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. | International journal of hematology 20040701 |
| Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation. | International journal of hematology 20040701 |
| Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report. | International journal of hematology 20040701 |
| In the erythroleukemic cell line HEL Prostate-apoptosis-response-gene-4 (par-4) fails to down-regulate Bcl-2 and to promote apoptosis. | Leukemia & lymphoma 20040701 |
| Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation. | Leukemia & lymphoma 20040701 |
| Oral lichenoid eruption secondary to imatinib (Glivec). | The Journal of dermatological treatment 20040701 |
| Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. | The New England journal of medicine 20040617 |
| Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. | Blood 20040615 |
| Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. | Blood 20040615 |
| Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. | Cancer 20040615 |
| Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. | The Journal of clinical investigation 20040615 |
| Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. | Cancer research 20040615 |
| Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040615 |
| Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. | The Journal of biological chemistry 20040611 |
| Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. | International journal of cancer 20040610 |
| CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. | Annals of hematology 20040601 |
| Visual disturbance due to retinal edema as a complication of imatinib. | Leukemia 20040601 |
| Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib. | Leukemia 20040601 |
| Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. | Leukemia research 20040601 |
| Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. | Leukemia research 20040601 |
| Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. | Leukemia research 20040601 |
| C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib. | The Journal of urology 20040601 |
| Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. | European journal of haematology 20040601 |
| Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. | British journal of cancer 20040601 |
| Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. | Cancer 20040601 |
| Imatinib mesylate causes hypopigmentation in the skin. | Cancer 20040601 |
| Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. | Cancer research 20040601 |
| Imatinib in patients with metastatic gastrointestinal stromal tumours relapsing after hepatic transplantation. | European journal of cancer (Oxford, England : 1990) 20040601 |
| Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? | Cancer cell 20040601 |
| Imatinib mesylate in the treatment of chronic myelogenous leukemia. | International journal of hematology 20040601 |
| Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. | International journal of hematology 20040601 |
| Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia. | International journal of hematology 20040601 |
| Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. | International journal of hematology 20040601 |
| Chronic myeloid leukemia: current status and controversies. | Oncology (Williston Park, N.Y.) 20040601 |
| Natural history and staging of chronic myelogenous leukemia. | Hematology/oncology clinics of North America 20040601 |
| Imatinib therapy in chronic myeloid leukemia. | Hematology/oncology clinics of North America 20040601 |
| Investigational strategies in chronic myelogenous leukemia. | Hematology/oncology clinics of North America 20040601 |
| Clinical resistance to imatinib: mechanisms and implications. | Hematology/oncology clinics of North America 20040601 |
| Contemporaneous pulmonary sarcoidosis and chronic myeloid leukemia. | Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 20040601 |
| Gold standard or wrong standard? | Cancer biotherapy & radiopharmaceuticals 20040601 |
| [Efficacy and safety evaluation of imatinib in the treatment of patients with chronic granulocytic leukemia in accelerated phase]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20040601 |
| [Establishment of an imatinib resistant cell line K562/G01 and its characterization]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20040601 |
| Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate. | Journal of experimental & clinical cancer research : CR 20040601 |
| Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis. | Leukemia & lymphoma 20040601 |
| Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. | Leukemia & lymphoma 20040601 |
| Adult ALL: where are we and where are we going? | Clinical advances in hematology & oncology : H&O 20040601 |
| Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040525 |
| Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. | Blood 20040515 |
| Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. | Cancer 20040515 |
| Imatinib for small cell lung cancer, aiming for a target in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040515 |
| c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040515 |
| Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040515 |
| Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression. | Biochemical and biophysical research communications 20040514 |
| Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. | Blood 20040501 |
| Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. | Blood 20040501 |
| Imatinib attenuates diabetes-associated atherosclerosis. | Arteriosclerosis, thrombosis, and vascular biology 20040501 |
| Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis. | Leukemia 20040501 |
| Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene. | Leukemia 20040501 |
| Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib. | Leukemia 20040501 |
| Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases. | Leukemia 20040501 |
| Clinical results with imatinib in chronic myeloid leukaemia. | Leukemia research 20040501 |
| Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. | Leukemia research 20040501 |
| Lessons learned from the development of imatinib. | Leukemia research 20040501 |
| Molecular mechanisms of resistance of leukemia to imatinib mesylate. | Leukemia research 20040501 |
| Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. | Leukemia research 20040501 |
| Imatinib mesylate (STI571) for myeloid malignancies other than CML. | Leukemia research 20040501 |
| Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. | Leukemia research 20040501 |
| A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. | Leukemia research 20040501 |
| Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. | Leukemia research 20040501 |
| Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. | Leukemia research 20040501 |
| Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. | Leukemia research 20040501 |
| Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia. | European journal of haematology 20040501 |
| A novel pathogenetic mutation in clonal eosinophilia. | Current hematology reports 20040501 |
| Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. | Nature genetics 20040501 |
| Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. | Nuclear medicine communications 20040501 |
| Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate. | Journal of pediatric hematology/oncology 20040501 |
| Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. | Annals of surgical oncology 20040501 |
| Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. | Cancer research 20040501 |
| Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. | The Journal of clinical endocrinology and metabolism 20040501 |
| Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. | Cancer chemotherapy and pharmacology 20040501 |
| Protective role of imatinib in atherosclerosis. | Arteriosclerosis, thrombosis, and vascular biology 20040501 |
| Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. | Urology 20040501 |
| Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. | Haematologica 20040501 |
| The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. | Molecular cancer therapeutics 20040501 |
| Interstitial pneumonitis during imatinib therapy. | British journal of haematology 20040501 |
| Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells. | British journal of haematology 20040501 |
| Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses. | Archives of dermatology 20040501 |
| [Lung cancer: molecular targeting therapy]. | Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040501 |
| Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies. | International journal of clinical practice 20040501 |
| [Cutaneous side effects with imatinib (Glivec)]. | Annales de dermatologie et de venereologie 20040501 |
| Imatinib in gastrointestinal stromal tumors. | The Journal of the Association of Physicians of India 20040501 |
| Chronic myeloid leukemia. | The Journal of the Association of Physicians of India 20040501 |
| Current management of GIST. | Clinical advances in hematology & oncology : H&O 20040501 |
| Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040425 |
| [Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha]. | Orvosi hetilap 20040425 |
| Cancer stem cells: are we missing the target? | Journal of the National Cancer Institute 20040421 |
| High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. | Blood 20040415 |
| The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. | Blood 20040415 |
| Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. | Blood 20040415 |
| BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. | Blood 20040415 |
| A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. | Blood 20040415 |
| Imatinib mesylate in polycythemia vera. | Blood 20040415 |
| NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. | Cancer research 20040415 |
| Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. | Chemico-biological interactions 20040415 |
| The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. | Blood 20040401 |
| Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. | Annals of hematology 20040401 |
| Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. | Cancer chemotherapy and pharmacology 20040401 |
| Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism. | The Journal of pharmacology and experimental therapeutics 20040401 |
| Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. | Cancer biology & therapy 20040401 |
| Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy. | Leukemia 20040401 |
| Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. | Leukemia 20040401 |
| Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. | Leukemia 20040401 |
| Tyrosine kinase inhibitor STI-571: the new wonder drug of cancer therapy. | Cancer biology & therapy 20040401 |
| Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate. | Histology and histopathology 20040401 |
| Use of moving optical gradient fields for analysis of apoptotic cellular responses in a chronic myeloid leukemia cell model. | Analytical biochemistry 20040401 |
| Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. | Cancer 20040401 |
| Neo-adjuvant STI571 therapy for high-risk gastrointestinal stromal tumour. | ANZ journal of surgery 20040401 |
| Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. | Experimental hematology 20040401 |
| Favorable early response of secondary chronic myeloid leukemia to imatinib. | American journal of hematology 20040401 |
| Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature. | American journal of hematology 20040401 |
| Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. | Anti-cancer drugs 20040401 |
| Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. | British journal of haematology 20040401 |
| Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. | Cancer research 20040401 |
| Gene expression signatures in lymphoid tumours. | Immunology and cell biology 20040401 |
| Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). | Clinical cancer research : an official journal of the American Association for Cancer Research 20040401 |
| Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040401 |
| Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. | Haematologica 20040401 |
| [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia]. | Ai zheng = Aizheng = Chinese journal of cancer 20040401 |
| Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. | European journal of haematology 20040401 |
| [Gastrointestinal stromal tumors (GIST)]. | Zeitschrift fur Gastroenterologie 20040401 |
| Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines. | Leukemia research 20040401 |
| Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. | Leukemia research 20040401 |
| Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. | Leukemia research 20040401 |
| [Structure-activity relationship analysis]. | Gan to kagaku ryoho. Cancer & chemotherapy 20040401 |
| [A patient with unresectable gastrointestinal stromal tumor responded to STI571]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20040401 |
| Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. | Leukemia & lymphoma 20040401 |
| Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). | Leukemia & lymphoma 20040401 |
| An interview with Doriano Fabbro, Ph.D., Novartis Biomedical Research Institute. Interviewed by Vicki Glaser. | Assay and drug development technologies 20040401 |
| A widening prospect: Imatinib and novel applications of targeted therapy. | Seminars in oncology 20040401 |
| Role of KIT and platelet-derived growth factor receptors as oncoproteins. | Seminars in oncology 20040401 |
| Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. | Seminars in oncology 20040401 |
| Increasing tumor uptake of anticancer drugs with imatinib. | Seminars in oncology 20040401 |
| Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. | Seminars in oncology 20040401 |
| Molecularly targeted treatment for dermatofibrosarcoma protuberans. | Seminars in oncology 20040401 |
| Gastrointestinal stromal tumors--a review. | Acta orthopaedica Scandinavica. Supplementum 20040401 |
| Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. | Acta orthopaedica Scandinavica. Supplementum 20040401 |
| High efficacy of imatinib for recurrent gastrointestinal stromal tumor in the jejunum: a case report. | Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20040401 |
| Experimental design in reversed-phase high-performance liquid chromatographic analysis of imatinib mesylate and its impurity. | Journal of chromatography. A 20040326 |
| Management of gastrointestinal stromal tumors: from diagnosis to treatment. | Swiss medical weekly 20040320 |
| Gleevec: prototype or outlier? | Science's STKE : signal transduction knowledge environment 20040316 |
| Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. | Blood 20040315 |
| A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. | Blood 20040315 |
| [Molecular target therapy for hematologic malignancy]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20040310 |
| [Recent progress in diagnosis of and therapy for patients with leukemia]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20040310 |
| Oral imatinib mesylate (STI571/gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. | Circulation 20040309 |
| As targeted therapies evolve, challenges remain. | Journal of the National Cancer Institute 20040303 |
| Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment. | Virchows Archiv : an international journal of pathology 20040301 |
| Do cells need CDK2 and ... Bcr-Abl? | Cell death and differentiation 20040301 |
| Treatment of systemic mast cell disease: beyond interferon. | Leukemia research 20040301 |
| Imatinib sensitizes CLL lymphocytes to chlorambucil. | Leukemia 20040301 |
| Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a). | Leukemia 20040301 |
| Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial. | Bone marrow transplantation 20040301 |
| Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. | Leukemia 20040301 |
| P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. | Leukemia 20040301 |
| Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST). | Cancer biology & therapy 20040301 |
| Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group. | Leukemia 20040301 |
| Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. | Journal of cellular physiology 20040301 |
| Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. | Blood 20040301 |
| Advances in molecular targets and cancer therapeutics. | Drug discovery today 20040301 |
| Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301 |
| Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20040301 |
| Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. | British journal of haematology 20040301 |
| Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. | European journal of cancer (Oxford, England : 1990) 20040301 |
| [Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia]. | Der Pathologe 20040301 |
| [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding]. | Zeitschrift fur Gastroenterologie 20040301 |
| Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib. | European journal of clinical investigation 20040301 |
| Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it. | Molecular and cellular biochemistry 20040301 |
| Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. | Mini reviews in medicinal chemistry 20040301 |
| [Gastrointestinal stromal tumor]. | Gan to kagaku ryoho. Cancer & chemotherapy 20040301 |
| [Tailored therapy in gastrointestinal and hepatic cancer--toward ideal medicine through genomic science]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20040301 |
| Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant. | Current opinion in oncology 20040301 |
| Hypopigmentation from imatinib mesylate (Gleevec). | Journal of pediatric hematology/oncology 20040301 |
| [Bone marrow morphologic features in patients treated with imatinib for Philadelphia chromosome positive chronic myeloid leukemia]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20040301 |
| Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. | Blood 20040215 |
| Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040205 |
| Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. | Cancer chemotherapy and pharmacology 20040201 |
| Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. | Journal of cancer research and clinical oncology 20040201 |
| Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome. | Leukemia 20040201 |
| Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase. | Leukemia research 20040201 |
| Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. | Leukemia 20040201 |
| Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. | British journal of haematology 20040201 |
| Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. | Virchows Archiv : an international journal of pathology 20040201 |
| Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. | Journal of clinical pharmacology 20040201 |
| Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. | Journal of clinical pathology 20040201 |
| Clinical and epidemiologic burden of chronic myelogenous leukemia. | Expert review of anticancer therapy 20040201 |
| Anemia and a large abdominal tumor in an adolescent. | Pediatric blood & cancer 20040201 |
| Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory. | American journal of hematology 20040201 |
| Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. | Seminars in cancer biology 20040201 |
| Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. | Annals of oncology : official journal of the European Society for Medical Oncology 20040201 |
| Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. | The British journal of surgery 20040201 |
| Gastrointestinal stromal tumours (Br J Surg 2003; 90: 1178-1186). | The British journal of surgery 20040201 |
| Re: 'Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors'. | Surgery 20040201 |
| Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040201 |
| Targeted molecules in small cell lung cancer. | Seminars in oncology 20040201 |
| Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. | Cancer cell 20040201 |
| The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. | Haematologica 20040201 |
| Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. | Haematologica 20040201 |
| C-myc expression in cell lines derived from chronic myeloid leukemia. | Haematologica 20040201 |
| Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib. | Internal medicine (Tokyo, Japan) 20040201 |
| Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. | The Journal of investigative dermatology 20040201 |
| [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia]. | Rinsho byori. The Japanese journal of clinical pathology 20040201 |
| [Imatinib. An anticancer agents indicated in the treatment of chronic myeloid leukemia]]. | Revue de l'infirmiere 20040201 |
| [Clonal Ph-negative hematopoiesis with trisomy 8 in chronic myeloid leukemia during imatinib therapy]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20040201 |
| Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. | Leukemia & lymphoma 20040201 |
| Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. | Leukemia & lymphoma 20040201 |
| Inhibitory effect of imatinib on normal progenitor cells in vitro. | Blood 20040115 |
| Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. | Blood 20040115 |
| Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. | Blood 20040115 |
| Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. | Blood 20040115 |
| A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate. | Cancer genetics and cytogenetics 20040115 |
| Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosome-positive chronic myelocytic leukemia. | Cancer genetics and cytogenetics 20040115 |
| Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. | Cancer research 20040115 |
| Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040115 |
| Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040115 |
| Cancer treatment with kinase inhibitors: what have we learnt from imatinib? | British journal of cancer 20040112 |
| Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. | Journal of the National Cancer Institute 20040107 |
| Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040105 |
| In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. | Blood 20040101 |
| Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. | Leukemia 20040101 |
| A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl. | Leukemia 20040101 |
| Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment. | Bone marrow transplantation 20040101 |
| p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22). | Leukemia research 20040101 |
| Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. | Oncology reports 20040101 |
| Mechanisms and implications of imatinib resistance mutations in BCR-ABL. | Current opinion in hematology 20040101 |
| Clinical, genetic, and therapeutic insights into systemic mast cell disease. | Current opinion in hematology 20040101 |
| Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. | British journal of haematology 20040101 |
| Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. | British journal of haematology 20040101 |
| The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. | Cancer 20040101 |
| Treatment options for newly diagnosed patients with chronic myeloid leukemia. | Current hematology reports 20040101 |
| Chronic myeloid leukemia-still a few questions. | Experimental hematology 20040101 |
| Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. | Experimental hematology 20040101 |
| Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer? | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20040101 |
| [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study]. | Der Internist 20040101 |
| High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. | The hematology journal : the official journal of the European Haematology Association 20040101 |
| Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. | Haematologica 20040101 |
| [New reversing agents that target membrane transporters]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20040101 |
| Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia. | European journal of haematology 20040101 |
| Metastatic gastrointestinal stromal tumor with an exon 11 c-kit mutation responding to the tyrosine kinase inhibitor imatinib. | Digestive surgery 20040101 |
| Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib. | Digestive surgery 20040101 |
| [Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report]. | Journal francais d'ophtalmologie 20040101 |
| Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. | Oncology research 20040101 |
| Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. | International journal of hematology 20040101 |
| [Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20040101 |
| [Chronic myeloid leukemia and imatinib mesylate therapy]. | Vnitrni lekarstvi 20040101 |
| [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia]. | Vnitrni lekarstvi 20040101 |
| The BCR-ABL story: bench to bedside and back. | Annual review of immunology 20040101 |
| Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. | The hematology journal : the official journal of the European Haematology Association 20040101 |
| Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. | Surgery today 20040101 |
| Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital. | JPMA. The Journal of the Pakistan Medical Association 20040101 |
| Biology of gastrointestinal stromal tumors: KIT mutations and beyond. | Cancer investigation 20040101 |
| Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells. | Annals of hematology 20040101 |
| Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). | Annals of hematology 20040101 |
| Spotlight on imatinib mesylate in chronic myeloid leukemia. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20040101 |
| Effects of POH in combination with STI571 on the proliferation and apoptosis of K562 cells. | Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20040101 |
| A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients. | Journal of gastroenterology 20040101 |
| Optimizing treatment of chronic myeloid leukemia: a rational approach. | The oncologist 20040101 |
| Indications for imatinib mesylate therapy and clinical management. | The oncologist 20040101 |
| Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance. | Acta haematologica 20040101 |
| Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome. | The Annals of pharmacotherapy 20040101 |
| FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis. | The hematology journal : the official journal of the European Haematology Association 20040101 |
| Switching off oncogenic signals in chronic myeloid leukaemia. | The hematology journal : the official journal of the European Haematology Association 20040101 |
| Detecting a small bowel tumor via wireless capsule endoscopy: a clinical case study. | Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates 20040101 |
| KIT and PDGF as targets. | Cancer treatment and research 20040101 |
| Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas. | Cancer treatment and research 20040101 |
| Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia. | British journal of biomedical science 20040101 |
| Molecularly targeted therapy: have the floodgates opened? | The oncologist 20040101 |
| STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells. | Anticancer research 20040101 |
| Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells. | Stem cells (Dayton, Ohio) 20040101 |
| [Lichenoid cutaneous reaction to imatinib]. | Annales de dermatologie et de venereologie 20040101 |
| Imatinib as a paradigm of targeted therapies. | Advances in cancer research 20040101 |
| [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome]. | Terapevticheskii arkhiv 20040101 |
| Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. | Drugs & aging 20040101 |
| Cystic changes in intraabdominal extrahepatic metastases from gastrointestinal stromal tumors treated with imatinib. | Korean journal of radiology 20040101 |
| Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. | BMC cancer 20040101 |
| Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. | Annals of clinical and laboratory science 20040101 |
| Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. | Annals of clinical and laboratory science 20040101 |
| PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients. | Anticancer research 20040101 |
| Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. | Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20040101 |
| A report of three patients treated with immunocell therapy with imatinib mesylate. | Anticancer research 20040101 |
| Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines. | Anticancer research 20040101 |
| Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. | Anticancer research 20040101 |
| CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? | Laboratory hematology : official publication of the International Society for Laboratory Hematology 20040101 |
| [Imatinib--a new perspective in the treatment of tumors]. | Casopis lekaru ceskych 20040101 |
| Chronic myelogenous leukemia and myeloproliferative disease. | Hematology. American Society of Hematology. Education Program 20040101 |
| Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia. | Acta haematologica 20040101 |
| [Targeted anticancer drugs and their development]. | Duodecim; laaketieteellinen aikakauskirja 20040101 |
| Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate. | Medical oncology (Northwood, London, England) 20040101 |
| Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature. | Allergy and asthma proceedings 20040101 |
| Surgical interventions during STI 571 treatment of metastatic GIST: experience in six patients. | Acta chirurgica Belgica 20040101 |
| [Perspectives in the use of imatinib in the treatment of childhood cancers]. | Przeglad lekarski 20040101 |
| Glivec and CML: a lucky date. | Journal of biological regulators and homeostatic agents 20040101 |
| Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. | Blood 20031215 |
| Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. | Blood 20031215 |
| ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. | Blood 20031215 |
| Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. | Cancer 20031215 |
| Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. | Cancer 20031215 |
| Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031215 |
| Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. | Journal of chromatography. A 20031205 |
| A validated LC method for imatinib mesylate. | Journal of pharmaceutical and biomedical analysis 20031204 |
| Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. | Blood 20031201 |
| Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. | Leukemia research 20031201 |
| ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. | Leukemia research 20031201 |
| Effects of lower dose of imatinib to CML patients. | Leukemia research 20031201 |
| STI571 inhibits growth and adhesion of human mast cells in culture. | Journal of leukocyte biology 20031201 |
| Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. | Leukemia 20031201 |
| Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. | Leukemia 20031201 |
| Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML. | Leukemia 20031201 |
| EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. | Blood 20031201 |
| Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. | The Annals of pharmacotherapy 20031201 |
| Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. | British journal of haematology 20031201 |
| Imatinib mesylate causes hypopigmentation in the skin. | Cancer 20031201 |
| Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. | American journal of hematology 20031201 |
| [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031201 |
| Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies. | Clinical and laboratory haematology 20031201 |
| David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031201 |
| Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031201 |
| Imatinib-associated pulmonary alveolar proteinosis. | The American journal of medicine 20031201 |
| Imatinib mesylate-induced interstitial pneumonitis. | Mayo Clinic proceedings 20031201 |
| Is there a role for surgery in patients with 'unresectable' cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? | American journal of surgery 20031201 |
| Is KIT an important therapeutic target in small cell lung cancer? | Clinical cancer research : an official journal of the American Association for Cancer Research 20031201 |
| Phase II study of imatinib in patients with small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031201 |
| [Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome]. | Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20031201 |
| Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors. | Expert review of anticancer therapy 20031201 |
| Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response. | Haematologica 20031201 |
| The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines. | The Journal of surgical research 20031201 |
| First case of immune-mediated haemolytic anaemia associated to imatinib mesylate. | European journal of haematology 20031201 |
| [The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells]. | Zhongguo shi yan xue ye xue za zhi 20031201 |
| Patent news. | IDrugs : the investigational drugs journal 20031201 |
| Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases. | Journal of the National Medical Association 20031201 |
| [Gastrointestinal stromal tumors. Current data]. | La Tunisie medicale 20031201 |
| Innovations in the management of leukemia: role of biologic therapies. | Cancer nursing 20031201 |
| Efficacy of imatinib mesylate in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy with epirubicin. | Journal of experimental & clinical cancer research : CR 20031201 |
| Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial. | Journal of experimental & clinical cancer research : CR 20031201 |
| Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck. | The Journal of biological chemistry 20031128 |
| Combinations of targeted therapies take aim at multiple pathways. | Journal of the National Cancer Institute 20031119 |
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | British journal of cancer 20031117 |
| The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. | Blood 20031115 |
| Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia. | Biochemical pharmacology 20031115 |
| Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. | Biochemical pharmacology 20031115 |
| Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031115 |
| CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031115 |
| SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. | Cancer research 20031115 |
| [Effect of imatinib treatment of gastrointestinal stromal tumors]. | Orvosi hetilap 20031109 |
| B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. | Blood 20031101 |
| CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. | Blood 20031101 |
| Imatinib: resisting the resistance. | Leukemia research 20031101 |
| Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571. | Leukemia research 20031101 |
| Interaction of imatinib mesilate with human P-glycoprotein. | The Journal of pharmacology and experimental therapeutics 20031101 |
| Fatal hepatic necrosis following imatinib mesylate therapy. | Blood 20031101 |
| Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. | Blood 20031101 |
| Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases. | Cancer genetics and cytogenetics 20031101 |
| Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. | Cancer 20031101 |
| Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. | Experimental hematology 20031101 |
| Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome. | American journal of hematology 20031101 |
| Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20031101 |
| Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. | The American journal of medicine 20031101 |
| Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. | Haematologica 20031101 |
| Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. | Cancer research 20031101 |
| Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. | British journal of haematology 20031101 |
| T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. | PLoS biology 20031101 |
| [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia]. | Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20031101 |
| Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells. | Molecular cancer research : MCR 20031101 |
| A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). | Annals of hematology 20031101 |
| [Current screening for molecular target therapy of cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20031101 |
| [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia]. | Gan to kagaku ryoho. Cancer & chemotherapy 20031101 |
| Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. | Oncology (Williston Park, N.Y.) 20031101 |
| [Synergism of As2S2 and STI 571 in inducing apoptosis of K562 cells]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20031101 |
| Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. | Leukemia & lymphoma 20031101 |
| GI clinical research 2002-2003: the year in review. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20031101 |
| Adenosine-anchored triphosphate subsite probing: distinguishing between HER-2 and HER-4 tyrosine protein kinases. | Bioorganic & medicinal chemistry letters 20031020 |
| Imatinib administration in two patients with liver metastases from GIST and severe jaundice. | British journal of cancer 20031020 |
| Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. | Oncogene 20031020 |
| [Several patients with a metastasised gastrointestinal stroma-cell tumor for whom the tide turned by the introduction of imatinib]. | Nederlands tijdschrift voor geneeskunde 20031018 |
| [New oncological treatment principle with imatinib]. | Nederlands tijdschrift voor geneeskunde 20031018 |
| [Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor]. | Nederlands tijdschrift voor geneeskunde 20031018 |
| [Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans]. | Nederlands tijdschrift voor geneeskunde 20031018 |
| Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. | Blood 20031015 |
| Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. | Blood 20031015 |
| Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. | Cancer 20031015 |
| Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031015 |
| STI-571 inhibits in vitro angiogenesis. | Biochemical and biophysical research communications 20031010 |
| Minimal residual disease in chronic myeloid leukemia. | The New England journal of medicine 20031009 |
| Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. | The New England journal of medicine 20031009 |
| Chronic myeloid leukemia--advances in biology and new approaches to treatment. | The New England journal of medicine 20031009 |
| Residual disease in chronic myeloid leukemia after induction of molecular remission. | The New England journal of medicine 20031009 |
| Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. | Oncogene 20031009 |
| STI-571: an anticancer protein-tyrosine kinase inhibitor. | Biochemical and biophysical research communications 20031003 |
| Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. | Cancer chemotherapy and pharmacology 20031001 |
| Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI). | European journal of haematology 20031001 |
| Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571. | Clinical and laboratory haematology 20031001 |
| Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. | Blood 20031001 |
| Chromosomal abnormalities in Ph- cells of patients on imatinib. | Blood 20031001 |
| Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. | Blood 20031001 |
| Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. | Cancer 20031001 |
| Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. | British journal of haematology 20031001 |
| Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). | Leukemia 20031001 |
| FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. | Leukemia 20031001 |
| Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission. | Leukemia 20031001 |
| Gastrointestinal stromal tumours. | The British journal of surgery 20031001 |
| Targeting tumor cells. | Current opinion in cell biology 20031001 |
| Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. | British journal of haematology 20031001 |
| A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. | Anti-cancer drugs 20031001 |
| Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? | Anti-cancer drugs 20031001 |
| Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. | Haematologica 20031001 |
| Safety and efficacy of stem cell mobilization under imatinib therapy. | Haematologica 20031001 |
| Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. | The Journal of clinical endocrinology and metabolism 20031001 |
| Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. | Cancer research 20031001 |
| Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. | Clinical rheumatology 20031001 |
| Revised advice on use of imatinib for chronic myeloid leukaemia. | Nursing times 20031001 |
| Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes. | International journal of hematology 20031001 |
| Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. | Surgery 20031001 |
| Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. | Seminars in oncology 20031001 |
| Resistance to imatinib (Glivec): update on clinical mechanisms. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20031001 |
| [Chronic myeloid leukemia in 2003]. | Revue medicale de Bruxelles 20031001 |
| [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene]. | Rinsho byori. The Japanese journal of clinical pathology 20031001 |
| Fibrous dysplasia masquerading as extramedullary relapse after bone marrow transplantation for chronic myeloid leukemia. | Leukemia & lymphoma 20031001 |
| Chronic myelogenous leukemia. Clinical practice guidelines in oncology. | Journal of the National Comprehensive Cancer Network : JNCCN 20031001 |
| How to monitor patients with chronic myelogenous leukemia. | Journal of the National Comprehensive Cancer Network : JNCCN 20031001 |
| [Gastrointestinal stromal tumors]. | Deutsche medizinische Wochenschrift (1946) 20030926 |
| Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec). | International journal of cancer 20030920 |
| Scientists probe cancer cell resistance: new insights may help development of new drugs. | JAMA 20030917 |
| Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. | Blood 20030915 |
| Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). | Blood 20030915 |
| Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro. | Blood 20030915 |
| The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. | Blood 20030915 |
| Case 3. Resection of originally inoperable liver metastases of gastrointestinal stromal tumor after imatinib mesylate therapy. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030915 |
| Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. | Cancer 20030915 |
| BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030915 |
| Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. | Cancer research 20030915 |
| Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. | Cancer letters 20030910 |
| [Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)]. | Ugeskrift for laeger 20030908 |
| [FDG-PET and CT in gastrointestinal stromal tumor treated with imatinib]. | Ugeskrift for laeger 20030908 |
| Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030905 |
| Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. | Cancer chemotherapy and pharmacology 20030901 |
| Farnesyl transferase inhibitors in myeloid malignancies. | Blood reviews 20030901 |
| Specific targeted therapy of chronic myelogenous leukemia with imatinib. | Pharmacological reviews 20030901 |
| Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia. | Current oncology reports 20030901 |
| A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL. | Annals of hematology 20030901 |
| Comment: Usefulness of herbal and dietary supplement references. | The Annals of pharmacotherapy 20030901 |
| Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. | Blood 20030901 |
| Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective. | Bone marrow transplantation 20030901 |
| Successful unrelated allogeneic stem cell transplantation after treatment of lymphoid blast crisis CML with imatinib and imatinib-containing conditioning regimen in a 16-year-old male. | Bone marrow transplantation 20030901 |
| Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. | Cancer 20030901 |
| Targeted therapies for the treatment of cancer. | American journal of surgery 20030901 |
| Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. | Gastroenterology 20030901 |
| [Treatment of systemic mastocytosis]. | La Revue de medecine interne 20030901 |
| OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease. | European journal of cancer (Oxford, England : 1990) 20030901 |
| Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. | European journal of cancer (Oxford, England : 1990) 20030901 |
| 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). | European journal of cancer (Oxford, England : 1990) 20030901 |
| Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. | Leukemia 20030901 |
| Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo. | Leukemia 20030901 |
| Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. | Leukemia 20030901 |
| Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. | Leukemia 20030901 |
| Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. | Leukemia 20030901 |
| Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. | Leukemia 20030901 |
| Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case. | Leukemia 20030901 |
| Expression of Kit and platelet-derived growth factor receptors alpha and beta in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571). | Anti-cancer drugs 20030901 |
| STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030901 |
| Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib. | The British journal of dermatology 20030901 |
| Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation. | The Keio journal of medicine 20030901 |
| The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro. | Leukemia & lymphoma 20030901 |
| Eosinophilic variant of chronic myeloid leukemia with vascular complications. | Leukemia & lymphoma 20030901 |
| [Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20030901 |
| Strategies for the treatment of imatinib-resistant chronic myeloid leukemia. | Clinical advances in hematology & oncology : H&O 20030901 |
| Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec. | Oncogene 20030828 |
| A 41-year-old woman with chronic myelogenous leukemia. | JAMA 20030827 |
| Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. | Lancet (London, England) 20030823 |
| c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. | International journal of cancer 20030820 |
| Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. | British journal of cancer 20030818 |
| Imatinib for systemic mast-cell disease. | Lancet (London, England) 20030816 |
| Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. | Cancer 20030815 |
| Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030815 |
| Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. | Transplantation 20030815 |
| Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. | Cancer research 20030815 |
| Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. | Wiener klinische Wochenschrift 20030814 |
| From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism. | Journal of the National Cancer Institute 20030806 |
| Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. | British journal of cancer 20030804 |
| Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma? | Medical and pediatric oncology 20030801 |
| Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571). | Medical and pediatric oncology 20030801 |
| Imatinib in small cell lung cancer. | Lung cancer (Amsterdam, Netherlands) 20030801 |
| Functional consequence of MDR1 expression on imatinib intracellular concentrations. | Blood 20030801 |
| Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib. | Blood 20030801 |
| Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons. | British journal of haematology 20030801 |
| Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. | American journal of hematology 20030801 |
| Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20030801 |
| Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. | Leukemia 20030801 |
| [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha]. | La Revue de medecine interne 20030801 |
| F-18 FDG PET imaging in gastrointestinal stromal tumor. | Clinical nuclear medicine 20030801 |
| Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. | Experimental hematology 20030801 |
| The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. | Experimental hematology 20030801 |
| Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. | Journal of pediatric hematology/oncology 20030801 |
| [Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia]. | Ai zheng = Aizheng = Chinese journal of cancer 20030801 |
| Does hope match the hype for targeted drugs? | The Lancet. Oncology 20030801 |
| Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571). | Internal medicine (Tokyo, Japan) 20030801 |
| Hypopigmentation in an African patient treated with imatinib mesylate: a case report. | Journal of the National Medical Association 20030801 |
| The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. | Haematologica 20030801 |
| Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia. | Haematologica 20030801 |
| [Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)]. | Gan to kagaku ryoho. Cancer & chemotherapy 20030801 |
| [Target-based therapy against gastrointestinal stromal tumors--from molecular diagnosis to molecular target therapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20030801 |
| [Imatinib]. | Gan to kagaku ryoho. Cancer & chemotherapy 20030801 |
| Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. | Molecular cancer therapeutics 20030801 |
| Beyond Herceptin and Gleevec. | Current opinion in chemical biology 20030801 |
| Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia. | International journal of hematology 20030801 |
| Ocular side-effects associated with imatinib mesylate (Gleevec). | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20030801 |
| [The early efficacy of imatinib in the treatment of 54 cases of chronic myeloid leukemia]. | Zhonghua nei ke za zhi 20030801 |
| An overview of targeted treatments in cancer. | Clinical therapeutics 20030801 |
| Gastrointestinal stromal tumour--a paradigm shift in management of solid tumours. | The Journal of the Association of Physicians of India 20030801 |
| [Chronic myeloproliferative diseases. Diagnosis and therapy]. | Der Internist 20030801 |
| New drugs in acute myeloid leukemia. | Clinical advances in hematology & oncology : H&O 20030801 |
| [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]. | Nederlands tijdschrift voor geneeskunde 20030726 |
| Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. | Journal of the National Cancer Institute 20030716 |
| Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. | Blood 20030715 |
| Imatinib or transplant for chronic myeloid leukaemia? | Lancet (London, England) 20030712 |
| Imatinib or transplant for chronic myeloid leukaemia? | Lancet (London, England) 20030712 |
| Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705 |
| KIT in ovarian carcinoma: disillusion about a potential therapeutic target. | Journal of the National Cancer Institute 20030702 |
| Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. | Blood 20030701 |
| Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. | Blood 20030701 |
| 2-methoxyestradiol alters cell motility, migration, and adhesion. | Blood 20030701 |
| Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors. | Current oncology reports 20030701 |
| Recent advances in the management of gastrointestinal stromal tumors. | Current oncology reports 20030701 |
| Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction. | Nature neuroscience 20030701 |
| Erythema following imatinib mesylate. | British journal of haematology 20030701 |
| Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. | British journal of haematology 20030701 |
| Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. | Leukemia 20030701 |
| STI571-resistant KT-1 cells are sensitive to interferon-alpha accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1. | Experimental hematology 20030701 |
| Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. | British journal of haematology 20030701 |
| Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. | Haematologica 20030701 |
| Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. | Haematologica 20030701 |
| Glivec enhances the down-regulated cytotoxicity of adriamycin in acquired tamoxifen-resistant MCF-7 cell line. | Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20030701 |
| [A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20030701 |
| GIST: an update. | International journal of surgical pathology 20030701 |
| [Metastatic gastrointestinal stromal tumors responded to the treatment with STI571 after polysurgery for recurrent lesions--report of two cases]. | Gan to kagaku ryoho. Cancer & chemotherapy 20030701 |
| Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. | Leukemia & lymphoma 20030701 |
| Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571). | Leukemia & lymphoma 20030701 |
| Management of molecular-targeted therapy for chronic myelogenous leukemia. | Journal of the American Academy of Nurse Practitioners 20030701 |
| Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia. | Clinical advances in hematology & oncology : H&O 20030701 |
| Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. | Oncogene 20030626 |
| Hypereosinophilic syndrome. | The New England journal of medicine 20030626 |
| [Imatinib--en epoch-making new drug against chronic myeloid leukemia]. | Lakartidningen 20030626 |
| Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. | Blood 20030615 |
| Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. | Blood 20030615 |
| The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. | Blood 20030615 |
| Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. | Blood 20030615 |
| [New trends in therapy for leukemia: Approach from the point of view of molecular information]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030610 |
| [Evidence-based therapy for chronic leukemia]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030610 |
| Gynaecomastia in men with chronic myeloid leukaemia after imatinib. | Lancet (London, England) 20030607 |
| Drug maker's vow to donate cancer medicine falls short. | The New York times on the Web 20030605 |
| Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. | Blood 20030601 |
| Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response. | Annals of hematology 20030601 |
| Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias. | Hematology (Amsterdam, Netherlands) 20030601 |
| Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center. | Hematology (Amsterdam, Netherlands) 20030601 |
| Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase. | Blood 20030601 |
| In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. | Leukemia 20030601 |
| Current CML therapy: progress and dilemma. | Leukemia 20030601 |
| Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. | Leukemia 20030601 |
| Questioning the aim of CML therapy in the era of Imatinib? | Leukemia 20030601 |
| Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. | Cancer 20030601 |
| Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601 |
| Pharmacotherapy of gastrointestinal stromal tumours. | Expert opinion on pharmacotherapy 20030601 |
| Imatinib mesylate in the treatment of chronic myeloid leukaemia. | Expert opinion on pharmacotherapy 20030601 |
| Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance. | Journal of pediatric hematology/oncology 20030601 |
| Severe hemolytic anemia and skin reaction in a patient treated with imatinib. | Annals of oncology : official journal of the European Society for Medical Oncology 20030601 |
| Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030601 |
| The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030601 |
| Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. | Bone marrow transplantation 20030601 |
| The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. | Hematological oncology 20030601 |
| Protein kinase inhibitors as a therapeutic modality. | Accounts of chemical research 20030601 |
| [Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib]. | RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 20030601 |
| Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. | American journal of clinical pathology 20030601 |
| Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. | Cancer science 20030601 |
| [In vitro effect of STI571 on expression of c-kit in bone marrow cells from patients with acute non-lymphocytic leukemia]. | Zhongguo shi yan xue ye xue za zhi 20030601 |
| A successful case of oral molecularly targeted therapy with imatinib for peritoneal metastasis of a gastrointestinal stromal tumor. | International journal of clinical oncology 20030601 |
| [Treatment of 54 chronic myelogenous leukemia with Gleevec]. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20030601 |
| [Successful induction of complete cytogenetic response with high-dose imatinib mesylate and subsequent allogeneic stem cell transplantation for CML blastic crisis]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20030601 |
| STI571 as a targeted therapy for CML. | Cancer investigation 20030601 |
| A hope for the future. | Cancer investigation 20030601 |
| A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. | The New England journal of medicine 20030529 |
| Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. | International journal of cancer 20030520 |
| Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. | Annals of internal medicine 20030520 |
| Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. | Blood 20030515 |
| C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030515 |
| [Targeted therapy with imatinib has reformed the treatment of chronic myeloid leukemia]. | Ugeskrift for laeger 20030512 |
| [Molecular targeting therapy for chronic myelogenous leukemia]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030510 |
| Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. | Blood 20030501 |
| TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. | Blood 20030501 |
| BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs). | Blood 20030501 |
| Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. | Annals of hematology 20030501 |
| Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117). | Annals of oncology : official journal of the European Society for Medical Oncology 20030501 |
| Clinical applications of BCR-ABL molecular testing in acute leukemia. | The Journal of molecular diagnostics : JMD 20030501 |
| Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. | Annals of hematology 20030501 |
| Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. | Cancer 20030501 |
| Imatinib restores expression of CD62L in BCR-ABL-positive cells. | Journal of leukocyte biology 20030501 |
| Fighting leukemia. Survival rates have tripled thanks to new, more effective treatments. | Mayo Clinic women's healthsource 20030501 |
| Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration. | British journal of haematology 20030501 |
| Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. | Cancer research 20030501 |
| Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. | Cell death and differentiation 20030501 |
| Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report. | Haematologica 20030501 |
| SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. | Molecular cancer therapeutics 20030501 |
| Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. | Leukemia 20030501 |
| Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. | Leukemia 20030501 |
| Histological features of acute hepatitis after imatinib mesylate treatment. | Leukemia 20030501 |
| Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis. | British journal of haematology 20030501 |
| Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL. | British journal of haematology 20030501 |
| The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution. | Virchows Archiv : an international journal of pathology 20030501 |
| Targeting oncogene dependence and resistance. | Cancer cell 20030501 |
| PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. | Cancer cell 20030501 |
| Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia. | Annals of the New York Academy of Sciences 20030501 |
| [Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20030501 |
| [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20030501 |
| Targeted therapies for the treatment of leukemia. | Seminars in oncology nursing 20030501 |
| Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. | Transplantation 20030427 |
| Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard? | Lancet (London, England) 20030426 |
| Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. | The Journal of biological chemistry 20030425 |
| Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. | Cancer letters 20030425 |
| Cancer: Escape from inhibition. | Nature 20030424 |
| Dose-dependent severe cutaneous reactions to imatinib. | British journal of cancer 20030422 |
| [Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients]. | Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20030418 |
| Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. | Blood 20030415 |
| Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. | Blood 20030415 |
| Practical management of patients with chronic myeloid leukemia receiving imatinib. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030415 |
| LRP: role in vascular wall integrity and protection from atherosclerosis. | Science (New York, N.Y.) 20030411 |
| Is there a cloud in the silver lining for imatinib? | British journal of cancer 20030407 |
| Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. | Clinical and laboratory haematology 20030401 |
| An FDG positron emission tomographic study in a case of gastrointestinal stromal tumor. | Clinical nuclear medicine 20030401 |
| Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. | European journal of haematology 20030401 |
| Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. | European journal of haematology 20030401 |
| The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. | The Journal of clinical endocrinology and metabolism 20030401 |
| Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas. | Anti-cancer drugs 20030401 |
| Mycosis fungoides-like reaction in a patient treated with Gleevec. | Journal of cutaneous pathology 20030401 |
| Gleevec does not cross blood-brain barrier. | The Lancet. Oncology 20030401 |
| Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. | Haematologica 20030401 |
| Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). | Leukemia 20030401 |
| Intramuscular edema as a complication of treatment with imatinib. | Leukemia 20030401 |
| G-CSF for imatinib-induced neutropenia. | Leukemia 20030401 |
| Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. | Leukemia 20030401 |
| Is another bcr-abl inhibitor needed for chronic myelogenous leukemia? | Clinical cancer research : an official journal of the American Association for Cancer Research 20030401 |
| Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030401 |
| A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030401 |
| The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030401 |
| Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20030401 |
| Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. | Bone marrow transplantation 20030401 |
| Precipitation of porphyria cutanea tarda by imatinib mesylate? | British journal of haematology 20030401 |
| Clinical trials referral resource. Current clinical trials of imatinib mesylate. | Oncology (Williston Park, N.Y.) 20030401 |
| Images in pathology. Morphologic features of response to Gleevec (Imatinib) treatment of GIST. | International journal of surgical pathology 20030401 |
| Chronic myeloid leukemia in the imatinib era. | Seminars in hematology 20030401 |
| Imatinib: a targeted clinical drug development. | Seminars in hematology 20030401 |
| Imatinib treatment: specific issues related to safety, fertility, and pregnancy. | Seminars in hematology 20030401 |
| Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. | Seminars in hematology 20030401 |
| Quality of life on imatinib. | Seminars in hematology 20030401 |
| Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy. | Seminars in hematology 20030401 |
| Prediction of response to imatinib by cDNA microarray analysis. | Seminars in hematology 20030401 |
| Cytogenetic studies in patients on imatinib. | Seminars in hematology 20030401 |
| The cytogenetic response as a surrogate marker of survival. | Seminars in hematology 20030401 |
| Molecular monitoring of chronic myeloid leukemia. | Seminars in hematology 20030401 |
| Cytogenetic and molecular mechanisms of resistance to imatinib. | Seminars in hematology 20030401 |
| Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. | Seminars in hematology 20030401 |
| Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies. | Seminars in hematology 20030401 |
| Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials. | Seminars in hematology 20030401 |
| Clinical decisions for chronic myeloid leukemia in the imatinib era. | Seminars in hematology 20030401 |
| [Pathophysiology and treatment of acute myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20030401 |
| [Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20030401 |
| Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. | Cancer science 20030401 |
| [A new drug in the therapy of chronic myeloid leukemia: ST1571]. | Minerva medica 20030401 |
| [Gleevec: an novel inhibitor of bcr-abl tyrosine kinase]. | Sheng li ke xue jin zhan [Progress in physiology] 20030401 |
| The hypereosinophilic syndrome and the biology of cancer. | The New England journal of medicine 20030327 |
| A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. | The New England journal of medicine 20030327 |
| Tyrosine kinase inhibition and grey hair. | Lancet (London, England) 20030322 |
| Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. | Cell 20030321 |
| A myristoyl/phosphotyrosine switch regulates c-Abl. | Cell 20030321 |
| Structural basis for the autoinhibition of c-Abl tyrosine kinase. | Cell 20030321 |
| Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. | Journal of the National Cancer Institute 20030319 |
| High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. | Blood 20030315 |
| Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. | Statistics in medicine 20030315 |
| MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. | Blood 20030315 |
| Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. | Blood 20030315 |
| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. | The New England journal of medicine 20030313 |
| Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia. | The New England journal of medicine 20030313 |
| [Current therapy of chronic myeloid leukemia]. | Orvosi hetilap 20030302 |
| Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. | Blood 20030301 |
| Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. | Current problems in surgery 20030301 |
| Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line. | Blood 20030301 |
| Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. | The Journal of pharmacology and experimental therapeutics 20030301 |
| Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation. | European journal of gastroenterology & hepatology 20030301 |
| A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). | British journal of haematology 20030301 |
| Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. | American journal of ophthalmology 20030301 |
| Abl family nonreceptor tyrosine kinases modulate short-term synaptic plasticity. | Journal of neurophysiology 20030301 |
| Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030301 |
| Gleevec: tailoring to fit. | Drug discovery today 20030301 |
| Polycythemia vera responds to imatinib mesylate. | The American journal of the medical sciences 20030301 |
| Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. | Leukemia 20030301 |
| Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. | Leukemia 20030301 |
| The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. | British journal of haematology 20030301 |
| Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. | British journal of haematology 20030301 |
| Current use of imatinib in the treatment of chronic myeloid leukemia. | Haematologica 20030301 |
| Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. | Haematologica 20030301 |
| Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. | Haematologica 20030301 |
| Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. | Cancer chemotherapy and pharmacology 20030301 |
| Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. | Molecular cancer therapeutics 20030301 |
| Overcoming resistance to imatinib by combining targeted agents. | Molecular cancer therapeutics 20030301 |
| [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation]. | Gan to kagaku ryoho. Cancer & chemotherapy 20030301 |
| High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia. | Leukemia & lymphoma 20030301 |
| A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. | The Journal of biological chemistry 20030221 |
| Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). | Oncogene 20030220 |
| Platelet-derived growth factor receptor inhibition reduces allograft arteriosclerosis of heart and aorta in cholesterol-fed rabbits. | Transplantation 20030215 |
| Programs established by FDA to expedite patient access to medications. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030215 |
| A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. | The Journal of biological chemistry 20030214 |
| Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. | Oncogene 20030206 |
| Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. | Molecular pharmacology 20030201 |
| Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML. | Blood 20030201 |
| Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. | The Lancet. Oncology 20030201 |
| Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030201 |
| Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030201 |
| Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. | British journal of haematology 20030201 |
| Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. | Journal of the American Academy of Dermatology 20030201 |
| BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia. | Molecular cancer therapeutics 20030201 |
| Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia. | Experimental hematology 20030201 |
| Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. | Leukemia 20030201 |
| Effect of imatinib on haematopoietic recovery following idarubicin exposure. | Leukemia 20030201 |
| Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation. | Leukemia 20030201 |
| Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. | Leukemia 20030201 |
| Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. | Leukemia 20030201 |
| Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. | Leukemia 20030201 |
| The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. | Laboratory investigation; a journal of technical methods and pathology 20030201 |
| Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. | Haematologica 20030201 |
| Chromosomal abnormalities in Philadelphia (Ph)-negative cells of patients with chronic myeloide leukemia treated with Imatinib (ST1571). | Haematologica 20030201 |
| [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20030201 |
| Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. | Bone marrow transplantation 20030201 |
| Lack of c-kit overexpression in soft tissue sarcomas. | The Israel Medical Association journal : IMAJ 20030201 |
| C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus. | Journal of chemotherapy (Florence, Italy) 20030201 |
| BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. | FEBS letters 20030130 |
| Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. | Blood 20030115 |
| Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. | Blood 20030115 |
| The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. | Blood 20030115 |
| BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. | Blood 20030115 |
| Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy. | Blood 20030115 |
| A new era in cancer therapeutics? | Drug discovery today 20030115 |
| Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). | Blood 20030101 |
| Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. | Blood 20030101 |
| Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. | Blood 20030101 |
| A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines. | Nature immunology 20030101 |
| Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia. | Blood 20030101 |
| Chronic myelogenous leukemia. | Current opinion in oncology 20030101 |
| Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030101 |
| Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. | Molecular cancer 20030101 |
| Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030101 |
| [The new mechanisms and reversal of drug resistance]. | Gan to kagaku ryoho. Cancer & chemotherapy 20030101 |
| Imatinib alone and in combination for chronic myeloid leukemia. | Seminars in hematology 20030101 |
| Management decisions in chronic myeloid leukemia. | Seminars in hematology 20030101 |
| Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients? | International journal of hematology 20030101 |
| Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. | Drugs 20030101 |
| [Gain-of-function mutation of c-kit gene and molecular target therapy in GISTs]. | Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20030101 |
| [Gastro-intestinal stromal tumors: news and comments]. | Bulletin du cancer 20030101 |
| [How I treat...chronic myeloid leukemia]. | Revue medicale de Liege 20030101 |
| Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. | Cancer biology & therapy 20030101 |
| Dodging the magic bullet: understanding imatinib resistance. | Cancer biology & therapy 20030101 |
| Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. | Seminars in hematology 20030101 |
| Cutaneous drug reaction case reports: from the world literature. | American journal of clinical dermatology 20030101 |
| Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. | Pathology oncology research : POR 20030101 |
| Gleevec approved for first-line treatment of CML. | FDA consumer 20030101 |
| Gleevec resistance: lessons for target-directed drug development. | Cell cycle (Georgetown, Tex.) 20030101 |
| Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. | Stem cells (Dayton, Ohio) 20030101 |
| Imatinib: the promise of a 'magic bullet' for cancer fulfilled. | Journal of the Medical Association of Georgia 20030101 |
| [Chronic myeloid leukemia as a model for the development and therapeutic use of tyrosine kinase inhibitors]. | Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 20030101 |
| Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. | Blood cells, molecules & diseases 20030101 |
| [Gastrointestinal stromal tumors: a new model for target therapy]. | La Clinica terapeutica 20030101 |
| Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation. | Pathology oncology research : POR 20030101 |
| Imatinib (STI-571) heals a gastrocutaneous fistula resulting from a malignant gastric stromal tumor. | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20030101 |
| [Nephrotoxicidad for imatinib]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20030101 |
| Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. | Anticancer research 20030101 |
| Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor. | Journal of gastroenterology 20030101 |
| Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate. | Current hematology reports 20030101 |
| [Surgical treatment of gastrointestinal stromal tumors: personal cases]. | Tumori 20030101 |
| [Molecular therapy of breast carcinoma in the advanced phase]. | Tumori 20030101 |
| Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. | Advances in experimental medicine and biology 20030101 |
| Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. | Advances in experimental medicine and biology 20030101 |
| Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571. | In vivo (Athens, Greece) 20030101 |
| [Imatinib mesylate: a major breakthrough in the treatment of chronic myelogenous leukemia]. | Medecine sciences : M/S 20030101 |
| Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. | Annals of medicine 20030101 |
| FDA approves Gleevec for pediatric leukemia. | FDA consumer 20030101 |
| Inhibiting tyrosine kinases: successes and limitations. | Cancer biology & therapy 20030101 |
| [Therapeutic efficacy of imatinib mesylate (glivec) in chronic phase of myeloid leukemia]. | Terapevticheskii arkhiv 20030101 |
| Effects of STI571 (gleevec) on pancreatic cancer cell growth. | Molecular cancer 20030101 |
| Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy. | Cancer investigation 20030101 |
| Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases. | Journal of gastroenterology 20030101 |
| Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign. | Dermatology (Basel, Switzerland) 20030101 |
| [Imatinib-induced purpuric vasculitis]. | Annales de dermatologie et de venereologie 20030101 |
| Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate. | Acta dermato-venereologica 20030101 |
| Targeted therapy in cancer and transgenic animal model. | Cancer investigation 20030101 |
| Chronic myeloid leukemia. | Hematology. American Society of Hematology. Education Program 20030101 |
| Gastrointestinal stromal tumors: biology and treatment. | Oncology 20030101 |
| RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. | Anticancer research 20030101 |
| Effective treatment of hypereosinophilic syndrome with imatinib mesylate. | The hematology journal : the official journal of the European Haematology Association 20030101 |
| No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). | The hematology journal : the official journal of the European Haematology Association 20030101 |
| Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML). | Acta medica (Hradec Kralove) 20030101 |
| Imatinib mesylate-induced maculopapular drug rash. | The National medical journal of India 20030101 |
| Recent advances of molecular targeted agents: opportunities for imaging. | Cancer biology & therapy 20030101 |
| The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). | Neoplasma 20030101 |
| [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease]. | Lijecnicki vjesnik 20030101 |
| Pharmacology of oral chemotherapy agents. | Clinical journal of oncology nursing 20030101 |
| Medication sheets for patients. Oral chemotherapy. | Clinical journal of oncology nursing 20030101 |
| Isolated abdominal wound metastasis from a gastrointestinal stromal tumor. | International journal of gastrointestinal cancer 20030101 |
| Hematopoietic stem cells in chronic myeloid leukemia. | Archives of medical research 20030101 |
| Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. | Abdominal imaging 20030101 |
| [Tyrosine kinase inhibitor STI571--a breakthrough in leukemia treatment?]. | Postepy biochemii 20030101 |
| Plasma cell myeloma and leukemia. | Cancer chemotherapy and biological response modifiers 20030101 |
| Imatinib results in better quality of life for CML patients than interferon/Ara-C. | The journal of supportive oncology 20030101 |
| Current management of metastatic gastrointestinal stromal tumor: a case report. | Clinical advances in hematology & oncology : H&O 20030101 |
| Chronic myelogenous leukemia clinical practice guidelines in oncology. | Journal of the National Comprehensive Cancer Network : JNCCN 20030101 |
| Update: chronic myelogenous leukemia clinical practice guidelines. | Journal of the National Comprehensive Cancer Network : JNCCN 20030101 |
| Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). | Cancer research 20021215 |
| Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519. | Cancer letters 20021210 |
| Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. | Oncogene 20021209 |
| Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571. | Oncogene 20021209 |
| [Chronic myeloid leukemia--case report]. | Deutsche medizinische Wochenschrift (1946) 20021206 |
| [Chronic myeloid leukemia--treatment]. | Deutsche medizinische Wochenschrift (1946) 20021206 |
| Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. | Current treatment options in oncology 20021201 |
| Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. | Cancer 20021201 |
| Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. | Leukemia 20021201 |
| Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). | Leukemia 20021201 |
| Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas. | Expert opinion on investigational drugs 20021201 |
| Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia. | Bone marrow transplantation 20021201 |
| Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. | Surgery 20021201 |
| STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation. | Haematologica 20021201 |
| Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia. | Haematologica 20021201 |
| Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. | Molecular cancer research : MCR 20021201 |
| Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction. | Expert review of anticancer therapy 20021201 |
| Decitabine has promising clinical activity in chronic myeloid leukemia. | Expert review of anticancer therapy 20021201 |
| Protein tyrosine kinases: autoregulation and small-molecule inhibition. | Current opinion in structural biology 20021201 |
| Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. | International journal of hematology 20021201 |
| Gleevec: zeroing in on cancer. | Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses 20021201 |
| A functional genomics approach to Kaposi's sarcoma. | Annals of the New York Academy of Sciences 20021201 |
| Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML. | Haematologica 20021201 |
| Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. | Leukemia & lymphoma 20021201 |
| Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia. | Leukemia & lymphoma 20021201 |
| Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. | Best practice & research. Clinical haematology 20021201 |
| Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? | Journal of the National Cancer Institute 20021120 |
| Synthetic lethality: killing cancer with cancer. | Journal of the National Cancer Institute 20021120 |
| Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. | Journal of the National Cancer Institute 20021120 |
| Gastrointestinal stromal tumors: chemotherapy and imatinib. | Current oncology reports 20021101 |
| Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib. | Current oncology reports 20021101 |
| Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership. | Leukemia research 20021101 |
| The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice. | Leukemia research 20021101 |
| IL-10 induces mesangial cell proliferation via a PDGF-dependent mechanism. | Clinical and experimental immunology 20021101 |
| Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. | Leukemia 20021101 |
| Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. | Current opinion in oncology 20021101 |
| Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. | American journal of hematology 20021101 |
| Managing cutaneous reactions to imatinib therapy. | Blood 20021101 |
| Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. | Cancer research 20021101 |
| Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. | Cancer research 20021101 |
| The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). | Annals of surgical oncology 20021101 |
| Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase. | Annals of oncology : official journal of the European Society for Medical Oncology 20021101 |
| Management of malignant gastrointestinal stromal tumours. | The Lancet. Oncology 20021101 |
| Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20021101 |
| Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. | Clinical cancer research : an official journal of the American Association for Cancer Research 20021101 |
| The stem cell factor-c-kit system and mast cells in human pancreatic cancer. | Laboratory investigation; a journal of technical methods and pathology 20021101 |
| Unexpected pleural effusions in 3 pediatric patients treated with STI-571. | Journal of pediatric hematology/oncology 20021101 |
| DNA damage and repair in BCR/ABL-expressing cells after combined action of idarubicin, STI571 and amifostine. | Anti-cancer drugs 20021101 |
| Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. | International journal of hematology 20021101 |
| [A patient with diffuse peritoneal metastases of GIST who was administered STI571]. | Gan to kagaku ryoho. Cancer & chemotherapy 20021101 |
| Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia. | Leukemia & lymphoma 20021101 |
| [New data presented at ASCO 2002 concerning small cell bronchial cancer]. | Revue de pneumologie clinique 20021101 |
| BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. | Cancer genetics and cytogenetics 20021101 |
| [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia]. | Orvosi hetilap 20021020 |
| NICE widens patient group for leukaemia drug. | BMJ (Clinical research ed.) 20021019 |
| Cancer drugs. Smart weapons prove tough to design. | Science (New York, N.Y.) 20021018 |
| [Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells]. | Deutsche medizinische Wochenschrift (1946) 20021018 |
| [Imatinib combination therapies--the new CML Study 4]. | Deutsche medizinische Wochenschrift (1946) 20021018 |
| BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. | Blood 20021015 |
| Hypersensitivity pneumonitis related to imatinib mesylate. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021015 |
| Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. | Cancer research 20021015 |
| [Tumors of the small intestine]. | Praxis 20021009 |
| Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. | American journal of hematology 20021001 |
| Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia. | Leukemia 20021001 |
| Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. | Leukemia 20021001 |
| Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. | British journal of haematology 20021001 |
| Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. | British journal of haematology 20021001 |
| Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. | British journal of haematology 20021001 |
| Position paper on imatinib mesylate in chronic myeloid leukaemia. | British journal of haematology 20021001 |
| Sti571-induced Stevens-Johnson Syndrome. | British journal of haematology 20021001 |
| STI-571 in chronic myelogenous leukaemia. | British journal of haematology 20021001 |
| Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. | Cancer research 20021001 |
| Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation. | Bone marrow transplantation 20021001 |
| Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20021001 |
| Imatinib mesylate, the first molecularly targeted gene suppressor. | Pharmacotherapy 20021001 |
| [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)]. | Journal de chirurgie 20021001 |
| Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. | European journal of haematology 20021001 |
| Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. | Seminars in hematology 20021001 |
| [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20021001 |
| Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. | Molecular cancer therapeutics 20021001 |
| Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. | Hematology/oncology clinics of North America 20021001 |
| Clinical trial designs for targeted agents. | Hematology/oncology clinics of North America 20021001 |
| [Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group]. | Der Internist 20021001 |
| [Gastrointestinal stromal tumors: open problems]. | Il Giornale di chirurgia 20021001 |
| [Effect of STI-571, a c-kit tyrosine kinase inhibitor, in mestastasic gastrointestinal tumor]. | Medicina clinica 20020928 |
| A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. | Blood 20020915 |
| Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. | Leukemia research 20020901 |
| Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. | Blood 20020901 |
| The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. | Blood 20020901 |
| Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. | British journal of haematology 20020901 |
| Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. | Leukemia 20020901 |
| Effects of imatinib on bone marrow engraftment in syngeneic mice. | Leukemia 20020901 |
| Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020901 |
| Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020901 |
| The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. | Cancer research 20020901 |
| Progress toward virtual screening for drug side effects. | Proteins 20020901 |
| Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis. | The American journal of pathology 20020901 |
| Imatinib: can one outwit chronic myeloid leukemia? | Haematologica 20020901 |
| The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. | Haematologica 20020901 |
| Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. | Urology 20020901 |
| Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020901 |
| Signal transduction inhibitors (STI571): molecularly targeted therapy. | Puerto Rico health sciences journal 20020901 |
| Rational drug design: making drugs that make a difference. | Transplantation proceedings 20020901 |
| Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest? | Applied immunohistochemistry & molecular morphology : AIMM 20020901 |
| Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function. | Anti-cancer drugs 20020901 |
| [Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20020901 |
| Imatinib: a selective tyrosine kinase inhibitor. | European journal of cancer (Oxford, England : 1990) 20020901 |
| Pharmacology of imatinib (STI571). | European journal of cancer (Oxford, England : 1990) 20020901 |
| Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). | European journal of cancer (Oxford, England : 1990) 20020901 |
| Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). | European journal of cancer (Oxford, England : 1990) 20020901 |
| Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts. | European journal of cancer (Oxford, England : 1990) 20020901 |
| Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. | European journal of cancer (Oxford, England : 1990) 20020901 |
| Imatinib: the first 3 years. | European journal of cancer (Oxford, England : 1990) 20020901 |
| Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. | European journal of cancer (Oxford, England : 1990) 20020901 |
| Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. | Drugs of today (Barcelona, Spain : 1998) 20020901 |
| Targeting protein kinases in cancer therapy. | Current opinion in drug discovery & development 20020901 |
| Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. | The Journal of biological chemistry 20020830 |
| Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. | Oncogene 20020829 |
| Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). | Oncogene 20020822 |
| a suitable case for treatment. The National Institute for Clinical Excellence's change of heart over cancer drug Glivec has been applauded by clinicians--and patients. | The Health service journal 20020822 |
| Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. | International journal of cancer 20020820 |
| A molecular star in the wars against cancer. | The New England journal of medicine 20020815 |
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. | The New England journal of medicine 20020815 |
| Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. | The New England journal of medicine 20020815 |
| Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. | The New England journal of medicine 20020815 |
| Severe periorbital edema secondary to STI571 (Gleevec). | Cancer 20020815 |
| Imatinib mesylate and gray hair. | The New England journal of medicine 20020808 |
| Changes and challenges--the world post-Gleevec (Glivec). | Current opinion in pharmacology 20020801 |
| Protein tyrosine kinase inhibitors: new treatment modalities? | Current opinion in pharmacology 20020801 |
| Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. | Blood 20020801 |
| Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. | Blood 20020801 |
| Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. | Blood 20020801 |
| Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances. | Urology 20020801 |
| Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. | Blood 20020801 |
| Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). | Cancer research 20020801 |
| c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). | Cancer chemotherapy and pharmacology 20020801 |
| Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. | The British journal of dermatology 20020801 |
| The ATP site of protein kinases as target for drug development: from natural compounds to gleevec. | The Israel Medical Association journal : IMAJ 20020801 |
| [New therapeutic targets and strategies in lung cancer]. | Archivos de bronconeumologia 20020801 |
| Resistance in the land of molecular cancer therapeutics. | Cancer cell 20020801 |
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. | Cancer cell 20020801 |
| Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. | Japanese journal of cancer research : Gann 20020801 |
| Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. | Biochimica et biophysica acta 20020718 |
| Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. | Blood 20020715 |
| Imatinib and chronic-phase leukemias. | The New England journal of medicine 20020704 |
| Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. | Current opinion in hematology 20020701 |
| Systemic therapy for advanced soft-tissue sarcomas. | Current oncology reports 20020701 |
| Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. | Leukemia 20020701 |
| Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). | Leukemia 20020701 |
| Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. | Leukemia 20020701 |
| ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL). | Leukemia 20020701 |
| Binding of imatinib by alpha(1)-acid glycoprotein. | Blood 20020701 |
| Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph-negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI-571 therapy. | British journal of haematology 20020701 |
| Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020701 |
| Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020701 |
| Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. | Nature reviews. Drug discovery 20020701 |
| Chromosomal translocations and sarcomas. | Current opinion in oncology 20020701 |
| In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. | Experimental hematology 20020701 |
| [The principles of cancer treatment--changes in chemotherapy]. | Gan to kagaku ryoho. Cancer & chemotherapy 20020701 |
| Imatinib provides lasting treatment for patients with advanced GISTs. | Oncology (Williston Park, N.Y.) 20020701 |
| Trial results of a new combination therapy for myeloid leukaemia. | Nursing times 20020701 |
| Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia. | European journal of haematology 20020701 |
| Cancer studies explore targeted therapy, researchers seek new prevention strategies. | JAMA 20020619 |
| Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20020615 |
| Doctors condemn NICE's guidance on leukaemia drug. | BMJ (Clinical research ed.) 20020608 |
| Not so NICE for CML. | Lancet (London, England) 20020608 |
| BCR-ABL-induced adhesion defects are tyrosine kinase-independent. | Blood 20020601 |
| Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine. | Molecular pharmacology 20020601 |
| Stevens-Johnson syndrome after treatment with STI571: a case report. | British journal of haematology 20020601 |
| Low concentrations of STI571 in the cerebrospinal fluid: a case report. | British journal of haematology 20020601 |
| Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. | Leukemia 20020601 |
| Lichenoid eruption to STI 571. | American journal of hematology 20020601 |
| Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. | Cancer 20020601 |
| Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. | Cancer cell 20020601 |
| Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. | Cancer cell 20020601 |
| Critical role for Gab2 in transformation by BCR/ABL. | Cancer cell 20020601 |
| [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]. | Bulletin du cancer 20020601 |
| [c-kit: an irresistible ascension from diagnostic marker to therapeutic]. | Annales de pathologie 20020601 |
| The mechanism of STI571 inducing apoptosis of K562 cells. | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20020601 |
| [STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia]. | Ugeskrift for laeger 20020527 |
| Cerebral oedema as a possible complication of treatment with imatinib. | Lancet (London, England) 20020518 |
| Decrease of resistance to imatinib in leukaemia. | Lancet (London, England) 20020518 |
| Decrease of resistance to imatinib in leukaemia. | Lancet (London, England) 20020518 |
| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. | Blood 20020515 |
| Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. | Blood 20020515 |
| Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. | Blood 20020515 |
| Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. | Blood 20020515 |
| Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. | Blood 20020515 |
| In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. | Cancer 20020515 |
| The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. | British journal of cancer 20020506 |
| Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. | British journal of cancer 20020506 |
| Treatment of hypereosinophilic syndrome with imatinib mesilate. | Lancet (London, England) 20020504 |
| BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. | Oncogene 20020502 |
| Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. | Blood 20020501 |
| Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. | Blood 20020501 |
| High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. | Blood 20020501 |
| Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020501 |
| Imatinib mesylate (Gleevec) in the treatment of 2 patients with Philadelphia-positive ALL relapsing after allogeneic stem cell transplantation. | International journal of hematology 20020501 |
| Diagnosis of gastrointestinal stromal tumors: A consensus approach. | Human pathology 20020501 |
| Clinical management of gastrointestinal stromal tumors: before and after STI-571. | Human pathology 20020501 |
| Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. | Human pathology 20020501 |
| [Recent progress in the treatment of ED small cell lung cancer]. | Nihon rinsho. Japanese journal of clinical medicine 20020501 |
| [Oncogene products inhibitors in the treatment of cancer]. | Polskie Archiwum Medycyny Wewnetrznej 20020501 |
| Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease. | British journal of cancer 20020422 |
| On the offensive. | Nature 20020404 |
| Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020401 |
| STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. | Leukemia 20020401 |
| New drugs 2002. Part II. | Nursing 20020401 |
| [A patient with metastatic gastrointestinal stromal tumor who responded to STI571]. | Gan to kagaku ryoho. Cancer & chemotherapy 20020401 |
| STI-stop transplanting immediately? | Journal of hematotherapy & stem cell research 20020401 |
| Unable to resist. | Nature reviews. Cancer 20020401 |
| Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. | Seminars in hematology 20020401 |
| [Molecular diagnosis in hematologic malignancies]. | Rinsho byori. The Japanese journal of clinical pathology 20020401 |
| [Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology 20020401 |
| Diagnosis of gastrointestinal stromal tumors: a consensus approach. | International journal of surgical pathology 20020401 |
| Protein kinases--the major drug targets of the twenty-first century? | Nature reviews. Drug discovery 20020401 |
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. | Blood 20020315 |
| Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315 |
| The promise of gene expression analysis in hematopoetic malignancies. | Biochimica et biophysica acta 20020314 |
| From the Food and Drug Administration. | JAMA 20020306 |
| High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020305 |
| The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. | Blood 20020301 |
| Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. | Blood 20020301 |
| Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. | Blood 20020301 |
| What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia? | Haematologica 20020301 |
| [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]. | Deutsche medizinische Wochenschrift (1946) 20020301 |
| The advent of targeted therapeutics and implications for pathologists. | American journal of clinical pathology 20020301 |
| ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. | American journal of clinical pathology 20020301 |
| Acute myelogenous leukemia: advances and limitations of treatment. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20020301 |
| Imatinib. Novartis. | Current opinion in investigational drugs (London, England : 2000) 20020301 |
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. | The New England journal of medicine 20020227 |
| Imatinib mesylate--a new oral targeted therapy. | The New England journal of medicine 20020227 |
| Adverse events after imatinib mesylate therapy. | The New England journal of medicine 20020227 |
| Adverse events after imatinib mesylate therapy. | The New England journal of medicine 20020227 |
| Resistance to targeted therapy in leukaemia. | Lancet (London, England) 20020209 |
| Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. | Lancet (London, England) 20020209 |
| BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. | Lancet (London, England) 20020209 |
| Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. | Experimental cell research 20020201 |
| Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020201 |
| Challenges in oncology. Case 4. Response of metastatic gastrointestinal stromal tumor including CNS involvement to imatinib mesylate (STI-571). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020201 |
| Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. | Leukemia 20020201 |
| STI571 (imatinib mesylate): the tale of a targeted therapy. | Anti-cancer drugs 20020201 |
| [Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy]. | Harefuah 20020201 |
| Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. | Cancer cell 20020201 |
| Perspectives on the development of a molecularly targeted agent. | Cancer cell 20020201 |
| [STI571: a new dimension in the treatment of chronic myeloid leukemia]. | Nederlands tijdschrift voor geneeskunde 20020119 |
| Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. | Blood 20020115 |
| Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. | Blood 20020115 |
| [Molecular therapy of chronic myeloid leukemia--a new era in the treatment of malignant diseases]. | Medizinische Klinik (Munich, Germany : 1983) 20020115 |
| [Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase (Glivec)]. | Medizinische Klinik (Munich, Germany : 1983) 20020115 |
| [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]. | Medizinische Klinik (Munich, Germany : 1983) 20020115 |
| [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia]. | Medizinische Klinik (Munich, Germany : 1983) 20020115 |
| Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). | Medizinische Klinik (Munich, Germany : 1983) 20020115 |
| [Drug therapy of chronic myeloid leukemia]. | Medizinische Klinik (Munich, Germany : 1983) 20020115 |
| Tyrosine kinase inhibitors: a clinical perspective. | Current oncology reports 20020101 |
| BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. | Nature genetics 20020101 |
| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. | Blood 20020101 |
| Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. | Blood 20020101 |
| STI571: a paradigm of new agents for cancer therapeutics. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101 |
| Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101 |
| Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. | Cancer research 20020101 |
| Autotransplantation for chronic myeloid leukemia: is it useful? | Haematologica 20020101 |
| [Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)]. | Nihon rinsho. Japanese journal of clinical medicine 20020101 |
| Recent advancements in the treatment of chronic myelogenous leukemia. | Annual review of medicine 20020101 |
| [The tyrosine kinase antagonist imatinib mesylate]. | Medizinische Monatsschrift fur Pharmazeuten 20020101 |
| Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. | British journal of haematology 20020101 |
| [Update on malignant hemopathies]. | Bulletin du cancer 20020101 |
| [Chronic myeloid leukemia as a model for modern noncytostatic therapy of malignant diseases. From Virchow to STI 571]. | Vnitrni lekarstvi 20020101 |
| Imatinib mesylate. | Clinical journal of oncology nursing 20020101 |
| Unexpected leukocytosis in a preoperative patient. | The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society 20020101 |
| Is red tape stifling the progress of new anticancer drugs? | The Lancet. Oncology 20020101 |
| FDA licences imatinib mesylate for CML. | The Lancet. Oncology 20020101 |
| STI571 (Gleevec) as a paradigm for cancer therapy. | Trends in molecular medicine 20020101 |
| The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities. | The hematology journal : the official journal of the European Haematology Association 20020101 |
| Multifaceted approach to the treatment of bcr-abl-positive leukemias. | The oncologist 20020101 |
| Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. | Blood cells, molecules & diseases 20020101 |
| New Gleevec treatment approved. | FDA consumer 20020101 |
| FDA approves new drug for gastrointestinal stromal tumors. | Clinical journal of oncology nursing 20020101 |
| Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. | Stem cells (Dayton, Ohio) 20020101 |
| [Graft vs. tumor effect in chronic granulocytic leukemia]. | Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 20020101 |
| Imatinib mesylate. | Reviews in gastroenterological disorders 20020101 |
| Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. | Pharmacology & therapeutics 20020101 |
| Inhibition of protein kinase B/Akt. implications for cancer therapy. | Pharmacology & therapeutics 20020101 |
| GIST 1, chemotherapy 0, with a brand new hitter up next. | Cancer investigation 20020101 |
| Oral lichenoid reaction to imatinib (STI 571, Gleevec). | Dermatology (Basel, Switzerland) 20020101 |
| Pityriasis rosea associated with imatinib (STI571, Gleevec). | Dermatology (Basel, Switzerland) 20020101 |
| Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. | Blood cells, molecules & diseases 20020101 |
| Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review). | Oncology reports 20020101 |
| Gastrointestinal stromal tumours (GIST): biology and treatment. | Annals of oncology : official journal of the European Society for Medical Oncology 20020101 |
| Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. | The oncologist 20020101 |
| U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. | The oncologist 20020101 |
| Chronic myelogenous leukemia. | Hematology. American Society of Hematology. Education Program 20020101 |
| Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment. | In vivo (Athens, Greece) 20020101 |
| STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia. | The National medical journal of India 20020101 |
| [Treatment of residual disease in chronic myeloid leukemia with STI-571 (Glivec)]. | Acta medica Austriaca. Supplement 20020101 |
| [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors]. | Duodecim; laaketieteellinen aikakauskirja 20020101 |
| Imatinib for relapsed BCR/ABL positive leukemias. | Annals of hematology 20020101 |
| The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. | Health technology assessment (Winchester, England) 20020101 |
| Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571. | Cancer biology & therapy 20020101 |
| Beyond directed therapeutics--are two drugs always better than one? | Cancer biology & therapy 20020101 |
| Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. | Cytokines, cellular & molecular therapy 20020101 |
| Breakthrough of the year. The runners-up. | Science (New York, N.Y.) 20011221 |
| Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. | Blood 20011215 |
| Imatinib for chronic myeloid leukaemia: a NICE mess. | Lancet (London, England) 20011201 |
| Imatinib for chronic myeloid leukaemia: a NICE mess. | Lancet (London, England) 20011201 |
| Imatinib for chronic myeloid leukaemia: a NICE mess. | Lancet (London, England) 20011201 |
| Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. | Laboratory investigation; a journal of technical methods and pathology 20011201 |
| Top ten health stories of 2001. | Harvard health letter 20011201 |
| Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011201 |
| Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. | Leukemia 20011201 |
| Imatinib mesylate. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20011201 |
| [Introduction: chronic myelogenous leukemia leading advanced clinical oncology]. | Nihon rinsho. Japanese journal of clinical medicine 20011201 |
| [Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor]. | Nihon rinsho. Japanese journal of clinical medicine 20011201 |
| [Treatment plan and informed consent]. | Nihon rinsho. Japanese journal of clinical medicine 20011201 |
| Chronic myeloid leukemia. Sceptical scientists. | Lancet (London, England) 20011201 |
| Thriving with chronic myeloid leukaemia. | Lancet (London, England) 20011201 |
| Stem cell factor: laboratory and clinical aspects. | Blood reviews 20011201 |
| [New molecular therapy options in hematology and oncology, exemplified by STI571]. | Der Internist 20011201 |
| Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser. | Journal of hematotherapy & stem cell research 20011201 |
| Gastrointestinal stromal tumors. | Current treatment options in oncology 20011201 |
| Research on resistance to cancer drug Gleevec. | Science (New York, N.Y.) 20011130 |
| Imatinib for chronic myeloid leukaemia: a NICE mess. | Lancet (London, England) 20011103 |
| Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo. | Leukemia research 20011101 |
| Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. | Blood 20011101 |
| Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571. | Leukemia 20011101 |
| Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. | Cancer research 20011101 |
| Chronic myelogenous leukemia: the news you have and haven't heard. | Cleveland Clinic journal of medicine 20011101 |
| [Effect of a tyrosine kinase inhibitors in a patient with a metastatic gastrointestinal stromal tumor]. | Annales de chirurgie 20011101 |
| ST1571: a paradigm for clinical trials of molecularly targeted agents. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20011101 |
| Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. | Lancet (London, England) 20011027 |
| Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. | Cancer research 20011015 |
| Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. | The Journal of biological chemistry 20011012 |
| Chronic myeloid leukemia: current treatment options. | Blood 20011001 |
| STI571: a magic bullet? | European journal of cancer (Oxford, England : 1990) 20011001 |
| Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. | Annals of medicine 20011001 |
| Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. | Bone marrow transplantation 20011001 |
| The biology of signal transduction inhibition: basic science to novel therapies. | Seminars in oncology 20011001 |
| Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. | Seminars in oncology 20011001 |
| Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. | Seminars in oncology 20011001 |
| Platelet-derived growth factor receptors: a therapeutic target in solid tumors. | Seminars in oncology 20011001 |
| Signal transduction inhibition: changing paradigms in cancer care. | Seminars in oncology 20011001 |
| Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. | Oncogene 20010927 |
| Roots of clinical resistance to STI-571 cancer therapy. | Science (New York, N.Y.) 20010921 |
| Roots of clinical resistance to STI-571 cancer therapy. | Science (New York, N.Y.) 20010921 |
| Cancer treatment in the STI571 era: what will change? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010915 |
| Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. | MedGenMed : Medscape general medicine 20010907 |
| Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. | Blood 20010901 |
| Cancer in the crosshairs. | Scientific American 20010901 |
| Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. | Experimental hematology 20010901 |
| Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. | Haematologica 20010901 |
| A possible role for STI571 in the treatment of idiopathic myelofibrosis. | American journal of hematology 20010901 |
| Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia. | Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology 20010901 |
| [Chronic myelogenous leukemia]. | Gan to kagaku ryoho. Cancer & chemotherapy 20010901 |
| Improving the management of chronic myeloid leukaemia. | Hospital medicine (London, England : 1998) 20010901 |
| [Chronic myeloid leukemia and tyrosine kinase inhibitors]. | La Revue de medecine interne 20010901 |
| [STI571: the resistance organizes!]. | Bulletin du cancer 20010901 |
| STI-571: current status and future prospects. | Current opinion in investigational drugs (London, England : 2000) 20010901 |
| Bcr-Abl inhibition as a modality of CML therapeutics. | Biochimica et biophysica acta 20010831 |
| [New target-aimed molecular cancer treatment of chronic myeloid leukemia and gastrointestinal stromal tumor]. | Ugeskrift for laeger 20010827 |
| Cutaneous reactions to STI571. | The New England journal of medicine 20010823 |
| STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. | Oncogene 20010816 |
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. | Science (New York, N.Y.) 20010803 |
| PDGF-beta receptor expression in the dorsocaudal brainstem parallels hypoxic ventilatory depression in the developing rat. | Pediatric research 20010801 |
| Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. | Cancer research 20010801 |
| Chronic myelogenous leukemia. | JAMA 20010801 |
| Targeting protein kinases for tumor therapy. | Onkologie 20010801 |
| ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy. | Cancer chemotherapy and pharmacology 20010801 |
| New-age drug meets resistance. | Nature 20010719 |
| New drug targets genetic malfunction in chronic myeloid leukemia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010715 |
| From the Food and Drug Administration. | JAMA 20010704 |
| STI571 revolution: can the newer targeted drugs measure up? | Journal of the National Cancer Institute 20010704 |
| After 30 years of laboratory work, a quick approval for STI571. | Journal of the National Cancer Institute 20010704 |
| Anti-cancer drug success emerges from molecular biology origins. | Trends in pharmacological sciences 20010701 |
| Approval heralds new generation of kinase inhibitors? | Nature biotechnology 20010701 |
| New leukemia drug receives FDA approval. | Mayo Clinic health letter (English ed.) 20010701 |
| Chronic myelogenous leukaemia--new therapeutic principles. | Journal of internal medicine 20010701 |
| [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia]. | Bulletin du cancer 20010701 |
| [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results]. | Bulletin du cancer 20010701 |
| [STI571 and gastro intestinal stromal tumors]. | Bulletin du cancer 20010701 |
| Clinical trials referral resource. ST1571. | Oncology (Williston Park, N.Y.) 20010701 |
| Cancer treatment. New drugs, new hope. | Harvard health letter 20010701 |
| Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia. | Seminars in hematology 20010701 |
| The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology. | Seminars in hematology 20010701 |
| Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. | Seminars in hematology 20010701 |
| Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. | Seminars in hematology 20010701 |
| Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition. | Seminars in hematology 20010701 |
| Implications of imatinib mesylate for hematopoietic stem cell transplantation. | Seminars in hematology 20010701 |
| BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. | The Journal of biological chemistry 20010629 |
| Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor. | Oncogene 20010628 |
| Cancer research. Why some leukemia cells resist STI-571. | Science (New York, N.Y.) 20010622 |
| Researchers optimistic about sea change in cancer treatment. | JAMA 20010613 |
| Gleevec (STI-571) for chronic myeloid leukemia. | The Medical letter on drugs and therapeutics 20010611 |
| Quick success for cancer kinase treatment. | Nature medicine 20010601 |
| Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good? | Blood reviews 20010601 |
| ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. | Leukemia 20010601 |
| Gastrointestinal stromal tumor workshop. | Human pathology 20010601 |
| Chronic myelogenous leukemia in chronic phase. | Current treatment options in oncology 20010601 |
| FDA approves Novartis' Gleevec. | Expert review of anticancer therapy 20010601 |
| New hope for cancer. | Time 20010528 |
| Cancer's mechanics. Targeting errant cells. | U.S. news & world report 20010521 |
| Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha. | Blood 20010515 |
| In search of the silver bullet. | Fortune 20010514 |
| Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. | International journal of cancer 20010501 |
| STI571: a gene product-targeted therapy for leukemia. | Current oncology reports 20010501 |
| Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. | Leukemia 20010501 |
| Novel therapies for chronic myelogenous leukemia. | Experimental hematology 20010501 |
| The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. | Current cancer drug targets 20010501 |
| ARG tyrosine kinase activity is inhibited by STI571. | Blood 20010415 |
| Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. | The New England journal of medicine 20010405 |
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. | The New England journal of medicine 20010405 |
| Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. | The New England journal of medicine 20010405 |
| Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. | The New England journal of medicine 20010405 |
| PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. | Kidney international 20010401 |
| In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. | Blood 20010401 |
| Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571. | Blood 20010401 |
| Leukemia cells fall on their swords. | Trends in molecular medicine 20010401 |
| Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. | Cancer research 20010401 |
| Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. | British journal of haematology 20010401 |
| Mechanisms of transformation by the BCR/ABL oncogene. | International journal of hematology 20010401 |
| Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. | Leukemia 20010401 |
| In vivo PDGF beta receptor activation in the dorsocaudal brainstem of the rat prevents hypoxia-induced apoptosis via activation of Akt and BAD. | Brain research 20010323 |
| Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. | Leukemia 20010301 |
| Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma. | European journal of cancer (Oxford, England : 1990) 20010301 |
| Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. | British journal of haematology 20010301 |
| Promising clinical trials on kinase inhibitor. | Trends in cell biology 20010301 |
| Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer. | Current opinion in investigational drugs (London, England : 2000) 20010301 |
| Inviting leukemic cells to waltz with the devil. | Nature medicine 20010201 |
| Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. | Nature medicine 20010201 |
| Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010201 |
| Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20010201 |
| Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20010201 |
| New therapies show promise for patients with leukemia, hemophilia, and heart disease. | JAMA 20010110 |
| Chronic myelogenous leukemia. | Current opinion in oncology 20010101 |
| Hope for leukemia. | Health news (Waltham, Mass.) 20010101 |
| PDGF receptor inhibition prevents cardiac allograft arteriosclerosis in cholesterol-fed rabbits. | Transplantation proceedings 20010101 |
| The biology and treatment of chronic myelogenous leukemia. | Oncology (Williston Park, N.Y.) 20010101 |
| The oncologic four-minute mile. | The oncologist 20010101 |
| STI571: targeting BCR-ABL as therapy for CML. | The oncologist 20010101 |
| Current treatment approaches for chronic myelogenous leukemia. | Cancer journal (Sudbury, Mass.) 20010101 |
| Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. | Dermatology (Basel, Switzerland) 20010101 |
| Small molecule: large hopes. | Internal medicine journal 20010101 |
| FDA approves Gleevec for leukemia treatment. | FDA consumer 20010101 |
| Imatinib. | Drugs 20010101 |
| An update on chronic myeloid leukaemia. | Clinical medicine (London, England) 20010101 |
| Chronic myelogenous leukemia. | Hematology. American Society of Hematology. Education Program 20010101 |
| [Molecular treatment of cancer. Imatinib]. | La Clinica terapeutica 20010101 |
| Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. | European journal of haematology 20010101 |
| Imatinib mesylate: a new pill for chronic myelogenous leukemia. | Cancer practice 20010101 |
| STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology? | Tumori 20010101 |
| Signaling proteins as innovative targets for antineoplastic therapy: our experience with the signaling protein c-myc. | Tumori 20010101 |